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Abstract 
 
Often externally invisible, and currently considered incurable, chronic lymphocytic leukaemia 
(CLL) presents with variable progression outcomes from indolent, through actively progressive, 
to terminal in some cases.  Diagnosed with CLL myself, and having learned much of what I know 
about my disease online, this virtual ethnography triangulates autopathographic narrative with 
object oriented philosophies to map digital narrative circulations relating to the 
disease.  Observing that key CLL online support sites function as hubs within complex networks 
connecting through to a variety of narrative enactments of CLL, this thesis draws on Actor-
Network-Theory (ANT) throughout to explore and explain these narrative phenomena. The 
work shows that stories relating to CLL circulate in differing forms across networks peopled 
with varied actors (both human and non-human artefacts), key among which is the informed, 
connected and empowered ‘e-patient’. These digital actors mobilize a wealth of information 
from translations of the complex evolving science pushing the boundaries of biomedical 
understanding and treatment, to sharing the daily effects of living with a cancer whose 
sufferers record exceptionally low emotional well-being. By exploring the intersection of 
circulating narratives of a single disease online from a perspective of their material rather than 
representational effects, I locate them as inscriptions of the practices enacted by the 
individuals, organizations and institutions producing and putting them into circulation. In doing 
so, I argue that this study successfully puts into practice an innovative approach for studying 
disease and its narrative performances in online support and knowledge exchange networks, 
revealing complex networks of intersections among the multiple narrative inscriptions of CLL 
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online. The work identifies some of the key actors and narratives engaged in that process, 
demonstrating some of the network effects produced when they come together. Notable 
among the multiple effects generated through these complex assemblages of collaborative 
narrative circulation in online communities are changing patterns of knowledge exchange in 
clinical relationships, an over-arching potential for a variety of forms of patient empowerment, 
and the emergence of new open and generative forms of digital pathographies.  
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Introduction 
In Our Blood: Mapping Narrative Circulation in Online Leukaemia Networks  
 
I am a former emergency and psychiatric nurse who graduated as a mature student in English 
and media studies, and moved into academia as a University lecturer specializing in the 
intersection between representations of crime, conflict, illness and trauma with new media 
technologies. On a late afternoon in March, 2011 I left work early to pick up the results of a 
blood test from my GP.  Less than an hour later, I sat in his consulting room absorbing a 
diagnosis of chronic lymphocytic leukaemia. I was temporarily silenced by shock but as my voice 
slowly returned, key questions emerged about the disease and its likely impact on my future.  
 
These are the answers I got. Chronic lymphocytic leukaemia (hereafter CLL) is currently 
considered incurable. It is treatable however. Its progress varies widely. Some people might die 
of conditions related to their disease within 2-5 years, whilst others might live twenty years or 
more. There was no way of knowing where I personally would sit on the spectrum of disease 
progression. It is, I was told, regarded a ‘good’ cancer due to its - often slow progression, and 
relatively manageable symptom burden in the early stages.  
 
Although still the most common form of adult leukaemia (accounting for approximately a third 
of all leukaemias diagnosed in the UK) CLL remains relatively rare with an annual incidence in 
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the UK of about 3.7 cases per 100,0001.  Not all GPs are familiar with treating patients with the 
condition, and patients with a suspected diagnosis of CLL will be referred to a haematology 
consultant.  My own GP was unable to answer the fundamental questions I asked as I struggled 
to absorb the implications of a shockingly elevated white cell count and the words ‘probable 
CLL’ printed on the test results he handed me that afternoon.    
 
Played out daily in clinics and GP’s surgeries across the land, these are the quotidian moments 
that change lives forever. On the tails of lab reports such as this, the potential of imminent 
mortality comes shrieking into lives with all of its insistent, demanding questions. Its clamouring 
displaces everything. How long would I live? Would I need chemotherapy?  What would life 
with CLL be like? My GP was sorry – he didn’t know what this would mean for me. 
Acknowledging the dreadful paradox of so grave a diagnosis with so little information, he 
referred me to a haematologist, and advised me to go home and “look it up on the internet" in 
the meantime. Two mutually intertwined research projects began that day. The first, and most 
immediate, focused on the task of gaining the knowledge I needed to move forward and 
survive. Growing out of that came the second – this four year doctoral exploration of narrative 
circulation in online CLL networks.  
 
Awaiting my first Consultant appointment, I followed my doctor’s orders with evangelical zeal, 
scanning the internet for all of the information I could find on CLL.  I learned that most patients 
 
1 Figures pertain to 2011, and can be found at: Cancer Research UK (2012).  
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are fifty years old or older, usually male and often asymptomatic or mildly symptomatic when 
diagnosed, and most do not require immediate treatment. Some patients never require 
treatment, yet for others, an indolent phase evolves into disease progression indicated by 
deteriorating blood counts, increasing fatigue, frequent infections, and enlargement of the 
lymph nodes or spleen. When symptoms impact severely on quality of life, or become life-
threatening in their own right, treatment is advised.  
 
Chemoimmunotherapy (CIT) regimes have formed the ‘gold standard’ of CLL treatment for over 
a decade now, improving outcomes for many on the previous standard chemotherapy2. A 
subset of patients with particularly favourable genetic profiles still find themselves in remission 
up to twelve years following their initial treatment, leading to hopeful speculation about the 
possibility of a ‘cure’ in these cases. A significant number of patients relapse much sooner 
however, requiring subsequent rounds of further treatment. Currently, those requiring repeat 
cycles see diminishing returns and increased impacts from the significant toxicity accruing from 
CIT, and their disease eventually enters a terminal phase (assuming more serious secondary 
malignancies triggered by the toxic effects of chemo don’t kill them in the meantime). I learned 
that currently, the CLL world is buzzing with optimistic accounts of a brave new world of 
molecular treatments and even potential cures, many of which are rolling out from trial to 
market across the globe. These have the potential to positively influence outcomes for current 
and future CLL patients. I also learned that translation from pharmaceutical research and 
 
2 In a randomized study of FCR versus FC alone, Hallek et al. (2009), concluded that ‘FCR induced a higher overall 
response rate than FC (95.1 vs 88.4%) and more complete remissions (44.1 vs 21.8%; p<0.001). With the addition 
of Rituximab, Median PFS (progression free survival) extended from 32.8 mo for FC alone to 51.8 mo for FCR.  
Julia Kennedy 
4 
 
development to accessible prescription is a long-tail process rendering the discourses of hope 
and excitement chimerical for many currently suffering from CLL. This dissonance became 
frustratingly clear to me when it later transpired that my own CLL was not of the indolent 
variety.  
 
In that early process of researching CLL online I was struck by the heterogeneous nature of a 
disease that kills some patients within months from diagnosis, leaves others alive and relatively 
well for decades, and presents a range of potential outcomes between these extremes. It 
seemed then (as it does now) that uncertainty is the only current certainty of diagnosis with 
this disease, and inconsistencies in levels of information given to patients, as well as 
approaches and access to prognostic testing and treatment are apparent. One certainty 
however was the drive among some CLL patients for collaborative exchange of information and 
experience.  This was evidenced by the broad range of support sites, blogs, and user-generated 
content in relation to the disease, dealing not just in biographical narratives, but very clearly 
engaged with a broad range of information and discourses contingent on disease experience. 
 
Although researchers are beginning to explore online communication and support in chronic 
illness generally (Fox, S. and Purcell, K., 2010), chronic blood cancer experiences are woefully 
under-represented. Given that CLL accounts for around a third of all leukaemias diagnosed in 
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the UK (8,300 altogether in 2009)3, this represents a significant gap in the literature4. Evans et 
al (2011) outline the negative psychological impacts of living with this “incurable, invisible, and 
inconclusive” disease, recommending widespread recognition of patient requirements for 
ongoing information (Evans et al.  2011:1).  No work has been published to date on how this 
group mobilizes the internet to address their information and support needs, nor what can be 
learned from that about both living with CLL and the internet cultures of disease generally. Yet I 
was discovering that a vibrant exchange of knowledge and experience and the mechanisms that 
enable it remain largely hidden away in semi-closed online communities5.  This work sets out to 
bring some of that to the surface where its potential range of impact might be broadened.  
 
Throughout this thesis, I draw on Actor-Network-Theory (ANT) to explore and explain 
phenomena that I discuss. What ANT is, how it can be used as a theoretical framework, and the 
primary research methods that it draws on, such as ethnography, are explained in detail later. 
Here, I note that key CLL online support sites function as hubs within complex networks that 
connect through to a variety of narrative enactments of CLL. These stories circulate in differing 
forms across the networks. Such networks are peopled with many different actors, to draw on 
this word as used by ANT to refer to both human and non-human artefacts – those with CLL and 
 
3 According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute 
(2012), in the US It was estimated that 16,060 men and women (9,490 men and 6,570 women) would be 
diagnosed with and 4,580 men and women would die of chronic lymphocytic leukemia in 2012.  
4 Two CLL health related quality of life projects were conducted in 2007, and 2008 recording dramatically lower 
emotional well-being scores for this patient group in comparison to both the general population, and people with 
other cancer types (Shanafelt, T. et al, 2007; Else et al, 2008) 
5 As Shani Orgad notes in her work on online support communities for women with breast cancer, the potential of 
online narratives to transform broader public debate surrounding serious illness is to a large extent restricted by 
the closed/semi-private nature of many online communities (Orgad, 2006b). 
Julia Kennedy 
6 
 
those without. Key among them is Tom Ferguson’s6 (2007) vision of the informed, connected 
and empowered ‘e-patient’ at work, tapping into and sharing a wealth of information from the 
complex hard science of a disease poised at a crossroads of biomedical understanding, to the 
daily effects of living with a cancer whose sufferers record exceptionally low emotional well-
being (Shanafelt et al, 2007). 
 
In an evolving model of medical citizenship where digital cultures are beginning to re-shape 
traditional dualistic roles of knowledge exchange between patients and their clinicians7, virtual 
narrative accounts of disease experience play a significant role in peer-to-peer and professional 
communication relationships. We are witnessing a powerful revolution in the hegemony of 
medical knowledge production/consumption, at the heart of which sits Ferguson’s “well-wired 
patient” (Ferguson, 2007). Here, ‘patient-centredness’ is being reconfigured as ‘patient-
connectedness’, and both patients and clinicians alike must work on reconstructing traditional 
identities. Part of that task involves understanding the complex networks that the experiences 
of disease are meshed into and that, arguably, the internet has made more immediately visible 
and accessible. Online narratives speak of multiple disease experiences from multiple actors 
and their traces and intersections can be effectively mapped. 
 
 
6 US physician and writer Tom Ferguson envisioned a medical democracy enabled by the internet in which ‘e-
patients’ feature  as “individuals who are equipped, enabled, empowered and engaged in their health and health 
care decisions”. For the fifteen year duration of his struggle with multiple myeloma ending with his death in 2006, 
Ferguson promoted health care as an equal partnership between e-patients and health professionals and systems 
that support them (e-patients.net, 2009 ). 
7 This e-democracy mirrors a wider call for the democratizing of medicine through medical education, including 
patient involvement (Bleakley, Bligh and Browne, 2011; Bleakley 2014). 
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Patient narratives of CLL online are networked into a complex mesh of social, political, 
economic, and cultural threads – connected by global systems of information exchange, yet 
grounded in local contexts of health care delivery, disease management, and personal 
experience. As my own story became enmeshed in these complex networks, I began to get a 
sense of the many actors involved in bringing a disease into being: connecting our blood cells to 
lab technologies and scientific research; relating clinical treatment decisions to the 
pharmaceutical industry, its investors and regulators; linking governance of local health care 
delivery to political economies; relating all of these aspects (and more) of our disease to the 
information technology that enables their (and our) various narratives to be shared; and 
acknowledging the cultural attitudes that frame the stories we tell each other and ourselves 
about disease. These are the ‘circulating’ elements across networks that ANT describes and that 
frames a new kind of phenomenology, where ‘actors’ – whether artefacts, ideas (ways of 
thinking) or persons (ways of being) present themselves in differing forms according to context 
and thus remain relatively unstable. Understanding such actors (epistemology) is secondary to 
appreciating their varied appearances (ontology). Where these appearances are written or 
talked about within networks of symptoms and illness, this is usually referred to as ‘illness 
narratives’ or ‘pathographies’.    
 
The production and study of illness narratives or pathographies is a rich scholarly field in its 
own right pre-dating internet communications by many years. The varied montages of narrative 
objects circulating in online health networks however defy the kind of generic certainties 
required to pin down what we define as “illness narratives” in the traditional literary sense 
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(biographies, short stories, poems, journals and so on). Time spent in digital narrative networks 
also makes it clear that digital pathographies begin to defy traditional binary models of 
‘evidence-based’ versus ‘narrative-based’ medicine in which the latter is located as 
demonstrative acts of individual agency set against the de-personalizing institutional medical 
gaze of the former (Riessman, 2002; Bell 1999; Langellier 2001). With their ongoing and 
unfinished nature, resistant to generic containment, digital illness narratives become an 
“amalgam of literary and non-literary forms, including autobiography or biography, journal, and 
medical chart” 8(McLellan, 1997: pp100-101). In this thesis, I suggest that we add scientific 
research papers, international medical conference proceedings, medical education sites, news, 
social media, and popular cultural artefacts to the amalgam. I also ask how CLL pathographies 
online might be read as evolving forms of health narratives that, with their collaborative and 
hypertextual nature, often present as an accretion of multiple practices and motivations.  My 
aim here is not to produce a schism between traditional illness narrative approaches and digital 
forms. Instead, I want to offer a view of an evolving form of pathography open to new 
possibilities in line with evolving forms of identity and technocultures  per se, contextualized by 
the changing relationships between medical professionals and patients, and by a re-
consideration of narrative form in an information culture.  
 
Walter Benjamin has argued that: “narrative could not survive the moment of information” 
(1992: 73-89). This ‘moment of information’ can be read through the rise of database culture 
 
8 Faith McLellan (1997) defines the digital health narrative as an “unruly text” in comparison to more traditional 
literary forms of health writing which, although open to interpretation, are in some sense ‘finished’ and contained 
by their singular completeness. 
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which, it is suggested, can in itself be read as symbolic of life in Lyotard’s “computerized 
society” (1979). ‘Database’ in this context is seen by Manovich as an organizational cultural 
framework in a postmodern vacuum of grand narratives into which has rushed “an endless and 
unstructured collection of images, texts, and other data records” (Manovich, 1998:2). The urge 
to develop a poetic, aesthetic and ethical framework for the database appears to be strong 
however (ibid). Narrative forms threatened on Benjamin’s terms may evolve into new 
communicative practices that retain the imaginative alongside the informational, and that 
might lend themselves to less hierarchical modes of production, access and exchange. 
 
Bassett (2007) suggests that information-pervasive new media forms operate as complex, 
multi-layered assemblies (both temporally and spatially) challenging traditional linear notions 
of narrative:   
 
Narrative, understood as an extensive arc constituted by a process of emplotment that 
both reaches back into the horizon of the event and forwards into the horizon of the 
reader, can make sense of these experiences through a form of assembly that is not 
retrospective but in process, not necessarily linear but rather expansive, and that is 
certainly open and indeed generative (Bassett, 2007:3). 
 
Narrative is presented here as “an intrinsic part of a new informational economy which 
becomes its material and which it holds and articulates” (Bassett, 2007:3). “Which it holds and 
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articulates” is the important point here in relation to my own work.   
 
So, does the contemporary illness narrative encountered online demonstrate the ability to 
assemble the more informational narratives in the CLL network into its fabric in the expansive 
and generative way suggested by Bassett?  I believe so, and through a process of mapping the 
connections and intersections of a range of circulating narratives online, this work sets out to 
test that hypothesis.   
 
It is through my interest in the material effects of multiple narratives of a nominally singular 
disease coming together, that I draw for my methodological design on the ontological politics of 
disease proffered by scholars such as Annemarie Mol in her (2002) ethnography of 
atherosclerosis, and John Law and Vicky Singleton (2004) in their work on the multiple sites and 
enactments of alcoholic liver disease. As a CLL patient myself, my autopathographic narration is 
positioned as just one of many narrative dimensions in the network9, but an important political 
element of the research nonetheless, bringing an inside–out perspective to this ethnography of 
CLL online10 that also offers credibility and veracity.  In crafting a method that assembles the 
nuanced mapping of material relations of narrative enactments online, among which sits my 
own unfolding narrative of living with disease, I hope to create productive intersections 
between my own narrative enactments of CLL (of which this entire project is one), and a range 
 
9 Positioning my own narrative as just one object in a network accords with the ontological politics of the project, 
and as such addresses the critique of visibly incorporated subjective experience in ethnographic work as mere self-
absorption, and what Geertz (1988) has disparagingly referred to as “author saturated texts”. 
10 This is designed in line with a reflexive ethnographic approach that “fully acknowledge(s) and utilize(s) subjective 
experience as an intrinsic part of research” Davies (1999: 5).   
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of other enactments that shape my own. By inserting my own narrative enactments into the 
mix as a ‘native researcher’ (Ellis, 2004; Denzin and Lincoln, 2008), my initial aims were at once 
to write from the centre of my experiences and from the margins of a culture in which the 
diseased, the sick, the dysfunctional are so often spoken for. But it soon became clear that my 
own experience may be de-centred by others, and that I can’t talk uncritically of ‘margins’ and 
‘centres’ if I accept the flattened ontological landscape of circulating narrative objects, of which 
I am just one.  It is perhaps more fruitful to use my insider status to try to trace the network 
patterns that keep some actors more strongly tied into positions of control in some enactments 
of disease than others, and to ask if they might be changing in this new era of digital 
patienthood.  Although an auto-ethnographic presence is very clear in this work, I make every 
effort to present it as just one narrative force in a field of many others I have encountered. 
 
Mol (2002), and Law and Singleton (2004), whose work has been fundamentally influential on 
my own methodological practices, were located very differently as researchers observing day to 
day physical practices in the field – clinics, laboratories, waiting rooms and so on – and not 
having declared a diagnosis with the diseases that formed the object of their inquiry. My work, 
as a CLL patient-researcher, is situated with narrative practices of disease situated in a virtual 
field.  I am observing the circulation of virtual texts, inscriptions, and stories that signify the 
material enactments of a disease.  That raises an interesting methodological question about the 
object of study:  in a virtual world where all that exists of a disease (or any entity) is textual, do 
those texts become digital ‘objects’ in their own right rather than merely inscriptions of ‘real-
world’ practices? ANT would suggest so, offering such virtual enactments the same ontological 
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status as the ‘real’ (Latour, 2007). 
 
Multiple enactments of disease (or any phenomena) online have to be read at once as separate 
from the everyday situated practices of doing disease offline and intrinsically related to them.  
The virtual CLL networks explored here become the digital archives and mediators of 
inscriptions produced on the ground (research papers, newspaper reports, policy documents) 
for sure. But they are more than just databases of informational narratives. These narratives 
are actively mobilized into support networks. They are circulated and shared by key actors. 
They come into contact with each other and with the online narratives of other human actors in 
the networks (primarily CLL patients and their carers). They are put into dialogue with 
narratives specific to the online support community – the shared stories of experience that CLL 
patients exchange in these networks daily. They begin to produce network effects.  
 
I want to suggest then that when the inscriptions and narratives of institutional disease practice 
are put into circulation with patient narratives online, a potential for enacting offline practices 
of disease differently is catalyzed. Where productive narrative network effects are effectively 
mobilized into the everyday analogue practices they relate to, change might happen. The 
questions this work needs to ask then are primarily: What are these narratives? How do they 
circulate? Who or what does the circulating (that ANT refers to as ‘translations’)?  What, most 
importantly, do they tell us about the concerns of those living with and treating CLL and the 
potential of online narrative circulation to address them?  
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There is already a vibrant body of work exploring issues of patient empowerment through 
online communities of illness that are fundamentally concerned with the potential of narrative 
sharing to effect meaningful change in the way people approach illness. Mette Hoybe and 
colleagues (2005) for example identified three different modes of action through which women 
in online support communities confronted breast cancer: 
 
“verbal acts of writing and communicating experience; imaginative acts, embodied in 
metaphors, re-imagining their experience of the world and regaining power over a life 
that was shattered by breast cancer; and, finally, practical action for withstanding 
cancer treatment, nursing the body through diets and exercise and educating 
themselves about their disease” (Hoybe, 2002, cited in Hoybe et al., 2005:217). 
 
The potential for such communities to fulfil a range of needs for cancer patients through 
varying narrative enactments is clear. In Hoybe and colleagues’ respondents, the practices of 
crafting and imagining responses through attention to the communicative act of writing itself 
sits firmly alongside the practical necessities of communication purely as information exchange. 
Benjamin’s anxieties seem for the moment unfounded. It would appear that the informational 
does not necessarily exclude the narrative drive. We are, it seems, not easily inclined to 
expunge the poetic from the database.    
 
Like a good deal of the work in this area, Hoybe and colleagues take as their object narrative 
practices in a specific online community. This kind of focus contributes much to a fine-grained 
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understanding of very local communities of online narrative practice that may be extrapolated 
more broadly. In identifying these modes of action, Hoybe and colleagues aren’t concerned 
methodologically with the narrative flows, intersections and enactments that underpin them – 
it is not their object of inquiry.  Currently, there is very little research to be found on online 
support communities that wants to take on that mapping process. 
 
There is probably good reason for that. It is a laborious process, and some may say too ‘flat’, 
too concerned with the metaphysical ontology of narrative objects and network flows to make 
a difference to the lives of those living with disease11. I hope I have already demonstrated why I 
think it matters that attention is paid also to the complex networks emerging from the 
intersection of a range of narrative forms and themes amongst a variety of actors enacting CLL 
online12. By mapping the narrative distribution of CLL online, I want to reveal what might be 
 
11 For a critique of ANT methodologies see A. Saldhana’s (2003) Essay ‘Actor-Network Theory and Critical 
Sociology’, in which he reviews the following ANT texts: Law, J. and Mol, A. (Eds.) (2002) Complexities: Social 
Studies of Knowledge Practices; and Law, J. (2002) Aircraft Stories: Decentering the Object in Technoscience. 
12 What interests me particularly are the various interpretations of textual form either as a representational 
practice within the linguistic field, or as more Deleuzian interpretation of culture as a material force in which text 
operates as just one actor in a broader network, and is not regarded as a privileged locus of meaning in its own 
right. As Caroline Bassett points out,  “...here the cultural text itself, the narrative, is not to be explored in terms of 
representation but in terms of how it performs, acts upon us, or materially produces an effect”  (Bassett, 2007:23). 
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learned from a broad, heteroglossic landscape of multiple actors and objects. Part of that may 
involve exploring the inscriptions that maintain dominant forms of disease definition, and 
asking if or  how ‘e-patienthood’ is enacted to challenge the discursive power of those 
inscriptions. Importantly though, I want to explore how people with CLL translate, 
accommodate, re-iterate and re-define the multiple narrative enactments of CLL online. 
 
In her observations of the unfolding digital narrative written by the father of a boy undergoing 
treatment for acute lymphocytic leukaemia, Faith McLellan (1997) describes digital health 
narrative as ongoing, unfinished and unruly texts with the potential to reveal valuable 
information about experiences of illness not accessible through the arguably more singular and 
self-contained narratives of the print form.  With their mix of lab reports, journal entry, 
existential observation, requests for advice, experiential accounts, demonstrations of medical 
and scientific knowledge, links out to relevant sites and information, and responses to 
comments from other forum users, digital health narratives are potentially at once 
heterogeneous and collaboratively heteroglossic accounts. This raises the potential for 
individual narrative reconstruction online to become an ongoing reflexive project, drawing on 
and sharing a range of resources that is by its nature collaborative, multidisciplinary, and 
dialogic.  
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As well as seeking to fulfil the function of getting presently “hidden” voices out into the public 
domain, this project is concerned with exploring how those living with CLL and their carers are 
themselves enabled or empowered (or otherwise) through online narrative interaction 
surrounding the disease. Tom Ferguson concluded that “The art of ‘empowering’ patients is 
trickier than we thought” (Ferguson, 2007:23), noting that “clinician-provided content has few, 
if any, positive effects” (ibid, 24) where the patients’ own level of engagement with their illness 
has not undergone significant change.  
 
My aim to map the multiple contextual stories that touch the individual stories of people living 
with CLL online acknowledges that a disease is always experienced as the combined forces of a 
number of practices and interests.  By mapping patient stories and the broader interests that 
shape them, I suggest we can achieve several things: We can identify the key players and 
activities involved in holding a particular disease together as a single entity; we can identify the 
major concerns of those living with the disease; and we can perhaps begin to think about 
strategies for bringing the different enactments of a disease into more productive alignments.   
 
Diagnosed with a chronic cancer at these crossroads of knowledge and communications 
technologies then, I am well located to map the new territory as I negotiate it as native and as 
researcher through both insider ethnography and reflexive auto-ethnography. Triangulating 
ethnography and auto-ethnography with Mol (2002), and Law and Singleton’s (2004) 
ontological interpretation of ANT, this exploration of CLL online asks how multiple narrative 
objects circulating online translate to the lived realities of this form of leukaemia.  Whether 
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patients talk of changed relationships with their doctors, efforts to access trials and drugs, or 
the understanding of developments in CLL knowledge and treatment behind statements such 
as “I no longer have the sense that I have a sword of Damocles hanging over my head….” (In 
Our Blood survey respondent 25), this work sets out to map those effects. 
 
What can we learn about the various ways in which CLL is “done” to patients, and the way that 
those patients “do” this chronic blood cancer in an embodied, digitally connected, and 
increasingly genetically decoded world?  What are the implications of digital narrative exchange 
for an unfolding philosophy and anthropology of illness in a new bio-medical and technological 
landscape? This PhD sets out to address those questions through the aims set out below, and 
the following chapter outlines my methodological approach to that challenge. 
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PROJECT AIMS:  
 
• To explore and map the evolution of patient illness narratives as they move into circulation with 
a range of other narrative enactments of disease online. 
•  To locate and map the networks within which multiple CLL narrative enactments circulate and 
intersect online, identifying key nodes and actors. 
•  To make visible the key themes and issues faced by those living with CLL through mapping 
narrative themes online. 
• To reveal the major points of intersection of the various narrative enactments identified, 
highlighting synergies, tensions and obstacles in the bringing together of multiple enactments 
of CLL online.  
• To utilize and adapt object-oriented methodologies for mapping online narrative networks and 
flow.  
• To design a methodological approach for writing up multiple narrative enactments in a way that 
prefigures the ontological politics of the project.     
 
In the following chapter, I set out how I addressed these aims through choosing a 
methodological framework and then related research methods.    
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Chapter 1: Methodology    
 
“A reader, asking in what sense our theory of the social could be reconciled with ‘conventional’ sociology, 
offered as an objection the way AIDS patients mobilized as a group. Looking at traditional ‘social 
movements’ it was obvious to her that patients’ organizations corresponded to ‘conventional’ definitions 
of the social because she had entirely forgotten how deeply innovative it was for patients to make 
politics out of retroviruses. For us on the other hand, AIDS activism and, more generally patient-based 
organizations, is just the type of innovation that requires completely new definitions of the social” 
(Latour, 2005:23) 
 
Introduction to Methodology 
 
As set out in the introduction, this project was borne of a personally motivated interest in 
opening/illuminating the black box of CLL as a single knowable disease to reveal at least some 
of its varied versions and their connections.  I was struck by the complexities and multiplicities 
of narrative manifestations of CLL I found when I followed my doctor’s orders to ‘look it up 
online’.  I was diagnosed with CLL yet could find no single CLL to which I could relate my own 
experiences. Instead, I encountered various versions of the disease circulating around online 
networks of varied actors (persons, ideas and artefacts). 
 
Discrete nodes of interest meshed into a broader network of CLL communications. For example, 
information on drug regulation and funding from the NICE site finds its way into individual 
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stories surrounding access to new CLL drugs in support communities. Research papers from 
online journals revealing a panoply of new treatments and approaches to CLL circulate from 
clinicians and scientists to patients and then in conversation to family members and friends. 
They move across online networks alongside multiple inscriptions of CLL from graphs of 
prognostic curves predicting average survival times, news stories trumpeting miracle cures, 
documents outlining healthcare policy, and advice from dedicated support sites, finding their 
way into interactive forums hosting multiple individual narrative enactments of living with a CLL 
diagnosis.   
 
CLL-specific networks buzz with a vibrant energy borne of strong links and associations, and 
connect out into broader, diffuse networks in all manner of pathways by weaker links. These 
CLL ‘hotspots’ unite (non-human) technologies enabling online interaction with a range of 
(human) actors distributing multiple narratives of CLL across key nodes, also linked strongly and 
largely manifesting as support groups, advocacy sites, and patient or patient/physician blogs.  
Key to this work is how such narratives intersect in ways that not only make visible the tensions 
of ‘othering’ upon which each enactment to some extent depends, but are productive of effects 
that move to disrupt the ‘othering’ process through narrative amalgamation.   
 
I am arguing here that online narrative sharing allows for those caught up in particular modes 
of disease enactment to consider the effects of absorbing ’other’ narrative enactment of a 
disease into their own. Drawing on the work of Gilles Deleuze and Felix Guattari, we might say 
that these circulating narratives have the potential to de-territorialize and re-territorialize each 
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‘other’. Further, such territorializing work is often reported in the genre of travel writing replete 
with adventure, discovery, new horizons and cross-cultural exchange. Drawing further on 
Mikhail Bakhtin’s ideas, there is less and more coherent dialogue at every point as a polyphony 
of voices – continually challenging medicine’s quest for certainty (Bleakley 2015).  
 
I began this methodological journey favouring a traditional ANT approach which would allow 
for defining networks, identifying particular ‘network effects’, and tracing the involved actors  
(persons, artefacts and ideas given equal ontological status); translations (‘conversations’ 
between actors that potentially expand a network); intermediaries (actors involved that do not 
promote translation and then expansion of the network but may keep the network stable); and 
mediators (actors involved that destabilize but expand the network, working against 
crystallization and collapse).  This is important if a) we believe there is a value in harnessing the 
knowledge gained to underpin effective system design that might enhance that potential; or b) 
we are more broadly concerned with making visible how people in a digital era ‘do’ disease (or 
both).  This project doesn’t lean primarily towards drawing inferences about system design, 
although the findings may help inform effective online networking.  It is more concerned with 
mapping ways in which particular narrative enactments of disease online might come together 
in networks productive of change.  One of the driving tenets of this work is a conceptual shift 
from patient centredness to patient connectedness in which patient groups may provide labile 
nodes in a system rather than stable centres. Making visible the range of narrative practices 
and enactments behind that requires a bigger lens than the traditional sociological binary 
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biomedical gaze versus patient perspective, as Law and Singleton point out:  
 
Arguably if attention is directed to enactment, then the opposition between 
biomedicine and the patient perspective dissolves, to be replaced by studies of specific 
practices that create complex bodies and subjectivities which do not bifurcate along this 
join (Law and Singleton, 2003:11). 
 
The methodological evolution of the project has taken me from Latour and Callon’s earlier ANT 
approaches to the ontological turn informing Law and Singleton’s (2004) work on broadening 
out the range of object possibilities in their work on liver disease (particularly their concept of 
‘fire objects’) and, most emphatically, Mol’s (2002) approach to making visible multiple 
enactments of a putatively single disease object13. Further contexts for these concepts are 
explored in the first Perspective section of this chapter. 
 
While this work aims to locate and map the networks within which multiple CLL narratives 
circulate and intersect online, identifying key nodes and actors, it is about much more than 
seeking to reveal process. In line with another of the project aims, I set out to make visible the 
key themes and issues faced by those living with CLL, to understand and reveal the major 
 
13 For instance doctor and ethnographer Annemarie Mol has shown for lower limb atherosclerosis how different sets of 
relations in (for instance) the general practitioner’s surgery, the haematology laboratory, the radiography department, the 
physiotherapy service and the operating theatre each produce their object – the atherosclerosis in question. (Indeed it is more 
complicated than this since there may be differences between these objects – a point which we will come back to shortly) (Law 
and Singleton, 2003:4) 
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tensions and obstacles that might exist in the bringing together of multiple enactments of a 
single disease, and to identify areas where they may be intersecting productively or otherwise.  
The following short subsection describes how the chapter is structured to map the 
methodological decisions taken to meet those aims. 
 
Negotiating Method: Questions of Site, Self, Ontology, and Ethics 
 
Concerned as it is with mapping multiple narrative enactments of a single disease, the issue of 
site was the primary challenge in designing a method for this project, and will be addressed in 
detail in this chapter.  Not least among the considerations of site, is that of my own role in the 
work as an insider researcher living with CLL. Decisions about how to merge auto-ethnographic 
approaches with the object-oriented approach with which I have chosen to frame this work are 
outlined in the chapter, as are ethical considerations surrounding gathering data from a 
potentially “vulnerable” subject group, of which I myself am a member.  Finally, the chapter 
both explores and exemplifies my approach to writing up the work in a way that prefigures its 
ontological politics.   
 
These key (interdependent) methodological themes are set out as separate issues in sub-titled 
sections. In line with the project’s aims, the work is structured to layer relevant ‘perspectives’ 
or contextual work from existing literature, with examples, or ‘translations’, of circulating 
narratives presenting multiple enactments of CLL online. The philosophy behind textually 
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layering multiple narrative versions of CLL is explored later in the chapter, although I outline the 
practice briefly here for clarity.  ‘Translation’ sections set out to map key actors, nodes and 
mediators under the overarching theme of the chapter title. They allow for showing what 
discursive, institutional, and individual narrative enactments of CLL can be traced across the 
nodes, and then what networks can be identified. They reveal what knowledge, practices and 
change (acts of resistance/evolutions/becomings) might be produced where they intersect, and 
contribute to showing who or what drives the flow of these narratives around the CLL networks 
online, and what we might learn from them.  In this Methodology chapter, the approach is used 
to map the evolution of this project itself as a network, as an enactment of CLL, and as the 
product of a range of texts, technologies, discourses and subjective experiences in its own right.   
 
‘Perspectives’ sections allow for a consideration of some of the relevant literature or existing 
work in the field in relation to the themes identified, and Translations selected. These are 
intended to provide a diverse range of theoretical practices and institutional contexts 
surrounding the subject matter, and to populate the richly detailed map of connections I am 
aiming for.  
Perspectives: Multiple CLLs across Multiple Sites  
 
AnneMarie Mol trained as a doctor in the Netherlands but chose to become a medical 
anthropologist and ethnographer and then developed her work as a philosopher informed by 
radical feminist perspectives. In her radical ethnography of atherosclerosis, The Body Multiple, 
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she painstakingly identifies the fragments comprising a “whole” disease, mapping the networks 
of objects and activities that make it cohere, whilst always acknowledging that discursive 
networks do not expunge physical reality: “patients may interpret bodies, but they also live 
them” (Mol, 2002: 20). Readers see a disease take shape that is “both material and active”, 
made up of activities, experiences, interactions, texts, objects, conversations, drugs, incisions, 
scars, and stories (ibid).  
 
Mol’s work draws on the intrinsically Foucauldian object-oriented ontologies of Actor-Network-
Theory (ANT) developed by Bruno Latour, Michael Callon, and John Law. ANT is concerned with 
how different objects come together in various ways within networks to produce what appear 
to be complete technologies, knowledge forms, and ‘accepted scientific truths’ (Bassett, 2007: 
84). These ‘finished’ ways of knowing are understood to emerge from practices of mediation 
and translation through which objects may appear in many forms. Latour describes the initial 
blueprint plans for Paris’s proposed high-speed rail network Aramis, for example, through the 
design and political issues that dogged it, to its ultimate abandonment and translation to rust 
(Latour, 1996). Here, a network was promised, potential translations showed, but 
intermediaries rather than mediators (for example blueprint designs did not match the realities 
of actual engineering possibilities) dogged the project so that a network failed to materialize. 
The human and non-human presences in the network are regarded as symmetrical in their 
potential to mediate and translate (but not substitute) objects. The ontological politics (how 
existence of objects or actors is also a network of power relations) lay in the exploration of the 
factors contingent on keeping the object or knowledge recognizably consistent as it translates 
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across different modes. This is not about tracing ‘truth’ and its ‘representation’, but about 
understanding how the processes of mediation producing ‘truths’ can be seen as ‘productive 
and constitutive’ at different sites (Latour, 2000, cited in Bassett, 2007: 85). It is in this 
acknowledgement of multiple sites that a number of questions concerning my own research 
design emerge.  
 
Defining ‘Site’  
 
Site in this work could be myself; the narratives and texts I encounter; the condition as it 
appears through the narratives; the communities that emerge around these narratives; or the 
technologies that enable their presence on the internet, which could include its own subsets of 
computer technologies, biomedical technologies, and technologies of the self.  A clearly 
defined, encapsulated site is difficult to delineate in this case as all of the above intersect 
variously to produce CLL(s) online.  CLL shape-shifts across and between all of these sites (and 
more).  Hine echoes this when she warns that: “When a technology appears to offer up a clearly 
defined field site...these sensibilities suggest that one should become suspicious” (cited in 
Markham and Baym, 2009:4). Mol similarly observes: “blow up a few details of any site and 
immediately it turns into many” (Mol, 2002:51). 
 
A clearly defined research object itself is no easier to pin down.  Law and Singleton’s (2004) 
description of methodological struggle in their ethnography of alcoholic liver disease 
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demonstrates this ‘slipperiness’:  
 
 ...we slowly came to believe that we were dealing with an object that wasn’t fixed, an 
object that moved and slipped between different practices in different sites…This was 
an object that, as it moved and slipped, also changed its shape (Law, 2004:79). 
 
In other words, alcoholic liver disease was performed differently by different (or possibly the 
same) people in different places.  Mol says that diseases then are ‘done’ (Mol , 2002). Rather 
than tangible things inside bodies subject to a range of different perspectives, diseases are 
enacted into social being through multiple practices across multiple sites that coalesce (or not) 
in relatively stable networks through processes of coordination, translation and distribution. 
Method quite simply “never isolates these [diseases] from the practices in which they are, what 
one might call, enacted” (Mol, 2002: 33). 
 
A conceptual shift is required to circumvent the widely-held concept of an internal/external 
(subject/object) binary in which an objective ‘reality’ exists ‘out-there’ beyond us and invokes 
all manner of representational acts ‘in-here’ that relate to it. (Law, 2004:160). Alcoholic liver 
disease operating at the site of textbooks enacts the condition as a complex set of “aetiological, 
environmental, physiological, anatomical, and behavioural relations and effects which match 
the statements in the text” (Law, 2004:71). These textual inscriptions become sites of primary 
definition for our understanding of disease, the ‘in-hereness’ that represents its ‘out-
’therenesses.  Interacting with the sites of this particular methodological assemblage (medical 
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knowledge, training, and institutions) we are diagnosed, staged, treated, monitored, and 
(sometimes) discharged. The chronically ill enter a lifetime of monitoring, measuring and 
testing practices in which the body is read against the accepted inscriptions of “knowing” 
disease. There are inscriptions of disease knowledge outside of medicine too. Anyone who is or 
has been ill understands that its effects radiate out far beyond the body into a range of societal 
practices. Diseases are enacted at all manner of different sites, both within and beyond the 
body, and I am indebted to the work that has informed my approach to CLL In this way.  
 
There is a departure though - both Mol (2000) and Law and Singleton (2004) worked in physical 
fields (hospitals and clinics) to trace objects of disease (atherosclerosis and alcoholic liver 
disease respectively). My field is an online network of hubs, nodes and associations across 
which multiple virtual narrative enactments of this disease are distributed daily, raising the 
question of whether the technologically-enabled texts that make up the virtual become 
‘objects’ in their own right and not mere digital inscriptions of offline practices? Virtual CLL 
networks archive, circulate and mediate the inscriptions of its offline enactment but they go 
way beyond repositories for information storage and sharing.  Through active mobilization into 
support networks by key actors, these narrative enactments (or objects) jostle, clash, influence, 
and produce effects.   
 
The beauty of an online ethnography of this nature is the potential to shift the lens from 
analysis of local nodes and metaphoric description to the chains of associations they are 
meshed into as metonyms, revealing how the macro can be reconfigured as a cluster of micro 
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enactments tied into each other through a complex chain of associations and translations. The 
objects of interest in my work are not these local sites or nodes per se, but their role in the 
distribution of various narrative enactments of CLL online. Currently, ANT influence in online 
knowledge exchange research remains relatively rare14 and my hope is that this work might 
evolve the methodological field in some small way. It seems to me that while Mol and others so 
beautifully describe the complex sets of associations, enactments, and appearances for 
particular diseases in physical settings, the problem of translating disease experience across 
intersecting object boundaries requires meticulous ongoing attention so as to avoid 
inadvertently accounting for a disease as a metaphorical object/s, and thus undermining its 
tangibility as something that affects real bodies and the lives lived through them. This is 
perhaps more pertinent than ever when undertaking an ethnography of disease through the 
evolving virtual associations of online disease networks. We could do well here to heed Susan 
Sontag’s warning that diseases treated as metaphors turns real bodily suffering into abstract 
symbolic capital. Imagining a disease metonymically however allows for maintaining an 
experiential/ ontological dimension15 (the disease is real for all actors, from patient lab 
 
14 Fox and Ward (2006) triangulate ANT with Deleuzian perspectives in their work on attitudes of internet users to 
medical knowledge and technology in a range of health contexts.   
15 See also Munday (2011) for his interpretation of Jacques Derrida’s metaphysics of language in relation to 
metaphor/metonymy. “For him [Derrida] it is not the case that there are truths to the world that are already there 
waiting to find words. Rather, language generates a metaphysics through its own workings, through the repetition 
of words in connection with other words. Meaning is only possible through interdependence, and there is no final 
stability. This is metonymic because meaning is generated through contiguity (where one thing touches another) 
and not through representation (where one thing stands for or replaces something else). (Munday, 2011:136) 
Similarly, Munday draws attention to Deleuze and Guattari’s metonymic view of language as ‘rhizomatic’ - 
concerned with contiguities and intensities in and between languages rather than representations (ibid:137) – this 
allows for more nuanced concepts of the process of linguistic translation itself as a process of negotiating the 
contiguities that are “not exclusive to a home or target language but exist in endless chains that extend from one 
language to another” (ibid: 140). Much as my work here maps the translation of enactments of disease across 
boundaries through such chains of association and intensities. 
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technicians to suffering patients) in which many nodes of expression are possible, but they are 
linked. This places appreciation of the illness before explanation, as ontology precedes 
epistemology.    
 
Networks and Bracketing 
 
Some explanation of the definition of ‘network’ in this project is required at this point. It can be 
used to refer in one sense to computer networks themselves - a generic spatialized topography 
enabling the flow or circulation of texts around an intensely and strategically connected cluster 
of nodes. These are composed of human and non-human actors in the model of an actor 
network, but I want to bracket the connections holding generic computer networks together, 
and focus on specific networks holding CLL online together (or not), such as support sites, blogs, 
institutions, inscriptions and the research project itself. This process of bracketing relies on 
both suspending (bracketing out or striking through, a common practice in Derrida’s account of 
deconstruction, as a way of suspending final judgement and considering surplus), and eliding 
certain network practices in order that others can be foregrounded for exploration. Carefully 
utilized and acknowledged as a reflexive methodological tool, it enables focused study. 
Unthinkingly, in everyday contexts, it is also part of how we ignore complex translations in 
order to configure easy and potentially reductive object relations.  
 
For example, I subconsciously bracket the myriad technological, institutional, and human 
elements enabling advanced genetic profiling, such as the years of biomedical research, issues 
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of funding, lab equipment and personnel involved, other prognostic methods that might 
produce different results, or may never have made it to market and so on. When I get my test 
results, indicating a ‘bi-allelic 13q chromosomal ’deletion, I believe intuitively that the test has 
found that, and not produced or enacted it through practice. I know from reading the research 
that 13q deleted disease often progresses. By eliding all that sits behind the practices of 
prognostic testing and connects it to clinical implications, I can unproblematically read the 
results as one of a range of recognized indicators targeted at categorizing a common object of 
CLL that exists in my body. I can believe that I I feel ill because, as doctors and technicians have 
attested, I have this particular genetic version of CLL inside me, and it is progressing as my tests 
indicated it might.   
 
Is there a problem with thinking like that? Elision or bracketing is surely just shorthand for 
survival in a world where we don’t have time to consider every connection that makes things 
happen. In terms of my CLL progression, the chromosomal abnormalities indicated its 
likelihood, a number of different blood tests confirmed it was happening, as would a bone 
marrow biopsy, and as did my swollen lymph nodes and spleen on palpation.  The textbooks 
were right – the disease did progress as indicated, so it remains easy to imagine that the 
disease is in fact a singular object that can be known through tests and texts. 
 
But is it actually there?  A single entity in my body, made visible by these procedures? Or is it 
enacted differently in all of the different tests I have results for? Is it something a bit different in 
all of these? Might they even contradict each other, and if they do, then what is the tangible 
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‘truth’ of my CLL and where exactly is it located? Perhaps then there isn’t one? But working out 
how to hold multiple entities of a disease that one lives with requires some challenging 
conceptual work. It requires unraveling of our concept of objects as single entities occupying 
Euclidean space, readable from different perspectives, but consistent in their own right. It 
requires a refusal to accept disease as singular embodied pathological object subject to various 
external investigations. It requires thinking outside the body to explore the various practices 
that enact diseases and their connections. It requires thinking about how disparate practices 
and experiences might coalesce into a single disease.  
 
How is my CLL, which has taken me to the edges of dying, necessitated toxic therapies, 
hospitalized me twice, requires lifelong three monthly clinic visits and blood tests, defines me 
legally in the workplace, affects people’s attitudes to me (and my attitude to myself), and 
denies me access to life and travel insurance, readable as a single object? Like most sick people, 
I think of myself as having CLL, the experiences I have directly related to my being diseased. 
Despite any conceptual effort expended on seeing things otherwise, I would never dream of 
telling anyone that I do CLL, or have it done to me. Yet it is an invisible disease for the most 
part. One doesn’t look at someone and immediately identify them as having CLL.  Being 
relatively asymptomatic on diagnosis, the multiple narrative enactments I encountered online 
in the early days bizarrely preceded any real sense of actually incorporating the disease I was 
reading about. Prior to progression, it was perhaps easier to begin flipping the conceptual view 
of disease away from a primarily embodied singular entity to an unfolding ‘ontological 
choreography’ (Cussins, cited in Mol, 2002:43). So ingrained though is the socio-cultural frame 
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of the former, that it can still at times demand that we actively look for the rabbit in the duck or 
vice versa visually depicted in Jastrow’s famous ‘Duckrabbit’ image shown in Figure 1 below 
(Jastrow, reproduced in Kihlstrom, 2004):  
 
 
Figure 1: KIHLSTROM, J. F. (2004). Reproduction of Jastrow's Duckrabbit [Engraving]. [Online] Available at: 
http://socrates.berkeley.edu/~kihlstrm/images/Jastrow/JastrowDuckRabbit.jpg [Accessed 15/05/15].  
 
Once I could make myself think the objects of CLL as multiple and connected (a task far more 
taxing than holding together a two dimensional duck/rabbit in the field of vision), a decision still 
needed to be made about where to start with the process of mapping them.  The following 
translation outlines my response to that challenge. 
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Translation: “Look it up on the Internet” (The Journey Begins) 
 
This project grew from my own experiences of trying to piece together the narrative fragments 
from various sites I encountered in the early days of my own personal research, ultimately 
‘defining the argument’ of my ethnography. Driven to understand the multiple narratives of a 
heterogeneous, largely invisible, liminal yet potentially fatal disease in relation to my everyday 
embodied and disembodied experiences of it, I was already a multi-site ethnographer of CLL 
online from day one, concerned with the “chains, paths, threads, conjunctions or juxtapositions 
of locations in which the ethnographer establishes some form of literal, physical presence, with 
an explicit, posited logic of associations or connections among sites that in fact defines the 
argument of the ethnography” (Marcus, cited Gatson and Zweerlink, 2004: 180). 
 
Far removed now from the familiar practice of trying to self-diagnose online, a blood sample 
taken from my arm a week previously translated to the fact that I was indeed very sick. No 
amount of Google second-guessing could trump the evidence on the lab report that confirmed 
this (see figure 2 below for a copy of the initial lab report).  I knew what I had, or what it was 
called at least.  
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Figure 2: RCHT (2011) My Initial Diagnostic Readings, March, 2011 [Lab Report]. 
 
This was the primary textual inscription of my disease, but now I had to decide where to go 
next...  I needed to relate the numbers and acronyms on the lab report with me and the rest of 
my life. I tried starting with medical information. What is CLL?  What are the ‘smear’ cells 
mentioned on my initial diagnostic lab report (replicated in Figure 2 above). Why is my white 
count so high? How does it progress and can I stop it? Why do people get it? What treatment 
protocols exist? What clinical trials are in progress? How is knowledge in the field evolving? I 
found medical education sites, open-source research repositories, and sites from organisations 
involved with cancer and leukaemia care.    
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Medical education sites were useful in the first instance, particularly in relation to translating 
the acronyms and terms used in lab reports. Sites such as Pathpedia.com, defining itself as a 
‘global pathology resource’, and a ‘unifying concept in pathology’ describes its work online as: 
 
…a comprehensive web-based resource on human anatomical, clinical, and 
experimental pathology. The site serves a target audience including pathologists, 
pathologists-in-training, laboratory professionals, clinicians, medical scientists, and 
medical students. The site can also be useful to general public who want to learn about 
human pathology and medical laboratory tests (Pathpedia.com, 
http://www.pathpedia.com/AboutUs.aspx). 
 
Pathpedia was where I first turned to make sense of my initial diagnostic lab report, with 
particular reference to the term ‘smear cells’16 (otherwise known as smudge cells). Figure 3 
shows a visual representation and textual description of smudge cells taken from the Pathpedia 
site. 
 
 
16 Smear cells, formed when the cell is disrupted during the spreading of the film, are characteristic of CLL, although 
but not pathognomonic (Bain, 2003) 
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[CHRONIC LYMPHOCYTIC LEUKEMIA, BLOOD]. B-cell chronic lymphocytic leukemia is the most 
common chronic leukemia in adults in Western countries. Most cases involve blood and bone marrow 
with or without involvement of lymph nodes, spleen, liver, and other organs. The neoplastic 
lymphocytes are small but slightly larger than normal small lymphocytes and show scant cytoplasm 
and round to slightly irregular nuclei containing clumped chromatin (three arrows). Nucleoli are 
small to indistinct. A characteristic morphologic feature is the presence of “smudge” or “basket” cells 
(two arrowheads) that are essentially neoplastic cells that got “smudged” during slide preparation 
because of the fragile nature of these cells. Compare the cell size of CLL cells with a single large 
granular lymphocyte (curved arrow). 
 
Figure 3: Pathpedia site reproduction slide and accompanying textual descriptor of B-cell CLL showing and 
describing smudge cells. [Reproduction laboratory slides]. [Online] Available at 
http://www.pathpedia.com/education/eatlas/histopathology/blood_cells/chronic_lymphocytic_leukemia_(cll)
_b-cell.aspx [Accessed 12/04/2011]. 
 
Image removed due to copyright restrictions 
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Slowly, I constructed a picture of CLL at cellular level, as it infiltrates body systems, as it impacts 
on psychology, on the quality and length (see prognostic curves in Figure 4) of the lives of those 
who have it. Information was often dated, shaping my uninformed apprehensions with past 
prognostics. Similarly, narratives of hope for changing treatments and potential cure projected 
my understanding of and aspirations for the disease into an, as yet, only partially realized 
future. Then, as now, I suture together these temporally unstable fragments, unpicking and re-
weaving a delicate fabric of understanding as I go.   
 
 
Figure 4: MD ANDERSON CANCER CENTER. Survival of previously untreated patients with CLL, 1980-2002, 
classified by Rai stage [Graph]. [Online] Available at:  http://www.medscape.org/viewarticle/456068 [Accessed 
03/12/11].   
 
Image removed due to copyright restrictions 
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Undoubtedly, things started to make more sense once I encountered support communities as 
hubs where these disparate narratives converged in the communications of other people 
experiencing CLL. That I was not alone in a small private hell (as it felt at the time) was a 
revelation.  More useful still was the observation that these hubs forged multiple connections 
between medical, psychological, pragmatic, aesthetic, alternative, existential, employment-
related, economically oriented, and social narratives surrounding CLL. Here I could lurk, post, 
ask, and learn about a multiplicity of narrative CLLs. I could map translations from one site to 
another. For example, what does the sophisticated prognostic testing made possible by 
advancing genomic understanding, and set out in the kind of research papers online shown in 
Figure 5 (see below), mean when it translates into probable disease progress for a member 
writing online? What will it mean for me?  
 
 
Julia Kennedy 
40 
 
 
Figure 5:  BOTTCHER (2014) ‘Paving the Road to MRD-guided treatment in CLL’ [Screenshot].  Blood Journal 
[Online] 123 (2) 4.  Available at: http://www.bloodjournal.org/content/123/24/3683?sso-checked=true  
[Accessed: 12/05/2015]. 
 
I cut my teeth on the US based ACOR dedicated CLL community (listserv), before finding the UK 
based Macmillan’s CLL support group some weeks later. The Macmillan site interested me as a 
hub of collaborative connection between the multiple facets of CLL online, as a site where I 
could draw on Law and Singleton’s observations concerning the multiple enactments of liver 
disease to bring CLL on the internet into hubs “in here”, tracing the spokes to the rims “out 
there” (Law, 2004:160). 
 
Mindful of Christine Hine’s advice to maintain suspicion in the face of seemingly comfortably 
defined technological sites (cited in Markham and Baym, 2009:4) it wasn’t my intention to view 
Image removed due to copyright restrictions 
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this as my site per se, but as a point where various objects of CLL online come together through 
the community dialogue.  The sites converging at this hub include support communities around 
the world, institutional and independent advice sites, research databanks, personal blogs, and 
health insurance information. The following three click network graph (Figure 6) taken from 
online network visualising software site TouchGraph shows just a fraction of the sites that 
connect to the Macmillan site17.   
 
 
Figure 6: TOUCHGRAPH (2012) network connections to Macmillan CLL site and related searches [Network map]. 
[Online] Available at: www.touchgraph.com/seo/launch?q=macmillan%.20cll [Accessed 24/11/2012]. 
 
 
17 Due to the semi-private nature of the disease specific groups on the Macmillan site, it was not possible to make 
the CLL forum the centre of the site, but the basic early stage network representation enables a visual overview of 
the kind of networks, and of the multiple interests and perspectives represented within a network concerned with 
a singular disease. 
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Each site holds potentially converging and competing versions of CLL and my aim is to identify 
how narrative versions of these are mediated and translated across key nodes. I am interested 
in all of the narratives enactments/narratives of enactment co-existent in the ongoing struggle 
to shape CLL. They sit alongside each other, add to or displace each other, intersect and 
interfere with each other in a number of ways.  The ethos of multiple sites instilled from the 
outset has remained consistent, although the scope evolved as the human actors in my 
research network began shaping my design decisions as outlined in the following section. First, 
though, I have included a brief consideration of TouchGraph and its role as an important 
mediator for translating data in the project. 
 
A Word about TouchGraph and other Software 
 
Throughout this work, I have used images from data visualization company TouchGraph to 
demonstrate connections and links between key nodes and the webs they mesh into. The 
services available allow for mapping links between URLs, subjects or authors entered as a 
search on the TouchGraph site18.  Once the search object/s are entered, connections to related 
top domains are mapped as seen above. Data are also presented as a list of ‘related searches’ 
as shown above, a tabulated list of ‘top domains’, and the search results themselves with 
textual descriptor and URL (see Appendix 1 for expanded example). Largely a commercial 
product, aimed at companies wishing to access visual metaphors for their online networking, I 
 
18 The company describes their product thus: “Visualization goes beyond lists to reveal larger-scale patterns. 
Results are displayed in context – one can see how they fit into the big picture, how they relate to each other, and 
how they connect to metadata such as subjects and authors.” (Touchgraph, 2015) 
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have borrowed the basic free demo version to demonstrate the rich connections between CLL 
sites online. Unarguably, this tool works better in an interactive online context where the user 
can continue (infinitely) clicking into the various nodes to expand the map. Those reading this 
work online with Java installed on their machines can click on the URL to access the maps and 
continue the network mapping in order to make use of these important visual metaphors for 
enhancing the networking points I am making in this work. All readers can consider the part 
that technological software such as TouchGraph, Blogger, and SurveyMonkey, and the 
hardware that hosts them have played as essential non-human actors in making this a 
successful research network in its own right.  
 
Translation: Launching the Project: Inviting Participation    
 
Aiming to trace the connections between narrative objects and actors representing CLL online, 
and to identify key versions and sub-texts of CLL in those networks, I initially decided to 
observe, record, and map new and archived material posted by members to the Macmillan CLL, 
SLL, and HCL community from my date of diagnosis over a three year period. These included 
personal narratives, research papers, medical education texts, videos, blogs, advice from official 
support agencies and campaigns, lab reports, and news reports. At this stage I also decided to 
chapterise the work according to key themes addressed in the field. These were broadly 
divisible into concerns with diagnosis; prognosis; treatment; and survival. The latter was later 
dropped as a discrete chapter from the PhD due to word count limitations, although many of 
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the issues inherent in survival narratives are addressed in the remaining chapters 19, and it is 
my intention to publish the thesis as a book, including chapters on circulating narratives 
surrounding  ‘Survival’ and ‘Dying’.  Some of the themes produce more activity in the networks 
than others. Over the course of this four-year project, huge advances have been made in the 
treatment of CLL. I also found myself undergoing treatment during the project when my disease 
took a sudden and unexpected aggressive turn in 2013/14. Consequently, the Treatment 
chapter is considerably longer than the other chapters. I made the deliberate decision not to 
attempt to organize the multiple associations of the longer chapters into perhaps neater, but 
potentially reductive sub-themes, as the diverse, open-ended chain of thematic associations 
reflects the real-world rhizomatic nature of the fields studied. Initially concerned that this may 
be daunting for readers, I came to (what I hope proved to be the correct) conclusion that the 
narrative structure created by the Translation/Perspective sections in each broadly themed 
chapter already provides natural breaks for the reader.  
 
Permissions to launch the project on the site were obtained from the online community 
managers. Following Mann and Stewart’s (2000) suggestion for a separate site outlining aims 
and objectives of the research project, I set up a blog where potential respondents could read 
about the project, ask questions, and download consent forms to agree to their postings being 
used in the research (see figure 7). The project was then launched in the community with links 
to the blog (see Appendix 2 for invitation to participate, and Appendix 3 for a screenshot and 
 
19 Further work on survival (and death) in the CLL networks will be undertaken beyond this project however in 
order to make maximum usage of the data collected in the remit of this ethnography. 
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URL for the blog). 
 
 
Figure 7: JULESK (2013). “In Our Blood” Blog set up to inform participants and provide information and consent 
forms [Screenshot] 02/01/2013. Available at: http://julesk-inourblood.blogspot.co.uk/ [Accessed 02/01/2013]. 
 
Despite my best efforts to explain the project and reassure group members about 
confidentiality, I had anticipated some resistance to my dual status as member and researcher 
(Hudson and Bruckman, 2004). The initial trickle of responses were mainly positive, some 
requiring further information, and just one expressing concern that my dual status might 
threaten confidentiality and ability to post freely on the site. Another member insightfully 
interrogated my methodological approach:  
 
You talk of studying the collective 'stories' of the contributors from this forum and how 
the experience shared and support and advice given assists and informs on living with 
the disease … How will that be possible Jules if you don't get unanimous agreement to 
use 'stories and contributions? ...You will be aware that only a small percentage of 
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members actually contribute and there are indeed 'key players...who supply invaluable 
information and scientific updates (anonymous, private message Macmillan site 
22.11.12). 
 
Seeing this as an opportunity to articulate my methodology through interaction in the field, I 
responded in detail (see Appendix 4 for full response). The respondent in question was highly 
research-aware, and my response was pitched accordingly: 
 
I'm not actually looking at dynamics/hierarchies/roles of individuals in the community - 
but at the way we are linking and circulating information, and translating it into our 
everyday experiences. I need some examples of that translation, but I don't need to look 
at everyone's contributions for this to work - it's not an ethnography of the community 
itself, but of the disease as it is broadly represented in the community (Kennedy, private 
message, ibid). 
 
 
A reassuring absence of overt resistance was certainly overshadowed by a general lack of 
engagement at this stage. Initially exhilarated by finally going live with the project, this period 
was something of a ‘reality check’. A number of obstacles appeared that made it seem as if my 
research project as network might actually fail at this point. Was my project interesting enough 
or relevant enough to the community? Were my aims and objectives articulated clearly 
enough? Was the group de-stabilized by my “coming out” as a researcher?  I was forced to re-
think some of my approaches. Primary among those was the issue of how to gain informed 
consent from my respondents without appearing bureaucratic or threatening community 
privacy. To comply with the vulnerable subject research guidelines set out by the ethics 
committee and outlined in the following section, respondents faced the onerous process of 
downloading, signing, and returning consent forms. Although several determined members 
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completed this process (or variants of it such as e-mailing me consent), others disengaged. At 
this moment the research project as network began to fall apart. The issue of consent needed 
approaching in a different way or my project (like Aramis) might turn to rust as translations 
stuttered due to an excess of passive intermediaries over active mediators. The following 
section reviews some of the contexts and inscriptions I engaged with as a researcher during the 
process of moving the project forward.  
 
Perspectives: Ethics in Online Research 
 
The project aims demand close observation of the practices and postings of those engaged in 
selected CLL networks, and require informed use of participant postings, auto-ethnographic 
input, and broader observation of emerging traces and subtexts in the networks through digital 
fieldwork20. As virtual ethnography evolves into a distinct field exploring the cultures, practices 
and technologies that shape our everyday lives in a digital era, researchers encounter a new era 
of ethical challenges. These are particularly acute in online work with those considered 
‘vulnerable’. Whilst ‘vulnerability’ is an imposed assumption that may be challenged by those to 
 
20 In digital ethnography, the concept of ‘fieldwork’ is elastic, stretching traditional definitions to accommodate 
participant observation in a range of virtual contexts. Annette Markham (2012a) acknowledges that such radical 
adjustments to the activities of fieldwork are required in digital contexts that ‘they hardly resemble fieldwork 
anymore’, advocating scrutiny, problematizing, and systematizing of the ‘messiness’ of digital methods in order 
that innovation in the field is afforded visibility and validity. See Annette Markham for her pertinent blog post 
‘Deconstructing the Term Fieldwork’ concerning the need to reconfigure the perception of “fieldwork” in digital 
research environments (Markham, 2012a)  
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whom it is applied, in research guidelines21 it applies to subjects whose minority status, ill-
health, age, or infirmity may leave them open to physical, emotional or psychological 
exploitation. Eliciting informed consent, protecting confidentiality and privacy, and considering 
the risks and benefits of a study in contexts of fairness are all considered particularly significant 
when working with groups who may be vulnerable (Flaskerud, J.H. and B.J. Winslow. 1998: pp 
69-78) 22.  
 
As discussed, online health communications provide rich research data, some even claiming 
that more authentic narrative accounts can be found online than in formalized research 
settings (Suzuki and Beale, 2006; Grinyer, 2007). Others suggest that this provides opportunities 
for more ethical approaches to data collection than traditional face-to-face settings (Lewis, 
2006; Nosek et al, 2002). Online ethics is not without its challenges however. Issues of privacy, 
informed consent, definitions of vulnerability, location, autonomy, representation and control 
play out in a highly contested arena of ethical decision making online for which very few 
definitive guidelines exist.  Researchers are still picking their way across this ethical minefield, 
and each section of this chapter is set against that backdrop, addressing ethical issues as they 
arise in the methodological evolution of the project.   
 
 
21 See ESRC Framework for Research Ethics (2010), Updated September 2012.  
22  See Lancaster University’s excellent resources for social science research ethics for further discussion of 
vulnerable groups and individuals in research contexts http://www.lancs.ac.uk/researchethics/4-1-intro.html 
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In terms of confidentiality, arguments persist around definitions of privacy and ownership of 
content posted online. Bruckman questions the relevance of the human participant model of 
ethical approaches to internet research altogether, espousing instead a kind of creative 
commons of online artefacts. There are caveats though, where password protection, website 
policy prohibition, or ‘highly sensitive’ material are concerned (Bruckman, cited in McGeehin 
Heilferty, 2010:950). Bassett and O’Riordan see the privacy constraints of the human subjects 
model as potentially unethical if applied routinely in internet settings, emphasizing instead a 
‘political imperative for visibility’ through advocacy for those under-represented elsewhere 
(Bassett and O’Riordan, 2002: 243). Shani Orgad (2007) reflects this in relation to her work with 
online breast cancer support groups in her view that private communications can act to limit 
understanding of what it means to live with a particular disease.  
 
Tensions clearly exist then between definitions of ‘vulnerable subjects’ and ‘sensitive material’ 
inscribed in the human subjects approach, and the political imperatives of an advocacy 
approach. For many closed group members, being advocated for by external (or even member) 
researchers may not take priority over a sense of trust and control over who shares their 
stories. Site is also an issue. The Association of Internet Researchers Ethics Working Committee 
(Markham et al., 2012) calls for attention to the location of the research, differentiating 
between blogs, listservs, chatrooms, semi-private communities and so on; the nature of the 
participants, and the potential risks and benefits of the research. In each of these locations, 
members’ expectations of control over who is in their audience will differ. 
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Once a researcher has access to any respondent’s narrative it is vulnerable to all kinds of 
translation. McGeehin Helfeirty  (2010) identifies six key potential risk areas for those writing 
about illness online specifically:  
 
(1) the potential for the creation of ‘hero’ stories; (2) the potential to interfere with the 
author’s autonomy; (3) the multi-layered nature of ‘vulnerability’; (4) lack of proprietary 
control over life event descriptions of serious illness published online; (5) the ambiguous 
nature of the participant and object of the research; and (6) the relative ease of access 
to the writing (McGeehin Heilferty, 2010:951). 
 
 
Annette Markham expands on the threat to autonomy implicated above in observing the 
potential to “alter the narratives merely by seeking informed consent to study them” (ibid), an 
anxiety expressed by one of my own respondents:  
 
My only concern is that my utterances are very very un-earthshattering, and I worry that 
I will be aware of that when posting on the Mac site in the future and maybe (very 
unintentionally) change the way I respond (Macmillan Community Respondent 1, 
November, 2012). 
 
Such insight into the potential pressure to ‘perform’ in postings lends weight to those seeking a 
more nuanced view of the role of performativity more generally in the interpretation of illness 
narratives (Atkinson, 2010). Other scholars bring serious consideration to issues of 
representation in illness narrative research, particularly surrounding the interpretation of 
metaphor in illness narratives (Frank, 2008; Sontag, 1991). McGeehin Heilferty suggests that 
clinicians and researchers address such challenges by positioning themselves with respondents, 
rather than acting as a spokesperson for them. To do so demands sensitivity in political 
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advocacy approaches, and this chapter will address that in relation to my own role as a 
politicized member-researcher in due course. Next though, I focus on my failing project 
network and how I overcame the ethical obstacle of gaining consent to keep it alive.  
 
Translation: From Hub to Nodes with Consent 
 
Around this time CLLSA UK23 launched a new site hosted on HealthUnlocked, a community 
network site that currently boasts around 70,000 members, sharing more than 800,000 health 
experiences according to its website24. Membership uptake on the site grew rapidly in the first 
few weeks, with a global mix. Although a significant element of cross-membership can be 
traced between the CLLSA site on HealthUnlocked and Macmillan sites, the virtual architecture 
of the former seemed to lend itself more intuitively to a research based exploration. The 
inclusion of polls, blogs, and direct questions into the design of the site itself offers a range of 
discursive possibilities for discussing CLL, underpinned by the spirit of inquiry that characterizes 
the HealthUnlocked ethos (see Figure 8).  The site has gone from strength to strength with 
constantly growing membership, and is a successful network held together by key actors, some 
 
23 The CLLSA UK is a registered UK charity with a membership of around 900 set up in 2005 by a group of four CLL 
patients (Robert Cork, Chonette Taylor, Howard Pearce and Sue Waldie) who initially made contact over the 
internet. The main aim of CLLSA is to provide help and support for patients with CLL (and similar related 
conditions) and their carers. (CLLSA UK 2014a)  
24 The site hosts over 170 condition and wellness communities from established organisations such as the CLLSA 
UK. The CLLSA site invites members to write and respond to blogs, to ask questions and seek advice from the rest 
of the community on a range of issues experienced by those living with the disease, and to post and respond to 
short polls about those experiences  (Health Unlocked, 2014). 
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of who feature large in the coming chapters. 
 
 
Figure 8: HEALTHUNLOCKED CLLSA (2013). Member  Homepage [Screenshot]. [Online] 21/01/2013. Available at: 
cllsupport.healthunlocked.com [Accessed 21/01/2013]. 
 
Aside from the obstacle of gaining written consent, it was also becoming clear that focusing on 
the Macmillan site alone was overly restrictive. This highlights a need for researchers to 
acknowledge a high degree of flux and evolution in online support communities as field. 
Memberships change, old sites might fail or weaken as networks as new sites emerge, and 
people “drift” between nodes. Useful research could be carried out using the methodological 
design I experiment with here to explore exactly why some networks weaken and others grow 
stronger, but that is not the prime focus of this iteration of my research. 
 
Image removed due to copyright restrictions 
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Shifting the focus on the Macmillan site from my central “hub” to just one “node” in a broader 
network of CLL communication online, I expanded the range of the project’s aims for a dynamic 
multi-sited ethnography of CLL online. If single sites as points of convergence are too restrictive, 
and people move constantly between nodes, then it made sense to follow Marcus (1998) when 
he says that creative ethnographers need to  “follow the story, follow the people, follow the 
metaphors” (cited in Markham, 2013). I also wished to follow metonymic chains of association 
and likeness. I would follow the narratives of CLL across the networks, identifying key nodes, 
connections, actors and themes. To target as many of these as possible, I needed to launch my 
project into several of the key global communities – not just one. 
 
Starting with HealthUnlocked, and drawing on my experience of launching the project on the 
Mac site, participation was invited from the 160 plus25 membership through the site’s private 
messaging facility.  The invitation was re-written in response to a perceived lack of clarity in the 
first iteration launched on Macmillan (see Appendix 5 for the revised version). Launched on 29th 
December, 2012, I received around 20 responses from people willing to participate over the 
following days. 
 
Two key obstacles persisted, and my responses to them changed the shape and impact of the 
project as network significantly. Firstly, gaining informed consent online continued to present 
 
25 Membership figures on the site recorded as 1700 plus in January, 2015 (CLLSA UK, 2015). 
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challenges26.  Eventually, all information from the consent form approved by the ethics 
committee was transferred to a secure, encrypted online consent form hosted via online survey 
company SurveyMonkey (see Appendix 6 for a sample consent form), and all respondents were 
messaged with information and links to the online form. I perceived this approach to be more 
accessible, less laborious, and offering a higher degree of confidentiality.  Respondents were 
wholly positive, one in particular expressing relief:  
 
Well done! I wondered whether to respond earlier about how your requirement to 
print, sign, scan and email the consent statement was quite likely a major factor behind 
your limited responses and I see you’ve successfully overcome that (AussieNeil  3 Jan 
2013). 
 
 
Secondly, several people replied stating that they were keen to actively participate, but that 
they would rather contribute their experiences directly to me via e-mail in response to 
questions, rather than consent for me to use their online postings. As a group member myself, I 
understood this desire to retain control over contributions, and maintain autonomy, freedom 
of expression and confidentiality of their community online postings (McGeehan Heilferty, 
2010; Markham, 2008). On the strength of this feedback, I designed a questionnaire, described 
in detail in the next section. 
 
 
26 Respondents were asked to consent by copying and pasting a statement from the invitation into their response 
message, obviating a need for hard copy consent forms, but problems persisted with a lack of consistency in 
responses to this request. 
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Including the CLLSA Health Unlocked site, and opening up online consent forms and 
questionnaire had the unexpected result of attracting global attention as networked CLL 
patients around the world became aware of the project and actively sought inclusion. Within 
weeks the project had been launched on the ACOR list, through Facebook CLL support site Bad 
to the Bone, and through dedicated support site CLL Canada. Several high-profile CLL bloggers 
and advocates also expressed interest and consented to my use of their postings (see Appendix 
7 for a selection of support messages). Obstacles removed, nodes added, networks opened up, 
and this PhD project turned in a matter of weeks from a failing research object to a vibrant 
network actor in its own right.  
 
Translation: Accommodating Respondent Needs for Privacy (A Survey is 
Born)    
 
The need for a more specific, direct form of eliciting information to enable those who didn’t 
want their postings used as data was a significant issue that I hadn’t considered in my original 
project design. My original vision had been one of mapping respondent postings to selected 
sites in their ‘natural’ day to day practices, and around 50 respondents consented to this 
making my aims viable. However, the fact that many more people didn’t want to participate in 
this way whilst expressing very real desires to be part of the project led me to reconsider. Not 
wishing to exclude willing participants to the project by imposing a rigid methodological 
approach to data collection led to the introduction of an online survey also using 
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SurveyMonkey, and launched in the same e-mail as the consent form.   
 
Asking the Right Questions 
 
The survey allowed for some focused questions surrounding the online practices of 
respondents in relation to their disease. This was an unexpected bonus of the questionnaire 
element as it allows for incorporation of respondents who don’t post regularly online. 
Functioning as a mediator, the questionnaire both extended the range of data collection and 
created visibility in the network for some previously unseen actors27. The first eight multiple 
choice questions elicit data on online practices through interrogating sites used; levels and 
types of participation; and whether internet use translates to effective coping strategies and 
clinical relationships. This allowed for identification of key nodes and actors in CLL online, and 
how online narratives might produce effects for managing the disease in everyday life.  
 
Questions 8-14 are open questions, inviting comment on the key themes of living with CLL 
already identified through fieldwork.  This was largely a case of identifying the major concerns 
for discussion surrounding experiences of CLL online, and following narrative chains of 
associations to some of the broader social, cultural, and scientific contexts relevant to each. A 
condensed list is provided here as a framework for question 8 through to 14: 
 
 
27 In this way, the research tool itself becomes an actor - literally a ‘body’ of research, a concept that can be more 
broadly extrapolated to the status of the research project as a whole as a ‘network’ in its own right.   
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• Dealing with diagnosis 
• Understanding and coming to terms with prognosis 
• New treatments and expectations for the future 
• Learning to live with CLL 
• Impact of chronic leukaemia on perceptions of time 
• Impact of disease on relationships 
 
Each question asks the respondent to write as much or as little as they like about the issue, and 
to identify if and how they have used the internet to help negotiate it. Question 15 seeks 
comments on any areas the respondent feels I may have overlooked, allowing for identification 
of any versions or sub-texts of CLL not already recognized through fieldwork. Responses from 
these key themes were eventually organized under the streamlined chapter headings of this 
work as Diagnosis, Prognosis, and Treatment, with a dedicated CLL Online chapter to outline 
the practices of CLL activity online and its contexts.  
 
Dhiraj Murthy (2008) extols the virtues of online questionnaires as an element of digital 
ethnography, citing ready access to large data sets without the need for transcription, and the 
relative ease of implementing a range of structured responses, adaptive questions, and point-
and-click responses (Murthy, 2008: 842). Gunter et al. (2002: 233) have also observed a 
tendency towards speedier and higher rate of return than with traditional survey methods, and 
‘richer’ responses to open-ended questions (ibid). The survey collection closed early in 2014 
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with 260 people starting the survey and a completion rate of 184 (72.7%) (See Appendix 8 for 
sample copies of the completed survey). 
Translation: Managing and Analysing the Data 
 
Through daily fieldwork, I was able to identify and selected the key narrative flows that form 
the Translation sections in this work. Blog excerpts, conversational threads, research papers, 
news reports, institutional documents and so on were observed daily over a four year period 
according to narrative type and source, the particular enactments of CLL they speak for, 
emergent themes, and intersections with other textual actors in the network.  The Translations 
in this work were selected as particularly relevant examples of the multiple narrative actors and 
enactments I encountered, and their various intersections. The criteria was to include as many 
enactments and translations as possible to demonstrate the multiple ontologies of CLL online, 
and to demonstrate network effects between enactments where possible. 
 
As far as data from the questionnaire is concerned, SurveyMonkey’s built-in analytical software 
enables downloading of responses as completed individual questionnaires, or by numbered 
question, allowing for individual case studies as well as drawing out universal narrative themes 
or sub-texts. The closed questions have contributed quantitative secondary data revealing the 
major networks, and some qualitative assessment of online practices.   
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Having inflected the questions toward the key themes of narrative interest already identified 
obviated the necessity for coding data from scratch, and allowing for data alignment with 
fieldwork, although data analysis remained alive to emergent possibilities not already noted. 
The survey produced a fascinating overview of internet use among CLL patients, identifying key 
nodes in the network, key actors, patterns of online behavior, key themes of concern for CLL 
patients, and over 100,000 words of open-text responses from CLL patients globally. As such, it 
became a central pillar of data collection for this work, and represents one of the major CLL 
specific research projects of patient behaviours and opinions undertaken to date. The themed 
findings and analysis chapters are preceded by a chapter dedicated to mapping the survey 
responses specifically, and individual responses are threaded through all sections in an attempt 
to layer their voices with the multiple other textual objects making up each themed section. 
One of those textual objects is my own story, and the following perspective section explores 
some of the methodological contexts for that. 
Perspectives: Autopathography as Auto-Ethnography 
 
As the story of this project so far has revealed, my own experience of disease is central to the 
imperatives for, and politics of my research. However, my methodological approach 
acknowledges that my particular narrative object of CLL is mutable, and that I am just one 
amongst a range of actors whose stories circulate online. This section will address contexts for 
accommodating my own story into the ontological politics of my research design, starting with 
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some of the literature on illness narratives as a form of identity re-construction.   
 
The task of transition to “becoming” seriously ill is a process of adjustment to the changes 
imposed on lifestyle or identity by a diagnosis of illness enacted through the body28. The pre-
diagnosis notion of self or selves is challenged by both the ‘othering’ effects of the language of 
illness, and changes imposed on the body by physical symptoms. The sick move through the 
world in bodies foregrounded by their failings, flaws, and fault-lines, in which time and being 
are circumscribed by the knowledge and practices necessary to manage the impact of the 
compromised body on daily routines. Such embodied change, it is suggested, must be 
accommodated somehow into an ongoing “'story' about the self” (Giddens 1991: 54). Easy 
assumptions behind assertions that everyone has a need to re-write selves and identities in ill-
health are contestable as will be seen later in this work, but as the literature reveals, 
contemporary society offers a number of generic ‘templates’ for illness narratives (innocent 
victim, deserving victim, warrior, restitution, passive recipient, stoic to name a few) which are 
variously taken up, problematised, or rejected outright by those writing about their own or 
others’ experiences. A growing field of practice in offline and online contexts, autobiographical 
narratives of illness or disability constitute a generic form of literature in their own right, one 
that G. Thomas Couser refers to as ‘autopathography’ (Couser, 1997: 5). Autopathography that 
relates personal experience of illness to broader cultural questions is in a sense a form of auto-
 
28 See David Morris’s (2008)  work on Diabetes, Chronic Illness and the Bodily Roots of Ecstatic Temporality for an 
in-depth consideration of phenomenological understanding of chronic illness in relation to time and the body. In 
this paper, Morris draws on Merleau-Ponty’s  Phenomenology of  Perception (1962), and Heidegger’s Being and 
Time (1962) to explore implications for self-management of chronic illness. 
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ethnography - a methodology for exploring what it means to live with disease for those who are 
actively engaged in doing so. As illness progresses, so one enters new territories that invite 
translation, almost as a travel writer where the encountered inhabitants of the ‘discovered’ 
world are circulating actors (subjects and objects) – online in my case. Translations are less 
semiotic or sign-based (although, as the reader can see, I discovered many diagrammatic 
representations in my journeys) than affective, sense- and bodily-based. The encounters with 
new territories and the translations necessary for understanding, despite their - often virtual – 
(de)natures, are necessarily felt in the body as ‘foreign bodies’ (Lingis, 1994).      
 
As someone actively engaged in living with disease, I have found autopathography to be a 
useful method for exploring what that means for me. I have practiced it in personal writing 
about my experiences, some of which remains private, but much of which has been posted in 
support communities, or written into this project. But what place can autoethnography occupy 
in a multi-sited ethnography? Being a participant observer living with the disease I am 
researching leaves me queasy when encountering the work of ‘healthy’ researchers seeking to 
externally impose forms of narrative coherence on the stories of their ‘sick’ respondents. This 
can be read as a research network effect in itself – a particular enactment of illness narratives 
that produces the results it is looking for rather than uncovering them as a truth that is waiting 
to be found29. Resisting a tendency towards positivist claims of universal truths underpinning 
 
29Mike Bury (2010)  wonders in relation to his earlier work on biographical disruption whether concepts of 
narrative construction, and re-construction in illness are merely artefacts of the research process itself that can’t 
really lay any valid claim to the ‘realities’ of individual experiences (see Reeve et al, 2001: 210  for further 
discussion on Bury’s insightful re-visiting of his earlier conclusions).   
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dominant methods, postmodern ethnographic method challenges the realist conventions and 
objective observer position of standard ethnography. Similarly, postmodern autobiography calls 
into question the notion of a coherent, individual self (Reed-Danahay, 1997:2). Identities are 
characteristically seen in such work as constructed and multiple, ‘subject to’ rather than 
‘subjects’, and in contemporary feminisms, often in subjection. For pathographies, selves may 
be abject too (Kristeva, 1982). 
 
Synthesizing ethnography and autobiography, autoethnography emerged as a response to the 
‘crisis of representation’ in dominant positivist methodologies. In an approach to research and 
writing that seeks to “describe and systematically analyse (graphy) personal experiences (auto) 
in order to understand cultural experiences (ethno)” (Struthers, 2012: 23) the methodological 
outcome of auto-ethnography is at once ‘process and product’ (Ellis et al., 2011:1).  This is 
evident in my own project that incorporates my unfolding experience of living with disease and 
the resulting relationships formed with other actants (process) into the research artefact itself 
(product). However, I remain alive at all times to the fact that my presence as one actor in a 
multiplicity is no guarantee that I will keep my interpretive hands off the others. Resisting that 
can only ever be a constant work in progress if we accept that “the self is porous, leaking to the 
other without due ethical consideration” (Tolich, 2010:1607).  
 
Autoethnographic method is in itself a contested practice. Some see it as the goal of reflexive 
ethnography to “fully acknowledge and utilize subjective experience as an intrinsic part of 
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research”30 (Davies, 1999: 5). Visibly incorporating subjective experience into ethnographic 
work can be interpreted disparagingly as “author saturated texts” (Geertz, 1988) ceding 
sociological relevance to self-absorption. In response, Leon Anderson suggests synthesizing 
evocative, deeply personal ethnography with more traditional ethnographic practices, listing 
key features of a model for ‘analytic autoethnography’:  
(1) complete member researcher (CMR) status, (2) analytic reflexivity, (3) narrative 
visibility of the researcher’s self, (4) dialogue with informants beyond the self, and (5) 
commitment to theoretical analysis (Anderson, 2006: 374).  
 
 
Although I make no claim to pure ‘analytic autoethnography’ in this project, I could certainly 
satisfy all five criteria at face value31, although notions of membership are complicated in multi-
sited ethnographies where a researcher can be a member of a larger, more diffuse network 
without being a bona fide member of some of the more local nodes in the network. However, 
there is a sense in Anderson’s methodological aspirations of research driven to a particular 
endpoint, rather than an exploration in its own right as privileged by those narrative 
approaches that resist abstraction and explanation. Phenomenological experiential accounts 
are regarded by the latter as wild, unruly, and rebellious forms of inquiry, locating ‘ethnography 
as a journey’ as opposed to a teleological ‘destination’ (Ellis and Bochner, 2006: 431).   
 
 
30 Poststructuralist feminists such as Hélène Cixous (Cixous,1981) problematize such ‘felt self’ experience where 
the ‘feminine’ self may best be expressed as an impression of expressed breast milk, as a gesture of succour, and 
as an ‘invisible ink’ that is the trace of ‘mother’s milk’. The subjective experience may then never be gathered in as 
capital, as is common in a patriarchal model, but is constantly expressed as succour, as (m)othering. 
31 although arguably the notion of ‘complete membership’ requires interrogation, as no two individuals are likely 
to share all characteristics comprising their membership (Buzard, 2003) 
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Denzin’s view of autoethnography as exceeding subjective account in its attempt to “reflexively 
map multiple discourses that occur in a given social space” (Denzin, 1997, cited in Spry, 
2007:727) reflects my desire to map, not analyse, my presence as one actor amongst the 
multiple actors populating my research. It acknowledges the fluid subjectivities, multiple 
identities, shifting cultural boundaries and axes of power contingent on notions of self and 
society in late modernity.  The following very brief Translation section incorporates exchanges 
between me and the ethics committee surrounding their initial concerns about my 
autoethnographic presence in the work. It demonstrates once again a moment where the 
inscriptions and traditional practices of enacting research presented as a temporary obstacle to 
my progress, and how I engaged with those inscriptions to produce network effects enabling 
the work to progress.  
Translations: The Ethics of Autoethnography  
 
I have already acknowledged that being a participant observer doesn’t preclude me from a 
potential, however unintended, to position myself at the top of a hierarchy of actors, nor does 
it exclude me from the power dynamics of my parallel position as a university lecturer and 
academic. Despite these challenges, commitment to visibility for multiple actors involved in CLL 
online, including myself as an individual with privileged access to the networks, is a significant 
factor in achieving my research aims.  
 
Julia Kennedy 
65 
 
When my proposal went to the RNUAL Ethics Committee in 2012, the response made a number 
of observations, prime among them being the suggestion that “the applicant should consider 
the effects of disclosing her own circumstances on this matter” (RNUAL Ethics committee 
response, 2012). Implicit here is the notion that my declared status as a CLL patient might 
actually prove coercive in its own right. The following excerpt is taken from my response (see 
Appendix 9 for full transcript): 
        
...my own status as a person with CLL cannot be concealed  within the current project 
design ... The spirit of this research as a collaborative endeavour within an already 
established group of which I am an active member is fundamental to achieving my 
aims...(Kennedy,2012).  
 
                  
In the context of continuing reflexivity surrounding my dual role as member/researcher, strong 
emphasis is placed on the importance of my status as a “native researcher” (Ellis, 2004; Denzin 
and Lincoln, 2008). I could not see a way that I could progress the work without disclosing my 
status as a CLL patient, not least as I would have had real trouble gaining membership to the 
groups set up for CLL patients and carers in the first place, apart from the factor of the 
dishonesty I perceived to be inherent in concealing such a significant fact. 
 
In crafting a method that assembles the nuanced mapping of material relations through ANT 
alongside the raw auto/biography of material reality, I hope to create productive sites for 
political work at points where the two methods both converge and clash.  Autopathography is 
an important political position here, but rather than trying to read all of the actors through the 
lens of my own experience, I want to flip the point of view so that my own narrative becomes 
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just one of the textual actors in field of multiple enactments.  In network terms my presence 
can be seen variously as actor, network, and mediator, depending on my role at various stages 
and sites and of the work, and I constructed a detailed response to the committee’s concerns 
based on my methodological position as Appendix 9 demonstrates.   
 
After at their next meeting, the committee responded in full on 13th July, 2012, informing me 
that my work was cleared to proceed, that they were  impressed with my defence of a fully 
disclosed auto-ethnographic position in the work, and suggesting that  “the applicant 
incorporates a full ethics section into her PhD or produces a journal article on this topic, as her 
discussion and resolutions seem to advance the field rather than merely comply with it” 
(Extract from the minutes of the Research Ethics Sub-Committee’s consideration of revised 
research ethics application submitted in response to the Committee’s comments made at their 
meeting on 21st February 2012 (see Appendix 10 for a full transcript). 
 
The project was back online, and the following Perspective section outlines briefly the evolution 
of the methodological field of ANT into current ontological approaches informing my design 
decisions to position my disclosed autoethnographic role as one of the multiple objects I want 
to work with.    
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Perspectives: ANT and the Ontological Turn 
 
Disease itself can be read as a concatenation of technological and human knowledge and 
practices produced and held together by multiple narratives. Diseases as entities are at once 
scientific, social, political, and fundamentally corporeal. The narrative semiotics on which ANT 
are based allow for bringing together bodies, texts and hardware to explore how together in 
networks they produce the practices and inscriptions on which knowledge and experience of 
disease is based.  ANT provides a method for fine-grained readings of what passes between the 
social and the technical in the production of technological knowledge and behaviour32.  Hybrid 
networks of humans and non-humans acting on equal footing produce techno-scientific 
knowledge, disavowing bifurcations such as natural/technical, human/non-human and focusing 
instead on the network transformations and translations that produce technological knowledge 
and practices. Some scholars have read techno-cultures themselves in this way (Plant 1997; 
Haraway 1997, Bassett, 2007). This approach is not without its critics. ANT (1990) has been 
criticized for being overly concerned with the ‘how’ of network associations in its attempts to 
show the embedded-ness of technology in keeping human relations hanging together, thus 
effacing the ‘who’ or the ‘what’ (Couldry, 2004).  Through mapping sites in which political 
questions might be posed, rather than attempting to answer pre-determined questions through 
the mapping itself, some critics see ANT as copping out with an “I map, you decide; my map is 
 
32 In ANT the important work of peeling back and pinning out the layers of multiplicity, consensus, tension, and 
fragility that form the solid objects of institutions and knowledge is assumed to be more effective in catalyzing 
progressive awareness and potential change, than the process of suturing them together with existing social 
theory. 
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neutral” approach (Saldhana, 2003: 426). Saldhana wonders whether the ‘politics’ of simply 
revealing the material messiness of phenomena doesn’t ultimately serve to “put the researcher 
outside the field, just like in positivism”33 (Saldhana, 2003: 426).  
  
I can certainly engage with these criticisms as a researcher with a fundamentally personal- 
political investment in my work. 1990 ANT 34 is a little too bound in its rigid terminology, and 
just a little too flat in its ontological approach for me to work with comfortably. I tried, but it 
was with the post-1990 work of the ‘ontological ’turn that I felt most at home, where I felt that 
I could attend to matters of concern that I and others engaged in CLL networks as human actors 
rub up against every day. 
 
Digital illness narratives often present as storied assemblages of the human and non-human 
objects that make up the disease experience. They become complex accounts of the way such 
networks of objects produce material effects on individuals and at the same time they operate 
as circulating objects in disease networks online with the potential to transform and translate 
knowledge in their own right. This work has so far acknowledged the role of technological, 
institutional and professional practices inherent in multiple enactments of CLL, and seeks to 
make them visible in the coming chapters. Those multiple enactments include patients’ 
autopathographic accounts articulating what happens when the technologies of disease 
 
33 Again, for a fuller For a fuller explanation see A. Saldhana’s deconstruction of some of Law and Mol’s work in his 
(2003) Essay ‘Actor-Network Theory and Critical Sociology’. 
34 For an overview of the evolution of ANT, including a definition of the term ANT 1990, see Sanna Rimpilainen’s, 
useful (2009) paper, ‘Multiple Enactments?’ 
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intersect with or produce material human responses such as fear, grief, loss, pain, hope, relief, 
isolation and confusion. The ANT insistence on absolute symmetry between human and non-
human actors can elide network effects and practices in the shadow of its dominant quest to 
identify the immutable mobile objects of scientific knowledge35.   
 
The ontological turn, led by Mol (2002), and Law and Singleton (2004), locates objects as 
potentially mutable, and mobile, yet still hanging together. The complex glossary of ANT is 
superseded by new metaphors implying flux, and the ability for objects to travel across 
networks in different ways, and in multiple enactments. Fire objects (Law and Singleton), 
multiple objects (Mol), or fractal realities (Watson, 2010) characterize evolutions of ANT that 
seek to configure new forms of object relations. Law and Singleton, for example, distinguish 
between ‘fluid objects’ that change relatively gently and ‘fire objects’ that are more unstable in 
the sense that they show radical discontinuities. This evolution of conceptual mapping of 
objects states is important as it allows ANT to evolve approaches beyond earlier criticisms, yet 
acknowledge that current social science methods are poor at dealing with a number of facets of 
social life – for example: 
 
 
35 Very basically speaking – immutable mobile objects are inscriptions that remain consistently anchored into the 
centre as they cross borders, and combine with other objects. Jones (2005) uses the example of a map which is “ 
mobile while the actual land is not. It is immutable while a native man’s drawing on the sand is not. So by drawing 
a map on paper, you bring the remote land back to the center while you are not really taking the actual 
land with you” (Jones, 2005:16). This notion is often used in the case of scientific imagery, but nuanced by Kaiser 
(ibid) who argues that such imagery (diagrams, graphs, phots and so on) demonstrate a ‘plasticity as they circulate 
across different research territories. For a full explanation of Immutable mobiles in scientific research see 
Professor David Jones’s (2005) paper In Conversation with Bruno Latour:Historiography of “Science in Action”.  
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• The distributed (that is to be found here and there but not in between, or that 
which slips and slides between one place and another). 
• The multiple (that which takes different shapes in different places, with the non-
causal, the chaotic, the complex). 
• The sensory (that which is subject to vision, sound, taste, smell). 
• The emotional (time-space compressed outbursts of anger, pain, rage, pleasure, 
desire, or the spiritual). 
• The kinaesthetic (pleasures and pains that follow the movement and 
displacement of people, objects, information and ideas).  
(Law and Urry 2004, cited in Watson No date: 37).  
 
 
To think of CLL as a unified category, or a singular pathology, is misguided. CLL is a 
heterogeneous disease with applications to all of the above phenomena. It is distributed in that 
it slips and slides between varying enactments; multiple, in that it takes different shapes both 
within its own textbook inscriptions, and within the various practices that shape it; sensory, 
particularly in relation to its invisibility; profoundly emotional for those living with it; and 
kinaesthetic, in the often ongoing painful displacement of CLL patients from biographical 
frameworks and social worlds. 
 
Latour himself has recently drawn attention to what he describes as the ‘exhausting’ limitations 
of contemporary critique which he now sees as somehow failing in its approach (and here he 
includes his own work) to adequately account for ‘experiences, beliefs and passions – engaged 
with but not reducible to the facts of material life’ (cited in Jurecic, 2012:16). Latour 
acknowledges his own mortality in the reference to colon cancer tucked away in an eclectic list 
of experiences unaccountable for simply by fact (or fetish):  
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I am, I have always been, when I know, for instance, that the God to whom I pray, the 
works of art I cherish, the colon cancer I have been fighting, the piece of law I am 
studying, the desire I feel, indeed the very book I am writing could in no way be 
accounted for by fetish or fact, nor by any combination of those two absurd positions  
(Latour, cited in Jurecic, 2012:16). 
 
 
Latour calls for scholars to “approach matters of concern with tools whose purpose is not to 
“debunk” but to “assemble” (ibid). Paying attention to matters of concern, assembling them as 
and in relation to other objects doesn’t expunge the things that matter to humans from 
network studies. Mapping the intersections, translations, clashes, tensions, or interferences 
between multiple online narrative enactments in terms of the’ who’, and ‘the what’, reveals 
something of the ontological politics of disease. Who shouts loudest when clashes occur, and – 
importantly - about what?  Patient advocates and access to drug trials for example. 
Patient/physician blogs exposing the tensions between clinical and patient enactments of CLL 
that underpin frustrations in clinical relationships in an attempt to improve them might be 
another example. Further, there are the everyday network effects of digital platform use for 
mutual sharing of personal enactments of CLL through stories in support communities, and so 
on.    
 
Understanding how objects hang together in multiple sites is still an important aim. That the 
often disparate enactments of a disease still coalesce under a single name is testament to the 
work required to avoid total fragmentation. The multiple body acted out or on in practice still 
hangs together in the hospital field as the object of a single disease. A disease enacted, Mol 
tells us, is “more than one – but less than many” (Mol, 2002:55). Does that, I wonder, translate 
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to multiple narrative enactments of a disease online, which archives and circulates inscriptions 
from newspaper articles and lab reports, through policy documents and research papers, to 
pharma stocks and shares, family photos and memorial sites? To test this out is a big task, but 
CLL online is distributed across all of these narrative forms at key sites. By observing the 
topography and activity, I can think about ‘how’ CLL networks are formed online. By observing 
‘who’ it is that circulates them, I can identify key actors in the CLL ‘networks’ online. By 
observing the concerns of the circulating narratives, I can reveal ‘what’ is important to people 
with CLL. By observing the intersections, translations, and interferences, I can explore the 
potential for circulating CLL narrative objects to exert material effects on each other and actors 
that produce and consume them. Such nuanced data collection presents challenges in writing 
up the complex assemblages of information orchestrated in this project. In short, as I travel 
more deeply into the territory of CLL I appreciate a complex set of landscapes that I inhabit as a 
multiplicity of symptoms and not as a coherent illness or disease. This, in turn means that 
ethnographic work carried out in these multiple landscapes must offer multiple translations, 
dialogues and polyvocality. As a fundamental element of the project design, these issues will be 
addressed in the following Translation section.  
 
Translation: Writing the Network through Textual Layering  
 
I am by no means the first academic to write my disease-as-research. In Teratologies (1997), 
Jackie Stacey combines autobiographical narrative with a cultural study of cancer. Stacey 
organises the cultural, the personal, and the methodological through text and image in themed 
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chapters in this touching and powerful assay of living with cancer. Her political stance (feminist) 
is clearly articulated in her work, foregrounded as critical analysis, and illustrated through 
autobiographical experience. Implicit in work such as Stacey’s is the fact that selves are always 
located in relation to the things that make up the world, the technologies, institutions, 
ideologies and systems within and through which human selves operate. 
 
Already referenced, AnneMarie Mol’s (2007) ethnography of atherosclerosis, The Body Multiple 
lays bare the relationship of a disease to the texts and technologies that define it through an 
ontological philosophy drawing on earlier incarnations of ANT.  Through careful layering of field 
observations and relevant literature in the presentation of her work, Mol writes through the 
politics of her method, resisting analysis and abstraction.  Instead, she brings together empirical 
observation from her fieldwork that accommodates text and images as a continuous discrete 
text running along the top of the pages in the book. Underneath them, like a continuous, 
detailed footnote to the entire text, runs a separate reflexive literature review and 
methodology. The two cannot be merged and read as one text. The reader is required to find a 
way to read them separately yet still to relate them one to the other. In structuring her work in 
this way, Mol makes the point that these are simply two different enactments of research. 
Marrying the theoretical to the empirical in a seamless text constructs a new reality in which all 
that happens in the clinic and to the patients is subjected to the analytic frames, abstracted to 
them and explained away by them. Such analytic coherence is easier to read, and to write, yet it 
is arguably too tidy, too insistent, too conclusive to accommodate multiplicities both of the 
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research objects and of the research as an object in itself. 
 
In his story of Aramis (1996), Bruno Latour assembles multiple practices, documents, and 
interviews in a non-hierarchical account of the planned high-speed transportation system for 
Paris’s ultimate failure to get off the ground. In structuring the narrative as an assemblage, 
Latour positions the reader as an actor network theorist. Poet Tan Lin’s 2012 work Heath 
Course Pak36, a ‘novelistic’ exploration of online responses to actor Heath Ledger’s death in 
2008, positions his readers similarly with a focus on the poetics of writing the social:  
 
As a test case, the writing explores Actor-Network-Theory, considering Heath both as an 
actor-network in ANT terms and a coterminous mode of sociological accounting...What 
Lin's poetics specifically shares with ANT is an emphasis on demystifying through 
detailed description, tactical citation, assemblage, and deployment through mediators 
and their relations, where every actor is a network...These 'born-digital' actors include 
intellectual property disclaimers, popular advertisements, autobiographical details, 
ticket stubs, rejected articles, celebrity blogs, and RSS feeds (Snelson, 2010). 
 
 
Tan Lin brackets very little in his literary accounting of Ledger’s fans’ engagement online and off 
with reports of his death, from the copyright of the RSS feed logo, links to online bookstores for 
books underpinning his method, autobiographical detail of the fans own lives, and the 
packaging of the takeaway coffee they consume whilst online, he stretches out the detail into a 
 
36 See also Lin’s earlier work, Heath (plagiarism/outsource), notes towards the definition of culture, untitled heath 
ledger project, a history of the search engine, disco OS (2009) – a montage of cut and paste online data described 
by Danny Snelson (2010) as a test case, in which the writing “explores Actor-Network-Theory, considering Heath 
both as an actor-network in ANT terms and a coterminous mode of sociological accounting…What Lin's poetics 
specifically shares with ANT is an emphasis on demystifying through detailed description, tactical citation, 
assemblage, and deployment through mediators and their relations, where every actor is a network.…” (Snelson, 
2010: no page). 
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nano-narrative of daily life focused on responses to the death of an individual among online 
fans (see figure 9). 
                                                        
  
Figure 9:  Figure 9: LIN, TAN (2009) Excerpt from Plagiarism/outsource: notes towards the definition of culture : 
untitled Heath Ledger project : a history of the search engine : disco OS [Scan]. Tenerife: Zasterle. 
 
Inspired by the narrative approaches of Latour and Lin, my aim is that ‘In our blood’ will 
function similarly as actor network and sociological account. I have created a narrative 
structure that draws on the layered presentation of Mol, and Stacey’s organization of critical 
materials under emergent sub-texts read through biographical experience. Each themed 
chapter reflects the key issues addressed in the nodes and networks observed through 
Image removed due to copyright restrictions 
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ethnographic fieldwork. The work is structured in a format that layers relevant contextual or 
theoretical ‘perspectives’ with examples, or ‘translations’ of circulating narratives presenting 
multiple enactments of CLL online. In the Translation sections there is a focus on the range of 
narrative forms, sources and intersections allowing for mapping of key actors, nodes and 
mediators. Screenshots and images from relevant texts and online platforms are interspersed 
throughout to convey a visual sense of network nodes and inscriptions. These might include 
(but not exhaustively): 
 
o Personal narratives from community members. 
o Research papers. 
o News features. 
o Lab reports. 
o TouchGraph/SurveyMonkey visual data. 
o Medical Drs.’ letters. 
o Medical Imaging. 
o Blog postings. 
o Screenshots and quotes from videos. 
o Relevant methodological and theoretical literature.  
o My own autopathographic narrative. 
 
In its interpretive role, the writing up element of the research process is a profoundly political 
one, and as we begin to explore evolving narrative cultures through evolving methodological 
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frames, it seems more pertinent than ever to remember that “the more human inquiry 
becomes qualitative, the more it needs to ask what is required of writing and of language” (Van 
Manen, 2002).   
 
The narrative approach of this work sets out to demonstrate a number of key issues, for 
example: What discursive, institutional, and individual narrative enactments of CLL can be 
traced, across the nodes and networks identified; what knowledge, practices and changes (acts 
of resistance/evolutions/becomings) might be produced where they intersect; who (or what) 
drives the flow of these narratives around the CLL networks online; and what might we learn 
from them?  The Translations and Perspectives of the following chapters aim to address these 
issues under their respective themes.  
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Chapter 2: CLL Online 
Introduction 
 
As suggested in the introduction, CLL patients have a particularly active online presence. The 
chronic progressive nature of the disease gives people time to research their condition and 
establish and maintain online support connections. Although findings from the Pew Report 
‘Chronic Disease and the Internet’ (2010) indicated that people living with a chronic disease are 
less likely to have regular internet access due to a number of external factors (including the 
older age range of this group), it concluded that, once online, their disease management was 
likely to be significantly influenced. ‘They unearth nuggets of information. They blog, they 
participate in online discussions. And they just keep going.’ (Fox and Purcell, 2010:4). This 
overall view is supported by internet use amongst CLL patients, and this chapter sets out to 
nuance that through mapping of online CLL networks, and exploration of individual behavior 
through responses to the online survey forming part of the fieldwork in this ethnography, and 
outlined in the Methodology chapter.   
 
The chapter outlines who was active online, what sites they felt were most useful, if and what 
they posted themselves, why they might choose not to post, whether engaging with CLL 
communities online helped them to live with their CLL, and whether it had any impact on their 
clinical relationships with their doctors. As such it does some of the work of identifying key 
actors, networks and nodes, and prefaces the thematic chapters that follow.  
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Perspectives: From Sick-Notes to E-patients   
 
Dominant perspectives in medical sociology can be broadly categorized as functionalism, 
political economic, and social constructionism (Lupton 2012).  Traditional functionalist 
approaches stress the physician’s social function in legitimizing the ‘sick-role’ (Talcott Parsons, 
1987). Political economists instead focus on medical professionals as major agents of social 
control in late modernity, complicit in coding contemporary health care in ways which both 
elide the underlying causes, and continue to commodify health care itself as a narrow range of 
biomedical products37 (Illich, 1976; Zola, 1981; Epstein, 1990; Russell and Schofield, 1986). This 
economically determinist model has largely been superseded by the kind of social 
constructionism that precedes the methodological approaches I have drawn on for this work. 
For example, Michel Foucault (1973) reconfigures ‘the medical gaze’ as diffuse micro-systems 
of power producing knowledge and subjectivities that can be both repressive and productive. 
Institutional surveillance is taken up by individuals in practices of self-surveillance in response 
to various discursive regimes.  
 
Foucault has been criticized for his view of patients passively submitting their bodies to medical 
power and surveillance, aligning himself in later years with fellow French post-modernists Gilles 
Deleuze and Felix Guattari, whose ‘body-without-organs’ metaphor symbolizes resistance to 
dominant external powers (bio-medicine in this case) through constant re-definition and re-
 
37 Such approaches have been criticised as unrealistically radical and unreasonably nihilistic in its view of an 
oppressive dichotomy in the doctor patient relationship (Lupton, 2012: pp6-7), 
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territorialization by alternative discourses. Here, the striated space of medicine with its 
traditional, historically-contingent hierarchies is re-territorialized by the smoother space of 
multi-disciplinary, patient-centred healthcare. This process of ‘becoming other’ resonates in 
how the chronically ill accommodate changing identities, and collaboratively manage treatment 
decisions in increasingly accessible, interactive and rhizomatic information networks (networks 
that remain largely invisible yet are pervasive, and do not seek vertical structures of hierarchy 
but expand horizontally through associations).  
 
The ‘e’-patient: An Overview 
 
Drawing on changing power relations in the clinical relationship alongside evolving cultures and 
technologies of communication, informed, connected, and empowered “e-Patienthood” 
(Ferguson, 2010) is the current expression of emerging forms of patient power. Digital 
communication has been credited with a range of democratic advances, eroding hierarchies 
between producers and consumers (Rheingold, 1992; Castells, 2000; Atton, 2004). Online 
health communications specifically is an expanding biopolitical arena, as patients mesh into 
expanding networks to exchange narratives, and potentially galvanise action from local 
grassroots to global levels. Through a range of online practices from everyday narrative 
exchange to active advocacy, these online actors contribute to participatory culture’s power to 
destabilise normative “regimes of truth” (Jenkins, cited in Burgess and Green, 2010: 122).  
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Hardt and Negri  (2009)38 outline what they see as a contemporary displacement of a 
traditional binary public/private divide (and its socio-political manifestations) with a ‘common 
wealth’ of networked communicative practices producing new forms of capital, for example 
emotional capital, redistributed through identification empathy online (similar to identification 
with characters in fictional narratives). Networked cultures are seen as re-shaping traditional 
social relations in a number of ways (Castells, 2000). Andreas Wittell for example draws on 
Bauman’s (2000) concept of ‘liquid modernity’, in which network sociality substitutes 
traditional enduring narrational social relations with the continual integrations and 
disintegrations of informational exchange. Information does not necessarily structure into a 
story, remaining as data; yet, of course there are stories about information or data (Bleakley, 
2005). 
 
Exchanges in online support communities might support Wittell’s view of “fleeting and 
transient, yet iterative social relations; of ephemeral but intense encounters” (Wittell, A., 2001: 
51). The growth of knowledge exchange in online health support networks locates the internet 
as a significant archive of contemporary health care culture, supporting Lev Manovich’s view of 
the database as a key form of cultural expression of the computer age (Manovich, 2001). It is no 
longer enough to question how various cultural practices (medicine for example) might be 
enhanced by new knowledge economies. Rather, it becomes necessary to consider the effects 
of digital technologies on our cultural identities in general or, as Sherry Turkle puts it, how they 
 
38 Commonwealth (2009) is the third of Hardt and Negri’s trilogy of texts addressing the evolving concepts and 
practices of organizing of capital and power in late capitalism. It is preceded by Multitude (2004) and Empire 
(2001). 
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are shifting our “fundamental notions of who we are and what we need to do and who we 
should do it for” (Turkle, cited in Ferguson, 2007: xii).   
 
From this evolving landscape emerges a powerful revolution in the hegemony of medical 
knowledge production/consumption, with the potential to subvert traditional power bases, as 
acknowledged by Ferguson’s prediction that “the principal protagonist of our next-generation 
healthcare system will not be a computerized doctor, but a well-wired patient” (Ferguson, 
2007: xii). Patient-centredness (itself a hard-won subject position for patients39) is arguably in a 
process of displacement by patient-connectedness requiring some degree of identity 
(re)construction for both patients and clinicians alike. The challenge for acknowledged experts 
in coming to terms with the cultural and hierarchical shifts that new technologies can produce 
in their field is well-documented:   
 
Really substantive innovations – the telephone, the copier, the automobile, the personal 
computer or the internet – are quite disruptive, drastically altering social practices. [So] 
our established experts may be those least capable of helping us find our way safely 
through the disruptive social innovations these new technologies will require (Brown, 
cited in Ferguson, 2007: 21). 
 
 
US haematologist, Richard T. Penson and colleagues (Pensonet al, 2002) researched the 
potential positive impact of online health support communities in the context of  professional 
 
39 The term ‘patient-centred’, originally coined by Balint in 1969, expressed a belief that every patient “has to be 
understood as a unique human-being,” patient-centered medicine emerged as a descriptive account of how 
physicians should ideally interact and communicate with patients. See S. Saha et al. (2008) for an outline of the 
evolution of ‘patient centredness’ in their paper ‘Patient Centeredness, Cultural Competence and Healthcare 
Quality’ published in the Journal of the International Medical Association’. 
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anxieties surrounding misinformation, concluding judicious internet use to be overwhelmingly 
positive and empowering for patients and, in some cases,  professionals (Penson et al, 2002: 
555). However, the imperative to view change through the lens of a culture within which actors 
are already situated can result in downplaying or actively resisting innovative developments, 
and the survey Translations in this chapter evidence a degree of reluctance among some 
clinicians to embrace the democratizing potential of modern medical communications currently 
encouraging patients “to access content, connect with others, and collaborate with others in 
ways never possible before” (Ferguson, 2007: 22). Others though are actively engaging with the 
cultural shifts in clinical relationships, even becoming key actors in online support networks, as 
this work reveals.  
 
Patients may also resist or struggle with various elements of ‘e-patienthood’. The use of online 
support communities by e-patients is an emerging field of study from a number of perspectives 
(Maloney-Krichmar and Preece, 2005; Orgad, 2005; Leimesiter et al, 2006; Hoybe et. al, 2007). 
Whilst very few research projects conclude that online healthcare support has proved harmful, 
some have identified tensions including: uncritical assumptions of empowerment and agency as 
positive outcomes of online support (Sandaunet, 2007); social exclusivity in online support 
groups (Eun-Ok et al, 2007); narcissism and ‘ego-casting’ in online spaces (Rosen, 2004; 
Mahato, 2011; Faigley, 2001); insufficient proof of effectiveness (Eysenbach et al, 2004); and 
the potential of the internet to affirm a range of normative ideals (Pitts, 2004). 
 
The following Translation section provides a quick snapshot of some of the dominant CLL nodes 
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used by survey respondents, from online support communities to social media before going on 
to explore online experiences and practices among respondents.  
 
Translation: Dominant Nodes in the CLL Networks 
 
Survey questions opened with multiple choice selections for major sites used by respondents, 
drawing from a list of my own impression of the key nodes compiled from my own field-work, 
and inviting patients to tell me about any sites they used that I had omitted.  Results can be 
seen in Figure 10 below: 
 
Figure 10: IN OUR BLOOD SURVEY (2012) Reported % use of online sites used regularly in 2012 by In Our Blood 
survey respondents to gain information and support about CLL [Graph].  
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A plethora of site-specific comments such as the very small selection below demonstrate 
loyalty, trust and a sense of historical evolution/development in particular sites: 
 
It is fascinating to have watched the 1st acor and granny barb sites grow into such 
resources. I picked the clinical trial in 2000 based on information from these sites (IOB 
Survey Respondent 106). 
 
I cannot imagine not having ACOR when I was diagnosed. I have been on the internet 
since its inception and ACOR was all there was at dx. It was a lifesaving experience (IOB 
Survey Respondent 30). 
 
You have to be careful which sites you look at as some can scare the pants off you! I only 
look at MacMillan[sic] as I know it's a trustworthy site (IOB Survey Respondent 201). 
 
In addition to the % usage reported for the sites listed above by the 216 respondents answering 
the question, 77 respondents also used the comment section to report other sites used. (Please 
refer to Appendix 11 for the key alternative sites identified by respondents at the time of the 
survey, and a short narrative analysis of key sites and analytics observed through fieldwork in 
March, 2013).  
 
Network activity is dynamic, with sites growing or fading in popularity over time due to a 
number of factors. Actor-Network-Theory disavows evaluating network quality on the basis of 
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raw numbers of participants alone, focusing on translations across all actors (persons, artefacts 
and ideas) involved in creating network activity: 
 
Intermediaries fail to translate effectively, causing potential networks to stall, fade, 
collapse or crystallize (for example a website that deposits information but does not 
allow for interaction), where mediators (for example an interactive component on a 
website) facilitate translation between actors and the expansion of a network to 
produce more potent network effects (Bleakley, 2012).  
 
 
Specific site functions and stability will be looked at more closely through the Translation 
sections of the themed chapters where I map the flow of selected narratives across sites. This 
brief snapshot of site usage at a given point in 2013 can only reveal the range of knowledge-
sharing activity in the networks at the time. From dedicated research sites, through specialist 
sites with translational and interactive functions, to community forums and social networking, 
no one particular site or site-type provides all of the information and functionality required to 
keep the networks vibrant and to engender the flow of CLL narratives around them.  
  
Human actors also work at different levels of ‘e-patient’ participation in the networks, from 
those who set up and maintain sites, creating hubs and connections, to those who simply read 
or ‘lurk’. This work will reveal some of the key actors in the network as it unfolds, and the next 
section looks at survey responses to the question of individual participation levels. 
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Translation: Levels of Active Participation (Posters and Lurkers) 
 
There were 221 responses to the question about levels of participation, with 80 respondents 
commenting further on their activities.  
 
In summary,  24 respondents (11%)  claimed to ‘actively’ post online about CLL issues on a 
regular basis (more than six posts annually), with the largest group of 86 (40%) claiming 
‘occasional’ posting. Not far behind them though were the 81(37%) of respondents who logged 
in to CLL sites regularly, but never posted. Bracketing this majority middle group of occasional 
posters and ‘lurkers’ were the 30 people (14%) at the other end of the participation scale who 
said they rarely visited CLL sites or posted online about their disease. 
 
Responses vary widely from those who never post: 
 
I was not aware of any such website (IOB Survey Respondent 226). 
 
I never contribute to sites online (IOB Survey Respondent 215).   
 
To those who contribute very frequently (daily in some cases):  
 
Post daily, as blog or in reply to questions or response to PMs generated by groups and 
individuals seeking answers or replies (IOB Survey Respondent 5). 
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The majority of people answering this question though claimed moderate levels of posting 
activity from monthly to 2-3 posts a year.  Several respondents nuanced their answer by 
providing context around the triggering points for making a post: 
 
I read two lists every night, and also read Brian Koffman's blog almost every night. I post 
if I feel I have something to add to what has already been said. This can be either about 
my personal experience (CLL and breast cancer) or just trying to get a clarification. 
Maybe once or twice a month (IOB Survey Respondent 44). 
 
  
My frequency depends on what is happening in my life. I was on W&W for 11 years 
before treatment. Now I am on partial remission and basically back on W&W (IOB 
Survey Respondent 226). 
 
 
During my treatment and just prior to I posted more regularly now I mainly read (IOB 
Survey Respondent 100). 
 
  
Unsurprisingly, levels of online interaction for many CLL patients correlated with key milestones 
on a trajectory of disease progression and treatment interventions such as living in watch and 
wait, prognostic testing, treatment, relapse and dealing with secondary malignancies or co-
morbidities.  
 
Newly diagnosed respondents reported particularly high levels of activity as they seek to learn 
about the disease and its implications: 
 
Only diagnosed about 4 weeks ago, but CLLSA Health Unlocked Group looks good and I 
have already made 3 contributions (IOB Survey Respondent 131). 
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 I am only recently diagnosed (14 Feb 2013) so I am using the communities to learn and 
get some support when I feel low, I also find it helps to write about feelings and support 
others too. I probably post around once a week for my own purposes and reply as I feel I 
need to others. I check the forums at least 3 to 4 times a day (IOB Survey Respondent 
144). 
 
  
Some group members acknowledge an important role in making unconditional responses to 
any other member requesting information, whereas the following respondent calls for 
members to take responsibility for updating themselves on the basics before posting questions:  
 
I used to post on the CLLSA site but became discouraged that people did not read 
information already available before posting basic questions (IOB Survey Respondent 
25).  
 
 
Comments such as this indicate a range of definitions of “support” amongst individuals using 
these groups, and the potential for disengagement amongst those members with a more 
autonomous approach to understanding the disease when interacting in support groups with 
those less well informed than themselves.  It also indicates how the definition of “basic” 
questions might change as group members learn more about their disease.  Another 
experienced user described using personal mailing facilities to contact individual forum 
members rather than making a public post: 
 
If I did this form 8 years ago I would say I did it daily, however these days I just read the 
post and hardly ever post, however I sometimes send private emails to those that I feel 
need support (IOB Survey Respondent 72). 
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This response shows how frequency of interaction may lessen for those who have 
accommodated the disease into their lives – a phenomenon I have observed in my own 
engagement. It also indicates an interesting private/public distinction in communities where 
support interventions are not always perceived as best served by public forum postings where 
private messaging facilities are available. The issues of actual, perceived or imagined audience 
response to public postings will be explored later in the chapter in relation to reasons for non-
posting, but responses showed how some novice members saw the process of acclimatizing to 
online debate as a learning curve requiring preparation through observation and modelling on 
current community approaches before taking the plunge:  
 
I have posted only once being fairly new to participatory sites, however, I feel will post 
more in the future. I do log in and read posts frequently thereby getting a feel about how 
such sites operate (IOB Survey Respondent 212). 
 
 
It's a new experience sharing personal information/comments with 'strangers' so for me 
I need to read the type of posts and articles before I feel comfortable in participating in a 
more active way... (IOB Survey Respondent 212). 
 
 
As well as wanting to know the levels of participation amongst CLL patients online, I was 
interested in the motivations of those who did post. 
Translation: What do People Say Online? 
 
101 respondents answered a question about the varying motivations behind their 
contributions. 39% reported sharing information and links with others. 63% reported posting to 
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seek advice for themselves. 61% said they posted about the physical and psychological impacts 
of living with CLL, and three respondents (3%) reported having their own CLL related blog, and 2 
(2%) reported posting videos about CLL to YouTube. 
 
Several respondents described posting as an altruistic pursuit -a means of helping other 
patients, and of appreciating and lending support to the contributions of their fellow members: 
 
I post to respond to others expressions of the impact of living with CLL. I post to express 
appreciation and commentary about anthers [sic.] writings (IOB Survey Respondent 67). 
 
 
I was a caregiver, I generally write personally to new patients rather than post and tell 
them about CLL Topics & Updates - which was enormously helpful to us, as well as 
general info that might help them as newcomers (IOB Survey Respondent 42). 
 
 
…moral support, especially for newcomers, and basic resources to start one's education, 
ways of dealing with being new, like taking a recording device to appointments, usually 
privately, connections to other resources or people who might be helpful (IOB Survey 
Respondent 20). 
 
 
 
The therapeutic value of ‘reciprocal-helping’ in support communities both on and offline has 
been noted in previous studies of online health communities (Maloney-Krichmar and Preece, 
2005:219), and Preece and Ghozati conclude their work into online empathy with the 
observation that ‘empathy appears to occur naturally’ (although not necessarily exclusively) in 
those communities specifically set up for support amongst people with health issues (cited in 
Rice and Katz, 2001: 257). However, there is a range of ‘house-styles’ across the key 
communities, some more concerned with information sharing than social or emotional support. 
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In a study comparing information seeking effectiveness and perceived social support—on 
perceived empathy in online health communities set up by institutional health care 
organisations, the author concludes that “it is the information seeking effectiveness rather than 
the social support which affects ’patient's perceived empathy in online health communities run 
by HCOs”40 (Nambisan, P., 2011). A need to understand network activity within the contexts of 
the perceived motivations, aims and interface of specific sites is important. 
 
Others cited more specific content, related to their own disease experience, such as secondary 
infections, and allergic reactions:  
 
reading and exchanging experiences of treatment and Dr. patient inter action on 
explanation of disease progression or side effects from infections etc. (IOB Survey 
Respondent 214). 
 
 
Posted regarding an allergic reaction to antibiotic during treatment (IOB Survey 
Respondent 175). 
 
 
Postings are used to solicit and share information tailored to the poster’s particular disease 
contexts and experiences. Archive facilities on sites such as ACOR accumulate rich repositories 
of discussion threads on specific disease aspects. These collaborative databases contribute 
significantly to disease knowledge through the potential for meta-analysis of a broad range of 
experience and knowledge not necessarily available through one-to-one patient/clinician 
 
40 P. Nambisan concluded that such communities need to focus on developing tools to enhance the flow of 
effective information seeking (Nambisan, 2011) 
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relationships (however experienced the physician might be). The issue of big-data sharing in 
online contexts will be explored further in the Treatment chapter. 
Others were engaged in broader debates surrounding CLL related issues such as diet, nutritional 
supplements such as ECGC (green tea), curcumin, vitamin D41, and physical fitness: 
 
I am particularly interested in physical fitness and how it is affected by CLL or how it 
affects CLL (IOB Survey Respondent 173). 
 
 
The nature of sharing and mutual support demonstrated by much of the activity in online 
networks and reiterated in these comments speaks of a general ethos of advocacy at personal 
and community levels. Some in the networks however take on and espouse a more directly 
political level of advocacy. This respondent describes how they used posting as a means of 
political campaigning, lobbying the Canadian government for access to front line drugs in the 
treatment of CLL in specific states: 
 
As a member of CLLPAG I have written and lobbied the provincial Minister of Health re 
the lack of access to Rituxan except as a first line of defence. Ontario is the only province 
in Canada with such a restriction (IOB Survey Respondent 101). 
 
 
41  Both curcumin (the active ingredient in the spice turmeric) and the green tea extract epigallocatechin-3-gallate 
(EGCG) have been shown to demonstrate marked effects on the apoptotic machinery in CLL. In their (2009) paper 
for the Journal of Clinical Cancer Research, Angelo and Kurzrock concluded that ‘these results provide a preclinical 
foundation for future clinical use of these compounds in this disease’. Vitamin D insufficiency at diagnosis has also 
been associated with inferior time to treatment and overall survival in initial studies by Shanafelt et al. (2009), 
leading to calls for further studies in the field. 
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As new treatments roll out, raising questions about funding and access, more CLL patients are 
becoming politically active in their advocacy and this will be explored in greater detail in the 
Treatment chapter.  
 
The following response maps a trajectory of engagement from online information and plans to 
manage future disease progress using ‘www’ to face to face interactions with global specialists 
at a conference discovered online: 
 
At peace with diagnosis. The leukemia and lymphoma society was a great place to read 
and then research links to learn about CLL when first diagnosed from 2008-2009. 
Learned about an International CLL/lymphoma conference from this society-attended 
lectures in 2009- and met with top researchers, doctors, patients and survivors When I 
go from watch and wait to a change I would go to this site and start looking for updates 
on the www (IOB Survey Respondent 110). 
 
 
Using online sites to source conferences, expert care provision, or to connect with other 
patients and professionals offline is a commonly witnessed phenomenon across support 
networks, demonstrating potential for digital community engagement to mesh users into 
broader health support networks offline.  
 
Translation: Non-Participation (Why People Don’t Post) 
 
Almost as many respondents as those reporting the demonstrable benefits of active reciprocal 
engagement in online support networks claimed to visit sites regularly but not post, raising 
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questions about the nature and definition of ‘engagement’ in online communities. The 
phenomenon of 'participation inequality' is widespread and well documented, with an apparent 
spread across most online communities in which “90% of users are lurkers who never 
contribute, 9% of users contribute a little, and 1% of users account for almost all the action” 
(Nielsen, 2006). 
 
Those respondents to the IOB survey claiming to actively read and engage with communities 
but never or rarely post gave a variety of reasons. 31% said it was ‘too time-consuming’. 
Furthermore, a sense that too much time spent online might over-determine people’s lives with 
their disease was relatively common in the written responses, with an ethos of just wanting to 
“get on with life” and not “dwell” on the disease:  
 
I very occasionally look online to see if my tiredness or perhaps various aches and pains 
may be attributed to this disease and shared by others - generally I would rather just get 
on with life until such time as I need treatment (IOB Survey Respondent 223). 
 
 
I do not want to dwell on my CLL as I have responded well to 6 months of treatment and 
just want to get on with my life and stop thinking about it! (IOB Survey Respondent 220) 
 
 
Several respondents described avoiding direct participation as a strategy for reducing anxiety 
provoked by engaging with others’ stories/experiences and, in some cases, of avoiding 
imposing their own experiences on others whose disease courses may be very different. Again, 
this is related to the heterogeneity of CLL and the fact that an individual’s experiences and 
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disease course may be significantly different from that of other members: 
 
I don’t use many sites as I believe that there is a lot of contradictory information and it 
only ads[sic] to the confusion and I find that some of the blogs are used to publish 
unhelpful information. I prefer to use sites like CLL Topics as it gives clear information 
that, in my case has been correct, and I am [sic] can discuss with my consultant. It is not 
some horror story from someone who has not listened to their consultant or diagnosis 
and has heard the words CLL or Leukaemia and have decided their lives is [sic] coming to 
an end, or everyone has to understand that their case is worse case and everything is 
doom and gloom. I believe that some of these sites are harmful and do more damage 
than good, that is why I do not use them (IOB Survey Respondent 172). 
 
 
This respondent expresses a belief that narrative sharing in support communities tends towards 
the negative, describing narratives therein as ‘horror’ stories, attributing them to people who 
have ‘not listened to their consultant or diagnosis’, but have responded to the word ‘leukaemia’ 
to jump to grim (and supposedly uninformed) conclusions about their mortality. Of course, CLL 
can and does result in grave illness or early death, so there may be an element of denial in this 
response, as in the perception of a kind of competitive mortality or attention seeking going on 
in the observation that ‘everyone has to understand that their case is worse case and everything 
is doom and gloom’. This respondent sees this as ‘harmful’, expressing a need to protect 
themselves from the less positive personal stories of others (with perhaps a more aggressive 
CLL than their own) by avoiding communities encouraging this kind of exchange.   
 
It also reflects a preference for positive narratives and attitudes observed in previous work on 
online cancer communities (Orgad, 2005, 2006; Pitts 2004; Sharf 1997). Orgad’s work on online 
communications in a breast cancer community noted that stories of death or despair were 
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excluded or re-framed by community ‘veterans’ into narratives of enablement and hope, the 
dominant community discourse being shaped into one about ‘living with disease rather than 
dying from it’ (Orgad, 2006: 892).  
 
The extreme heterogeneity and differing rates of progression of CLL means that the range of 
immediate health concerns being faced by those in the same community can be considerable.  
It can be challenging to share a narrative disease space with others who are struggling for their 
lives if one’s own disease is currently well controlled. However, an estimated 4,600 people died 
of CLL in the US alone in 2013, perhaps accounting for some of the ‘horror’ stories resisted by 
respondent 172. 
 
The challenge of managing the less optimistic narratives they encountered online was recorded 
by several as a reason for non-participation. Others spoke of having to learn to manage the 
effects of encountering difficult narratives on their own anxieties about the future: 
 
Diagnosed 2008. Thought to have had CLL for up to 5 years before that. Took a while to 
work through shock and assimilate it all. Progressing very slowly so still on watch and 
wait. Find too much exposure to distress of others brings it all to the front of my mind to 
the extent I start to become unable to 'live for the day’ (IOB Survey Respondent 179). 
 
I don't find it helpful to read other people's treatment journeys. They do not usually 
come with a health warning up front and having lived with this disease for 4 years, 
through 3 rounds of treatment and a bone marrow transplant there is a degree of self- 
preservation required. As such I don't post either as my journey has been tricky and I 
wouldn't say that helpful. Perhaps that will change if I reach a period of stability but not 
yet unfortunately. I use the Internet mainly for factual research on drugs, side effects, 
conditions & research (IOB Survey Respondent 256). 
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The latter respondent indicates that his or her concerns about coming into contact with 
distressing narratives which ‘don’t come with a health warning’ keeps them from sharing his or 
her own difficult story online for fear of distressing others, or making them ‘unable to live for 
the day’ like the first respondent. This expresses the need to retain hope in the face of a 
chronic, unpredictable and life-threatening cancer, and the relationship between hope and 
information seeking behavior in cancer patients has been explored in previous research. As 
Geraldine Leydon and colleagues discovered in their in depth interview study of cancer 
patients’ information needs and information seeking behavior, hope and fear are closely 
related, many patients oscillating between periods of information exposure and avoidance. 
Strategies such as cessation of research, silence, and self-censorship enabled patients to 
“circumvent negative information about their illness, which poses a constant threat to hope” 
(Leydon et al., 2000: 913). 
 
A sense that the heterogeneous nature of the disease was not always accommodated 
effectively in forums created a significant point of tension for the following user, who came to 
feel that they could not post “honestly” about their experiences: 
 
I found out fairly early on that because CLL is a disease that has a different course in 
some people i.e. some people have a very indolent version and are much older, well into 
their 70's when diagnosed, that they completely misunderstood some of the emotional 
issues I had with a more progressive course of CLL and being diagnosed at a relatively 
young age (50). I started to feel as if I was moaning and not being positive and I found 
this distressing and patronising and that just made me more angry. I still work, even 
though the fatigue is quite severe. I was not annoyed at the responses on a personal 
level, I just realised that even people with the same disease can be quite ignorant 
because of the very heterogeneous nature of CLL itself. I was actually honest once on the 
site about one of the comments made (not in any way horrid) and someone actually left 
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the online forum. There are some wonderful people who are totally and fully supportive 
but because of my experience I found it difficult to continue to contribute as I had done. 
Because I work and get very tired, I also found it exhausting to be online too often 
talking to others, although I do read the posts (IOB Survey Respondent 19). 
 
 
The question of imagined audience perception when posting to a community is an important 
issue, and was raised by several respondents when talking about their reasons for non-posting. 
This is reflected by the 27% of respondents who didn’t post as they were ‘worried about 
upsetting others with the 'wrong' comment/issues’. The practice of regulation or self-
censorship of both reading and writing honest narratives of the challenges of living with CLL has 
very real implications for those patients actively seeking online support with issues of 
aggressive progression, death and dying. As noted in a previous context, member perceptions 
that affirmations of empowerment and agency were the only available narrative positions in 
self-help groups was a significant barriers to participation (Sandaunet, 2007: 142). The tensions 
between the need to retain hope and the need to discuss the challenging issues faced by those 
with progressive or poorly controlled disease in CLL communities is a perennial problem across 
some sites, and requires further focus which could extrapolate to a range of online health 
communities.  
 
The lack of visual cues indicating age, race, gender and general health amongst posters online in 
tandem with heterogeneity of disease experience troubled this respondent: 
 
I prefer face-to-face contact when discussing such a personal issue, given the different 
experiences people go through, I feel that one size does not fit all and doing over the 
internet people are more likely to force a theory than they would if talking face-to-face 
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i.e. if a 44 year old female was having one experience, it could be very different from a 
64 year old male's experience. This would be quite obvious if people could see each 
other, but not so if contributing to a discussion online (IOB Survey Respondent 163). 
 
 
 
Defining homophily as a desire to communicate and increased perceived empathy between 
sources and receivers who are ‘alike’ (similar life experiences and life events), Nambisan  (2011) 
notes that patient absorption of health information and satisfaction with group interactions are 
enhanced when acquired from people who are similar or have ‘similar disease experience’ 
(Nambisan, 2011). Whilst being a ‘CLL patient ‘ is a universal title amongst those in the 
communities, the experience of CLL as a disease is far from universal. As demonstrated, the lack 
of homophily amongst community members can act to undermine group satisfaction and 
empathy, and lead in some cases to total disengagement.  
 
Of the 39% simply ‘not comfortable’ posting online about CLL, comments indicated concerns 
about personal boundaries surrounding the private nature of personal medical detail, and the 
public anonymous nature of online forum communication: 
  
Don't tend to open up to others in general and never so on medical matters! (IOB Survey 
Respondent 228) 
 
I have never felt any inclination to share my experience other than face-to-face or with 
people I know well (IOB Survey Respondent 205). 
 
  
I am shy about speaking in public, this feels the same to me (IOB Survey Respondent 42). 
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Additional comments indicated concerns about not being articulate enough, and having nothing 
new to add. A clear thread of generalized discomfort with online discussion emerged. Whilst 
many CLL patients have comfortably migrated online, those in the CLL demographic are not 
digital natives:  
 
I am about to turn 71; I am, nevertheless, very computer/web savvy and use the internet 
all the time. However, I find that I am generally uncomfortable about expressing myself 
to such a large, and unknown, audience. I prefer to PM when necessary, although I 
occasionally do post. I am somewhat ashamed of not posting more, since I gain so much 
from what many others contribute (IOB Survey Respondent 26). 
 
 
Again, the private/public distinction in contexts of an imagined audience is apparent in a 
preference for private messaging. Also of note is the guilt expressed at adopting the role of 
recipient and not donor in a perceived ‘one-way relationship’ of support. Others felt that they 
had little to contribute themselves, but much to learn from more experienced members in a 
perceived hierarchy of community knowledge:  
 
I am mostly a reader, since most of the issues are educational and discussed by patients 
with much more experience and knowledge than myself (IOB Survey Respondent 96). 
 
  
At just 30 months into this "experience," and despite all my personal research, I am still 
tremendously ignorant into the actual course of this disease, my prognosis for leading a 
semi-normal life, and the emerging courses of treatment. I am still learning but I have 
little of value to contribute to others with the same disease (IOB Survey Respondent 82). 
 
  
Several respondents made the point that infrequent posting did not relate to their engagement 
with the forums as readers, going against the grain of ‘the preconceived notion that you must 
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be an active poster to be part of a community.’  (Nonnecke and Preece, 1999): 
 
Rarely post--do not like to live my life in public; however, I always read, and occasionally 
contribute if I think I have something useful to say (IOB Survey Respondent 26). 
 
 
Post occasionally; read every day (IOB Survey Respondent 37). 
 
  
 
It must be acknowledged however that not everybody using the CLL networks seeks this sense 
of community. The desire to find information without participatory communication was 
expressed quite clearly by this respondent: 
 
I use the sites only to get information about CLL and to keep up to date with research 
etc, I do not feel the need to communicate with other people with CLL (IOB Survey 
Respondent 195). 
 
 
Finally, 14% were concerned enough about confidentiality and privacy issues online not to post 
as indicated by the following patient considering site types they might be willing to contribute 
to in the future: 
 
I'm a Watch & Wait lurker. When I have something to ask or something to say, I'll post 
on forums that have a modicum of confidentiality (e.g. NOT Facebook) (IOB Survey 
Respondent 69). 
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Translation: Impact on Life with CLL (Does Online Information Help?) 
 
Whether active posters or not, I was interested in the extent to which respondents felt more 
informed as a result of online use. In total, 225 responses were recorded to the question, ‘Do 
you feel that your internet use surrounding CLL has made you into a more informed patient?’ 
Of those, 208 (93%) said it did, 4 (2%) said it didn’t, and 13 (6%) said they weren’t sure. 
 
                             More important to understand however is and whether and how being informed might 
translate into a positive impact on living with CLL.  Asked if online information helped them to 
live with CLL, 187 (83%) of the 223 responses declared having more information as helpful in 
living with the disease. Thirty three people (15%) felt that it helped them some of the time, 
sometimes, whereas a minority of 6 people (3%) answered no to this question as shown in 
Figure 11. 
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Figure 11: IN OUR BLOOD SURVEY (2012) % responses reported by In Our Blood survey responses to Q7 - Do you 
think that having more information helps you to live with CLL? [Graph]. 
 
Amongst the responses, a number of themes emerged. 
 
For some, simply having information (whatever its nature) reduced overall anxiety and afforded 
some sense of being in control of the situation:  
 
The known is less scary than the unknown; better a cobra in a flashlight beam than 
stumbling in the dark wondering where the cobra is! (IOB Survey Respondent 111) 
 
 
… feel much more in control of my life since I have begun reading the various lists to 
which I belong. I had been diagnosed for a year and a half before I found the various 
lists; the difference in my sense of well-being before and after is striking (IOB Survey 
Respondent 26). 
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It is remarkable that patients express a sense of comparative relief once having found sources 
of information on the internet, despite already being diagnosed with CLL and having been in the 
care of a medical team for some time:  
 
I've had over 15 years of CLL -- doctor visits, chemo, non-chemo treatments -- and ONLY 
online information really tells me what is happening and what can be done. Far more 
detailed than doctor visits, hospital stays, etc. My confidence over the years has been 
bolstered by online information. I've never been "afraid" of CLL because of what I learn 
online from reputable sources (IOB Survey Respondent 17). 
 
 
This certainly raises questions about the levels of information many CLL patients are getting 
from their clinicians alone. A group of ‘watch and wait’ CLL patients surveyed in 2011 reported 
feeling that they were not treated as being really ‘ill’ by their consultants, with a consequent 
lack of provision for information and emotional support. Whilst the authors (including 
haematologists) acknowledge that it can sometimes be a clinical strategy not to concern 
patients with possibilities of progress that might not transpire, they also cite the conclusion of a 
meta-analysis of the literature on oncological clinical relationships (Arora, 2013) that 
underestimating  patients’ information needs can cause unnecessary  confusion and 
uncertainty, concluding themselves that CLL ‘patients in our study (and many others) routinely 
say that they would prefer information.’ (Evans et al, 2011: 9). This paper is an important 
circulating narrative in the networks and will be presented as a Translation in the Diagnosis 
chapter. 
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Across the support networks, and in the survey, patients treated by CLL specialists rather than 
general ‘haem-oncs’ reported feeling more informed about current CLL research and 
treatments. Geographical location often dictates access to specialists and research centres:  
 
Since I had no local specialist, knowing about the disease, its progress, and the 
treatment options helped me make informed choices when the time came for treatment. 
Furthermore, society is so heavily committed to the concept of treating cancer 
immediately, it helped to have widespread anecdotal support about the wisdom of 
"watch and wait", which I did for 7 years (IOB Survey Respondent 54). 
 
 
I firmly believe that one is responsible for one's own health and should know everything 
possible about diagnosed conditions. Also, since I do not live near any Cll experts, I rely 
on internet information to keep me up to date (IOB Survey Respondent 37). 
 
 
Aside from access to informed ‘specialist’ online disease communities proving effective in 
enabling patients to negotiate broader cultural discourses of disease, this response highlights 
the role of online knowledge sharing in going some way towards addressing inequalities in 
access to specialist clinical knowledge in the clinical setting, and this will be explored in greater 
detail in the themed chapters. As well as filling the information gap for those already in care, 
for the newly diagnosed, information seeking online can provide a means of pro-actively 
opening informed dialogue with clinicians from the outset:  
 
I have learnt a lot about the condition and symptoms, received some great advice and 
have lots of questions for my first Hematology appointment on 12th April (IOB Survey 
Respondent 144). 
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Knowing what questions to ask at a consultation, particularly when newly diagnosed or facing 
disease progression, is a common forum topic, listed by the following respondent as one of 
several ways in which online narrative sharing has helped them to live with CLL:  
 
It has helped in recognizing shared experiences what is normal, how to live better with 
and cope.How to: Understand protocols and standard of care and how best to work 
with the system. Understand my rights and realize expectations How and what 
questions to ask medics How to respond to a given situation (IOB Survey Respondent 5). 
 
 
The theme of supplementing information from time-limited clinical encounters through clinical 
interaction continues in responses. Pressures on clinical time forestall extensive discussion with 
consultants in clinics, and being informed through online interaction was employed as a 
strategy for getting the most out of the clinical relationship: 
 
My docs have only a little time. I need to know the big picture, review what I have 
forgotten, research something new to me, and read research abstracts and papers (IOB 
Survey Respondent 64). 
 
 
Limited clinic time wasn’t perceived as the only obstacle to satisfactory clinical communications 
however, with significant numbers citing poor communication from their clinicians as 
necessitating knowledge seeking online:  
 
Knowledge truly is power- especially in dealing with Oncologists who don't always 
communicate effectively or who do not really disclose everything that may be useful to 
me in making medical decisions (IOB Survey Respondent 82). 
 
Julia Kennedy 
108 
 
very little information given at hospital visits about the latest developments [sic] for CLL 
treatment. In fact consultant takes the view not to worry about treatments until [sic] 
they become necessary! I feel far better having gained information about current 
treatments and the future proposals (IOB Survey Respondent 153). 
 
 
If it wasn't for online I would no [sic] little to nothing about this disease. Although my 
onc is a nice guy I feel is attitude is "trust me because I'm the expert and I will tell you 
what you NEED to know” (IOB Survey Respondent 151). 
 
 
Can't imagine how I would have coped otherwise. The info I get otherwise is at best 
inadequate, and sometimes just wrong (IOB Survey Respondent 148). 
 
 
 
Learning online can be challenging however, requiring considerable investment in time, not to 
mention the ability to absorb, select and differentiate between multiple complex materials 
available: 
 
Medical professionals are not the most willing communicators so an in depth 
understanding of an individual’s unique CLL experience is usually obtained by searching, 
reading and absorbing over time the information that can really only be accessed on the 
internet. It depends on just how much someone wants to invest in the process (IOB 
Survey Respondent 96). 
 
 
‘E-patients’ adopt an active role in their own care (Ferguson, 2010). Through all of these 
responses runs a theme of knowledge seeking online that translates into negotiating, improving 
on, or supplementing the clinical encounter.  It is about pro-activity, and taking some control:  
 
My aim is to actively share in the management of my illness - something you cannot 
easily do without a reasonable knowledge of the illness, its effects, progress and 
management.. I will not accept being 'done unto' (IOB Survey Respondent 128). 
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Absolutely, it is essential to be proactive in dealing with this disease. I took charge of my 
CLL from day 1, when my local lab misread my biopsy results. I read everything I can 
about the disease, including the latest treatments (clinical trials and others), the movers 
and shakers in the field, and more. I attend CLL conferences annually for up-to-date info 
(IOB Survey Respondent 123). 
 
Access to resources addressing alternative approaches to treatment was also raised as a benefit 
of online engagement:  
 
There are many points regarding alternative therapies and/or treatments that are not 
available from doctors. They will insist on following golden rules and treatments proven 
from clinical trials, but sometimes there are alternative options one could take, 
depending on prognostic factors (IOB Survey Respondent 96). 
 
 
Online networks accommodate a broader range of views than might the traditional clinical 
encounter, as the “erection of boundaries around what might be termed ‘orthodox’ or 
‘legitimate’ knowledge and the ‘non-orthodox’ does not necessarily exclude both from 
occupying space within the Internet” (Hardey, 2001: 402). The above respondent is careful to 
include the proviso about prognostic factors in relation to taking alternative options however, 
and most CLL sites and discussions are at pains to separate out those approaches considered 
‘alternative’ from more mainstream or ‘legitimized’ approaches to treatment and care. The 
Acor group for example has formalized its approach by keeping all ‘alternative’ treatment 
discussions off its main list, having set up a dedicated and separate list for these discussions. 
The use of some ‘natural’ products to treat CLL - such as ECGC found in green tea, and Vitamin 
D have a long history of debate across the networks, to some extent straddling the divide 
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between mainstream and alternative, but both having been studied to some extent in small 
scale trials and therefore legitimized as evidence-based. 
 
Aside from personal learning and empowerment, the sense of community and collaboration 
inherent in online support groups was writ large across many of the responses: 
 
It helps me consider matters I might not have thought of on my own and it makes me 
feel part of a larger community with something shared rather than a solitary sufferer 
(IOB Survey Respondent 73). 
 
  
Without much support from my husband, I don’t know how I would have survived 
without the constant caring and support I get from the ACOR list I belong to (IOB Survey 
Respondent 78). 
 
 
My reason for keeping in touch with CLLSA, if I'm honest, is to check how I compare with 
other people suffering this condition. I rely mainly from my haematologist team, for 
support and information (IOB Survey Respondent 251). 
 
  
CLL is a rare condition that can also impact your sociability due to increased infection 
risk. How it progresses also varies greatly. Its rarity unfortunately means that patients 
can be provided with inappropriate treatment due to lack of experience with the 
condition by medical professionals. On line communities dramatically improve your 
chances of finding other people with whom you can share your journey, benefiting from 
the experiences of others and helping others to avoid the complications you've had. They 
also provide you with a means to reassure yourself that you are being offered 
appropriate treatment, or support to seek out better health services should that prove 
necessary (IOB Survey Respondent 4). 
 
 
More information, especially on other people's experiences can help the "isolation" felt 
by most CLL patients at some time (IOB Survey Respondent 178). 
 
 
I can communicate with fellow sufferers who show a lot more compassion and in some 
cases understanding of CLL then my Haemotlogist [sic] does. I get Good advice and its 
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[sic] also helps me appear more then [sic] just a helpless patient at clinic appointments. I 
feel empowered and i thank god i live with the disease in the time of the internet (IOB 
Survey Respondent 145). 
  
 
Not so much about information for me support and knowing there are others having 
same experiences (IOB Survey Respondent 129). 
 
  
The positive social impact of online communities on cancer patients is well documented (Buis, 
2008; Penson et al, 2002; Reeves, 2000; Hoybe et al., 2005). These responses illuminate the 
sense of isolation experienced by many CLL patients, and the profoundly beneficial impact that 
online community participation has had on that for them.  
 
Tom Ferguson defines the e-patient as empowered and ‘informed’. However, it is clear that the 
level of information patients can deal with is dependent on individual levels of health literacy. 
CLL communities accommodate members discussing the disease at extremely high levels of 
scientific knowledge, alongside others without the knowledge or language required to 
participate at the same level. This left some feeling alienated or excluded by the technical 
detail, although still finding more emotional disclosures useful:  
 
I struggle with the detail - a lot of people comment in detail about b cells and things like 
that. It is too much information. I do appreciate though when people say how they feel it 
is reassuring to know I am not on my own when I feel rubbish! (IOB Survey Respondent 
199) 
  
Alienation wasn’t the only response to technical exclusion though. The following respondent 
describes a strategy of befriending others in the network more medically literate than 
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themselves, and thus able to provide translations:   
 
While I don't understand much of the very technical information sometimes posted or in 
links, I feel that I am reasonably up to date on what's current and up and coming 
treatment wise, as well as how to interpret my labs, etc.,and I have developed 
friendships with people who do understand the very technical reports and know that 
they can and will explain them if I ever need more information (IOB Survey Respondent 
20). 
 
Those technically competent individuals tend to become key actors in communities, circulating 
research papers and important CLL news into local nodes across a global network, and bringing 
them into contact with the everyday lives and stories of support community members through 
the intermediary function of the digital platforms hosting various sites.   
 
Translation: When Knowledge isn’t Always Power… 
 
Whilst a sense of empowerment, control, and connection was expressed widely across the 
significant majority of positive responses, some acknowledged the challenge of confronting 
information that might not always be positive: 
 
Sometimes, periodically it depresses me other time panics me so I take a breather and 
come back later (IOB Survey Respondent 77). 
 
 
It's a question of extracting the level of detail I need when I am feeling upbeat enough to 
deal with the inevitable negatives I come across! (IOB Survey Respondent 257) 
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sometimes too much information about what will happen as the disease progresses is 
too scary for me - I know I will have to face it but the knowledge of where to find the 
information when I need it is sufficient for me right now (IOB Survey Respondent 247). 
 
 
I may not particularly like what I might find but knowing gives me the opportunity to at 
least adjust or perhaps put up some resistance to what might be or about to be 
happening. The only trouble with the Ostrich Syndrome is that it leaves a certain part of 
your anatomy exposed (IOB Survey Respondent 231). 
 
 
I have researched my own bone marrow biopsy results and found some distressing 
information from research papers regarding my own perceived position. This made me 
more scared and a little depressed about my future (IOB Survey Respondent 19).  
 
 
 
 A number of respondents claimed that internet use did nothing to help them live with CLL. 
Gatekeeping information within very defined or hierarchical structures, whether at professional 
or online community levels, can be seen as a constraining factor in the democratization of 
knowledge. However, many respondents remarked on the obverse experience of information 
overload when the brakes are taken off the flow of information in networks: 
 
There is the possibility of information overload and a sense of 'coming to me sometime 
soon' feeling. Pure information for the sake of it can be daunting, i.e. percentage of 
people with CLL who go on to contract secondary cancers and their reduced OST etc. 
There are times when purist technical stuff has little applicable benefit and can cause 
alarm and generate anxiety. Some information should be restricted to clinicians and not 
used simply to inform patients if it can cause nothing but anxiety (IOB Survey 
Respondent 14). 
 
 
This respondent articulates a number of concerns associated with what might metaphorically 
be described as drinking from the fire-hose of CLL information online. Skills are required to 
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negotiate the fine line between quenching a thirst for knowledge, and drowning in it. Again we 
see the issue of aggregate statistics, this time around susceptibility to secondary cancers, 
implying a second order of risk for CLL patients. In referring to such knowledge as ‘pure’, 
‘purist’, and ‘information for the sake of it’ the respondent implies its uselessness in the applied 
sense, and links it to raised anxiety levels. In their closing comment, the respondent articulates 
a wish to make it stop – to put the genie of unalloyed information flow back firmly into the 
bottle of professional control.  The art of discerning and managing the relevance of unregulated 
information in the networks to one’s own life is a difficult one, and whilst some learn to 
negotiate that, for others it translates ultimately to a lack of trust: 
 
There is so much conflicting information that I feel it is difficult to trust any of it (IOB 
Survey Respondent 156). 
 
 
However, as you will know most of the net is not peer reviewed. That means that for the 
'ordinary person' (no scientific back ground, no medical or science qualifications) it is a 
question of the loudest voice wins. So many people believe what is actually incorrect. 
This can be subtly incorrect, or just an emphasis on useless aspects or ideas (IOB Survey 
Respondent 168). 
 
 
Whilst this may be true for individuals researching alone from databases and sources in the 
network, this work also evidences high levels of engagement with technical and medical 
information in the more dialogic spaces of the community. Support networks are bringing 
together highly competent lay people with professionals across a range of medical and related 
disciplines so an extremely well-informed and robust level of debate filters down into many of 
those communities forming the most vibrant nodes in the network, and identified as popular 
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sites by the survey respondents. Furthermore, that information does not remain external to the 
clinical relationships that patients have with their own doctors, allowing (in the best case 
scenario where doctors are open to collaborative relationships with their patients) for the 
professional experience and knowledge of the clinician to mediate or translate online 
information into the individual clinical context of a particular patient. Highly competent 
patients might also bring new information to their doctors in a circular flow of online/offline 
narrative exchange. 
 
Translation: Impact of Digital Knowledge on Clinical Relationship  
 
Decreasing respect for the hierarchies of knowledge and expertise in medicine has produced 
internet users comfortable to seek information beyond that deemed suitable for a ‘lay’ 
audience (Hardey, 2001:402). Ferguson (2000) observes that the chronically ill online can 
display ‘impressive’ knowledge of their own disease, functioning not only as valuable resources 
for other patients, but also as ‘valuable resources and allies for health professionals’ (Ferguson, 
2000: X).  I was interested in testing out the effects that online narrative sharing practices were 
having on respondents’ own clinical relationships. Two hundred and twenty respondents 
answered the question ‘do you discuss what you learn online with your doctors?’, and 158 
chose to expand on their response.  
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One hundred and seventy six (79%) of the 220 respondents answering the question said they 
did discuss online information with their doctors, the remaining 46 (21%) did not. Text 
responses indicated overwhelmingly positive experiences with clinician responses to their 
online learning. Seventy three per cent (114) of the 158 text responses reported positive 
experiences, albeit that those positive experiences were inflected in various ways reflecting 
some interesting themes for exploration in this section. Sixteen per cent (25 people) reported 
neutral experiences (neither especially positive nor negative), and 17 people (11%) reported 
negative experiences. 
 
One respondent took the time to reflect on this question in relation to the traditional 
clinician/patient relationship, making insightful observations about the potential threat that 
informed patients might pose to doctors, and the strategies they may adopt to deal with it: 
 
This is the biggest issue for the patient/doctor relationship I believe. It's probably much 
easier to be a passive, accepting patient (not necessarily safer though!) and it 
challenges the clinical 'mentality' that patients may even have read beyond their level 
on their subject. The fact that patients also understand the information and want to 
discuss it's [sic]relevance to their care can make doctors resort to their fall-back position 
of 'a little knowledge is dangerous'. With CLL, it's been a Cinderella subject for so long 
that I think patients have seized the initiative. I've found the Consultant happy to 
discuss research, developments etc. but possibly more resistance with his junior staff 
who possibly feel more threatened and surprised. It's balancing being a 'know-all' with 
fighting for the very best services and maintaining a good relationship with the clinical 
team. Patients who put on the nightie, look suitably afraid but grateful probably make 
the easiest patients. My GP admits 'I challellenge [sic] him' and he enjoys it! (IOB Survey 
Respondent 14) 
 
 
Having to negotiate a balance between appearing too “pushy” and demanding the best 
treatment and services available is well articulated in this response. Patients who are active 
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researchers at home have reported actively performing a passive recipient role in the clinic to 
avoid ‘the negative reactions they anticipated receiving from physicians’ (Kivits, 2006:279). 
Respondent anxiety about being perceived as reading ‘beyond their level’ is supported by 
observations in the literature that informed and connected online patients can be treated with 
hostility or irritation by doctors who label them as “over-informed” or “problem” patients 
(Broom, 2005:336). Perceived pressure to be a “compliant” patient is also acknowledged by this 
respondent, although keeping informed is seen as having improved the clinical relationship, 
albeit described as a somewhat grudging resignation on the part of the doctor: 
 
My doctor doesn't seem interested in my knowledge, just wants me to be a compliant 
patient. I think this is due to not having enough time, too many patients to see each day. 
But my understanding and knowledge do make it easier for us to work together. I have 
emailed and phoned her as well as seeing her at the clinic: she's approachable and 
answers all my questions but not in detail, often with a 'leave it to us to know what 
we're doing' tone (IOB Survey Respondent 15). 
 
 
 
Demands on clinical time raised by this respondent appear in the literature as a significant 
factor in perceived physician resistance to engaging with informed patients in clinical settings 
with physicians concerned about “the time-consuming effort required to contextualize and 
interpret information for patients” (Ahmad et al., cited in Jacobson, 2007: 5)42. Despite general 
positivity to the increased understanding of disease demonstrated by patients researching 
 
42 Taken from a Canadian meta-analysis of work studying the effect of the internet on empowering the physician-
patient relationship (Jacobson, 2007: 5) 
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online43, doctors calculated that engaging with informed patients added an average of 10 
minutes to the clinical meeting (Helft et al., 2003: 946). A sense that doctors might eventually 
adjust to patients’ increased knowledge and its attendant demands was commonly reported, 
demonstrating an evolution in cultural attitudes to clinical relationships, although variations 
across medical team members persist for some:  
 
My doctor in the beginning wanted me off the internet to stop scaring myself, but she 
has come to trust my judgment and now have ongoing discussions about trials, etc. (IOB 
Survey Respondent 66). 
 
 
Ten years ago was different, however as the years went by and some consultants learn 
to treat patients as part of the team, being well informed helped…(IOB Survey 
Respondent 72). 
 
  
My doctors (Hematologist and Family practioner) [sic] have both commented that I know 
more about CLL than they do. They are glad that I am a proactive patient (IOB Survey 
Respondent 94). 
 
 
The ones I have now seem to engage me without being threatened by my lack of 
intimidation in their presence. Doctors vary in this regard; some are "take charge" 
and/or "listen to the expert-me" to the point of rudeness (IOB Survey Respondent 111). 
 
 
My GP is fine and supports me very well. The head of team at Cancer Care encourages 
an informed approach. Occasional locum does not and likes to patronise. It has given me 
confidence to prepare my questions and ask for copies of letters to GP and blood tests 
(IOB Survey Respondent 179). 
 
 
 
43 As demonstrated in a study of clinicians’ engagement with informed online patients in clinical settings, carried 
out by Helft et al (2003). 
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The issue of perceived “threat” to clinicians from online knowledge-sharing among patients 
continues in responses to this question, not always attributable simply to subverting traditional 
knowledge hierarchies. Clinicians may also worry about becoming subject to personal criticisms 
by patients online, adding another dimension to clinical attitudes to digital patient 
empowerment:  
 
My doctor makes a point of not subscribing to any of the lists (she says she is afraid she 
might read something negative about herself--though that is never the case, in fact; 
she's very popular). However, she is willing to talk to me about anything I've learned or 
have questions about. She seems to be one of those doctors who tells her patients as 
much as she thinks they can handle; she knows I'm informed, so she is pretty straight 
with me (IOB Survey Respondent 26). 
 
 
 
As medicine enters the arena of online consumer networks, it is unsurprising that clinicians 
might fear negative feedback from disgruntled patients. A 2012 study concluded that, whilst 
the practice of patient ratings of clinicians was becoming more widespread, there was in fact 
‘no evidence that they are dominated by disgruntled patients’ (Gao et al, 2012), although the 
following respondent indicates perhaps why some clinicians may be worried if informed 
patienthood might reveal gaps in their knowledge:  
 
Currently, the reading up on CLL on-line has helped to realized that my Hematologist 
does not seem to know much about CLL as he is unable to answer the questions I ask 
(IOB Survey Respondent 71). 
 
   
Again, patient dissatisfaction with clinical knowledge translated into strategic response in many 
cases, ranging from the extreme measure of changing doctors altogether to the kind of pro-
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active collaborative approach to improving clinical knowledge described by the following 
respondent living in an area not serviced by a CLL specialist:   
 
We have no experts in Atlanta. I went to SanDiego twice for better advice. I have a 
support/discussion group here and we tried to get all CLLers to use Dr. xxx  [name 
redacted by me]. This way she might become more "expert." No such luck. I emailed 
her 3x about PCI 32765 and at my last IVIG she didn't know yet what it was. I 
changed doctors the next month, after 10 years with her. My new condition 
requires more expertise now (IOB Survey Respondent 30). 
 
 
 
Translation: How Patients Employ Knowledge in the Clinical Setting  
 
Patients described a range of practices for employing knowledge gained online during 
consultations.  For some, it provided the context required to make sense of clinical decisions, 
advice and results: 
 
It gives me context, more than anything. My range of understanding has expanded a 
great deal over the 18 months since my diagnosis, so I feel more comfortable talking 
about my blood tests and about possible future treatment options (IOB Survey 
Respondent 117). 
 
 
…I am happy that what the doctors say is in agreement with what I understand from the 
internet (IOB Survey Respondent 45). 
 
 
I ask better questions and understand their answers better (IOB Survey Respondent 
255). 
 
  
What I learn online gives me insights to better understand what doctors are telling me. I 
don't feel a need to cite the online material. I just have much more confidence in 
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dialoguing about my CLL (IOB Survey Respondent 17). 
 
 
Doctors have noted the positive elements for informed patients’ sense of control over their 
disease management inherent in an ability to engage in “more equal, intellectual discussions” 
(Helft et al., 2003: 945). The following response shows how informed patients may feel 
confident to take the lead in a frank dialogue concerning outcomes that doctors might have 
been reluctant to initiate: 
 
Doctors seem to not want to tell you the bad things only the not so bad. Finding the bad 
things on line allows me to get them to open up (IOB Survey Respondent 56). 
 
 
Others used their information in much more pro-active ways to take a lead on their treatment 
decisions and choices, including changing clinicians where they felt this to be appropriate: 
 
MY CURRENT DR. WAS SURPRISED ABOUT MY LEVEL OF KNOWLEDGE CONCERNING THE 
DISEASE. SHE IS GLAD I USE THE INTERNET BECAUSE I HAVE ALERTED HER TO SOME 
THINGS THAT SHE WAS NOT AWARE OF. SHE WAS GOING TO USE FCR FOR MY 
TREATMENT, BUT DUE TO MY FOLLOWING DR. HAMBLIN'S ACOR ADVISE, I PURSUADED 
HER TO USE CHLORAMBUCIL/RITUXAN. SHE IS HAPPY I WENT THAT ROUTE BECAUSE SHE 
SAID SHE HAS NEVER HAD A PATIENT THAT RESPONDED TO THAT TREATMENT WITH 
SUCH SUCCESS. I AM APPROACHING A 3 YEAR REMISSION WITH ONLY A VERY BARE 
MINIMUM RESIDUAL DISEASE, ACCORDING TO BMB (IOB Survey Respondent 59). 
 
 
My local general Hem/Onc commented that I was "a singularly well-informed patient." 
Since he confessed that he had never treated a CLL patient, that they mostly "die with 
the disease instead of from it", most of my information from the internet was more up-
to-date than his. He was happy to do the extra tests I requested, and to discuss the 
results with me, and when treatment time came, happily sent my records to the CLL 
specialist I chose. When I saw the specialist, he was pleased that I understood my 
options, and I was able to begin a clinical trial immediately (IOB Survey Respondent 54). 
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Skin specialist now schedules regular check-up due to increased risk of skin cancer (IOB 
Survey Respondent 49). 
 
 
…diagnosed in 2008 I was referred when the level doubled in 6 months to the local 
Haematology unit in May 2011. Monthly blood tests continued until Sept 2012. At that 
point having had 3 infections and a count of over 200 I asked about treatment and was 
assured all was well. At that point I used cllsa website to find another consultant and got 
myself transferred (IOB Survey Respondent 226). 
 
 
I basically tell the doctors what is required (IOB Survey Respondent 117). 
 
 
Respondents commonly reported sharing links to interesting studies with their consultants, and 
downloading research papers to take to clinic. For one respondent, this activity led to an 
advisory role for new patients at their local hospital, the kind of scheme now legitimized by NHS 
hospitals in the UK as part of the Expert Patients Programme44 for those living with chronic 
disease: 
 
Many of my questions to my CLL Specialist regarding my CLL Diagnosis are based upon 
information I learned. Additionally, I also share info learned online with my GP giving her 
the URL to the reference materials (IOB Survey Respondent 124). 
 
  
My doctor knows that I'm very involved and has connected me with newer patients (with 
my permission), as has have the social workers at UCLA. My other specialists often ask 
me questions about CLL, as they also know that I do a lot of reading, attend conferences, 
etc. I have provided them with booklets, reports, etc. regarding CLL in general and 
specific questions they might have or issues that I feel need to be addressed (IOB Survey 
Respondent 20). 
 
 
44 For further information about the Expert Patient Programme in the UK see,  
http://www.nhs.uk/NHSEngland/AboutNHSservices/doctors/Pages/expert-patients-programme.aspx 
Julia Kennedy 
123 
 
 
For some respondents, the experience of sharing knowledge with their clinicians was simply a 
positive one, and actively encouraged.  This seems particularly to be the case where clinicians 
are already acknowledged as global experts in their own right:  
 
My Dr. reacts very positively to this as he is a world-renowned specialist in CLL. He 
encourages his patients to be well-informed on the latest treatments available (IOB 
Survey Respondent 93). 
 
CLL medical experts are often academically inclined. A patient orientated discussion can 
therefore become a 'conversation between experts'. Most enjoy this (IOB Survey 
Respondent 254). 
 
 
 My oncologist is fine with it. Otherwise, I would find a different doctor (IOB Survey 
Respondent 124). 
 
 
Despite many overwhelmingly positive responses, some respondents reported very negative 
experiences:   
 
They are not interested really. Standard of CLL w an w care is minimal. You have to be 
pushy to get answers. Get much more information from informed websites and own 
research (IOB Survey Respondent 169). 
 
  
My doctor normally does not really support or encourage information such as all of the 
available prognostic tests or alternative natural therapies that could have a small effect 
on disease progression (IOB Survey Respondent 96). 
 
 
The doctors did not seem interested at all in what I learned on line. One doctor actually 
seemed amused (IOB Survey Respondent 33). 
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A degree of lag in the evolution of the medical profession to accommodate new modes of 
information and support exchange taking place online is perhaps inevitable. The era of the ‘e-
patient’ radically shifts traditional cultural models of healthcare delivery in industrialized 
society, challenging lingering paternalism and autocracy in the medical profession. Some 
respondents accepted this as a fact of life, giving up sharing information with their clinicians: 
 
The doctors seem to dismiss what I find out on line as unsuitable, so I don't bother now 
(IOB Survey Respondent 186). 
 
 
Whilst others refused to accept or bow to disapproval: 
 
I think my internist, who originally suspected I had CLL thinks my research is “ fluff “. I 
ignore him on this and still do it! (IOB Survey Respondent 31) 
 
  
Even in the era of the so-called expert-patient, some patients simply prefer to leave 
management of their disease entirely to their doctors:  
 
My consultant is always clear in his messages to me, and I've never read anything that I 
have felt I should raise with him (IOB Survey Respondent 201). 
 
 
Some of the information is contradictory and although it seems a cop out I trust my 
consultant. I am on a treatment which on the internet is given as a course after a period 
of remission and according to the USA research is not as good as the older FCR.It is 
getting results for me though and I don't feel like rocking the boat  (IOB Survey 
Respondent 199). 
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I would rather trust my doctor than anything picked up from some website I may have 
come across. When first diagnosed I visited the web and it scared me to death! It gave 
the impression that I was on deaths door. That was 10 years ago and I have not used the 
web to help diagnose my CLL, I leave that to the professionals, Some web sites came 
across as ill informed and it became clear that it was hard to differentiate between the 
genuine and the freaky, so I do not bother looking (IOB Survey Respondent 156). 
 
 
A 2000 study showed that this was mainly the case for older, male patients, and patients in the 
study cited ‘Wanting to be seen as a “good customer”, trusting what a doctor says, and 
“ignorance” and the consequent (perceived) inability to assimilate medical information’ among 
their reasons for not seeking their own information (Leydon et al., 2000:912).  
 
Finally, concerns about general practitioner knowledge of CLL are expressed frequently in 
online communities, and repeated in the survey:  
 
The Consultant will always discuss any queries I might have. GPs are disinterested, as 
well as poorly informed (IOB Survey Respondent 195.) 
 
  
only with my consultant as my gp does not give me a lot of confidence (IOB Survey 
Respondent 188). 
 
 
 
The lack of confidence in GP provision amongst patients with CLL indicates a need for further 
research in this area, and a need for improved communications between CLL specialists, 
support groups and GPs addressing the current knowledge gap and its implications for support 
in primary health care contexts.  
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Chapter Summary 
 
Evidently, significant numbers of people with CLL are accessing the internet for support and 
information. Key milestones in the disease such as diagnosis, the receipt of prognostic markers, 
starting treatment, and changes in rate of progression are common themes in the subject 
matter of community discussions. Even patients with indolent, or stable disease status maintain 
strong links with networks, keeping up with current treatment innovations, CLL news in general, 
and accessing psycho-social support systems, although a desire to minimize exposure to 
distressing narratives from people at more advanced disease stages was commonly expressed.   
In general, patients report positive impacts from their online knowledge sharing, echoing 
findings from co-existing general literature on online health communities. Specific to CLL 
networks are the tensions noted in narrative support communities resulting from the wildly 
heterogeneous nature and outcomes of CLL, attitudes of an older demographic to online 
communications and hierarchies of medical knowledge, and the rapidly evolving field of 
knowledge and treatment protocols in CLL.  Also key are inequalities in access to CLL specialists, 
and the role of online information sharing for those not under specialist care. Finally, and of 
very real significance, is the fact that CLL is currently considered incurable, placing those living 
with it into a position where their foreseeable futures will be intertwined with other online 
actors. Strong, and long-term, links are forged and maintained.  
 
The impact of online information seeking on patients’ relationships with doctors was 
particularly interesting, with again a fairly positive picture emerging of a move towards more 
Julia Kennedy 
127 
 
collaborative and informed relationships in many cases. However, there is still some way to go 
before the traditional notion of top-down information exchange from doctor to patient in the 
clinical setting is universally challenged. This point was evidenced both in some of the feedback 
from those patients actively researching online and meeting with resistance from their doctors, 
and also from a group of patients themselves not wishing to challenge the status quo. 
 
The thematically presented network mapping that follows is intended to be read in relation to 
the voices replicated in this chapter, and readers will encounter more of them as the work 
proceeds. It is all too easy to make assumptions from field observations about why people do 
what they do online, and what they might get out of it. Simply observing online community 
narrative exchange could lead to a conclusion that a high percentage of CLL patients are active 
actors in the networks, benefitting from their interactions. The survey allows for nuancing those 
assumptions through thick description from respondents, some of whom don’t actively 
participate in the networks in ways that can be captured by field observation, and illuminates 
areas left in the shade by online field observation alone.  
 
It is important to remember, however, that many patients with CLL may never engage with 
online resources. At a recent CLL support meeting in Cambridge in the UK, as a member of a 
panel discussing patient advocacy, I asked the 120 strong audience to indicate if they used 
online resources to research CLL or stay connected with others by a show of hands. A significant 
number of the audience did not raise their hands. Although motivated and engaged enough 
with their disease to travel to attend a regional support meeting, voices such as these remain 
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outwith the research I have carried out here. It is not possible to hazard a guess at the numbers 
of people with CLL who neither engage with face-to-face or online support resources, and this 
would make for useful further research perhaps conducted through local haematology centres. 
Non-engagement with online resources may well be a matter of choice, but the CLL 
demographic are not digital natives and, as the following survey respondents show, people  
aren’t necessarily aware enough of the resources that exist online to make an informed choice 
about engagement: 
 
I was not aware of any such websites (IOB Survey Respondent 226). 
 
 
I didn't know about any of the other sites! This has already inspired me to start 
searching… (IOB Survey Respondent 201) 
  
Of course, the survey itself is to some extent self-selecting as it was distributed online with the 
aim of enriching the network information for this study gained through fieldwork rather than 
establishing a broader picture of engagement with online resources amongst CLL patients45. It 
should be read both as an active network in its own right, and an important tool for making 
visible some of the enactments of online practices both mapped in further detail and absent 
from the themed network mapping that follows.    
  
 
 
45 The responses certainly reveal useful information about online practices and attitudes among this group that 
could usefully be extrapolated to support further work exploring inclusivity measures for an older patient group to 
engage with digital communities and resources. 
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Chapter 3: Diagnosis 
Introduction 
 
Diagnosis with CLL is devastating experience for most. Learning that one has an incurable, 
chronic form of leukaemia can come as a profound shock, and a lack of public and at times 
general medical familiarity with the disease makes it difficult to access empathetic support. As 
the survey work in the previous chapter demonstrates, CLL patients are actively accessing and 
creating online resources in varying ways to help them to live with their disease. For most, this 
engagement begins shortly after diagnosis, and often in response to a perceived lack of clinical 
information:    
 
My initial reaction was of complete shock which was exacerbated by the manner in 
which I learned of my diagnosis from my GP. In the absence of any useful information 
from my GP and whilst waiting for a consultant appointment I turned to the internet to 
learn more about CLL (IOB Survey Respondent 212). 
 
 
The shock of a cancer diagnosis for many preceded the sense that responses from clinical staff 
did not correlate with the extreme distress they were experiencing. This work shows that a 
significant number of CLL patients feel that the heterogeneous progress of CLL, and its older 
demographic, render it less important than more acute cancers in the minds of clinicians and 
the general public alike, belying the very real challenges that living (and dying) with CLL can 
present. Patients report feeling mis-understood, misinformed, or even ‘fraudulent’ in a culture 
more attuned to acute cancers. The mismatch between the catastrophic effect that diagnosis 
Julia Kennedy 
130 
 
had on many CLL patients, and the casual or uninformative clinical manner attitude with which 
they felt the news was delivered by doctors emerges as a very strong theme indeed in this 
chapter.       
 
Those newly diagnosed with CLL often face a profoundly counter-intuitive situation. Diagnosed 
with chronic, incurable leukaemia, yet obliged to wait until symptoms become acute before 
commencing treatment, patients must learn to manage the cognitive dissonance inherent in 
accommodating rather than treating an insidious cancer in a culture strongly wedded to pro-
active battle metaphors in relation to cancer. Occupying an indeterminate grey zone between 
health and grave illness, immune-compromised, and often having little certainty about the 
future, the newly diagnosed and their families can struggle to make sense of their situations. 
Seeking knowledge, information, and social support online were key strategies adopted to 
manage the sense of fear and dislocation often experienced in the early days of diagnosis:  
 
I started researching online immediately and felt frustrated that my hematologist said 
prognostic testing was expensive, not useful and who would want to know anyway. CLL 
Topics and CLL Forum were very valuable as they brought to my attention detailed 
information about the disease. It took me a year to emotionally come to terms with the 
fact I had a terminal cancer with no idea on how long I had to live - very difficult to know 
what to do about life and business plans... (IOB Survey Respondent 15) 
 
 
Several key sites emerge from fieldwork, attracting frequent mentions amongst the 
respondents in their descriptions of the diagnostic experience. Especially popular are: Chaya 
Venkat’s CLL Topics; Andrew Schorr’s Patient Power site; the blogs of Brian Koffman, Sharman, 
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and Terry Hamblin; CLLSA UK and its Health Unlocked site; ACOR’s CLL listserv; CLL Canada; the 
Yahoo CLL sites and Macmillan. 
 
Between them, 165 survey respondents wrote around 10,000 words of text about their 
diagnostic experiences, from which a number of key themes emerged. Although in a significant 
minority, some patients reported that online information seeking around diagnosis made them 
feel worse as they often encountered upsetting patient stories or survival figures that 
undermined their own sense of hope for the future:  
 
…After the initial shock I did use the internet but this did little to help me, only to frighten 
me more… (IOB Survey Respondent 200) 
 
 
Most though reported that the internet had ultimately helped them to find information and 
support in the confusing and often terrifying early days of diagnosis: 
 
For me, knowledge is key. I can live with any diagnosis if I understand what the illness is, 
how it is likely to progress, what the prognosis is and how it will be managed. I obtained 
a comfortable understanding by a lot of online research (IOB Survey Respondent 128). 
 
 
This seemed to be the case even where early research was a difficult and overwhelming 
experience:    
 
When I was first diagnosed, I found information on the internet somewhat 
overwhelming. However, I became better informed about the disease through sites like 
CLL topics. Today, I find Andrew Schorr's site, Patient Power, provides thorough 
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information, especially about the latest research (IOB Survey Respondent 120). 
 
 
 
A good deal of literature exists on patient responses to a diagnosis with both acute cancers and 
chronic illnesses. CLL resolutely blurs the boundaries between both, and in this chapter’s 
perspectives I draw on studies from both fields in the recognition of a deficit of work on the 
impact of a chronic cancer diagnosis. Emphasis is placed on information seeking practices in 
cancer patients generally, notions of biographical disruption in the chronically ill, and the role of 
illness narratives (Frank, 1997; Kleinman, 1989; Hunsaker-Hawkins, 1999; Jurecic, 2012) in a 
digital era (McLellan, 1997). How do contemporary CLL patients mobilize their own stories of 
diagnosis in relation to a range of multi-perspectival narratives online to help manage the crisis 
of transition following diagnosis? 
 
For the translations in this chapter, I will explore three circulating narratives in the networks:  a 
physician patient blog addressing CLL’s contentious title of the ‘good cancer’; a research paper 
by a CLL expert and two health researchers evaluating the psychosocial difficulties of living with 
a disease that is ‘Invisible, Incurable and Inconclusive’; and excerpts from posts by a CLL patient 
tracing their narrative journey over several years from newly diagnosed and seeking help to 
accepting diagnosis and offering help to others.  
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Perspectives: A CLL Diagnosis 
 
CLL is a relatively slow growing B cell malignancy, treatable though currently considered 
incurable. According to Cancer Research UK, around 2,80046 people are diagnosed with CLL 
every year in the UK, and SEER estimates that 14,620 people will be diagnosed with CLL in the 
US in 2015, with an estimated 4,650 deaths47. Despite its relative rarity, CLL is the most 
common type of leukaemia, accounting for around 35 out of every 100 cases of leukaemia. 
More prevalent in men than women, it generally affects older people, with 75% of those 
diagnosed with the disease aged 60 or over. Cancer Research state that currently 44% of men 
and 52% of women diagnosed with the disease will survive for at least 5 years after being 
diagnosed, although individual outlook depends on the stage of the disease at diagnosis, and 
treatment regimes are evolving in a way that is likely to extend expected survival time based on 
older traditional protocols.  
 
Usually diagnosed from a routine blood test, early physical symptoms include recurrent 
infections, swollen lymph nodes, and fatigue. Microscopically, the disease presents as an 
abnormally high presence of immature white cells, often fragile and “smudging” on the slide as 
illustrated earlier in this work. Blood tests reveal elevated white blood cell and absolute 
lymphocyte counts with possible platelet and haemoglobin aberrations in advanced disease. 
 
46 Figures taken from http://www.cancerresearchuk.org/cancer-help/type/cll/treatment/statistics-and-outlook-
for-chronic-lymphocytic-leukaemia [accessed 24/07/14]. 
 
47 Figures taken from http://seer.cancer.gov/statfacts/html/clyl.html [accessed 31/07/15]. 
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Lymph nodes may be enlarged, most palpably in the neck, groin and armpits, with 
organomegaly, or swelling of the spleen and liver in advanced disease. Traditionally, the degree 
of progress read through these signs is translated into two staging systems named for the CLL 
specialists who pioneered them: Rai (1968) and Binet (1981) and compared in Figure 12 below:  
 
 
Figure 12: GRIBBEN, J. (2010) Median survival times in CLL, from ‘How I Treat CLL Upfront’. Blood Journal 
[Online] 115(2), 187–197. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941409/ and linked to 
CLL page on Lymphomation site. 
 
Still used in clinical settings, these classifications can appear somewhat crude and generic to 
patients whose particular genetic status and treatment choices may now alter expected 
outcomes in ways not foreseen at the time.  
 
As stated, CLL is a B-cell malignancy, and diagnosis is confirmed through immunophenotyping. 
Using a flow cytometer, this process reads surface molecular expressions on B cells against 
Image removed due to copyright restrictions 
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standard patterns exhibited in CLL, and allows for basic prognostic readings based mainly on 
CD38 expression48.  Currently, at this stage, CLL patients will be either placed on a “watch and 
wait” regime involving regular monitoring by their haematology consultant or GP, or given 
further prognostic testing if disease progress or differential diagnosis is evident49.   
 
Perspectives: Diagnostic Miscommunication (Where CLL Worlds Collide) 
 
The above section lays out clinical frameworks for a diagnosis with CLL. Fieldwork in this project 
demonstrates a shared sense among significant numbers of CLL patients that shows that their 
diagnosis could have been communicated more effectively by their clinicians. Many patients 
feel that the subjective experience of having a chronic, incurable cancer isn’t matched by the 
often casual manner of its diagnostic and ongoing clinical communication, or by the broader 
socio-cultural attitudes that such clinical attitudes to some extent shape.  Furthermore, where 
patients have already taken to the internet to research their own disease on diagnosis, resulting 
awareness of the complexity and potential seriousness of their condition may compound a 
sense of having been inadequately informed and poorly supported by doctors who downplay a 
CLL diagnosis. This section explores tensions between subjective, biomedical and social 
experience of illness generally in existing literature, in the context of previous research on 
 
48 CD38 is a surface protein, the presence of which is thought to be associated with a poorer prognosis in CLL, and 
is identifiable by flow cytometry. For an in depth discussion, See Del Poeta, G. Et al’s paper, ‘Clinical significance of 
CD38 expression in chronic lymphocytic leukemia’ published in Blood Journal (2001).  
49 CLL and small lymphocytic lymphoma (SLL) are different manifestations of the same disease; SLL is diagnosed 
when the disease is mainly nodal, and CLL is diagnosed when the disease is seen in the blood and bone marrow.  
Mantle cell lymphoma can have a clinical presentation very similar to that of CLL, but it is more aggressive. See 
Mir, M. et al (2015) for a full exploration of differential diagnoses in CLL. 
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quality of life for CLL patients specifically, and survey responses from my own work.  
 
Diagnosis translates symptoms to a disease, subjecting the diagnosed to a range of institutional 
and cultural enactments in its name. The life-world of the newly diagnosed is altered by the 
subjective experience of illness, and they may be redefined socio-legally as ‘sick’ formulating a 
new identity and an identity crisis50. Distinct biochemical, subjective, and social dimensions to 
understanding the various spheres in which ill-health operates are identified in the following 
triadic approach, and are useful for exploring the dissonance between the subjective illness 
experiences experienced by many CLL patients, and the clinical/social responses evoked:    
 
• Disease is a negative bodily occurrence as conceived of by the medical profession. 
• Illness is a negative bodily occurrence as conceived of by the person himself. 
• Correspondingly, sickness is a negative bodily occurrence as conceived of by society 
and/or its institutions.   
(Hoffman, 2002, cited in Da Rocha and Etxeberria, 2013: 61). 
 
 
 
For most people a diagnosis of leukaemia in relation to the often relatively mild (or non-
existent) symptoms experienced in early CLL comes as a complete shock:  
 
The shock of being diagnosed with CLL after a routine blood test was difficult. Only now after 16 
months and just starting treatment can I say the words "cancer" and "leukaemia" without 
feeling upset. I have found the Macmillan information on the internet and booklet… ( IOB Survey 
 
50 Talcott Parsons (1978 [1951]) was highly influential in defining the notion of a ‘sick role’ within the sociology of 
health and illness in the 1950s/60s, and its implications for doctor-patient relations. Parsons argues that the 
physical disability of serious illness creates a dependency in the afflicted which deviates from the expected social 
roles. Conforming to the expectations of a ‘sick role’ however, legitimates such deviancy and obviates the sick 
person from guilt or blame within specific parameters of behavior. See Lupton (2012: 4) for an expanded view of 
Parsons’ ‘sick role’. 
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Respondent 190). 
 
 
Often in the early stages of CLL, the patient’s perception of being ‘ill’ doesn’t correlate 
effectively with their broader cultural understanding of what it means to have leukaemia – a 
word so culturally loaded that the above respondent takes 16 months to be able to use it in 
relation to themselves without distress. The twin exclamation marks following the following 
response similarly indicate the disparity between the gravity of the diagnosis and the subjective 
experience of illness experienced in early or indolent CLL: 
 
My first reaction was - I don't feel ill!! (IOB Survey Respondent 251) 
 
CLL patients soon learn however that they are (and will remain) significantly immune 
compromised and vulnerable to serious infection and phases of debilitating fatigue, yet can 
often feel (and look) quite well.  Being defined as a ‘cancer’ patient, whilst not obviously 
satisfying cultural expectations of this most feared of diseases produces further tensions for 
patients. Furthermore, CLL defies universal recognition as a singular disease by shape-shifting 
from indolent to aggressive, from relatively benign chronic disease to acute killer, and even in 
its progressive manifestations may include fairly lengthy periods of watchful waiting with very 
few outward manifestations of disease. Attitudes from those without CLL, clinicians included, 
inevitably reflect its ambiguous nature, and can leave CLL patients feeling confused and 
unsupported.   
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Among IOB survey respondents, dissatisfaction with diagnostic communication related both to 
the attitude and circumstances of diagnosis and in the amount of information and support 
offered:   
 
My diagnosis was a shock and the doctor was pretty diabolical, insensitive and unhelpful 
so the Internet has provided information and support beyond what I could imagine. I 
found a Facebook group - this continues to be my main resource now that I have done 
extensive research it's just nice to have people to share thoughts with (IOB Survey 
Respondent 232). 
 
 
Diag 2003 age 44 . I feel it was badly handled by a dismissive GP, and Consultant. 
Consultant was already holding the door open for me to leave his office as he answered 
my question 'Is it curable? '(IOB Survey Respondent 148) 
 
 
My GP at that time gave misleading info and was very off hand. He told me via the 
’phone with little time for me (IOB Survey Respondent 150). 
 
 
I am still coming to terms with having been diagnosed with CLL. My GP was so 'matter of 
fact' when informing me. I have gained more information from the CLL site than from my 
GP (IOB Survey Respondent 253). 
 
 
‘Diabolical’, ‘insensitive’, ‘unhelpful’, ‘dismissive’, ‘misleading’, ‘off-hand’, ‘matter of fact’, the 
language used by this small selection of a much larger group of respondents making similar 
observations reads like a litany of insensitivity at best, and a lack of professionalism at worst. So 
why do so many patients feel their experience of CLL is grossly misunderstood? The relative 
paucity of quality of life studies in CLL alongside lower symptom levels in early stage disease, 
and the generally better prognosis of CLL than some acute cancers may lead to an under-
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appreciation of the psychological challenges faced by CLL patients, and a subsequent lack of 
‘effective interventions to address their needs’ (Shanafelt et al., 2007:262). 
 
Aside from its incurability, heterogeneity, and the current limitations of accurate 
prognostication (or access to it), access to expensive new molecular treatments remain 
inconsistent meaning that, despite excitement surrounding improved treatment protocols, for 
many contemporary CLL patients, chemoimmunotherapy (CIT) remains a sole option. Network 
responses to issues surrounding prognosis and treatment will be explored in the coming 
chapters. Although coming to terms with a cancer diagnosis for which most patients will be told 
there is no immediate treatment is a challenge, this work has shown that most patients soon 
accept that the toxic, diminishing returns of repeated CIT cycles means that not being treated 
early is preferable in reality. However, the psychological balancing act required to manage the 
impact of living with an insidiously progressing systemic cancer against the need to manage 
toxicity51 through CIT can take a tremendous toll on CLL patients. To co-exist comfortably with a 
potentially fatal cancer in this way would be unimaginable to most people, yet the ability to do 
so and to get on with life with very little recognition of the devastating emotional impact this 
can have is clearly assumed by many CLL clinicians:  
 
 
51 Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in 
Chronic Lymphocytic Leukemia (CLL) patients with around 10% of NHL (non-Hodgkins Lymphoma) patients dev 
eloping these potentially devastating complaints within 10years of CIT. Although disease-related immune-
suppression plays a crucial role in this process, there is concern that therapy further may further increase the risk. 
See Ricci, F. et al (2011) in their paper ‘Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and 
Waldenstrom’s Macroglobulinemia’ for further discussion.  
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In an era where 70-80% of patients with CLL are diagnosed with early stage disease, the 
failure to recognize and address the emotional impact of CLL on early stage patients 
could lead to substantial and possibly preventable distress (Shanafelt et al., 2007:262). 
 
 
In her online feature ‘Doc, How Long do I Have?’,  key network actor Chaya Venkat (whose site 
CLL Topics features as a translation in the next chapter) draws on Hollywood representations of 
acute cancer diagnosis to illuminate the dissonance between its dramatic cultural coding, and 
the reality of being diagnosed with a chronic incurable cancer: 
 
Given that CLL is supposed to be the “good” cancer, it is much more likely that instead 
of corny pathos and empathy you will get flip condescension and told not to worry your 
pretty little head about it, go home and not bother the nice doctor… (Venkat, 2012) 
  
Whilst acute leukaemias and lymphomas occupy an almost dis-proportionate space in popular 
cultural images of cancer, chronic leukaemias are diseases with almost no popular cultural 
resonances, being rarely depicted in the media52. Neither located as (preferably young) tragic 
victim, visibly dying from an incurable cancer, or brave warrior, visibly fighting for one’s life 
within the compressed narrative time frames of acute illness, the CLL patient occupies a 
narrative hinterland. The sense of ‘underwhelment’ often accompanying conveyance of a CLL 
diagnosis is not limited to the clinical sphere. The response of friends and family to a recently 
diagnosed CLL patient failing resolutely to display obvious cancer signifiers can include 
 
52 In an analysis of 40 Hollywood produced films portraying cancer from 1935 until the mid-nineties, 19 portrayed 
main protagonists suffering from leukemia or lymphoma. A similar dis-proportionate representation of patients 
under 30 years of age (50%) and under 40 years of age (75%) was noted. Author Robert Clark hypothesizes that “In 
order for films to continue to depict "clean" cancers, in young, attractive subjects, leukemia/lymphoma has 
become the modern movie cancer (Clark, 1999)  
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confusion, scepticism or outright disbelief53. 
 
Accurate diagnostic information is about much more than facilitating emotional adjustment. A 
cancer diagnosis can have a profound impact on expected lifespan, and information about how 
that is at least likely to play out will be a part of adjusting future plans and major life decisions 
accordingly. Consider the devastating impact of underplaying the potential of a CLL diagnosis on 
the following respondent, the partner of a CLL patient who was dead five years after being 
diagnosed with the ‘good cancer’: 
 
Truly would have lived those last 5 years of his life totally different because we could 
have managed financially but I kept working for health insurance reasons. Big mistake 
but we had been told this was the "good" cancer and he would likely live to die of 
something else. Wrong (IOB Survey Respondent 40). 
 
 
 In terms of the triadic model set out at the start of this section, the subjective (illness) 
experience of the patient can be read against the biomedical (disease) practices of the clinical 
team, and how the latter ultimately defines the socio-legal practices of institutions required to 
provide benefits, insurance and so on should the patient require them (sickness). Network 
discussions reveal that CLL patients often experience real difficulties with these overlapping 
spheres. Once diagnosed, a CLL patient may, find themselves categorized as a ‘terminal’ patient 
for insurance purposes, be unable to obtain life or travel insurance, and face problems with 
 
53 Several stories were encountered in the networks during the period of research outlining incidences of friends, 
family members, colleagues and employers casting doubt on the validity of a CLL diagnosis amongst those patients 
in watch and wait and with no visible outer signs of disease. For ethical reasons concerning privacy and consent, 
they cannot be replicated here. 
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equality in the workplace (some IOB survey and network respondents reporting losing their jobs 
soon after diagnosis due to absence or requirements for necessary adjustments). The same 
patients however report difficulties in accessing benefits, qualifying for medical or early 
retirement, or claiming their critical illness cover on existing life insurance policies. It seems that 
the social status of the CLL patient as ‘sick’ is as mutable within the various economies it 
impacts on as is its status within the broader hierarchies of disease according to medical 
professionals. While the subjective experience of illness with CLL itself operates on a wide 
continuum, contradictions in definition and practices in relation to this disease broadly remain 
significant, having a deleterious material effect on many patients’ lives.  
 
A posting selected from physician/patient Brian Koffman’s blog in the network Translation that 
follows allows us to consider the contexts that might underpin tensions between subjective and 
biomedical enactments of receiving and delivering a CLL diagnosis in the clinical setting.  
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Translation: Living With the ‘Good Cancer’ (A Physician/Patient Blogs)  
 
Figure 13:  TOUCHGRAPH (2015) network connections  from Brian Koffman’s Blog to Andrew Schorr’s advocacy 
Site, Patient Power [Network Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=brian%20koffman%20blogspot%20patient%20power [Accessed 
25/07/2015]. 
 
In the current absence of dedicated research among clinicians diagnosing CLL, speculative 
explanations for poor diagnostic communication experiences might include commonplace 
delivery of initial diagnosis by general practitioners; inconsistencies in cutting edge clinical 
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knowledge about the disease outside of a specialist setting; and its generalized status as a 
‘chronic’ cancer usually diagnosed in older patients, which may make it appear less immediately 
important to clinicians54. This Translation takes a closer look at clinical enactments of diagnostic 
communication in online narratives, and considers how such practices might be enhanced 
through strategic networked narrative circulation. 
 
Many CLL patients will, at some point, be told that we are lucky to have the ‘good’ cancer – an 
unacceptable oxymoron for many, despite its intentions to convey the relative preferability of a 
CLL diagnosis over a more aggressive cancer. Clinical use of comparative outcomes between 
acute and chronic cancers as a frame in diagnostic communication is explained, and to some 
extent supported (if the manner in which it is often communicated is not), by Brian Koffman in 
a posting about the so-called ‘good cancer’ issue on his blog ‘Learning from and about cancer 
(chronic lymphocytic leukaemia or CLL) in 2014: A US family doctor, Koffman was diagnosed 
with CLL in 2005. Narrative accounts of doctors become patients are well documented 
(Klitzman, 2007; Jones, 2005; Campbell, 2012; Granger, 2014; Tomlinson, 2014), at the same 
time illuminating the presence and indicating the potential porosity of the normative 
hierarchies underpinning clinical and patient roles in everyday practice. Catapulted by illness 
 
54 In ICM research 48% surveyed believed stereotypes and assumptions about the elderly held by health 
professionals contributes to the UK having some of the worst cancer survival rates in Europe for older people. 
These findings are echoed in recent reports published by the Royal College of Surgeons (2012) and the Department 
of Health (2012) evidencing that some health professionals make age-based assumptions about people’s ability to 
tolerate cancer treatment. See Macmillan.org news feature ‘Ageism in NHS stopping older cancer patients getting 
treatment’, 20/12/2012.  
55 See Tomlinson (2014) ‘When doctors become patients’, an entry posted on January 27, 2014 on Jonathon 
Tomlinson’s blog ‘A Better NHS’ for an excellent explication and literature review of the phenomenon and impacts 
of doctors experiences of patienthood. 
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into the role of patient, yet imbued with the professional knowledge and expertise of the 
trained clinician, such doctor/patients experience disease from a unique perspective55. Able to 
speak as a patient with the considerable clinical skills and insights gained from his professional 
experience, it is unsurprising then that Brian Koffman’s blog is hugely popular resource in the 
CLL networks.  Koffman himself is a key actor in CLL networks online, attending major 
haematological conferences, producing video interviews with CLL experts which he 
disseminates via his blog to several of the major CLL forums, and contributing to debate across 
the networks. He describes the aims of the blog thus:  
 
                 WHAT STARTED AS A PERSONAL JOURNEY MORPHED INTO A WAY TO SHARE WHAT’S 
UNIVERSAL IN DEALING WITH CANCER, IN MY CASE A NASTY LEUKEMIA (CLL), A 
FAILED TRANSPLANT AND SUCCESSFUL EXPERIMENTAL THERAPY. THE TELLING OF MY 
JOURNEY HAS BECOME A JOURNEY. IF YOU SHARE A NEED TO LAUGH AND TO KNOW 
AND AN UNWILLINGNESS TO ACCEPT THE IMPOSSIBLE, PLEASE FOLLOW ALONG. THIS 
BLOG IS HERE TO TEACH ON CLL AND BLOOD CONDITIONS AND CANCERS IN GENERAL. 
AFTER ALL, WE ARE ALL IN THIS TOGETHER (http://bkoffman.blogspot.com). 
 
 
On March 14th, 2014, the blog entry was entitled ‘The Good Cancer’, and was prefaced with 
the following statement: 
 
Here is a post I wrote in response to a spirited discussion in a CLL forum on the topic of 
how we patients are informed about our diagnosis and the unnecessary anguish called 
by sometimes well- meaning but poorly informed and of touch physicians. As is 
everything in CLL, it’s complicated and clear and sensitive doctor- patient 
communication is the starting point for a good outcome (Koffman, 2014). 
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From his vantage point of physician/CLL patient, Koffman introduces his blog post as a means of 
exploring doctor/patient communications in CLL. We learn that this post has already been 
circulated in the networks as a contribution to a forum discussion concerning the problem of 
poor and distressing diagnostic communication. Re-posting by the author across major network 
nodes in this way demonstrates how network narrative flow can be facilitated by key actors 
such as Brian Koffman, galvanizing debate on important themes across the wider CLL 
community online.    
 
Opening with the observation that ‘CLL is too often still called the "good cancer" and all of us 
CLL patients rightfully hate that’, Koffman initially locates himself in the narrative as a patient.  
He acknowledges the cultural loading of the word ‘cancer’ itself, arguing that it is not the word 
‘good’ that upsets patients, but the fact that it precedes the word cancer in a conceptually 
impossible coupling. “Cancer is such a loaded and malevolent word that the idea of putting 
something positive in front of it carries a similar horror and disbelief that would accompany 
anyone uttering a phrase such as: it was only a ‘gentle’ abuse” (ibid). But Koffman is a doctor 
too and, although by no means excusing what he defines as “poor doctor-patient 
communication”, in his clinical role he is able to identify potential institutional and professional 
barriers to effective diagnostic communication such as limited consultation time, and 
inconsistencies in medical literacy amongst patients: Many patients don't know what indolent 
means until well after they have been diagnosed, and to say slow growing, many patients might 
only hear the "growing" part especially when it is qualified with the adverb, "usually"(ibid). 
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Comparing the improving future outlook, and the slower progress of CLL to more aggressive 
cancers, Koffman positions the CLL reader as relatively privileged in comparison to those facing 
more aggressive cancers, directly appealing to them to try adopting the role of both patient and 
physician in imagining which diagnosis they would receive or give:   
 
Ask most patients with pancreatic cancer or MDS or glioblastoma multiforme or 
metastatic ovarian cancer if they would want to trade their cancer for ours. Ask any 
doctor which bad news he’d prefer to share with his patient (ibid). 
 
 
Expressing the belief that it is a health care worker’s responsibility to comfort through 
communicating hope “where hope is a real possibility” (ibid), Koffman acknowledges that this is 
a very hard balance to achieve in communicating a CLL diagnosis. Locating himself “as both a 
doctor and patient” (ibid) in the debate, he asks readers to consider the following delivery of a 
CLL diagnosis as an alternative to being told they have “a good cancer”: 
 
You have CLL, a chronic form of a blood cancer. (Pause) While all cancer is bad, some are 
much worse than others. Now I want you to listen carefully to what I am about to say. 
(Another pause) While no-one knows the future, CLL is most often, not always, but most 
often, one of the least aggressive kinds of leukemia (ibid). 
 
 
Koffman’s hypothetical approach acknowledges that, whilst ‘all cancer is ‘bad’, there are 
degrees of severity on that continuum. By replacing ‘good’ with ‘least aggressive’, and prefacing 
it with ‘not always, but most often’, Koffman explicitly uses comparative (worse) cancer 
experiences to convey a degree of comfort or hope in what is still clearly understood as a 
devastating diagnosis for the patient. It also acknowledges the very real possibility that, whilst it 
remains a likely scenario for many, the patient’s experience will not necessarily be one of living 
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with a slow-growing and manageable cancer.  This approach is similar to the one my own 
Consultant took, although he preceded his explanation by checking what, if anything, I already 
knew about CLL. This is vitally important. Koffman raises the issue of medical language and 
literacy as a potential block to effective diagnostic communication, but I would add that that 
can work both ways. As well as acknowledging that some patients may struggle with medical 
terminology,  clinicians should consider the possibility that patients may already be well-
informed about their diagnosis, possess high levels of medical literacy enabling them to 
assimilate  complex medical information, or be capable of leaving the clinic and conducting 
effective research into their diagnosis that will render over-simplistic or euphemistic 
explanations redundant and a potential source for mistrust in the clinical relationship.  
 
Locating this issue within the broader professional contexts of medical ethics and patient 
communication, Koffman acknowledges the difficulty faced by both physicians and patients in 
getting this right, pointing out that “These and similar and usually much easier issues are what I 
struggled with every day as a doctor turned patient” (ibid).  Without actually supporting a 
shorthand descriptor of CLL as a “good cancer”, and offering an alternative possibility, he 
positions readers to contemplate the clinical enactments of CLL that might underpin the 
approach they find so unacceptable.  By circulating this as a blog entry and support forum 
posting, he offers it as a dialogic gesture to other CLL patients and professionals reading in the 
networks.  The issue of diagnostic communication is articulated as a professional, ethical and 
subjective issue by someone who has experienced it both as patient and clinician. It is 
presented not simply as a closed narrative of abstraction and explanation, but instead as an 
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ongoing struggle grounded in existing systems of knowledge, communication, experience and 
practice up for debate and consideration in CLL networks online. Unusually, Koffman signs off 
this blog post using his medical qualifications that, as he points out, “I don’t usually do” (ibid). In 
establishing authorship explicitly in his professional role, he adds legitimacy to his observations 
as one who has not only received a diagnosis as a CLL patient, but works with and understands 
the clinical contexts within which diagnostic communication operates. The patients in the 
audience will understand this, as will fellow clinicians.  
 
I first encountered this blog entry on the membership only CLL Facebook page Bad to the Bone, 
where the following response from a CLL patient caught my eye: 
 
I didn't even get a good cancer or bad cancer from my doctor. I had to call for my BMB 
results at lunch time and got his nurse who said, "Oh, yea, your results are in. You have 
CLL. Gotta go! I have a patient." I managed to keep her on the phone long enough for 
her to tell me what CLL stood for, then she hung up. I went back to my classroom and 
googled CLL. Everything said I'd be dead in five years. I have been with friends when 
they got very bad news about their cancer, and have dealt with being told that I had 
breast cancer. In every other case the doctors were caring, compassionate, and 
informative. Why is it that doctors feel that it is in any way appropriate to tell a new 
patient that they have "the good cancer"? I know that my strong opinion about this is 
colored by the fact that I have just lost two friends to this "good cancer" and a third is 
fighting for her life, but I find the expression "good cancer" to be totally unacceptable! 
(‘Bad to the Bone’ group member Facebook, 11th March 2014). 
 
 
Clearly unimpressed with the off-hand manner in which her own diagnosis was conveyed, this 
group member effectively articulates her feelings about the misnomer of ‘good cancer’ in 
relation to a disease which has already killed two of her friends, and has another fighting for 
her life. The posting powerfully expresses the perceived flippancy with which many 
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respondents felt their diagnosis was conveyed, and its inadequacy in the face of actual 
outcomes for many CLL patients. Those actually subjected to the ‘good cancer’ routine by 
clinicians express similar anger and cynicism about their doctor’s communication skills and 
knowledge when their own and fellow online patients’ experiences soon prove otherwise:   
 
Used the internet for info as GP didn't know much - was told it was 'good' but it 
progressed within 6 months - lost job immediately (IOB Survey Respondent 9). 
 
 
At first I was shocked, then angry because the doctor kept referring to it as the "good 
cancer". It infuriates me that ANY doctor can think of ANY cancer as a good one  (IOB 
Survey Respondent 78). 
 
 
 
If doctors believe that simply telling a patient they have a ‘good’ cancer alleviates some of the 
burden of a CLL diagnosis, the comments encountered in Koffman’s blog, its responses, and 
across CLL networks online generally, indicate that they are clearly mistaken.  
 
Brian Koffman’s blog functions as a valuable narrative object in the networks, allowing readers 
to engage with a fellow patient who can legitimately make visible the professional and 
institutional practices underpinning CLL care. Koffman’s dual status as a CLL patient and 
physician enables him to map out some of the broader institutional connections that might 
hold what would seem to be a fairly widespread poor experience of diagnostic information and 
support for CLL patients in place. Importantly, he offers alternative approaches that consider 
professional enactments of CLL in relation to the patient experiences reported. This has the 
potential to transform clinical enactments of diagnostic communication, although this work 
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shows that respondents to discussions like this in online CLL networks are predominately 
patients. If more clinicians were to engage with the CLL networks then the narratives of distress 
conveyed by many CLL patients in response to diagnostic communication in the clinical setting 
might potentially exert some effect on clinical practices of communicating a CLL diagnosis, and I 
return in conclusion to ways in which the narrative knowledge circulating in online CLL 
networks might effectively be mediated into everyday clinical practice through strategic 
network activity.  
Perspectives: Filling the Void (Information Seeking in CLL Patients 
Online)  
 
As demonstrated, dissatisfaction with clinical communication and information provision on 
diagnosis was widespread among IOB survey and network respondents, and turning to the 
internet to bolster support and information was reported as a common strategic response:   
 
Initial diagnosis was a shock. Very little support or advice was given by my local hospital 
and I had to revert to the Internet for answers. My local hospital was, to be frank, 
dismissive of questions asked. I reverted to the internet and finally found a support 
group CLLSA who gave me answers. I then used internet to find a consultant who was 
extremely supportive and gave me answers to question… Since being under his care the 
fear has gone, I regularly get support if needed (IOB Survey Respondent 237). 
 
 
This respondent outlines his process of online information seeking in response to inadequate 
advice and support on diagnosis, leading ultimately to locating a supportive consultant. Using 
online networks to pro-actively manage access to satisfactory care in this way demonstrates just how 
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effective digital support and information seeking can be for patients. This contextual section 
looks at the information-seeking behavior of CLL patients in relation to that of cancer patients 
generally in the first section, explores the potential of online information seeking as a tool for 
adjustment to diagnosis in the second section and, in the final section, considers the impact of 
information seeking and lay expertise on the traditional hierarchies of medical knowledge 
exchange. 
 
Information Seeking on Diagnosis: Turning to the Networks 
 
Whilst low emotional well- being scores recorded by CLL patients (Shanafelt et al., 2009a) 
indicate that this is a group with special needs in terms of diagnosis, any diagnosis with cancer 
is likely to challenge both clinicians and patients in a number of ways.  Patients reflecting on 
receiving a cancer diagnosis in a 2001 study reported focusing on three key elements:  (1) 
content (what and how much information is told); (2) facilitation (setting and context 
variables); and (3) support (emotional support during the interaction) (Parker et al., 2001:2049). 
 
As this work shows, many CLL patients don’t fare especially well in any of the above areas on 
diagnosis, some reporting receiving the news by telephone, others having it conveyed by 
empathetic yet uninformed GPs, and others by seemingly unconcerned or overly casual 
practitioners in specialist clinics, yet the literature demonstrates hopefulness in cancer patients 
to be enhanced where clinicians demonstrate expertise and offer up to date information:   
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Patients indicated that the physician’s expertise and being given information on their 
condition and treatment options were areas of greatest importance to them… Sardell 
and Trierweiler [also] found that the behaviors that patients rated highest in 
enhancing hopefulness were those related to the technical and informational aspects 
of the communication (eg, physician offers most up-to-date treatments available) 
(Parker et al., 2001:2054). 
 
 
Considering CLL patients already experience lower emotional well-being following diagnosis 
than other cancer patients (Shanafelt et al, 2008), and that they frequently report poor 
diagnostic communication and support and inconsistency in disease-specific expertise of 
diagnostic clinicians, it is not difficult to see why so many CLL patients rely so heavily on other 
sources to learn about their disease.  After receiving what they perceived as their ‘death 
sentence’ from an unforthcoming consultant, the following respondent turned instead to the 
(now closed) Bristol Cancer Centre in the UK for support:   
 
I was diagnosed 10years ago. I asked the consultant what the prognosis was and her 
only words were 'ten years'. I then asked if there was 'owt I could do. This elicited the 
total response 'no'. So much for the famed progress in treating the whole person in 
medical training. I was so shocked by the diagnosis that I had nothing else to say - I'd 
had my death sentence and that was it, like Scrooge seeing his own headstone (IOB 
Survey Respondent 235). 
 
 
 
A cancer diagnosis radiates in its impact across social networks, and it is not only patients who 
turn to the internet following a diagnosis:   
 
Like most, my family and I found the diagnosis nothing short of catastrophic. My husband and 
parents initially used the internet and the CLL topics and CLL forum proved invaluable and to this 
day, are the ones I use. Having fantastic support from family and friends has been the key to 
coping with everything but the internet has been my main source for educating myself (IOB 
Survey Respondent 95). 
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Those going online to fill a void of diagnostic information are inevitably exposed to the 
inconsistencies in approaches to treatment and care they may face, and thus the cycle of 
knowledge-based self-management that often leads patients to challenge or even change their 
doctors begins, and the potential long-term benefits on the quality of life of CLL patients is 
clearly demonstrated by the 83% figure of IOB survey respondents reporting that online 
information helped them to live with CLL. However, the short-term perils of self- motivated 
online research for the uninitiated are manifold, key amongst them being the dissonance 
between the often bleak median survival times, and stories of rapid disease progression and 
death amongst CLL patients encountered by newly diagnosed patients with no frame of 
reference:  
 
I do not think medical people realise the effect of being told that you have CLL has on 
the patient. Often the diagnosing medical person is not an expert on CLL. A lay person 
researching on the internet internet can perhaps pick up on the wrong info, I read a 2-5 
year life expectancy out of context (IOB Survey Respondent 10). 
 
 
The level of information required by individual patients on diagnosis will of course vary. Many 
respondents in this work reported high levels of information seeking to help manage post-
diagnostic uncertainty, but some reported that too much information inhibited hope. Others 
reported cyclical searching patterns according to various phases of their disease, and some 
practiced total avoidance. This stratification reflects the identification in existing work on 
information-seeking practices in the newly diagnosed chronically ill of three distinct 
approaches, from actively seeking as much information as possible (even where that proved 
frightening), through selective interpretation of information in line with their ability to absorb 
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it, to outright avoidance in an attempt to remain calm and content whilst they still could 
(Pinder, 1990, cited in Radley, 2004:144).  
 
Transitions: From Abject Terror to Accommodation Online 
 
Many respondents describe an initial terror on diagnosis, and the belief that they were about to 
die. In the very early stage of diagnosis, online information in some cases compounded that 
fear, largely due to the lack of knowledge required to effectively evaluate its relevance to their 
own situation. However, initial panic subsides somewhat once it becomes clear that death is 
not necessarily imminent, and judicious use of the internet is reported as being ultimately 
helpful in relation to understanding that CLL is rarely an immediate killer:    
 
At the time of diagnosis I went through the classic stages of grief, and wanted to 
research all aspects of the disease this was through the internet, through a document 
given to me by my GP and through booklets sent through the post from CLL Support Ass. 
and Leukaemia Care. It was a journey that felt like a rocky road at the start, but is now a 
much more stable ramble along - the information gained helped me to understand the 
situation and put it all into context, although some data left me feeling scared and 
worried for my future - with hindsight I think i was just looking to see when I might die 
from this - now I get on and live with it and the data esp from CLLSA Healthunlocked [sic] 
helps me to do that (IOB Survey Respondent 185). 
 
 
This respondent reflexively acknowledges her response to diagnosis as one of loss, 
accompanied by the classis stages of grief. The psychosocial impact of a diagnosis with cancer is 
significant, as is the personal adjustment required to facilitate an act of transition from 
‘healthy’ to ‘ill’. Diagnosis is “literally the dawn of a new reality, the world of illness” (Brennan, 
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cited in Carel and Cooper, 2013: 136). Pertinent in the response is her shift from seeking 
information to ascertain when she might die from the disease to using it instead to help her get 
on and live with the disease.  In the literature, Fredrik Svenaeus draws on Heideggerean 
phenomenology in interpreting diagnosis with a life threatening disease as productive of a 
sense of alienation from the lived body, and of a generalized “unhomelike being-in-the –world” 
(Svenaeus, 2011, cited in ibid: 135). If the ability to return to some form of homelike being-in-
the world after diagnosis is to some extent dependent upon a patient’s success in adapting to 
the changes in and implications for their lifeworlds (ibid: 134), then maybe we can read 
Angela’s assimilation of ‘data’ gleaned from an online support facility over time as helping her 
transition to a world in which she can feel comfortable again.  
 
The nature of online data in relation to CLL is broad and multi-sited as this work has and will 
continue to demonstrate. Describing researching CLL through ACOR (an established on line 
community) as ‘an adventure’ in learning, the following respondent articulates the hub-like 
nature of an active network node, connecting users to a whole range of narrative enactments 
of CLL:  
 
In the mid-90s when I was diagnosed with CLL, there was little printed material 
available. But, I found an online support group (ACOR's) which opened hundreds of doors 
to me, including research, support, controversies, spotting "fake stuff," medical experts, 
understanding prognosis, understanding genetic elements, etc. I soon was familiar with 
the "jargon" of CLL, and comfortably read the research and entered into dialogue with 
others. So the first year or two after diagnosis was not full of fear; rather, it was more of 
an adventure to see what I could learn (IOB Survey Respondent 17). 
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Connecting multiple narrative accounts of CLL from multiple actors, online CLL networks have 
the potential to afford patients a degree of omniscience in relation to the various practices that 
bring their disease into being across biomedical, subjective, and socio-legal spheres, potentially 
enabling more effective transitioning. Despite this, some respondents were advised specifically 
NOT to use the internet:  
 
... I remember being told by my haematologist at diagnosis that "it's not cancer" and 
"don't check the internet"…I guess I blotted out how I felt at the time and it took me a 
few months before I could come to terms with my diagnosis and start seeking 
information on line. Thankfully I quickly found some reputable sites. Looking back, I can 
appreciate being told "not to check the internet", but being given a list of reputable sites 
would have been more useful!  (IOB Survey respondent 4) 
 
 
My diagnosis was in 2004 by my family doctor who told me "you have CLL, I'll refer you 
to a Hematologist, DON'T look on the Internet for information". I had no idea what CLL 
was and I worked in Health Care. Needless to say, both my Hematologist and Family 
doctor have been fired. It took me a while to get over the shock, find out what CLL was 
and get on the internet. As a result I have met a great group of CLLers and been involved 
in the CLL Patient Advocacy Group in Canada (IOB Survey Respondent 94). 
 
 
It might be reasonably assumed that edicts to stay away from the internet could be based on 
doctors’ well-meaning assumptions that their patients don’t have the knowledge or resources  
to filter information effectively. The previous chapter has demonstrated however that 
clinicians’ resistance to their patients’ online information seeking behavior can be as much 
about the consequent demands placed on them to contextualize findings in clinic as protecting 
patients from distress. Whatever the motivation, as respondent 4 insightfully points out, it 
would be more useful to suggest reputable sites for online support and information rather than 
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issuing ultimately impotent vetoes on online research altogether, as if the genie of access to 
information could be returned to its bottle by doctor’s orders not to look.  
 
A minority 2% overall of IOB survey respondents reported not finding the internet useful  in 
helping them to live with CLL, citing reasons such as finding the internet too impersonal, 
frightening or not comfortable for ‘personal issues’, and expressing a preference for face to 
face discussions with their clinicians, and ‘printed information’ from recognized support 
organisations:  
 
I found my diagnosis terrifying, never having previously even heard of CLL, and I thought 
I was under a death sentence. After the initial shock I did use the internet but this did 
little to help me, only to frighten me more. Only by speaking to the consultant at the 
hospital was I really able to get my head around the issue. As already mentioned, I found 
comments by other CLL sufferers within the CLLSA forum, frightening. I received the CLL 
handbook in the post and another similar booklet from the hospital which is where I 
learnt most about the condition (IOB Survey respondent 200). 
 
 
… I'm not a great internet user for personal issues and would much rather have printed 
information. I suspect quite a few people may be of a similar nature (IOB Survey 
respondent 231). 
 
 
The Macmillan booklets and Macmillan nurse were very helpful - the online info was too 
impersonal (IOB Survey respondent 219). 
 
 
Whether this is a generational issue or simply a matter of preference for those wanting to 
control information exposure requires further research with this patient group. 
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Perspectives: Knowledge and Power in the Networks: The closing 
Expert/Lay Gap and its Paradoxes 
 
Having gone online to identify their symptoms following an initial diagnosis of a probable 
hematological malignancy, the following respondent expresses some relief at having their 
suspected self-diagnosis of CLL confirmed by a doctor: 
 
In the time between the blood results and definitive CLL diagnosis, I scoured both the 
internet and print sources and found that in the absence of any acute symptoms the 
most likely diagnosis was CLL… …It was and I was actually rather relieved because it 
could have been much worse. The internet, especially the ACOR list and CLL Topics were 
priceless resources during this frightening time and they continue to be so seven years 
later. Lately I have also logged on to Patient Power … which gives me access to the views 
of CLL experts around the world (IOB Survey respondent 37).  
 
 
 
Such responses could be read as part of a repertoire of reflexive selfhood in contemporary 
health consumers in line with existing work that positions the world wide web as a “self-help 
agora” (Orgad, cited in Gauntlett and Horsley, 2000:146). Whilst clinicians retain a vital role in 
validating and legitimizing diagnosis56, patients primed through self-help are arguably better 
prepared to ask relevant questions of their doctors:   
 
My GP ...finally told me she was running blood tests for CLL and advised they were 
starting with the worse case sernario [sic] & working backwards. A week later it was 
confirmed I was stage A CLL, by which time I had massively researched online so was 
well prepared with questions for when it was confirmed. My GP was quite upfront & 
 
56 According to health online polls conducted by Wolterskluwerhealth.com (2015) a majority of consumers (77%) 
who use the internet to diagnose an illness say they follow up with a doctor to verify that diagnosis.  
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honest and said her knowledge was limited (IOB Survey respondent 211). 
 
 
Pertinent here is that, having already researched her potential diagnosis, respondent 211 is 
more informed about CLL than the diagnosing doctor. Like my own, her GP willingly professes a 
limited knowledge of the disease, challenging traditional hierarchies of knowledge transfer in 
doctor-patient relations. This work indicates that a significant number of well-informed CLL e-
patient know as much or even more than their GPs, and general haematologists, raising 
questions of how expert patients and doctors negotiate the subversion of traditional 
hierarchies. Diagnosis and first consultations represent the initial encounters of CLL patients 
with their medical teams, occurring at a point where patients are very often vulnerable and 
afraid. I have already noted work demonstrating a strong desire among cancer patients for 
competent and efficient clinical information on diagnosis, and the subsequent damage to trust 
in the clinical relationship that can occur in its absence. This work has also shown how the CLL 
patients surveyed commonly address the information void through judicious online research 
and collaborative support seeking in the networks, from which they can fairly quickly gain 
expert knowledge on their own disease. Yet to feel more informed than one’s doctor may tip 
the power balance of the clinical relationship too far for comfort for some, undermining the 
confidence of patients ultimately dependent on clinicians’ decisions about and access to 
prognostics and treatment, and for validation of the  ‘sick ’ role (Parsons) required to access to 
socio-legal benefits. After all, and as Foucault acknowledges, the medical encounter depends to 
some extent on “a differential of power and knowledge between doctor and patient” (Lupton, 
1997:119). 
Julia Kennedy 
161 
 
Enhancing the clinical relationship is about so much more then than patients becoming more 
engaged with medical knowledge. It is equally important that clinicians are fully engaged with 
the subjective reality of their patients’ illness experience in a two-way exchange of shared 
enactments. The role of narrative circulation online in re-defining the boundaries of acceptable 
ways of ‘doing’ disease is at the core of this project, and summed up neatly by Kathleen 
Pontius’s observations on the two-way value of the digital narratives of young people 
negotiating their lives with cancer when she wonders if “Perhaps by broadening the acceptable 
cancer narratives, young adult cancer patients will be able to influence medical and support 
providers to better fulfill the needs of all cancer patients”  (Pontius, 2008:99).  
 
Narrative circulation and sharing of disease experiences online is not limited to 
autopathographic exchanges however. Circulating academic research into quality of life for 
particular patient groups also means that both patients and professionals might be exposed to 
important findings about the impact of living with specific diseases traditionally confined to the 
limited audience of professional journals. A recent eponymous paper describes CLL as a disease 
that is “incurable, invisible, and inconclusive”, concluding that CLL patients in the watch and 
wait phase displayed similar levels of anxiety, depression, and reduced quality of life to their 
counterparts undergoing active treatment. Amongst the recommendations of this important 
paper were suggestions for specialists to acknowledge the psychological impacts of CLL, to 
actively listen to patients’ concerns, and to address their needs for information (Evans, Ziebland 
and Pettit, 2011: 1). Given the relevance of those findings to some of the comments made by 
CLL patients in this project, and the fact that this paper found its way into circulation in the 
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online CLL networks researched, the following Translation focuses on its content and network 
effects.  
Translation: Invisible, Incurable, and Inconclusive (A research Paper 
Raises Awareness) 
 
Benign as it may sound, the period of monitoring CLL prior to treatment known as  ‘watch and 
wait’ places CLL patients in an uncomfortable balancing act between an inner knowledge of 
latent sickness, and the outward manifestations of relative good health. For those more 
fortunate individuals with indolent disease, watch and wait can be a lifelong experience with no 
progression to aggressive disease. Even at its most benign however, CLL significantly 
compromises the immune system and retains the potential to mutate into more aggressive 
forms along its life-cycle. For these patients then, as well as those with more progressive 
disease, the calm state of attentive patience implicit in the term watchful waiting is entirely 
euphemistic: 
 
Watch and Wait stinks - it's more like Watch and Worry. I would say the first 6 or 7 years 
were awful, feeling like the guillotine was going to drop at any time. Now I don't think 
about it all the time, just a lot  (IOB Survey Respondent 93). 
 
 
"Watch and wait" has impacted on my future and current lifestyle plans leaving me with 
a sense of loss of control over what and when I do things (IOB Survey Respondent 254). 
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Although always challenging, this this can be particularly acute where information and support 
for this approach to care are lacking:     
 
Insufficient information and support offered to be able to be able to come to terms with 
it and live psychologically well with 'watch and wait' (IOB Survey Respondent 148). 
 
 
This translation looks at the circulation in the networks of a research paper entitled ‘Incurable, 
invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications 
for doctor–patient communication’, written by health researchers Evans and Ziebland57, and 
Consultant Haematologist, Pettit58, and published in the European Journal of Cancer Care in 
January, 2012. Figure 14 below represents one click TouchGraph showing the basic links out 
from the paper online at the time of writing, with important connections into major network 
nodes CLL Topics and Health Unlocked.  
 
 
 
 
57 Senior qualitative researcher, and research director respectively from the Health Experiences Research Group, 
Department of Primary Health Care, University of Oxford. 
58 Professor of Haematology, and Consultant Haematologist at Royal Liverpool and Broadgreen University Hospitals 
NHS Trust. 
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Figure 14: TOUCHGRAPH  (2011) network connections from  Evans et al.'s (2011) paper 'Invisible, Inconclusive 
and Incurable' [Network Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=invisible%20inconclusive%20and%20incurable [Accessed 
25/07/2015]. 
 
The research draws on qualitative interviews with twelve CLL patients managed by watchful 
waiting, concluding that patients on watch and wait demonstrate similar levels of depression 
and negative impact on their quality of life as those in treatment.  The abstract states that the 
qualitative interviews allow the authors to relate these findings to “perceptions of the illness 
state, doctor–patient communication, and work pressure” (Evans et al., 2011:2). Five other key 
points could be extrapolated from the abstract effectively reflecting the concerns of CLL 
patients across the online networks about diagnosis with CLL, and living in ‘watch and wait’: 
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1)”Patients with chronic lymphocytic leukaemia (CLL) find it hard to accept a diagnosis 
of an incurable cancer for which no treatment is recommended and which may not 
cause symptoms for many years…” 
 2)”Patients with CLL recalled being given little information about the condition and 
wanted to know more about how it might affect them in the future.” 
3)”The invisibility of CLL meant that some chose not to disclose the diagnosis to others. 
Check-ups sometimes felt cursory, causing dissatisfaction.”  
4)”As symptoms increased, lifestyle adaptations became essential, well before 
treatment was warranted.”     
5)”We recommend that specialists could better support patients by acknowledging 
psychological impacts of CLL, actively listening to patients’ concerns, and meeting their 
needs for information.”   (Evans et al., 2001:1) 
 
 
The perception that not enough information or support for the specific psychological needs of 
CLL patients is given on diagnosis is, as this work has shown, fairly widespread across the CLL 
community. Again, respondent 148 describes their perception of this: 
 
I really think that the lack of information, lack of support, apparent lack empathy 
towards the emotional effects not only of the diagnosis, but also of living with 
fatigue/'unwellness' , at the time of diagnosis, during the time since then, and also at 
present has resulted in a much greater negative impact on my life than might have 
otherwise been… (IOB Survey respondent 148). 
 
 
This respondent clearly feels that a lack of acknowledgement and support for the emotional 
stress of diagnosis, and physical symptoms of fatigue and malaise common to CLL has 
contributed significantly to a continuum of unnecessary suffering. A subsequent observation 
that recognition of this difficulty is ‘only just emerging’ evidences awareness of the current lack 
of research in the area of psychosocial support for CLL patients. 
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CLL’s invisibility to the outside world means that patients often choose not to disclose their 
disease, and face a degree of scepticism and confusion from others if they do. In their paper, 
Evans and colleagues define Talcott Parsons’ (1951) concept of the ‘sick ’role as a defined 
societal obligation for the sick to achieve complete recovery by eschewing normal social roles 
and complying with caregivers. Parsons later introduced the concept of the ‘part-time’ sick role 
(1975) to address the ongoing cycle of distinct periods of exacerbation, management, and 
relative good health experienced in chronic illnesses such as diabetes. The authors observe that 
some of their respondents questioned their status as ‘ill’ during the watchful waiting phase of 
the disease. Using Parsons’ part-time sick role model allows for the argument that, even in non- 
progressive disease phases, CLL patients are formally in role during clinic visits and periods of 
unwell-ness, and thus legitimately entitled to the same degree of support that any sick person 
might expect. The authors also use the concept of ‘liminality’ to explore the nebulous space 
between illness and health inhabited by CLL patients. Neither officially ill nor actually well in the 
early stages of disease, CLL patients occupy a slippery and often alienating cultural territory. As 
Evans and colleagues go on to point out, and as the previously cited respondent testifies, the 
debilitating symptoms of disease progression might leave a patient feeling legitimately ill long 
before clinicians confer a valid sick role.  
 
Dissonance between the lived realities of illness in CLL, and its medical recognition are core to 
the sense of marginalisation often reported by CLL patients during diagnosis and watch and 
wait as Evans et al acknowledge in their paper: “This mismatch in perceptions of the illness 
state could help to explain why doctors seem not to fully appreciate the impact of the illness on 
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patients” (Evans et al., 2011:8). 
 
Like Brian Koffman in his ‘Good Cancer’ blog post explored in the previous translation, the 
authors also hypothesize that what may be read as offhand and uncaring attitudes by patients 
may in part at least be a result of prioritizing time and energy by haematologists working in 
rigidly time-constrained system:  
 
Hard-pressed doctors working in the UK NHS understandably prioritise those patients 
who most need acute medical attention. In a haematology clinic, people with indolent 
CLL may seem to be of less interest to staff and in less need of professional care than 
those with acute leukaemia in hospital for lifesaving treatment. This may partly explain 
why some people with CLL believe that their specialists seem uninterested in their 
experience of the condition and do not appear to appreciate how it affects them either 
physically or emotionally (Evans et al., 2011:9). 
 
 
Co-authored by a Consultant Haematologist specializing in CLL, and published in a specialist 
cancer care journal, the paper’s primary intended audience would be multidisciplinary 
professional readers both directly involved in caring for those with CLL or other indolent 
cancers, and in the implications of doctor-patient communications on patient experience. 
However, circulating as a narrative in CLL support networks opens up the paper’s audience to 
CLL patients who will recognize their own experiences reflected in the respondents’ stories, and 
the discussion and analysis of the findings.  
 
The paper’s reference to a (1993) NICE recommendation that “all haematological cancer 
patients should have access to a specialist nurse who can offer psychosocial support and 
Julia Kennedy 
168 
 
continuity of care” (Evans et al., 2011:9) highlights institutional acknowledgement that 
increasing accessibility to emotional support for patients requires a multidisciplinary approach, 
using specialist nurses to alleviate the pressure on time for doctors. The reader is informed that 
there is an increasing reliance on specialist nurses for the provision of informational and 
emotional support for cancer patients across the board. However, this increasing reliance 
places nurses into the same time-pressured environment as the doctors resulting in triage 
based on the acute v chronic binary in which CLL is so often confined to second place: 
 
Using specialist nurses to talk to patients about their concerns during watchful waiting 
can give consultants more time to deal with the more difficult cases. However, if there 
are too few specialist nurses to cover all watchful waiting for chronic lymphocytic 
leukaemia haematological cancer patients, their time is likely to be prioritised in the 
same way as that of consultants, restricting their use to acute patients (Evans et al., 
2011: 9-10). 
 
 
CLL patient readers will be familiar at least with the effects, if not the economic politics of a 
binary opposition between acute (“more difficult”) cases, and chronic (themselves) in which a 
competition for limited resources is played out. The paper’s recommendations that specialists 
recognize the emotional needs, and offer better support and information to CLL patients are 
very firmly located within a discourse of the political economy of the UK NHS.  The reader is left 
in no doubt for example of the realities of time-management for “hard-pressed” clinicians with 
heavy loads of acute patients to manage. After reading about increasing reliance on the role of 
the specialist nurse as a key agent of patient emotional support, we learn that some of the 
nurses needed to spread the load of supporting patients emotionally have to be externally 
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funded by charities such as Macmillan.  
 
There is no doubt however that the rich description provided by the small cohort of research 
respondents clearly reflects many of the key issues discussed by CLL patients online. The voices 
of twelve CLL patients speak volumes in this paper through the authorship of a CLL specialist 
clinician and two academic health researchers. The title ‘Invisible, Incurable, and Inconclusive’ 
sums up the unholy trinity of features that make CLL such a difficult disease to understand, and 
to live with, and the five points raised in the abstract address many of the points made by 
patients in my own research (and experience). To a CLL patient, the publication of this paper 
represents a rare oasis of specialist professional insight into the psychological difficulties of the 
disease. Professional recognition of these issues has the potential to legitimize the 
psychological distress that so many CLL patients come to internalize as a personal aberrant 
(inadequate) reaction to their disease, or simply endure in the absence of clinical recognition 
and support.  
 
Recommendations for improved emotional support, presented predominately as a nursing 
rather than a medical responsibility in an environment where CLL patients must compete with 
more acute patients for limited resources, may do little to reinforce hope that things are likely 
to change radically for CLL patients any time soon. However, the fact that recognition of CLL 
patients’ specific and unique emotional needs has been articulated and published in a 
professional context was seen as a positive move in the network responses to this paper. 
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Circulation 
 
So how does a paper like this make it into support networks, and what impact might it have on 
CLL patients? After its publication in the European Journal of Cancer Care in 2011, the paper 
appeared in the network in the following sites and formats (this is not necessarily exhaustive): 
 
CLL topics updates, 16th November, 2011 – précis of paper and discussion 
http://updates.clltopics.org/4085-incurable-invisible-and-inconclusive  (56 responses) 
 
Lymphoma.com 16th November, 2011 – link to paper from CLL page 
‘CLL Topic Updates: “Incurable, Invisible and Inconclusive” http://bit.ly/uo6Bad Good discussion 
on having an indolent, currently incurable cancer that might also be of interest to those with 
follicular, malt etc.’ http://forums.lymphoma.com/archive/index.php/t-52507.html 
 
UK CLL Forum  - link to article posted on 18th November, 2011 in a thread on quality of 
life in CLL patients 
http://www.ukcllforum.org.uk/viewtopic.php?id=222 
 
CLLSA Health Unlocked, 2012, in a posting entitled ‘You are not imagining things nor 
are you alone and you may not feel listened to.’ 
 
Macmillan CLL/SLL/HCL community 16th November, 2011in a thread entitled ‘CLL 
News’ - link to paper 
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Macmillan CLL/SLL/HCL community October 2012 in a thread entitled ‘how living with 
CLL in watch and wait feels to me’ – link to paper (Hairbear) 
 
Maggies online centre 18th November, 2011, in a CLL blog – link to paper (Nick) 
 
Bluepeople.com, Depression and Mental Illness Forum, September, 2011 – link to 
paper 
 
 Musings of a Lymphomaniac blog in an entry entitled “living with the good cancer” 
16th November, 2011 
 
The spread of sites is interesting as it encompasses key nodes in the CLL network, alongside a 
personal blog, a generic lymphoma support site, and a generic depression and mental illness 
forum. Also pertinent to understanding the role of key mediators in circulating information is 
the fact that the paper was posted to three of the above UK sites by the same CLL network 
actor, entitling his post to the CLLSA Health Unlocked site ‘You are not imagining things nor are 
you alone and you may not feel listened to’ and prefacing it with the quote: 
 
If there ever was a must read paper to help explain what we may experience when living 
with CLL while on "watch and wait" then this is probably it. Published last year by the 
HERG study group at Oxford. It is a lengthy read but worth it. I know many of you have 
passed this onto your GPs to read. There are some interesting observations from 
patients and conclusions including recommendations made that are raising awareness 
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(Hairbear, CLLSA Health Unlocked, 2012). 
 
 
That post’s title itself shows empathetic recognition- that CLL patients might internalize their 
distress within a generalized sense of isolation redolent of the phenomenological concept of a 
sense of ‘’unhomelike being-in-the–world (Svenaueus, 2011). Hairbear makes the point that the 
paper is ‘raising awareness’ of these issues. This underscores its value as a circulating narrative 
in the networks based on its function as a tool for drawing attention to and validating the 
difficulties and isolation experienced by CLL patients, for opening the issues up for debate in 
the forums, and for bringing those issues professionally to the attention of clinicians. The 
practice of patients passing the paper on to their own doctors demonstrates how narratives 
spill over from online networks into face-to-face encounters with the potential to influence 
practice in receptive clinical environments.   
 
Network Responses  
 
CLL patients encountering this paper are positioned as readers to consider the institutional and 
professional enactments that frame their experiences in the clinic, recognizing their place in a 
competition for finite resources in an over-stretched clinical market. The political-economic 
discourse of the paper is not openly addressed anywhere in the network responses. 
Professional recognition of CLL patients’ unmet needs for emotional and informational support 
seems to be the dominant narrative feature driving the circulation of and responses to this 
paper across support networks. This perhaps demonstrates a degree of instrumentality in the 
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way that narratives are circulated and read according to a hierarchy of perceived relevance in 
the community. Responses may of course be influenced by the way the importance of paper is 
framed by the actor posting it. In this case, improving professional awareness of the challenges 
experienced by CLL patients, and the paper’s narrative function in reassuring patients that they 
are not suffering alone are key drivers behind encouraging its flow in CLL networks.   
 
These factors are privileged in network discussions over the institutional political-economic 
implications of its recommendations. The point here seems to be that, at last, there is 
professional recognition of a problem CLL patients struggle with almost universally, and the 
posting of this narrative into the networks allows for CLL patients to reflect on their own 
struggles as a broader problem, now validated by professional research findings, and not as 
something they should regard as a personal failure in coping. It is also presented as an 
opportunity for CLL patients to ‘educate’ their doctors by passing the paper on to them. Health 
professionals reading the paper will encounter clearly articulated narratives of the problems 
faced by CLL patients meshed into recognizable discourses of the institutional constraints 
contributing to (if not entirely explaining) failure to adequately recognize and support these 
problems. Once liberated from its narrow professional journal audience, and circulated among 
CLL patients online, this paper potentially mediates CLL across the boundaries of patient and 
doctor, narrativizing and validating the experiences of each to themselves and to the other. If 
there remains any doubt about the impact of the lack of recognition and support for patients 
from their clinicians that circulating this paper has the potential to change, then I return to the 
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words of IOB respondent 48: 
 
I really think that the lack of information, lack of support, apparent lack empathy 
towards the emotional effects …has resulted in a much greater negative impact on my 
life than might have otherwise been… (IOB Survey respondent 148). 
 
 
 
I want to pull two themes out of this Translation to consider in relation to the literature – those 
of ‘liminality’ used by Evans and colleagues (Evans et al., 2012) to describe the cultural gap 
between illness and health within which CLL patients find themselves, and ‘biographical 
disruption’. In this section, I have used the term ‘biographical disruption’ to describe a life 
interrupted by CLL. This is just one of several approaches in the literature to conceptualizing the 
impact of a serious illness on a life. Its relevance to this work lies in its importance to the field of 
illness narratives generally, and I want to explore existing work on biographical disruption in 
chronic illness alongside theories of narrative re-construction as a strategy for re-imagining a 
life radically altered by a diagnosis. These twin perspectives provide the foundation for looking 
at digital illness narratives as an evolving multi-sited and networked form of the genre.   
 
Perspectives: Liminality and the Narrative Hinterlands of CLL 
 
Evans and colleagues’ 2012 paper, ‘Invisible, Incurable and Inconclusive’, previously explored as 
a circulating narrative here in this chapter is a useful reference point for teasing out the 
peculiarities of CLL in relation to biographical narrative. The concept of ‘liminality’ employed by 
the authors is described as “a period and state of being between social statuses, or an 
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undefined status where people cannot classify themselves into culturally available categories”, 
and draws on anthropological work surrounding rites of passage. Victor Turner explains the 
liminal phase of the ritual process as one where ritual subjects’ understanding of the social was 
ostensibly improved by defamiliarizing and reconfiguring known cultural patterns with the 
intention of rupturing their ‘‘previous habits of thought, feeling, and action’’ and forcing them 
to reconsider ‘‘features of their environment they have hitherto taken for granted’’ (Turner, 
1987: 14). (1977a). In this sense, liminality as a space occupying the interstices of cultural 
categorization forces us to consider the categories it doesn’t fit into – wellness, and illness in 
this case – by defamiliarizing them. It turns out that they are porous, graduated, mutable 
definitions. They can it seems (when you live between them) overlap, co-exist, and are by no 
means mutually exclusive. Unlike time-limited rituals however, the liminality experienced by 
the chronic cancer patient (or the HIV patient) is a lifelong experience of blurred boundaries 
and fuzzy definitions. Patients occupying the interstices themselves may grow to understand 
just how fragile and contrived the taken-for-granted constructed boundaries of the social world 
of illness may be, but that level of understanding doesn’t necessarily extend to the social 
frameworks that define and categorize disease in the worlds they will experience it in. To the 
doctors that diagnose and treat them, to loved ones, friends, employers, insurance agents or 
anyone else whose understanding of health and illness is predicated on the familiar categories 
we have assigned them as a culture. 
 
CLL patients encountering this paper in the networks would understand very well the definition 
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of liminality: 
 
 I am on watch and wait. The main uncertainty is how long I am going to live and a fear 
of getting another more serious cancer I often look up websites to find out how long 
people have lived with CLL… (IOB Survey Respondent 178) 
 
 
Initially after diagnosis time seemed to shrink. I felt guilty about not being interested in 
looking ahead or writing a "bucket list"! Once in remission following treatment I kept 
waiting for the moment when I would feel "wow! it's gone!" Doesn't happen with CLL 
and ended up suffering from depression... (IOB Survey Respondent 175) 
 
 
Little and colleagues Little et al., (1998) identify three interdependent themes in the illness 
narratives of cancer patients in contemporary western cultures59 that they argue together are 
constitutive of ‘liminality’. They are worth sharing here in detail in view of their relevance to the 
CLL illness narrative. The first of the themes identified is what Little and colleagues refer to as 
“cancer patient-ness”. This is characterized in the early stages of illness by the impact of the 
diagnosis, particularly revolving around shock, disbelief, and the confrontation with mortality. 
Also included here is a sense of urgency to act to manage the disease, and tensions over 
surrendering autonomy to medical decisions. Cancer patient-ness doesn’t go away once these 
initial hurdles have been dealt with but remains as a persistent identification.  The second, also 
immediate recognizable theme is defined by Little and colleagues as “communicative 
alienation” which refers in the early stages to the knowledge that no-one else can actually 
really share the abject horror of the diagnosis and treatments, and evolves into an ongoing 
 
59 The distinction is made to draw attention to the fact that industrialized Western cultures specifically have come 
to regard illness as an abnormal event in a life trajectory. 
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state of social alienation bound up in the status of being a cancer patient. Finally, the authors 
use the term “boundedness” to describe the limitations imposed on a patient’s “time and 
empowerment, ability and agency”, experienced at first as having to relinquish existing socio-
economic and temporal frameworks to the demands of the medical system, and later 
expressed as existential constraints and deep uncertainty about the future (Little et al., cited in 
Roussi and Avdi, 2008:161). 
 
Respondents with CLL express all three of the above themes in their comments and, as Roussi 
and Advi demonstrate in their own work, liminality is kinetic, shifting from the shocking initial 
dislocation of diagnosis to an ongoing process of surviving in the interstices of cultural 
understandings of health and illness. As with all chronic diseases, disruption is experienced 
variously along the disease course from the acute phase of diagnosis to managing a life with the 
disease. Aside from having to take up the mantle of cancer patient-ness without access to 
immediate treatment, uncertainty for CLL patients is amplified by the disease’s heterogeneous 
outcomes, and social alienation exacerbated by immune system suppression and poor cultural 
understanding of chronic cancers. Progressive CLL presents patients with the long-term 
challenge of having to manage a liminality that ebbs (although never totally recedes) and flows 
from sustained to acute through the diagnosis/  progression/treatment/ remission/ progression 
cycle, a trajectory that may also be influenced by the unpredictable occurrence of infections, 
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secondary cancers, Richter’s transformation60,  and long term side effects of CIT.  
 
Temporal dimensions are then both contingent on and productive of the process of living in 
liminality. Frank (1995) uses the term “narrative wreckage” to describe the fracturing of 
biographical futures (and thus by default, the biographical present that precedes them) that 
occur when serious illness significantly destabilizes a person’s sense of future.  Uncertainty 
about whether one should be orienting life towards the prospect of dying an earlier death 
through a process of gradual closure of future narratives, or towards continuing to stay alive by 
keeping open the narratives of future possibilities despite knowing that the disease may render 
them fully or partially impossible presents CLL patients with a difficult conundrum.  Also living 
with a disease of the immune system with an ambiguous ‘terminal’ status, HIV-positive patients 
researched in the nineteen nineties expressed a similar liminal crisis.  
 
Davies (1997) noted a number of strategies adopted by HIV patients to deal with the crushing 
uncertainty they faced. Broadly, they managed either by focusing on living in the present with 
renewed appreciation for aspects of their everyday lives, by refusing to accept present 
limitations on a perceived future, or by living in a backward-facing ‘empty present’ able to focus 
only on a pre-diagnosis past (Roussi and Avdi, 2008:262). It would appear that to remain in the 
latter state for any length of time may impact negatively on the quality of a life, whilst either of 
 
60 Richter’s Transformation describes a shift from CLL to a more aggressive and difficult to manage form of b-cell 
lymphoma experienced by around 5% - 10% of all CLL patients. The prognosis is generally poor, with a median 
survival of about 10 months. For further information see Jain P, and O'Brien S. (2012) in their paper, ‘Richter's 
transformation in chronic lymphocytic leukemia’. 
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the former might allow for people to live tolerable and productive lives in the face of the kind 
of existential uncertainty that characterizes chronic, often progressive, and sometimes terminal 
diseases. This work evidenced examples of all three coping strategies:   
 
The old cliche Life is Short really comes into play with us, I try to live my life the best way 
that I can. Being a good and kind person as much as possible and really enjoying myself 
and my family (IOB Survey Respondent 118). 
 
 
I have toddler twins, so I am aggressively taking responsibility for my own future. I 
realize that I cannot really control it, but I will do whatever is within my control. CLL adds 
to my uncertainty about the future, but it has not meant planning my life around it. Even 
during treatment, I kept working and took only a few days off over a period of several 
months for treatment (including out-of-state travel…) (IOB Survey Respondent 122). 
 
I used to have great plans and ambitions, and that is an important part of being human I 
think. Have though really struggled with fatigue and wellness, still watch and wait. 
Ability to complete plans is often undermined by state of wellness so eventually plans 
become a bit pointless. Just getting through is about as far as things go (IOB Survey 
Respondent 148). 
 
 
On balance, however, there was a greater emphasis among patients on expressions of at least 
trying to live in the present with renewed appreciation of lives no longer taken for granted, 
although the chronic and unpredictable nature of the disease and the need for recurrent 
treatment means it is often difficult to maintain this as a consistent philosophy. Many patients 
adopt the strategy of foreshortening future plans according to treatment cycles/average life 
expectation statistics for CLL:  
 
I noticed a dramatic change in my time-sense immediately after diagnosis. My 
long-term dreams evaporated. I no longer looked at a small house, for instance, 
and thought, "I'd like to live there when I retire." My forward glance has now 
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shortened to a couple of years, as I will likely need to be treated again by the end 
of 2014 (IOB Survey Respondent 116). 
 
Perspectives: Metaphor and the Liminal Experience 
 
Given the cultural predilection for war and battle metaphors surrounding cancer, CLL’s status as 
a systemic blood-borne malignancy working at molecular level and infiltrating the bone locates 
it in a bleak metaphorical landscape. ‘Bad to the bone’, ‘bad blood’, ‘in the blood’ are all 
phrases used to connote that something (usually bad or unpleasant) is fixed into the body at 
the deepest level possible, genetically coded and unchangeable, and in constant and unceasing 
systemic circulation around the body. There is no solid tumour to “attack” in blood cancers. The 
abject and widely understood fear of cancer ‘spreading’ (also fixed as a metaphor for creeping 
corruption in social life) is irrelevant when the conduit for your cancer flows around every part 
of your body anyway. Those of us with blood cancer present as wholly cancerous bodies. We do 
not have tumours that can be isolated from the rest of our bodies and either removed or 
targeted specifically (although are constantly aware that they may come later in the form of 
secondary cancers).  
 
Leukaemia is ‘in deep’ to the marrow, and constantly circulating. In progressive disease, and in 
remission, blood tests will constantly monitor its status, underpinning an uneasy relationship 
with our blood that at once recognizes its fundamental life-giving nature yet is characterized by 
an ongoing cycle of anxiety and speculation. It keeps us alive, but carries the corruption that 
may ultimately kill us.  If being ‘bad to the bone’ is not enough to amplify liminality, then a 
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constant state of immune-suppression will suffice. CLL patients live among the 
immunosuppressed at the best of times, but acute phases of disease such as during and after 
chemo-immunotherapy can leave patients severely neutropenic and prone to sepsis61. To feel 
constantly at risk of infection is socially alienating and sets one apart (try travelling on a plane 
wearing a mask). This paranoia-inducing state can leave one feeling metaphorically like a 
‘borderless country’, ‘defenceless’, vulnerable to ‘invasion’. In an increasingly paranoid 
globalised environment where the metaphor of viral spread and invasion looms large, again the 
liminality of immunosuppression can be amplified by the language that defines our broader 
cultural understanding. Sadie Plant locates the metaphor of infection as central to late capitalist 
language of control: 
 
Paranoia has moved on since the sixties: even the rivers of blood are now HIV positive. 
Foreign bodies are ever more virulent and dangerous, insidious invasions of unknown 
variety threaten every political edifice. The allergic reaction to this state of emergency 
is security integration, migration policy and bio-control: the medico-military complex  
(Plant and Land, 1994: no page). 
 
 
Susan Sontag has famously explored the impact of metaphor on living with cancer and AIDS, 
and found it wanting in its reductive view of illness, and unhelpful in the way it positions the ill. 
“We are not being invaded. The body is not a battlefield.  The ill are neither unavoidable 
casualties, nor the enemy” (Sontag, 2002: 180).  For those of us already living in liminality, such 
metaphors simply reinforce a defamiliarised territory of ‘peace’ we can no longer inhabit. 
 
61 Susceptibility to infection among CLL patients is secondary both to the disease and its treatment. Multiple 
factors are involved including hypogammaglobulinaemia, neutropenia, impaired T-cell and natural killer cell 
function and defective complement activity. See Eichhorst et al. (2011) Chronic lymphocytic leukemia: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up, written for the European Society for Medical 
Oncology and published in the Annals of Oncology, 2011, for further information. 
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Perspective: Biographical Disruption and Narrative Reconstruction 
Online 
 
…When routine blood work revealed a high white count, I knew it must be some type of 
leukemia. Of course, I panicked and a quote from Tolstoy's "The Death of Ivan Ilyich" 
popped into my head: "It cannot be, but it is" (IOB Survey Respondent 37). 
 
 
There can hardly be a better way of describing the paradoxical moment of the unimaginable 
made real than the Tolstoy quote invoked at the moment of diagnosis for this respondent. 
Diagnosis with a potentially fatal disease locates us in exactly that impossible conceptual bind. 
It simply ‘cannot be’, but the business of dealing with the fact that ‘it is’ begins immediately, 
and often requires a radical re-writing of a previously imagined (or at least assumed) future.  
 
Previous perspective sections in this chapter have explored CLL patients’ online responses to 
diagnosis through information seeking practices in the newly diagnosed, the often vexed power 
relations of knowledge and expertise between informed patients and their doctors, and the 
experiences of liminality from which these practices are enacted for patients. At the heart of all 
of these issues lies the process of adjusting from health to illness. The two translations so far 
have shown how circulating narratives in the network have the potential to transport radically 
different versions or experiences of CLL across narrative boundaries. This perspective looks at 
the impact of the transition from health to illness as a form of biographical disruption, and 
explores the notion of narrative reconstruction as a strategy for managing it that I argue is 
evolving in the practices of narrative exchange online.   
 
Julia Kennedy 
183 
 
‘It cannot be’: CLL as Biographical Disruption   
 
Being a disease with no easy cure, the diagnosis affected my life greatly. I quit my job, 
tried to keep it a secret, terminated some friendships, drastically changed my eating and 
drinking habits, and experience many sleepless nights. CLL topics and the great wealth of 
information from Chaya Venkat helped me cope immensely (IOB Respondent 96). 
 
 
Several of the respondent comments looked at so far begin with the sense of extreme shock at 
a diagnosis with CLL. A sense of life literally fragmenting as conveyed by the above response to 
the far-reaching impact a CLL diagnosis had on their life. The rupture experienced on diagnosis 
with a chronic illness can be experienced as “a tear in the fabric of one’s life that can suddenly 
bring into question all of the assumptions upon which it was based” (Radley, 2004: 145). Such a 
sudden and catastrophic shift in one’s sense of place in the world forces a reflection on what 
unexamined assumptions and behaviour might have held it in place prior to diagnosis. Mike 
Bury (1982) draws on Giddens’s notion of the ‘critical situation’ (1979) to locate chronic illness 
as radical disturbance of everyday life, a form of what he refers to as “biographical disruption” 
(Bury, 1982:169). Corbin and Strauss (1987) sort the consequent biographical trauma into three 
dimensions – biographical time, concept of self and bodily capacities (cited in Radley, 
2004:145). These dimensions underpin the uncertainties that plague those newly diagnosed 
with a chronic illness such as CLL. How long will I live? Who will I be now I have cancer? What 
will I be able to do – can I still work, play, socialize, care for myself and others..?  Familiar with 
post-diagnostic disruption myself, I asked survey respondents to reflect on the impact of 
diagnosis on their sense of time. There was widespread expression of the challenges faced by 
patients trying to plan their lives, both in the short-term in the face of the ongoing inconclusive 
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nature of CLL: 
 
My planning is mostly short term as even during remission life is interrupted by medical 
concerns, infections etc. (IOB respondent 257). 
 
 
As someone who has always looked forward (having the memory retention of a gold fish 
it's difficult to look back!) this is THE most difficult thing to deal with (IOB respondent 
229). 
 
 
I find it hard not knowing what is likely to happen and when. It is difficult not to think at 
the start of treatment it will be over in 6 months but it doesn't work like that. Am I going 
to be able to look after myself in a years [sic] 2 years 5 years? I have not looked online or 
blogs in case they are offputting (IOB respondent 224). 
 
 
Many respondents reported struggling with uncertainty about the future on diagnosis, but what 
seems like a violent disruption to one person may be absorbed as just another life-event to be 
dealt with to another in a form of biographical continuity rather than disruption as Simon 
Williams (2000) notes, and the following (relatively rare) response indicates: 
 
CLL is just another bump in the road for me (IOB respondent 22). 
 
Variables such as age at diagnosis, staging and prognosis obviously have some potential 
influence on a response to diagnosis, but reactions may equally be shaped pre-existing 
attitudes, beliefs, and expectations. The extent to which people experience their diagnosis as 
‘biographical disruption’ then is always contingent and cannot simply be assumed as a 
knowable phenomenon. The role of uncertainty as a feature of illness experience is widely 
acknowledged as a powerful phenomenon however (Pierret, 1992; Bury, 1982; Radley, 2004). 
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CLL, a chronic, incurable disease with all of its heterogeneous forms and possibilities amplifies 
the uncertainty of illness with a range of additional questions such as: ‘will my disease actually 
progress?’; ‘do I have a genetically aggressive or refractory form of CLL?’; ‘can I actually be 
regarded as ‘ill’ or ‘sick’ at certain stages of my disease?’; ‘will my reduced immunity allow me 
to succumb to an opportunistic infection?’; ‘will my fatigue, commitment to hospital 
appointments, treatment, and infections make it impossible for me to work and socialize?’; ‘will 
my treatment (if I need it) damage me irreparably or kill me?’;  and ‘will this disease radically 
shorten my life span?’  
 
Williams argues that biography itself has become ‘a chronically reflexive theme in conditions of 
late modernity’ (Williams, 2000:61) in which we undertake a constant cycle of biographical 
revisions, regulations, and improvements in relation to our health (amongst other aspects of 
our lifestyles). In other words, as late-modern subjects we are re-writing the biography of our 
bodies in relation to ourselves on an ongoing basis. In the reflexive project of the self, 
suggested by Giddens (1991), illness may feature as one of many biographical adjustments in 
the ongoing construction of embodied selves already tied in to broader notions of risk, 
regulation, control, taste and status, supporting a view of the web as a kind of “self-help agora” 
for cancer patients (Orgad, 2000). The current popularity of pathographies that frame a cancer 
diagnosis as a catalyst for ‘improved’ attitudes, and behaviours perhaps underscores a fashion 
for reflexively narrativizing ourselves in relation to lifestyle choices.   
Underlying narratives of risk often drive obsessions with health and healthy lifestyles. 
Increasingly, public insight into the cultures and key themes of medicine and health care 
Julia Kennedy 
186 
 
provision is heightened through contact with popular cultural narratives from news, through 
self-help books, to medical drama and documentary, all edited to produce a constant and 
dramatic narrative flow of risk and regulation, “typically expressed in formulations of concerted 
care for the body and its healthfulness, whether for individuals or collectives, as a state of 
permanent emergency”62 (Blum, 2011:460). In this sense, informational culture in relation to 
health issues spreads far beyond a focused project of ‘looking things up’ when we suspect, or 
are diagnosed with an illness. The constant background noise of health-related narratives in 
everyday life that perhaps contribute to increasing porosity of the boundaries between medical 
and lay knowledge, also feeds into a pervasive paranoia about health perhaps most acutely 
realized when actually diagnosed with a serious illness.  
 
The way an individual responds to illness might be read as an attempt to assert his or her 
identity in relation to an existing sense of agency: “…autonomy can be observed in how agents 
manage to maintain a precarious identity with the ability to act so as to ensure the persistence 
of their agency” (Moreno and Casado, cited in DaRocha and Etxeberria, 2013:67). For example, 
for a patient already accustomed to independent information seeking in other areas of their 
lives, managing diagnosis with illness and informing clinical decision-making through self-
directed research sustains an existing identity as one who maintains control through strategic 
assimilation and application of knowledge. Arguably, if maintaining a comfortable identity 
 
62 Drawing parallels with the logical nexus that housed notions of nuclear deterrence and the cold war in the 
geopolitical system, Blum notes the particular burdens this places on the system, and the practitioners and clients 
that operate within it opening up a range of ethical questions around “concerns for governance regarding the 
quality of care, advice, expertise, information and conflicts between dependency and self-determination” (Blum, 
2011:460). 
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involves retaining faith in the clinician as holder of all knowledge in the patient/doctor 
relationship however, or in a belief that exposure to the narratives of others is a potentially 
distressing experience best avoided as some respondents have expressed, the agency gained by 
maintaining a recognizable identity may well turn out to be a risky form of autonomy.  
 
This perspective has demonstrated then that CLL patients live with at the very least a double-
articulation of risk, the broader pervading conceptual sense of bodies and health at risk 
(Giddens, 1991; Beck, 1992; Blum, 2011), and the corporeality of bodies as risky environments 
through which they must now experience the world. Furthermore, this is an outside world to 
which, for the most part they will appear as they always have, yet an inner world that is 
fundamentally changed for them in numerous ways, most of which cannot be planned for or 
accurately predicted. How they are able to respond to this potentially paralysing vortex of risk 
and uncertainty will depend to a great extent on their existing attitudes and expectations 
because however strongly they feel their diagnosis cannot be ... it very definitely is. 
 
‘…but it is’: narrative reconstruction in the networks? 
 
Reflecting on his diagnosis with prostate cancer, writer Anatole Broyard remembers that  “My 
initial experience of illness was as a series of disconnected shocks, and my first instinct was to 
try to bring it under control by turning it into a narrative” (Broyard, 1993:308). Broyard’s 
experience was of an acute and aggressive form of prostate cancer, the series of ‘disconnected 
shocks’ that defined its relatively short course radically shifting and truncating his particular life 
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narrative (he died in 1990 following diagnosis in 1989). For most people diagnosed with a 
chronic disease, the task of re-imagining a life narrative involves revision of plot, structure, and 
maybe character over time, as opposed to a radically accelerated conclusion. Williams (1984) 
describes this process as “narrative reconstruction” (Williams, 1984, cited in Radley, 2004:146). 
People narrativize their illness experience in all sorts of ways from personal imaginings, through 
everyday conversations to written biographical accounts. Key among the literature surrounding 
study of the latter is the work of sociologist, cancer patient and heart attack survivor, Arthur 
Frank who sees narrative as a means of empowering bodies and voices ‘wounded’ and silenced 
by serious illness and its treatment. For Frank, ‘wounded storytellers’ are members of what he 
refers to as the ‘remission society’ accommodating  amongst others63, the chronically ill, the 
disabled, and anyone who has had cancer (Frank, 1995:8), and producing three dominant types 
of illness narrative:  
 
Restitution stories attempt to outdistance mortality by rendering illness transitory. 
Chaos stories are sucked into the undertow of illness and the disasters that attend it. 
Quest stories meet suffering head on; they accept illness and seek to use it. Illness is the 
occasion of a journey that becomes a quest (Frank, 1995:115). 
 
 
 
The value judgement inherent in this triadic typology seems clear. In the quest, Frank places 
emphasis on the active use of narrative to heal the wounds inflicted by illness on the self and 
others. Narrative is located as a resource for facing ‘head on’ the reconstruction of a coherent 
self, fragmented by traumatic experience. The idea of narrative as constitutive of self has its 
 
63 These ‘others’ include those living in recover from cardiac events, or from addiction or abuse, and anyone with a 
disease that requires continual self-monitoring or the management of prosthesis (Frank, 1995:8) 
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critics though. Crispin Sartwell (2000) cautions us “to resist the impulse to mistake narrative for 
life” (Woods, 2013:126) whereas Galen Strawson (2004) rejects outright the validity of any 
assumption that “human beings always conceive of life as a narrative” (Strawson, 2004:428). 
Paul Atkinson (2009) highlights ambiguity of voice and the role of performance in any narrative 
act, and is worried about dualistic personal/authentic lifeworld versus impersonal institutional 
discourses encouraged by framing illness narratives as an act of resistance to the silencing 
potential of the biomedical model (Atkinson, 2009: 2.6). The potential of culturally available or 
acceptable narrative discourses to marginalize alternatives needs to be considered in relation 
to narrative categorization of illness experience. CLL patients, diagnosed with a chronic, 
unpredictable, invisible, incurable disease that can loop from chaos back to order many times in 
its life cycle often find themselves in this exclusion zone:  
 
Unlike other types of cancer this one is difficult to accept as a "fight" making one feel 
helpless to battle it unlike "hard" cancers which have a clearly defined pathway ie 
diagnosis/treatment/recovery/all clear (IOB Survey Respondent 261). 
 
 
Narrative concerns, including post-modern scepticism surrounding the unproblematic 
alignment of a coherent ‘self’ with narrative technique seemingly have little impact on the 
enduring popularity of reading and writing pathography however. Some critics even question 
whether a contemporary philosophical de-centring of the self and meaning creates a vacuum in 
which “writers and readers find in personal narratives the authenticity and authority that 
postmodernism denies” (Hunsaker-Hawkins, 188). This may particularly resonate with the sick 
for whom even a reflexively constructed identity has received quite literally a body blow. Anne 
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Jurecic notes a scholarly emphasis on the importance of the body itself in health narratives 
“The theories of narrative set forth in the work of Charon, Frank, and Hawkins respect the 
irreducibility of the writer’s body” (Jurecic, 2012:15). Contemporary biography is, as already 
acknowledged, constructed in complex socio-cultural environments. Pathography emerges 
when the continuation of that biography is threatened by the compromises and mortal failings 
of the body itself, invoking a Cartesian dualism as Hunsaker-Hawkins notes “Illness intensifies 
the sense of the self: faced with disintegration and death, the self assumes a Cartesian 
certitutde – “I am sick therefore I am” (Hunsaker-Hawkins, 1999:189). 
 
Evangelistic claims for the healing powers of narrative reconstruction, and sceptical critiques 
notwithstanding, it would appear that many people do benefit at some level from writing and 
reading about the experiences of serious illness. Psychologist James E. Pennebaker has 
conducted empirical research on the therapeutic benefits of emotional expression through 
trauma writing and, whilst seeing its limitations, suggest that the ‘practice of composing’ itself 
provides a means for organizing an understanding of one’s life and self, and for gaining insight 
into uncertainty and the unknown (Jurecic, 2012:11). Anne Hunsaker Hawkins has identified 
three basic types of illness narrative, or pathography: testimonial pathographies, inspired 
primarily by didactic or altruistic motives; angry pathographies that describe patients' 
unhappiness with the way they or their illnesses have been treated; and narratives that deal 
"with finding alternative treatment modalities -modalities that sometimes supplement 
traditional therapies and sometimes replace them altogether" (Mclellan, 1997:101). 
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So how, if at all, might the concept of narrative reconstruction be read in relation to the 
circulating narratives in the CLL networks explored in this work? First I will look at that question 
in the light of the specific features of the disease, before going on to explore more fully a 
potential need to revisit illness narrative theory in the light of online health communications.  
 
As with a diagnosis with any chronic disease, CLL patients need to re-imagine a life that has 
become inextricably linked with their illness.  Restitution as proffered in Frank’s triad of 
narrative types is not (yet anyway) an option. As Arthur Kleinman notes:  
 
“Chronic illness is more than the sum of the many particular events that occur in an 
illness career...The trajectory of chronic illness assimilates to a life course, contributing 
so intimately to the development of a particular life that illness becomes inseparable 
from life history” (Kleinman, 1989:278). 
 
 
Where an unpredictable chronic illness like CLL – an incurable cancer with heterogeneous 
patterns of progression and outcomes64 - becomes part of that life history, it presents obvious 
challenges in re-narratavizing any form of coherent, linear, teleological structure surrounding 
future life plans. This was a commonly reported phenomenon among survey respondents: 
 
I have adjusted to living mainly in the present. I plan only in the short term and have 
accepted that things are often cancelled. It's very disappointing but I try and take 
pleasure from the small things that I do manage (IOB Survey Respondent 256). 
 
64 Interesting work is emerging questioning whether more successful approaches to treating many cancers, and a 
recognition that the impacts and effects of the disease and its treatments extend way beyond the treatment 
period, might mean that cancer in general should be regarded as a chronic disease. See Witter and LeBas (2008) 
for their overview of cancer as a chronic disease in M. D. Anderson Cancer Center’s publication, Oncolog: Report to 
Physicians published in April, 2008.  
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It may be the case that the only truly empowering form of re-narrativizing for a CLL patient may 
be that of re-imagining the self as one who can learn to accept and accommodate a life made 
vulnerable, uncertain, and problematic in ways that are often difficult for others to 
comprehend.  In some ways this could be read as the kind of re-narrativizing that might fit 
Frank’s notion of a quest. Whether or not all patients are conscious of an ontological or ethical 
need to elevate that beyond the personal level of managing life with a difficult disease as 
implied in Frank’s notion of the quest is contestable, although the very act of circulating and 
sharing personal narratives online and putting them into contact with multiple alternative 
narratives indicates a desire for public-facing and collaborative forms of narrativizing personal 
illness. As this work has noted, online narrativizing in the information economy can be read as a 
reflexive act, based more on transient, multi-faceted and ephemeral exchanges than the more 
sustained existential writings alluded to by Frank. Comments by respondents in the previous 
CLL Online Chapter also indicate that not all narrative sharing is expressed as an ethically 
motivated practice. I want to argue in the next section however that the more dialogic form of 
illness narratives shared in online communities make any potential benefits of shared 
experience readily available as a by-product or network effect whether or not their posting was 
primarily motivated by an ethical drive.    
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Digital Narrative Reconstruction: A New Paradigm? 
 
Diagnosed with a brain tumour in September 2012, digital artist and lecturer Salvatore Iaconesi 
accessed his digital medical records in search of a cure. Obliged to “crack” the files from their 
closed form to an open format for sharing, Iaconesi used them to spark a remarkable process 
beginning with the setting up of his site ‘Mia Cura: A Multi-Media Network for Cure’ (see 
screenshot in Figure 15) prefaced with the following aim: 
 
Just today I have been able to share the data about my health condition (about my brain 
cancer) with 3 doctors. 2 of them already replied. I have been able to do it because the 
data used open, accessible formats: they have been able to open the files using their 
computers, their tablets...I will progressively publish all the replies I will receive, using 
open formats, so that anyone with my same disease will be able to benefit from the 
solutions I will find (Iaconesi, 2010). 
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Figure 15:  IACONESI , S. (2013). ‘La Mia Cura’ open source cure [Screenshot] 22/04/2013. [Online] Available at: 
http://opensourcecureforcancer.com/ [Accessed: 17/03/2013].  
 
Successful ‘Me centred’ network sites such Iaconesi’s, user-generated personal accounts of 
illness on YouTube, and blogs with facilities to comment produce networks quite different to 
the more diffuse  communality imagined in ‘virtual communities’ (Rheingold, 1993).  As with 
Iaconesi, one individual is central to the network, but their own narrative accommodates the 
comments and responses of others. Iaconesi’s site publishes his x-rays, explains his situation, 
and invites responses under highly variable interpretations of ‘cure’.  Responses are grouped 
into  over 300 suggested ‘cures’ ranging from acidity to zebrafish  and posted by brain surgeons, 
through artists, to people with similar experiences and those who are just interested in 
contributing . I suggest that this ongoing re-shaping of individual narratives in response to the 
multiple narratives they intersect with applies just as readily to the more short-form exchanges 
Image removed due to copyright restrictions 
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taking place in online support community dialogues.  
 
On the face of it, Frank’s argument that ill people attempt to re-locate themselves learn by 
“hearing themselves tell their stories, absorbing others’ reactions, and experiencing their 
stories being shared” (Frank, 1997:133) is not far removed from what we see happening in 
online pathographies, whether in blog form, a collaborative project such as Iaconesi’s, or the 
shorter form exchanges more often seen in support communities and listservs. Frank and other 
proponents of the therapeutic value of illness narratives focus on their healing potential, not 
just of the illness itself but also of the perceived disempowering impacts of institutionalized 
approaches to care. As Atkinson warns us though, this view of treatment as having as much 
power to silence as the disease itself, and of narrative as providing the power to regain a voice 
can validate a reductive subject/object division between health care and the patient 
experience. Furthermore, such views need to be read in the light of changing power relations 
between doctors and their patients in a digital era as explored in chapter 2 of this work. 
Although this evolution is a slow one, and CLL patients in this research reported varying 
experiences in their own clinical relationships, attitudes and expectations towards the roles 
played by doctors and patients in relation to disease knowledge and management have 
changed considerably since Frank published the Wounded Storyteller in 1997.   
 
I don’t want to appear to throw the baby out with the bathwater here though. Despite obvious 
movements in a direction away from oppressive medical regimes, this work has shown 
consistently that many CLL patients do in fact feel silenced and voiceless in response to a 
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perceived lack of understanding of the issues faced on diagnosis. We are not yet in a position to 
claim that such silencing doesn’t or won’t still occur at some level. The question is more one of 
whether singular narrative quests are necessarily the only or indeed the most effective tool to 
help regain those voices now that more open-ended and rhizomatic narrative potentials are 
available through the digital health narrative?  This chapter has already demonstrated how 
circulation of narratives such as Brian Koffman’s ‘Good Cancer’ blog post, and a research paper 
‘Invisible, Incurable and Inconclusive’ (Evans et al., 2011) put patients’ own health narratives 
into dialogue with narratives that address the difficulties they face yet are written by and 
articulate the way CLL is enacted by representatives from the very institutions perceived as 
holding the power to silence them in the first place. Gaining understanding of the different 
objects of CLL in this way, learning to contextualize their own narratives in relation to the 
broader ones that shape their treatment and care alongside absorbing the narratives of other 
patients surely has the potential to frame the digital illness narrative as something more than 
just an empowering response to an act of oppression visited by disease and its treatments?  I 
will return to this in conclusion, after exploring some more narrative translations en route with 
this question in mind.  
 
As many respondents in this chapter have shown however, the CLL networks online have to 
some extent helped them to negotiate the difficulties faced in this respect on diagnosis (and 
beyond) by sharing narratives with fellow patients and (in some cases) professionals. Exposure 
to a flow of circulating personal and professional narratives can reduce a sense of isolation, 
exemplify alternative models for coping, and open up multiple versions of CLL against which to 
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consider one’s own personal story. Network actors approach this in different ways, and I want 
to focus in the final translation of this chapter on a longitudinal case study of a network actor’s 
use of narrative to transition from newly diagnosed information seeker to key agent of support 
for the newly diagnosed.   
 
Translation: A Newly Diagnosed Actor in the Network 
 
Very regularly in the CLL support networks, a plea for help, support and advice will appear from 
a newly diagnosed patient or a loved one of someone recently diagnosed. The requests take as 
many different forms as those posting them, but they are shot through with universal themes 
of shock, confusion, disbelief, disorientation and anxiety. Without fail, these pleas for help are 
responded to - very often by key actors in the community who have responded to similar pleas 
many times before.  
 
The closing translation selected for this chapter takes the form of a small case study of a 
particular actor in the CLL networks, mapping excerpts from three of his postings over a three 
year period to demonstrate a basic timeline of online narrative adjustment to a CLL diagnosis. 
Diagnosed in 2011, Hairbear is a now a major actor in the UK and global CLL networks, heading 
up online support groups, organizing face to face meetings with patients and clinicians, and 
operating as an active CLL advocate. The excerpts that follow are headed up under the original 
titles of the postings and trace his journey from a recently diagnosed CLL ‘newbie’ reaching out 
for advice through a narrative approach, through a process of acceptance raising interesting 
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questions about what forms an adjustment to a liminal life might take, to a much later response 
to another newly diagnosed patient seeking help in 2013. All of the postings were made to the 
Macmillan CLL/SLL support group:  
 
Making the Adjustment 
 
On 27 Jan 2011, new community member Hairbear made the following update entitled ‘Making 
the Adjustment’, to his blog ‘CLL NEWBIE’ on the Macmillan CLL/SLL community forum:  
 
Hello all thanks for welcoming me into the community. I didn’t realise that there could 
me so many of us in one place! With my limited knowledge I’ve found it easy to find my 
way around, well done techies. I was shocked how quickly I have been able to meet other 
patients of my age with CLL; we appear to be quite thin on the ground. Just exchanging 
information about symptoms we share that the haemos seem to dismiss within our age 
group, has taken away some of the fear that doubt creates. Sharing in the broader 
experiences of the community has already cleared much of the fog that still lingers 
following my diagnosis. I now know I do have a place where I can share the ups and 
downs caused by our disease (Hairbear, January, 2011).  
 
 
 
Hairbear’s opening paragraph acknowledges the relief expressed by many patients at finding a 
support group where they can communicate with others sharing a CLL diagnosis. Immediately, 
attention is drawn to the role played by technical support in the networks in providing a 
navigable interface. So often black-boxed in discussions in online support, Hairbear makes it 
clear how dependent community users are on those working behind the scenes to facilitate 
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such communication.  
 
The relative paucity of similar younger CLL patients can be a problem for those diagnosed in 
their forties and fifties (or younger in very rare cases), and the sense amongst this group that 
we are sometimes ‘lumped in’ with the generally older demographic receiving a CLL diagnosis in 
terms of clinical approach and available information is expressed here in Hairbear’s comment 
about the “dismissal” by haematologists of certain symptoms “within our age group”. As 
acknowledged earlier, CLL is generally speaking an older person’s disease. There is no doubting 
that this remains a devastating diagnosis at any age, but the difference between being 
diagnosed in one’s forties and at the average age of 72 is considerable in terms of potential 
impact on lifestyle, lifespan expectations, and disease management. The sense of liminality is 
heightened by living with the unquantified potential of a significantly truncated lifespan and by 
the impact on working/earning potential that a diagnosis with CLL in middle-age can bring. 
Doubt about the future can, as Hairbear notes, invoke fear, but for him the ability to share in 
“the broader experiences of the community” to some extent ameliorates that fear, dispersing 
some of the post-diagnostic “fog” and allowing him to reflect on the early process of coming to 
terms with the disease: 
 
It’s taken a while but I think I’ve managed to come to terms with the disease, what was 
holding me back was partly my own denial, combined with the complex nature of what 
diagnosis really means. Having to learn a new language just to interpret what CLL is, has 
taken the longest. At first you can’t see the wood for the trees. There’s so much 
conflicting information out there and it’s written in different medical languages, so each 
time you visit, you come away more confused and afraid (Hairbear, January, 2011). 
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Hairbear’s description here of the complex nature of a CLL diagnosis and the disorienting and 
often frightening process of researching the disease online accords with many of the comments 
made by the survey respondents in this and the previous chapter. As noted, not all patients 
wish to pursue an active independent approach to researching their disease for a number of 
reasons from existing beliefs in the hierarchies of medical knowledge exchange, through 
mistrust of online information to self-preservation in the face of unwelcome information. 
Hairbear never questions his need to interpret “what CLL is” for himself, but is clear about the 
challenges of learning to navigate both the language of medical discourse and the vagaries of 
conflicting information. There is a sense in the reflection that things get better as confidence 
with the language grows, as does the ability to discern which information we might rely on. The 
wood emerges from the trees slowly in this narrative. Arguably with most CLL experiences this 
can only ever truly be interpreted as the wood of uncertainty becoming visible through the 
trees of desire for exact answers, but coming to that conclusion may be a longer game than the 
perspective of Hairbear’s ‘newbie’ narrative allows for. What Hairbear does acknowledge with 
an articulacy that will resonate strongly with fellow community members is the difficulty 
experienced by the newly diagnosed in coming to terms with “watch and wait”:  
 
Perhaps learning to cope with “watch and wait” is one of the hardest! Everything you 
think you understand about cancer is turned on its head by this approach. To have to let 
the disease develop within you, whilst it gets stronger and you get weaker, must be one 
of the greatest adjustments to perceived convention that we make. Thankfully we ought 
to get respite for a good while after the time treatment comes. But it’s a bit of a double 
edged sword really; if you want treatment you can’t have it yet, and when you don’t you 
have little choice. At least we have time to be involved in the decision as to what therapy 
will best suit us (Hairbear, January, 2011). 
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In this chapter, I have already explored the acknowledgement of these difficulties faced by CLL 
patients in the circulating narrative of Evans and colleagues (2011) ‘Invisible, Inconclusive and 
Incurable’ research paper. Early after my own diagnosis I told a colleague that my leukaemia 
was not being treated immediately. With a look of abject horror, she informed me emphatically 
that my doctor was either negligent or stupid (or both), and that I should seek a second opinion 
as a matter of urgency if I wished to stay alive. Such is the received wisdom that cancer must be 
treated aggressively and immediately that no amount of explanation on my part would 
convince her that I wasn’t being duped into an early demise by a medical charlatan. When 
diagnosed with CLL, the paradox of having to accommodate it while it progresses produces a 
cognitive dissonance that is even harder to come terms with. As Hairbear powerfully puts it “To 
have to let the disease develop within you, whilst it gets stronger and you get weaker, must be 
one of the greatest adjustments to perceived convention that we make” (Hairbear, January, 
2011). 
 
Certainly that uneasy sense of sleeping with the enemy is a key theme in the diagnostic period 
and beyond amongst CLL patients, and Hairbear’s efforts to rationalise that through the 
potential of a decent remission ultimately involute into his narrative acknowledgement of lack 
of control over treatment timing. The knowledge that CLL treatment, however good the 
remission period may be, is ultimately a palliative rather than a curative response at present 
underscores this reflection, and again feeds back into the sense of liminality and uncertainty 
suffered by CLL patients and acknowledged previously in this chapter. Any narrative 
reconstruction taking place, as it is here by Hairbear in the early days of his diagnosis, must 
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accommodate that profound uncertainty as part of a post-diagnostic life moving forward. 
Seeing that form of narrative modelled in support communities has the potential to assist 
others with their own approaches as the following survey respondent indicates: 
 
… I was terrified, for the first year I had no support till I found a US site of like sufferers 
who were at the same stage as me, a god send we were on the same page! (IOB Survey 
Respondent 207) 
 
 
Hairbear closes his reflective posting by summing up his response to finding the community in 
the wake of his diagnosis. Fellow members are addressed as “friends” in a clear appeal to 
community values, and a forthright plea for narratives outlining the strategies employed by 
fellow members to adjust to “the new shape” of their lives acknowledges biographical 
disruption and a perceived need for narrative reconstruction of those lives: 
 
Cancer has opened my eyes to the effects on the patient, their loved ones, friends and   
lives. Nobody wants to be a member of this club, but having had no choice, I am glad to 
have found this address. I look forward for the opportunity of sharing highs and lows 
with many new friends within the wider community. Please let me know what has helped 
you adjust to the new shape of your lives. Take care, an optimistic newbie (Hairbear, 
January, 2011). 
 
 
Whether the optimism expressed by this self-confessed “newbie” refers to the expectations of 
support, the impact of the disease on his life, or both is left unclear, but that the posting ends 
on a note of clearly articulated optimism is important.  This reflective narrative has expressed 
fear, anxiety, denial, confusion, and some loss of agency, but it is presented as the rational and 
determined reflection of someone who is not willing to be crushed or silenced in the face of a 
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diagnosis and who will overcome what challenges he confronts. In reaching out to others for 
their stories of adjustment, there is an assumption that others too will have taken or will be 
taking this way forward in learning to live with CLL. At the same time as reaching out to be 
enabled by others, Hairbear’s narrative is in its own way potentially en-abling through 
modelling a narrative strategy for coping. The underlying story here is one of learning to cope, 
to manage conflict and challenge, and to collaborate through the sharing of stories. In setting 
up this model, Hairbear is working to make the support networks more active and dynamic. The 
next posting shows how the narrative of diagnosis progresses through a reflection on 
‘normalizing’ CLL as a part of everyday life. 
 
‘Is this Normal?’ 
 
Some seven months on in August, 2011, Hairbear makes another entry to his CLL Newbie blog 
on the Macmillan site reflecting on the phenomenon of ‘normalizing’ his disease experience: 
 
Looking at how I think about having CLL these days I seem to be thinking differently? I 
appear no longer concerned about the procedure of giving a little blood for routine testing, I 
even never seem to give a second thought about what the disease may be doing. Whether 
my counts may have altered dramatically from the last time. I know it's slowly marching 
(creeping up), but don't seem to be phased. The day to day symptoms that were new are 
now just a part of me, having adjusted my routine I seem to have forgotten what things 
were like before , so now feel normal again.  Is this normal, or am I in a form of denial 
again? (Hairbear, August 2011) 
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The tendency to ‘normalize’ or come to accept a diagnosis and accommodate it has been 
addressed earlier in this work, and Hairbear’s narrative reflections on this phenomenon, 
followed by his questioning of the definition of ‘normality’ when living in diagnosis “is this 
normal, or am I in a form of denial again?” alludes strongly to the liminality of a CLL diagnosis. 
Hairbear questions whether the benchmarks for what is perceived as ‘normal’ in the life of 
someone living with CLL actually do change, or whether perceiving the symptoms and impacts 
of the disease on daily life as a new ‘normal’ is somehow a form of denial of the real impact of a 
diagnosis with a chronic, incurable leukaemia on our lives. He attempts to answer his own 
question within a framework of altered expectations and new routines which, practiced daily, 
congeal over time into a new ‘normal’:  
 
I guess we adjust and become the "new normal". The altered expectations of the future, 
the being unwell, the new routine, the precautions, the medical environment and the 
necessary new knowledge are all assimilated. Incorporated and connected and become 
nothing more than part of your normal day (Hairbear, August, 2011). 
 
  
Locating this sense of normalizing that would once have felt entirely abnormal in a more 
specific symptom of living with CLL, Hairbear focuses on the phenomenon of infection 
experienced by CLL patients who are significantly immune-compromised: 
 
I seem to notice changes but they don't stand out, it's understood and expected. So as 
infection has become more frequent and harder to shake, I realise that has crept up on 
me too. Am I imagining how normal it feels? Because I'm sure something, that before 
would have seemed major, now is just another day and barely noticed, is this normal, or 
does this happen to us all? I remember when diagnosed, finding out about infection 
precaution and again thinking " how the hell am I going to discipline myself to take this 
on board"? Well I did and it must help with some, but not all. Now I am familiar with 
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many more antibiotics than before. I think this is why my interest has been peaked [sic] 
by much of the new research into combating pathogens, the search for a universal flu 
vaccine and even immunotherapy for CLL (Hairbear, August, 2011). 
 
 
CLL patients are constantly prone to infection, and what’s more – to infections that a 
competent immune system could fight off with ease, but that could be potentially fatal in the 
immune-suppressed. This brings with it a sense of real vulnerability and constant risk in the 
face of everyday pathogens. The need to ‘manage’ exposure to infection risk is productive of a 
constant sense of the body as a ‘borderless’ country, and one that needs to be protected 
constantly against the threat of invasion. This can have a negative effect on one’s sense of 
resilience and spontaneity in the world, and can be isolating. All CLL patients know this, and 
Hairbear appeals to that knowledge amongst community members through his narrative 
reflection, before rolling it into an exploration of recent research into fighting infection 
generally, and more specifically to CLL: 
 
There is work happening with T-cells, immunotherapy, and CLL... 
http://www.cllglobal.org/bios/cooper.htm 
Dr. Gribben at Barts-- 
http://www.cllglobal.org/research/alliance/updates/hosing_shpall_gribben.htm 
  
Kipps, Castros et al have been working on a number of CLL vaccines like ISF35 etc... 
http://www.memgenbio.com/technology/files/Memgen_ASCO_2011_Poster.pdf   
 
(Hairbear, August, 2011). 
 
   
The provision of links so that readers can visit the pages for themselves, and the 
contextualizing of the CLL specific work within a broader portfolio of work and links on 
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infection generally encourages readers to think about the world of pathogens and immunity in 
the broader sense. Yes, CLL reduces our immunity, but what do we understand about 
immunity, infection, and the current issues relating to them in the first place?  Hairbear links to 
research coming out of Cardiff into phyto-chemicals and Manuka honey, and to work on drug 
resistant pathogens.  “Salmonella strain, known as S. Kentucky, has developed resistance to 
the antibiotic Ciprofloxacin, often used for treating severe Salmonella cases.” Discerning 
between a BBC and an NHS article linked to in his narrative: 
 
 http://www.bbc.co.uk/news/health-14386654 
 
UK- NHS on the subject -http://www.nhs.uk/news/2011/08August/Pages/kentucky-
drug-resistant-salmonella-epidemiology.aspx 
  
      The NHS on the subject proved a much better read (Hairbear, August, 2011). 
 
 
Hairbear summarizes findings that the drug resistant pathogens originate in North Africa and 
the Middle-East, probably as a result of over-use of antibiotics in poultry farming, and appear to 
be trafficked by travel, poultry and some fruit and vegetables, contextualizing the risk for CLL 
patients: 
 
As we CLLers already employ preventative hygiene procedures around food and 
especially raw fruit and vegetables, that the NHS suggest. I would suspect that we are 
best prepared to avoid such a minuscule chance.  However the trend does show a small 
increase (Hairbear, August, 2011). 
 
 
 
Julia Kennedy 
207 
 
Infection in CLL, and the precautions required to minimize the negative impact of that on our 
lives is located as just one part of a broader machine of immunity/infection/treatment. The 
story of Hairbear’s coming to terms with those impacts on his life is narrated as part of a 
complex, interconnected world of science, biology, agriculture, transport, hygiene and 
pharmacology. Hairbear questions his shifting perception of ‘normality’ within this bigger-world 
picture, using research and knowledge assimilation as a means to understanding how he needs 
to re-shape his own world in relation to the broader worlds that shape it post diagnosis: “There 
seems to be much going on in the field of research that may produce results that improve our 
quality of life”. As well as hope, there is realism though. The research, the knowledge, 
understanding the bigger picture might help to comprehend and manage the contingencies on 
a particular disease, but it doesn’t remove the anxiety and fear of living with a progressive, 
incurable cancer altogether, and Hairbear is careful to acknowledge this in closing his narrative 
reflection on adjustment:  
 
None of it's gone away, the discomforts are all still here. As is the hammer over my head 
with knowledge that treatment will come. Maybe I'm just having a good day or maybe we 
do just adjust. Take care (Hairbear, August, 2011). 
 
 
The reader of this narrative learns that adjustment is possible, that it may vary in degrees from 
day to day and is not necessarily a linear process, that (for Hairbear) it has been aided by 
seeking a more complex understanding of the multiple impacts of the disease, but that the 
basic challenge of living with this uncertain disease remains central however well we may 
adjust. This is a positive model for other readers, but by no means unattainable or unrealistic in 
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its avoidance of potentially alienating claims of self-realization or ‘closure’ that might exclude 
those still struggling with diagnosis. This sense of hanging on to the difficult parts of diagnosis 
whilst attempting to move forward into a fulfilling post-diagnostic life is evident in the final 
posting in this Translation case study. 
 
 RE: New Diagnosis 
 
In November, 2013, almost four years on from his own diagnosis, Hairbear posted a response to 
a call for help and advice from a Macmillan community member following a recent diagnosis. 
The appeal for help is raw and immediate, and differs in that sense from the more reflective 
postings of Hairbear’s ‘newbie’ blog entries analysed here. For ethical reasons, I will not 
replicate the original posting here, but am concerned more with Hairbear’s response, the 
trajectory exemplified through his three postings from newly diagnosed and seeking help and 
advice to a key actor in the CLL networks dispensing advice to other newly diagnosed patients. 
In welcoming the new patient to the group, Hairbear acknowledges from experience the sense 
of fear that so often accompanies a CLL diagnosis, and introduces his own CLL ‘credentials’: 
 
Welcome to our group it is very scary and I can recall myself how debilitating that feeling 
is. I was diagnosed four years following a CT scan investigating other matters and have 
not required treatment yet (Hairbear, 2013c). 
 
 
This is followed by a brief explanation of CLL diagnostics in relation to the basic biochemistry of 
the disease that precedes personal recognition of the anxieties of awaiting a diagnostic blood 
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result:  
 
How unfortunate to have your results on Christmas Eve, I will be thinking of you. 
Waiting is very much a part of having CLL you may experience much waiting for even 
when everything is confirmed CLL is only treated when it has to be, so many here will be 
able to share how they cope with waiting. Right now you can probably not feel anything 
other than fear and how this news is making you feel (Hairbear, 2013c). 
 
 
Hairbear invokes a sense of community and personal concern in this response whilst 
acknowledging the likelihood of feeling overwhelmed by fear at this very early stage of 
diagnosis. The recipient is reassured that ‘right now’ this is an appropriate response, but – by 
example- that it will eventually subside. As we have seen with Hairbear’s previous narratives, 
one of his coping strategies has been that of learning about the disease. Knowing something 
about how the disease works and what to expect in terms of progression and management is 
presented as a positive step that the newly diagnosed can take to help themselves:  
 
learning a little about CLL can be very helpful and explain what to expect. As CLL tends to 
progress very slowly you should have a lot of time to take it all in, nothing will suddenly 
go bump in the night.  Here are some very current and understandable sources of UK 
patient information that may help you in the beginning. I am sure others will join you 
soon to share a little.  
 
 Leukaemia & Lymphoma Research: website is a good place for early   learning, it is 
supported with very recently updated information in booklets, Audio and videos and an 
extensive website written in an understandable 
manner.   http://leukaemialymphomaresearch.org.uk/information/leukaemia/chronic-
lymphocytic-leukaemia (Hairbear, 2013c).   
   
 
The sense that self-acquired knowledge and understanding can increase agency and contribute 
to a less traumatic period of adjustment to diagnosis is implicit here.  Also implicitly 
Julia Kennedy 
210 
 
acknowledged is the challenge and potential dangers of increasing fear inherent in unguided 
searching at an early stage of diagnosis, as reflected on in Hairbear’s first blog posting explored 
earlier in this case study. Hairbear goes on to provide the following list of links, filtered and 
selected as appropriate for a newly diagnosed patient venturing out to research CLL online, and 
already sorted into a range of aspects of the disease covering a range of dimensions from the 
physiological to the emotional:    
 
              Chronic Lymphocytic Leukaemia (CLL)                
              http://leukaemialymphomaresearch.org.uk/sites/default/files/cll_july_2012_3.pdf               
                         
 Information for those newly diagnosed with a blood cancer                
 http://leukaemialymphomaresearch.org.uk/newly-diagnosed-blood-cancer                
                              
Watch and Wait: Monitoring While Treatment Is Not Necessary                           
http://leukaemialymphomaresearch.org.uk/sites/default/files/watch_and_wait_dec_201
1_0.pdf  
                                                                                                                   
This is brief and current introduction to and overview of  CLL written by Professor Pettitt 
for the UK Lymphoma Association also a good place to start.         http://goo.gl/fQ0uI             
                                              
 Healthtalkonline, uses video snippets from CLL patients and medics to support   
information       
            
Reactions to the diagnosis 
http://www.healthtalkonline.org/Cancer/Leukaemia/Topic/3765/     
      
Other people’s reactions to the diagnosis 
http://www.healthtalkonline.org/Cancer/Leukaemia/Topic/3767/      
       
Watch and wait http://www.healthtalkonline.org/Cancer/Leukaemia/Topic/3792/   
 
Please just throw anything that's on your mind to the group, there are many here who 
can give you feedback. You are not alone here (Hairbear, 2013c). 
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With the final comment, the assimilation of research information in relation to the recipients 
own situation is presented as something that works effectively when it is dialogic and put into 
action in the broader collaborative narrative setting of the group. Drawing perhaps on the 
memory of his own early experiences of groping in ‘the fog’ that descends after diagnosis, of 
not being able to see ‘the wood for the trees’, and the difficulties of assimilating a new 
language and conflicting information, Hairbear attempts here to provide the kind of guidance 
that might ameliorate some of the terror that often accompanies solo online research in the 
early stages of diagnosis. 
 
From scared patient, reflecting on a new diagnosis and reaching out to others for their stories, 
to accomplished guide and advocate for the newly diagnosed, this case study has outlined the 
narrative evolution of a key actor in the networks. Hairbear’s use of reflective narrative, 
rhetorical questioning, collaborative mode of address, and enmeshing his ongoing story of 
diagnosis and reflexive adjustment into the broader networks it connects to hypertextually 
exemplify a form of evolving digital illness narrative. It is no surprise that Hairbear has become 
a key actor in the networks, and a significant mediator, linking people and the disease across 
network boundaries, and creating and holding together new nodes in the network. What 
motivates and equips some people to adopt this role and not others is beyond the scope of this 
research, but is flagged up for future exploration as it is central to an understanding of how 
successful network effects in cancer support might be replicated where they remain wanting.      
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Chapter Summary 
 
This chapter has explored various enactments of a CLL diagnosis through circulating narratives 
in the network. In translation, Brian Koffman’s ‘Good Cancer’ blog post , Evans et al.’s ‘Invisible, 
Incurable and Inconclusive’ research paper, and the case study of a patient’s own postings to a 
CLL support community alongside patient voices from the survey and networks have 
demonstrated something of the range, intersection and effects of circulating narratives of 
diagnosis in the CLL networks.  
 
Fieldwork has clearly shown that patient experiences of a CLL diagnosis are too often poor. 
Patients often feel that their sense of shock and devastation on diagnosis doesn’t correlate with 
some doctors’ uninformative and unsupportive manner in conveying the diagnosis. The 
widespread inconsistencies in clinical knowledge and approaches to treatment of CLL reported 
across the networks, in tandem with a perceived downplaying of the severity of CLL by 
clinicians very likely contributes to this group’s strong sense of dissatisfaction and low reported 
emotional well-being in the relatively rare quality of life studies that exist for CLL patients 
(Shanafelt, 2007). Furthermore, many patients report being placed in an impossible conceptual 
bind by being told that CLL is ‘a good cancer’ which, for a significant amount of them simply 
doesn’t turn out to be the case. A common response to this lack of support and information on 
diagnosis is to go online and access support networks. Findings in this chapter show that among 
those online patients studied, internet use seemed to be of very real benefit in coming to terms 
with a CLL diagnosis in most cases. In Perspectives, I look at the impact of an increasing lay 
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medical literacy on patient/iclinican relations in relation to hierarchies of knowledge exchange. 
Levels of clinical knowledge about CLL outside of the specialist setting are patchy at best, with 
many patients reporting the poorest levels of knowledge among GPs and family doctors. Even 
among some general haeamatologists, levels of knowledge and treatment approaches were 
reported as inconsistent, and it is not uncommon for CLL patients online to become as 
knowledgeable about the disease and its politics, if not more so, than their doctors. 
Technocultural shifts in the patient/clinician relationship are filtering through slowly into daily 
practice, and with varying degrees of acceptance from clinicians it would seem. Although some 
patients reported feeling overwhelmed, confused or excluded by online information and 
support narratives, they were in a significant minority. Their views are extremely important 
however, as they may well be representative of a much wider group of offline voices not 
captured by this work.  
 
In emphasizing narrative responses to tensions between clinical and patient enactments of a 
CLL diagnosis in the blog post and research paper selected for Translations, this section has 
shown some of the strategies adopted in online support networks to bring multiple and often 
conflicting enactments of CLL together for consideration. Accompanying perspectives have 
explored work on different dimensions of disease definition using a triadic model of subjective 
illness, biomedical disease and socio-legal sickness. It seems that the heterogenous and 
unpredictable nature of CLL locates it as a disease that defies easy categorization at the best of 
times, perhaps exacerbating existing tensions between subjective and biomedical enactments. 
Both Brian Koffman’s blog and Evans and colleague’s paper mediate between these 
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enactments, considering patient dissatisfaction with levels of clinical information and support 
against time constraints and professional attitudes to disease severity contingent on 
institutional and professional haematological practice in the clinical setting.  
 
Evans and colleagues’ observations of CLL as a disease whose invisibility, incurability, and 
inconclusiveness places patients in a liminal space between cultural understandings of illness 
and health shows the specific difficulties this patient group faces in coming to terms with 
diagnosis. This seems particularly acute for CLL patients in the watch and wait phase of their 
disease, and these challenges have been read alongside perspectives in this chapter exploring 
the processes of accommodating diagnosis in relation to theories of biographical disruption and 
narrative reconstruction. The final Translation shows how an individual CLL patient has used 
narrative strategies in an online support community to negotiate a transition from a terrified 
newly diagnosed member to a key network actor, sharing information and links to multiple 
narrative enactments of CLL online, and assisting both himself and the newly diagnosed to 
adjust to life with the disease.   
 
In demonstrating how patients and professionals have mobilized the internet to construct and 
share narratives of coming to terms with diagnosis in varying contexts, this chapter has worked 
towards advancing the argument that new forms of illness narratives in an informational age in 
which multiple narrative enactments intersect can act to create broader multidisciplinary 
understandings of the varied aspects of disease experience. 
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Given the complex biographical impact of a CLL diagnosis however, alongside unequal access to 
online facilities in the disease’s older demographic, simply relying on the fact that patients will, 
as my own GP suggested I did, ‘go away and look it up on the internet’ is by no means a 
satisfactory overall answer to this group’s often unmet need for diagnostic information and 
support. As already noted, this research is self-selecting of patients already online. It is 
impossible to calculate how many CLL patients do not use the internet, but it is undoubtedly a 
far greater number that are represented here as acknowledged by the following survey 
respondent:  
 
Before internet info, I was given a brochure by my consultant. I think we are very cut off 
in Cornwall for information. What about CLL people without the internet? (IOB Survey 
Respondent 2) 
 
 
 
This is an area that CLL patient advocate groups online could perhaps influence in collaboration 
with regional consultants through communication with primary health care providers, and it is 
an issue that urgently demands further research if future generations of CLL patients are to fare 
better than their current counterparts in terms of informational access and emotional well-
being. The above respondent also draws attention to the issue of inequities in treatment 
approaches and access to specialist clinical expertise and trials according to geographical 
location, another common theme emerging in the online survey and support networks, and one 
that will be explored in the following chapters.   
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For the time being, it would appear that most CLL patients already online are using circulating 
narratives to their benefit in understanding the various enactments that define their disease, 
and accessing the information and support that underpins pro-active approaches to their 
experiences of a diagnosis with CLL.  
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Chapter 4: Prognosis 
 
 
 
Figure 16: TOUCHGRAPH (2015) network connections between nodes addressed in ‘Prognosis’ chapter [Network 
Map]. [Online] Available at: www.touchgraph.com [Accessed 04/03/2015]. 
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Introduction: Living in Prognosis: The Bigger Picture 
 
…prognostic markers for me cause a lot of research to look for survivability times that 
seem to be different for all, hard to realize how much time is left…(IOB Survey 
Respondent 51). 
 
 
Employing a range of voices from the survey, online forums, and my own experiences, 
alongside key sites identified by users and network mapping tools, this chapter will show how 
people are forming and utilizing networks to help them to negotiate complex translations 
across the worlds of cells, science, time, pharmacology, medicine and the day to day business of 
living with a life-threatening disease in relation to prognosis and prediction of their likely 
disease course.   
 
Prognostic testing in CLL is becoming more sophisticated as biomedical understanding of the 
disease advances rapidly, and the range of tests available for typing, grading, and predicting 
likely progress of their disease is expanding. The boundaries between issues of being diagnosed 
and receiving a prognosis are barely discernible to the patient, so enmeshed are they, and my 
separating them out into two discrete areas may seem to some to be an artificial distinction. 
However, CLL prognosis can be a kinetic affair, evolving in some cases as the disease 
progresses, as treatments effect clonal evolution, and as residual disease begins to return 
following treatments. The impacts of prognostic testing and knowledge extend way beyond the 
moment of diagnosis in reality, and way beyond the clinical sphere too.   
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Of equal importance is the potential psychological impact of advanced prognostic knowledge 
on CLL patients. Does knowledge of likely disease course and outcome necessarily benefit a 
patient in the early stages of disease if it doesn’t offer a greater degree of control over how that 
progress might play out? How much benefit might it afford if it can’t predict future 
developments in treatment that might alter predicted courses anyway? These questions 
require careful consideration of the psychology of day-to-day disease management for those 
living with chronic diseases. As with diagnosis, they draw acutely on issues of perceptions of 
time in the lifeworlds of the chronically ill. As long as a gap remains between prognostication, 
and ability to significantly influence or halt disease progression, CLL patients will have to 
negotiate the yawning chasm between knowledge and control. As already demonstrated, 
contemporary life with CLL is very much a life in the interstices – between illness and health, 
between old treatments and new, between expert care and access to novel protocols and 
traditional generalist provision. As also demonstrated, and as will become clearer throughout 
this work, times are rapidly changing in cancer care per se, and in CLL care specifically. Any 
allusion to the impact of rapidly advancing genetic knowledge in disease treatment must 
address the issue of patients living in a transitional present where patients are exposed to 
varied experiences between traditional and evolving approaches to prognostication.   
 
As the previous chapter has shown, life with CLL becomes a liminal theatre upon whose stage 
we perform the functions of everyday life, whilst fully aware of the spectre of grave illness 
loitering in the wings. As one survey respondent put it, “I have grown to see it as the monkey 
that is on my shoulder, always waiting to drop in” (IOB Survey respondent 66).   Prognostic and 
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predictive indicators offer the closest alternative we have to stage directions for the timing and 
management of its entrance, but this remains something of an improvised script.  
 
Metaphorical monkeys and theatrical spectres hint at the crisis of meaning that ‘living in 
prognosis’ (Lochlann-Jain, 2007) invokes. However much technical knowledge patients might 
accrue, and whatever their degree of collaborative decision making in relation to treatment, 
questions still remain about how to think about shaping a life without any teleological certainty 
(always putative anyway of course), and how to interpret the deferred meaning of 
prognostication when the signification of one’s actual death slides constantly beneath the 
signifiers of generic descriptors and statistics. Despite, or maybe because of, the dissonance 
between statistical and actual experiences of life and death in prognosis, it is an obvious 
preoccupation for many people living with a life-threatening disease. As a ‘chronic’ cancer, CLL 
as a rule gives those living with it more time to consider the implications of their prognosis on 
both treatment and life choices. Unsurprisingly then, the CLL networks buzz with topics 
surrounding prognosis and prognostic indicators from a range of perspectives reflected in the 
rich responses yielded in the survey element of data collection. In total 160 respondents 
provided some 8,600 words describing their use of online resources surrounding prognosis.   
 
The survey responses were invaluable in sketching out the broader map of sites and themes for 
this area of the study.  The following respondents allude to some of the major sites utilized, and 
demonstrate the impact of information gained from them in understanding and coming to 
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terms with their own prognostic indicators: 
 
Discussion of prognosis comes up frequently at all sites and at all meetings. …Best 
resource? CLL topics again. (IOB Survey Respondent 168) 
 
 
A few months after diagnosis, our son found the list of CLL Specialist on the ACOR site 
through searching the Internet. I went to Mayo Clinic for the testing of Fish, Zap 70, etc. 
My CLL Specialist suggested joining ACOR's CLL List. My learning began at that point. The 
four months prior to that I was in panic mode believing I was going to die shortly…(IOB 
Survey Respondent 124). 
 
 
The dear, departed Dr. Terry Hamblin contributed to 2 of the 3 lists that I subscribed to. 
When I learned, 2 years after diagnosis, that I was unmutated, I had a brief bout of 
hysteria until some correspondence with Dr. Hamblin calmed me down. In retrospect, I 
know that his "prognosis" was based on extremely limited data, and should perhaps 
have not been taken so seriously, but the variability of everyone's experience (as I have 
learned via the lists) and the fact that there as so many new and exciting clinical trials 
underway (which I have also learned via the lists) have allowed me to live my life in a 
more measured and un-hysterical fashion (IOB Survey Respondent 26). 
 
  
…. CLL TOPICS was probably the most helpful in developing my understanding of the 
various prognostic markers. Having now read many research articles and followed 
journeys of a many CLL patients who write their stories in the forums and their blogs, I 
have come to appreciate the limitations of the prognostic markers…(IOB Survey 
Respondent 86). 
 
 
Respondents identified other sites (such as CLL Canada) in the survey, but the most active 
nodes selected for mapping in this area included the ACOR list, CLL Topics, the late Terry 
Hamblin’s blog ‘Mutations of Mortality’, and CLLSA Health Unlocked.  
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This chapter will address the issues above as they manifest in the circulating narratives of CLL 
online. Perspectives will address current prognostication in CLL, the important shift from 
prognosis in terms of life expectancy to prediction of a disease’s likely course in order to 
underpin strategic treatment planning, issues surrounding knowledge and power in prognosis, 
and what it means to live in risky bodies. Translations will look at a number of narratives 
circulating online from the most frequently mentioned sites in the survey, addressing prognosis 
in CLL from scientific advice and advocacy, through specialist advice to patients’ own narratives 
as they accommodate the inscriptions of science and medicine. 
 
Perspectives: Prognosis in CLL  
 
As already stated, the field of CLL prognostication and treatment is rapidly evolving, and a brief 
overview of the current state of genetic research underpinning advanced prognostication in CLL 
specifically will help to set the scene for the perspectives and translations explored in this 
chapter. 
 
Whole genome sequencing provides raw data on all six billion nucleotides in an individual’s 
DNA. The process has been applied specifically to CLL cells under the direction of Dr. Stephan 
Stilgenbauer (University of Ulm, Germany). The CLL cells are separated out from patient blood 
samples, and the chromosomes unraveled so that the nucleotide sequence of each gene can be 
determined. All human cells are exposed to a number of external and toxic stressors that 
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trigger mutations and change genetic coding at cellular level. These mutations are often silent, 
or repaired before they do any critical damage. However, some of them make significant 
genetic alterations leading to the growth of cancer cells. Comparative readings of mutated cells 
and healthy “normal” cells in the same patient allow researchers to identify deletions and 
abnormalities in the tumour DNA. Repeating the process across a range of patients allows for 
comparison of disease progression and treatment responses in relation to those genetic 
mutations related to CLL.  
 
It is openly acknowledged in current research that the prognostic techniques currently 
employed can be something of a blunt instrument in relation to the dynamic genetic 
complexities of CLL that genome sequencing has made visible: 
 
Current diagnostic approaches to treatment selection, response monitoring, and relapse 
prediction are limited to single genes and apply only to a minority of hematologic 
cancers. This is at odds with modern concepts of tumor propagation and maintenance, 
which propose that every cell in an individual cancer is characterized by a combination 
of mutation events that comprise tumorigenic (driver) mutations, passive (passenger) 
mutations, and possibly predisposing germline risk ’variants (Schuh, A. et al., 2012: 
4191). 
 
 
Schuh et al. used whole genome sequencing to track clonal evolution in three CLL patients 
subject to recurrent therapies, concluding that: “genomewide sequencing will become an 
effective approach to monitor disease progression systematically and also prospectively” 
(Schuh et al, 2012: 4195). The authors hypothesize that this will be far-reaching, directing 
future trials, clinical decisions, fundamentally altering treatment protocols, and contributing to 
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more cost-effective care of CLL patients with improved outcomes. But what does this mean for 
patients currently living with CLL? 
 
Prognostic testing at diagnosis varies globally according to local protocol. In any case, either at 
diagnosis or at the point at which treatment is deemed imminent, patients will currently 
undergo cytogenetic/fluorescence in situ hybridization (FISH) analysis. This genetic test reveals 
a range of markers providing baseline predictions of likely disease progression and response to 
treatment. In the US, this is part of a standard diagnostic work-up. In the UK, most patients 
wanting this amount of prognostic detail prior to needing treatment would currently have to 
pay a specialist research centre for a test unless fortunate enough to have one as their local 
hospital. This seemingly unequal right to access cytogenetic information at the point of 
diagnosis results in a good deal of debate in CLL networks online. However, despite the relative 
sophistication of current flow cytometry, and significant advances in the treatment of CLL, 
relapse remains the major cause of mortality and specialists recognize an urgent need to 
improve response prediction to new and traditional therapies so that effective treatment 
choices can be made in line with Anna Schuh’s optimistic predictions. Inevitably, CLL patients 
are caught up in the time lag between the advance of scientific knowledge and the health care 
systems that deliver the results and in reality a range of prognostic practices can be seen 
playing out in the support network narratives. One conceptual change underpinning practice is 
filtering through into network debate however, and that is the distinction between prognosis as 
impact on life expectancy, and prediction as a benchmark for therapeutic decision-making. 
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Perspectives: Motivations for Knowing: Prognosis or Prediction? 
 
Up until 1999, when prognostic tests began to be applied in trials, evaluating prognostic factors 
was largely a retrospective process. As Terry Hamblin puts it: ‘They were tested on samples that 
were sometimes more than 20 years old from patients who were treated in many different 
ways, often suboptimally’  (Hamblin, 2007). On the cusp of an era of personalized medicine 
however, biomarkers function as much more than prognostic indicators of likely potential 
lifespan. Predictive biomarkers can help physicians and their patients negotiate strategies for 
care based on individual disease profiles, irrespective of their broader prognostic signs:  
 
Whereas prognostic biomarkers indicate the overall clinical course of the disease 
irrespective of treatment, predictive biomarkers pinpoint patients most likely to 
respond to a specific therapy… ideally predicting treatment response before it is given, 
thereby protecting the patient from adverse effects caused by ineffective drugs  
(Alsolami et al., 2013: 362). 
 
 
As Schuh and colleagues’ (2012) work shows, an upturn in the availability of predictive 
biomarkers is likely as genomic knowledge advances. Currently, clinical use of CLL predictive 
markers is limited to the monitoring of minimal residual disease (MRD) following treatment as a 
surrogate marker for overall survival in trials (or to identify patients who might benefit from 
maintenance therapy), and the use of deletions and/or mutations of TP53 located at 
chromosome 17p13.1 to predict a poor response to chemotherapy amongst this group (ibid). 
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 If intervention in clinical decision making at this level may intuitively appear outside the remit 
of patients in general, this work reveals plenty of network evidence to show patients actively 
seeking out new treatment regimes, clinical trials and even switching care providers based on 
the implications of predictive and prognostic markers and the way their clinicians approach 
them:  
 
I have changed oncologists again in part because I was not entirely satisfied with the 
minimal prognostic testing and lack of communication about the results (IOB Survey 
Respondent 122). 
 
 
It is clear that in many cases these decisions, and the knowledge required to understand and 
make them, are significantly influenced by online research and discussion. However, not all 
respondents were positive about the benefits of researching prognostics online, with some 
advising caution:   
 
If I believed my prognosis I would have died last year. Ignore them and develop a positive 
attitude to beating cancer in your own way, the web gets in the way of this (IOB Survey 
respondent 156). 
 
 
This respondent actually couches the web as a barrier to developing autonomous coping 
strategies for, in this case, a poor prognosis already outlived. This shows that the imagined 
community of CLL online, with its untrammeled narrative flows of experience and information, 
is just as capable of exerting a negative influence on some users as it is a positive one on others. 
Prognosis is concerned with very personal parameters of life and death, yet is only ever 
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representable as something ‘other’ to an audience - someone else’s statistics, someone else’s 
story. It is easy to see why, outside of a model for predictive treatment planning, many patients 
find exposing themselves to wider spheres of prognostic abstraction difficult, or even harmful 
to negotiate. 
 
In the early days of my own diagnosis, I was desperate to know what the future might hold for 
me as a CLL patient, and embarked on my own (often stormy) voyage of prognostic discovery 
online. I want to start this chapter with two Translations each exploring one of two particular 
narratives I encountered in the search for prognostic information. The first, ‘Making sense of 
prognostic factors in CLL’, by Consultant Haematologist Professor Andrew Pettit (2008) is an 
introductory outline aimed at the newly diagnosed CLL patient available on the CLLSA UK site65.  
The second, ‘How I Treat CLL Patients up Front’ is a paper by CLL specialist Professor John 
Gribben, published in clinical haematological journal ‘Blood’ in (2010), and linked to the 
‘Prognosis’ section of lymphoma advocacy site66. Whilst both are written by CLL specialists, the 
former is specifically aimed at patients, whilst the latter is published in a professional peer-
reviewed journal, and focuses sharply on the issues of prognosis and prediction from the 
clinician’s perspective. 
 
 
 
 
65 http://www.cllsupport.org.uk/03%20Prognostic%20factors.pdf 
66 http://bit.ly/favAVV 
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Translations: ‘How long have I got?’ (Making Sense of Prognostic Factors 
in CLL) 
 
 
 
Figure 17: TOUCHGRAP (2015) network connections from CLL Support site (CLLSA UK) to Lymphomation site 
[Network Map]. [Online] Available at: www.touchgraph.com [Accessed 04/03/2015]. 
 
In the days immediately following diagnosis, having been sent home by my GP with very little 
information about CLL other than its incurable status and instructions to ‘look it up on the 
internet’, my main preoccupation was my prognosis, or ‘how long will I live?’ I spent much of 
the time awaiting my first consultation obsessively familiarizing myself with staging and median 
survival times, trying desperately to relate them to my increasingly unrecognizable life. I must 
have visited hundreds of sites in those early days, from personal blogs to institutional 
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information pages, all of them presenting information in different formats, from different 
perspectives, and for different audiences.  Traumatized by the diagnosis of an incurable, life-
threatening disease for which I had no frame of reference, I was at the mercy of the generic, 
the dated, and the sometimes erroneous information online. Information and median survival 
times based on earlier trials of continually evolving treatment protocols make for distressing 
reading for the recently diagnosed, and the difficulties inherent in making sense of them is 
articulated by the following respondent: 
 
I am a librarian and have become concerned about the older info which is online. 
Because cll treatments are evolving quickly I wonder how the average person will sift 
through it all (IOB Respondent 64). 
 
 
The question of how the newly diagnosed negotiate this terrain is of profound importance to 
the understanding of initiation into the network cultures of any disease, and is an issue directly 
concerning key network actors. In CLL networks online, various advocacy and support sites take 
different approaches to presenting information for patient-readers. There is strong evidence of 
efforts to provide distinct information for the newly diagnosed or ‘newbies’, for whom a much 
higher degree of informational gatekeeping may be assumed to be beneficial. Of course, 
questions must be asked about who guards the informational gates for the newly diagnosed, 
and why. Putting issues of control and power aside for now, it is generally assumed to be a well-
motivated desire aimed at reducing the potential distress inherent in going it alone when still 
reeling from diagnosis, and not necessarily conversant with the skills of internet research in 
general (the median age of diagnosis with CLL is 72).  
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The only lead I had been given by my GP was the CLLSA UK site, and it is to this site that I turn in 
the first instance to briefly outline its presentation of the staging systems and key prognostic 
indicators in CLL. The first information on prognostic indicators I read was ‘Making sense of 
prognostic factors in CLL’, a dedicated introductory outline for patients written for the site by 
Consultant Haematologist Professor Andrew Pettitt.   
 
Although written in June, 2008, many of the tests addressed in the document still remain core 
to the current portfolio of major prognostic and predictive testing and concerns, although Zap-
7067 has fallen out of favour somewhat and CD38 expression is controversial, the reasons for 
which will be addressed later in the chapter. The document introduces patients to a range of 
prognostic issues such as variability between patients; clinical staging; lymphocyte doubling 
time; chromosomal abnormalities; IgVH mutation and CD38; Zap 70; importance of 17p (p53) 
deletion in predicting response to therapy; and discordance (the co-presence of conflicting 
‘good’ and ‘bad’ markers). In the ‘Summary and Practical Advice’, Professor Pettit suggests that: 
 
For newly diagnosed patients requiring a broad picture of how their disease is likely to 
behave, a panel of prognostic tests is probably required including FISH for 17p-, 11q-, 
+12 and 13q-, and ideally at least two of the following: IgVH status, CD38 or ZAP-70. 
These tests are not routinely funded by the NHS and are usually only available at centres 
that specialise in CLL. However, most hospitals should have links with such a centre 
(Pettit, 2008:4). 
 
 
67 These more recent findings are summarized by a clinical research paper charting the progress of prognostics for 
CLL in the face of evolving genomic knowledge entitled ‘Clinical application of targeted and genome-wide 
technologies: can we predict treatment responses in chronic lymphocytic leukemia?’ 
(Alsolami et. Al, 2013)  and  linked to CLL forum CLLSA Health Unlocked  by members in early 2014, demonstrating 
how recent research is located and circulated by active individual mediators/translators in the networks thus 
keeping them continually updated.  
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For myself and others treated outside of specialist centres however, this wish list of prognostic 
tests turns out to be far from what is actually available at our local hospitals. In my case, FISH 
testing for chromosomal abnormalities was reserved for patients about to enter treatment, 
IgVH testing for mutational status - an accurate predictor of disease progression, was not 
budgeted for outside of clinical trials, as was the case with Zap-70 testing (Zap-70 is a tyrosine 
kinase and crucial molecule for the selective activation of T cells in downstream pathways, the 
test for which was considered useful in indicating likely disease progress). Initially somewhat 
confused and concerned by the inconsistencies, online discussion with other UK patients soon 
led me to understand that this was a common experience for those treated outside the major 
research centres. Discussions about seeking second opinions from a CLL Specialist, generally 
located in the big research centres are common across the communities (not just in the UK, but 
globally), and raise pertinent questions about inconsistencies in cancer care addressed 
throughout this work.  
 
Armed then with baseline blood tests, and the results from a basic flow cytometry test to 
identify a range of markers associated with the disease, I was confirmed as definitively having 
CLL, and put on ‘watch and wait’ to be monitored at three monthly appointments with my 
consultant. I was told I would not get any further prognostic testing until my CLL needed 
treating. 
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Translation: ‘How I Treat CLL Up Front’ (Clinical Enactments of 
Prognosis)  
 
As Figure 17 (p228 above) shows, when mapped using the TouchGraph tool, CLLSAUK, ACOR, 
and CLL Topics were linked to the Lymphomation.org site pages on prognostic indicators in CLL.   
 
Lymphomation.org was set up in 2002 by Karl Schwartz and the Patients Against Lymphoma 
group with the express aim of patient advocacy. It provides information on all lymphomas 
including CLL. The CLL section operates as a database linking out to current resources such as 
research papers, and sites providing information and support. The section on prognosis clearly 
shifts the emphasis from abstract prognostication to treatment specific prediction: 
 
Oncology does not need more prognostic factors, it needs predictive factors that are 
treatment-regimen specific.  Prognostic factors are unlikely to be used unless they are 
therapeutically relevant ... (Lymphomation.org). 
 
               
Drawing on the work of CLL specialist and active network presence Rick Furman, emphasis is 
placed on the limitations of prognostic markers as useful only in identifying which curve a 
patient might be on and not where on a median survival curve they might be located. “[For CLL] 
nothing is more helpful than the pace of your disease” (ibid). 
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This is followed by a link to a paper published in the clinical haematological journal ‘Blood’ in 
(2010) by CLL specialist John Gribben: ‘How I treat CLL up front’ (2010) focuses sharply on issues 
of prognosis and prediction from the clinician’s perspective. Although Gribben points out the 
paradox of high patient demand for prognostic testing despite its notorious ineffectiveness in 
accurately predicting precise outcomes for individuals, he acknowledges that he would want 
access to “as much prognostic information as possible for planning purposes” (Gribben, 
2010:31) were he to be diagnosed with CLL himself. However, in this paper, Gribben is careful 
to point out the difficulties in accessing IgVH testing, the inconsistencies inherent in current 
approaches to Zap70 testing, and disagreement surrounding the prognostic implications of 
CD38 results which change over time. Notable also are his observations surrounding patient 
motivation for prognosis, and the need to counsel for the potential impact of disappointing 
results. This is coded in terms of the clinical time and expertise needed to explain to patients 
the significance of prognostic testing:  
 
My own experience is that patients usually request these tests, hoping that they will 
have good prognostic markers; the finding of poor-risk features can often lead to 
increased anxiety, while not changing management, and this requires considerable time 
in clinic explaining the potential significance of the findings. It is, therefore, important 
that those caring for CLL patients have a full understanding of the clinical significance of 
any investigation that has been ordered (Gribben, 2010: 32). 
 
 
As with many of the research papers circulating in the CLL networks online, this paper is written 
primarily for a clinical audience. Linked to a patient advocacy site, it becomes a resource for 
patients too. CLL patient readers able to follow the paper in its entirety will encounter a 
narrative perspective on CLL that differs from their own, a different ‘object’ of their disease 
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(Law and Singleton, 2004). Understanding prognostic testing as a clinician sees it can be helpful 
for patients negotiating testing with their own doctors. The following table (see Figure 18, 
below), taken from the same paper and site outlines some of the more complex variables that 
might produce a poor prognosis in patients: 
 
 
Figure 18:  GRIBBEN, J. (2010) Poor prognostic factors in CLL, from ‘How I Treat CLL Upfront’. Blood Journal 
[Online] 115(2), 187–197. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941409/ and linked to 
CLL page on Lymphomation site. 
 
The table is just one stage of translation in the multiple iterations of information circulating 
around prognosis in CLL. Signs are first summarily translated from the body to clinical staging or 
laboratory tests and reiterated as median survival/likely response to treatment (‘good’ or 
‘poor’), then contextualized (in this case) in a clinical paper on disease management for 
Image removed due to copyright restrictions 
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physicians, before re-iteration in the networks as a patient resource. It is on the basis of these 
translations that the personal narratives of living with CLL in the network draw for their own 
iterations, ‘what does this mean for me in the context of my life?’, ‘what might it mean for you 
and yours?’  
 
Sites like Lymphomation.org might be taken for granted by those seeking information on 
lymphoma online, but setting up and maintaining an informational hub of this nature involves a 
vast amount of work by dedicated actors. The site is an incredibly rich, rhizomatic or 
‘mycorrhizal’68 resource, although one that may require some advanced knowledge or patience 
in navigation in comparison to sites that produce information already filtered for the newly 
diagnosed.   
 
Curating recent thinking on all the known lymphoma types, and linking out to a range of 
relevant resources, it is edited in the sense that links have already been selected as appropriate 
by someone acting in the role of mediator. Information is sorted into thematic categories 
covering the major aspects of disease definition, approaches to treatment, and ongoing 
research with multiple hyperlinks. These hyperlinks function as more than informational cul-de-
sacs of course, leading instead ever deeper into dense networks of information. As a new 
patient, I was somewhat overwhelmed at first by the sheer scale of the information reservoir 
 
68 Yrjö Engeström suggests that mycorrhizal structures offer a better metaphor than rhizomatic structures, where 
mycorrhizae are symbiotic fungal roots living with plant roots that can spread underground for miles – see 
Engeström’s paper, ‘From Teams to Knots: Activity-theoretical studies of collaboration and learning at work’ (2008) 
for further discussion of this theoretical approach. 
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pooling into this site, although I personally found it preferable to sites that actively attempted 
to direct my research practices as a new patient. As the survey work shows however, many 
patients find solo exploratory searching without a guide unhelpful, whilst others are 
autonomous in their search practices, using multiple sites located through Google searches and 
hyperlinks. Unfiltered access to prognostic information online can come at a cost however, as 
the following perspective outlines. 
 
Perspectives: Fore-knowing…Power or Cruelty? 
 
Lest my retrospective narrativizing of the key sites encountered in my early research 
surrounding prognostics online has rendered it into a neat and linear process, let me be clear – 
it was not. I bounced like a pinball from site to site in those early days, was convinced my death 
was imminent, was confounded often by conflicting information, was floored by encounters 
with personal narratives of people dying from CLL (a final blog entry from a CLL patient in his 
early sixties about to leave his home for the last time to die in a hospice from multi-organ 
failure following infection quite literally had me sobbing on the kitchen floor), and encouraged 
by stories of people who were surviving way beyond their allocated median survival times.  The 
knowledge I have gained since has helped me to avoid the pinball effect of uninformed internet 
research, and to cast off the misplaced sense of imminent mortality, but that is not to say that I 
don’t  still sometimes find myself in extremely challenging places.  
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Many newly diagnosed patients, or those facing key milestones in the course of their disease 
will inevitably encounter ‘median survival times’ as they try to locate themselves somewhere 
on a prognostic curve. Anyone who has ever attempted to relate their own life to a median 
survival time will understand the impact this can have, particularly in the early stages of 
diagnosis where the nature and discourse of generic prognosis can be both alien and terrifying 
to comprehend. 
 
 “How long do you think I will live?” I asked my Consultant plainly during my first meeting with 
him. 
 I drew (too quickly) on the knowledge gained from mean survival statistics on the internet to 
prompt him out of his measured consideration with my own suggestion. 
 “Ten years..? Maybe less..?” 
He told me that he didn’t know, pausing before adding that he thought it   “…a brave question.” 
 
I didn’t think so.  I think it would have been much braver not to ask. Like most people facing 
unexpected news of a life potentially foreshortened, I was not able to reach immediately (nor 
yet in fact) into bold reserves of calm acceptance, of que sera sera. I wanted to know everything 
about my disease from its specific genetic encoding to its probable timeline - a timeline now 
bound into a double helix with the timeline of my life.  It strikes me now as odd that I never 
hungered for this degree of anticipatory control over the future prior to diagnosis, but nothing 
transforms one’s own mortality from mere abstraction to cold, hard reality quite as effectively 
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as being diagnosed with a progressive, incurable disease.  Prognosis, fore-knowing, fore-seeing 
the likely course of my disease, is what I think I want, although I italicize the possibility that this 
is dangerous desire, and that maybe I should be careful what I wish for.  
 
Academic Susan Sontag experienced 3 episodes of cancer over three decades.  Having survived 
advanced stage metastatic breast cancer in the seventies, and ovarian cancer in the nineties, in 
early 2004 she was diagnosed with MDS, an acute and deadly form of leukaemia69.  Nine 
months later she was dead. Anne Jurecic describes Sontag’s belief that she could control her 
cancers over the years through knowledge and force of will as a form of ‘magical thinking’.  
After witnessing his mother’s distress when the unambiguity of the dismal prognosis for her 
MDS finally ruptured any potential for ‘magical thinking’, her son David Reiff asks the question 
in the context of life-threatening illness, “Is information, or knowing, power or is it cruelty?” 
(Rieff, 2008: 53). 
 
The implications of this question hover around the responses of CLL patients to questions of 
prognosis. The inevitable statistical abyss confronting individuals with any disease 
notwithstanding, CLL presents as a particularly slippery customer with many variations in 
disease presentation and potential outcome.  Even in an evolving landscape of more 
personalized disease markers, no aggregate will speak truth to the power of death and dying as 
 
69 MDS (myelodysplastic syndrome) often results from genetic mutations in the bone marrow caused by prior 
chemotherapy regimes. See Zhou, Y. et al. (2012) for a broader view on Therapy-related myeloid neoplasms 
following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic 
leukemia/small lymphocytic lymphoma, in Modern Pathology, 2012.  
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ultimately individual experiences. Indeed, the heterogeneity and mutability of CLL contribute to 
a sense of its current unknowability, leading some patients to make a conscious decision not to 
engage with prognostication until it becomes a necessity to guide treatment:   
 
I have never asked for my "markers" other than the counts that are checked routinely. I 
don't feel it is necessary to know until I need treatment and by the time I do, my disease 
may have evolved. If I do test, and it's bad news, I would worry more. If it's good news, I 
would feel horribly cheated if it turns out bad… I will not undergo treatment without as 
much information as possible, but I don't need it now. I have read that attitude from 
others on the ACOR list, so I feel it is a good decision (IOB Survey Respondent 68). 
 
 
 
Outlining the perceived perils of engaging emotionally with mutable prognostic information, 
this respondent confirms that their thinking has been influenced by and tested against the 
experiential narratives of others in a trusted online forum such as ACOR, a major node in the 
CLL network.  
 
Perspectives: Tagging the Diseased Self 
 
The practice of contributors signing themselves off using their prognostic indicators and 
treatment histories as they might list their qualifications after their names in forums such as 
ACOR is testament to the wide range of disease experiences represented by community 
members. Importantly, it allows members new and old to negotiate myriad patient narratives 
according their authors’ particular disease characteristics and histories. I currently sign off in 
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relevant forums with my age, cytogenetic status, and treatment regime to date, as ‘Julia 
Kennedy, age 54, diagnosed March 2011, 13q-, 6 rounds FCR November 2013 to May, 2014’. I 
have no idea how this tagline will evolve over the coming years. On the ACOR forum, some long 
term members are signing off with several lines of data, documenting over 15 years of changing 
disease status and treatments. These taglines themselves, into which shorthand form are 
condensed so many complex personal narratives of disease, provide a fascinating archive of 
evolving biomedical knowledge and changing treatment protocols in their own right and 
support Faith McLellan’s observation that online health narratives are ‘an amalgamation of 
journal and lab report’  (McLellan, 1997: 101).  
 
The practice of defining the diseased self online through listing biomarkers and disease 
experience as ‘qualifications’ in this way raises interesting questions about the impact of 
unfolding genetic knowledge in shaping human narratives of ancestry, identity and health. As 
we have seen, the genetic mutations occurring in the genesis and progression of cancer 
determine prognosis and, increasingly, treatment options, but genomic knowledge is also 
assimilated into the hopes, fears, and identities of those living with CLL.  
 
I draw here on Couser’s concept of the metaphor of the human genome as type of master text 
revealing aberrations and deviations which genetic medicine can read and ultimately aim to 
correct. “Disease/disability is cast as textual irregularity, and those in the biomedical 
community become editors who attempt to amend, delete, and correct the defective texts of 
disabled bodies” (Wilson, cited in Couser, 2004:182). Alongside acknowledgement of all the 
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potentially beneficial outcomes of the project, Couser also alerts us to the potential for 
eugenicist abuses of medical biopower. Such potential is of course undeniable, but this is not an 
issue generally raised in CLL community narratives. However, ambivalence to the knowledge of 
what is encoded into our genetic (already disclosed, or yet to be revealed) texts is a commonly 
encountered phenomenon in the networks. This plays out at much more than the basic level of 
“preferring not to know”. As yet, genetic mutations and expressions may dictate treatment and 
define prognosis for those with CLL, but they don’t always offer the potential of cure or agency 
in controlling the progression of the disease outside of the current drug regimes.  
 
At a deeper level still, once the genetic encoding of disease is complete, it has the potential to 
be read as part of the essence of individual identity in which disease becomes something that 
can’t be attributed to your behaviour or to fate, but becomes about literally who you are at a 
molecular level: “This places the disease deep into the body, internally, intrinsically, essentially 
within” (cited in Couser, 2004:181). Couser explores the potential for this biological 
essentialism at once to: “stimulate and to constrain first person narratives of illness” (ibid). G 
Thomas Couser’s observations on the relationship between life-writing as both narrative and 
non-verbal genetic practices in an era of advancing genomic knowledge are useful to 
understanding how access to genetic biomarkers might impact on the way we understand and 
write about living with disease at a point where: “DNA itself functions as a kind of non-verbal 
‘life-writing’ that is, a predictor or even ‘scripter’ of individual experience” (Couser, 2004:168).  
This chapter has already shown, and will continue to demonstrate how some patients at least 
choose to resist genetic knowledge as a potential ‘scripter’ of their lives. 
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Translation: ‘The Median Isn’t the Message’    
 
 
Figure 19: TOUCHGRAPH (2015) zooming in on network links for Stephen Jay Gould’s paper, the Median isn’t 
Message on www.cancerguide.org [Network Map]. [Online] Available at: www.touchgraph.com [Accessed 
04/03/2015]. 
 
As the network information on prognostics in CLL we have looked at so far shows, all prognostic 
markers be they genetic or otherwise tend to be extrapolated to median survival curves. The 
following survey respondents acknowledge the resources they found useful in beginning to 
negotiate the slippery terrain of ‘median survival’: 
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I was helped a lot by the discussions on the ACOR list about what "median survival" 
really meant, and especially by the helpful explanations of Dr. Hamblin before his 
untimely death.  (IOB Survey Respondent 44) 
 
 
ACOR and its archives were very helpful. Gould's essay on evaluating the stats on 
prognosis was a great help in gaining objectivity on my prognosis. (IOB Survey 
Respondent 28) 
 
 
‘Gould’s essay’ -so instrumental in helping respondent 28 gain objectivity - refers to Harvard 
based evolutionary biologist Stephen Jay Gould’s personal story of statistics: ‘The Median Isn’t 
the Message’, written in 1982 after being diagnosed with abdominal mesothelioma and given a 
median survival prediction of around eight months. Suspecting (probably correctly) that most 
non-statisticians would interpret this as "I will probably be dead in eight months” and 
describing this as “the very conclusion that must be avoided, since it isn't so, and since attitude 
matters so much” (Gould, 1982), Gould uses statistical knowledge to demonstrate how this 
median statistic bears limited relevance to him as an individual. Factoring in some of the 
positive elements on his side such as age and early identification of the disease, natural right 
skewing of the data70, and the inability of fixed statistics to accommodate evolutionary shifts in 
treatment and survival, Gould arrives at the conclusion that there is good reason to predict that 
he will be in the half of the group that live longer (median articulating central tendency as a 
kind of halfway point). It could just as easily have gone the other way of course, but Gould went 
 
70 Gould reasoned that, since his disease is only identifiable at death or before, the left of the distribution contains 
an irrevocable lower boundary of zero. This leaves little room for the distribution's lower (or left) half, which has to 
be compressed between zero and eight months. But the upper (or right) half can extend out for many years prior 
to dying. As Gould put it: “The distribution must be right skewed, and I needed to know how long the extended tail 
ran - for I had already concluded that my favorable profile made me a good candidate for that part of the curve” 
(Gould, 1982). 
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on to survive some 20 years after publishing his essay, his death the result of a secondary, 
unrelated cancer.  
 
Perhaps the reason that Gould’s essay still finds such a strong foothold in the networks of CLL 
(and other cancers) online is about more than its role as a story of hope in the face of despair 
and as much about its message of the empowering nature of knowledge for those whose 
bodies and lives have become inextricably entwined with discourses of science and risk. As 
Jurecic notes, the essay “draws attention to the very thing that does not interest the risk 
society theorists: how one man’s narrative makes personal meaning of impersonal statistics” 
(ibid). The relevance of this to CLL patients is reflected in the following posting from the ACOR 
CLL archives in 2001 (Gould died in 2002) emphasizing his ongoing role as an active member of 
society with much to offer despite his initial grim prognosis, and including a link to the essay for 
those list members not already familiar with it: 
 
For those who have an interest, Stephen Jay Gould (writer of the powerful words in 'The 
Median Isn't the Message') is apparently still doing well. I just read an article he wrote 
for the Times about the WTC bombing (he was also supporting the rescue efforts near 
Ground Zero). That would make nearly 21 years since he was diagnosed as a terminal 
cancer patient. For those who haven't read his inspirational words, they may be found 
at: 
 http://www.cancerguide.org/median_not_msg.html  (Anonymous respondent, ACOR 
CLL archive October, 2001). 
 
 
The essay, written over 30 years ago, continues to circulate, provoke discussion, and impact on 
peoples’ attitudes to their prognosis in very contemporary digital networks. Following the link 
pasted into the above posting, the reader arrives on CancerGuide’s ‘Statistics’ page  where a 
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copy of the essay is pasted next to a sidebar linking out to information about various aspects of 
understanding survival statistics organized as follows in Figure 19 below:  
 
 
         
 
 
 
 
 
 
 
Figure 20: CANCERGUIDE.ORG (2015) Sidebar from Steven Gould essay ‘The Median is not the Message’, on 
cancerguide.org   demonstrating links out to further information about how to interpret survival statistics. 
[Online]. Available at: www.cancerguide.org/median_ not_msg.html [Accessed: 28/03/2015]. 
 
Contextualizing the essay in this way locates it as a node in a network of supporting narratives 
that encourage the reader to negotiate survival statistics by building knowledge and 
understanding gained through a process of guided online research.  
 
‘The Median isn’t the Message’ is a powerful circulating narrative in the CLL (and other cancer) 
networks. Still actively transported across sites many years after its authorship, the essay has 
almost cult status in cancer communities seeking as it does to “humanize statistics and also to 
convince readers that knowledge, in particular ‘dry academic knowledge about science’ 
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constitutes power” (Jurecic, 2012:23). The enactments of CLL by scientific statisticians are 
translated from median survival predictions for patients for whom these statistics can be 
powerful drivers of hope or despair. 
Perspectives: Survival Statistics and Biopower 
 
Such translations can underpin a counter-voice to the potential biopower inherent in the 
institutional use of statistical information. When Kathleen Woodward observes in ‘Statistical 
Panic’: “Fatally, we feel that a certain statistic, which is in fact based on an aggregate and is only 
a measure of probability, actually represents our very future” (Woodward, (185) cited in 
Jurecic, 2012: 20), she acknowledges the process by which the seemingly portentious power of 
medical statistics for individuals can be harnessed to exert powerful control over entire 
populations. This concern was obviously keenly felt by the following survey respondent:  
 
What concerns me is that the doctors use truth tricks to calm people who post. I find this 
problematic. This approach is discussed in the paper DISCIPLINING BODIES AT RISK: 
Cardiac Rehabilitation and the Medicalization of Fitness by Elizabeth E. Wheatley in the 
Journal of Sport & Social Issues, Volume 29, No. 2, May 2005, Basically, the population 
based data that are used in medical studies are manipulated/interpreted to meet the 
needs of doctors (IOB Survey Respondent 71). 
 
 
 
This respondent’s reference to the Wheatley paper demonstrates a desire to deconstruct 
statistical discourses used by the medical profession and acknowledges their potential use as a 
form of the biopower discussed by Woodward.   
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Another approach to the potentially deleterious effects of statistical biopower (intentional or 
otherwise) emerged, with several respondents resisting translation of the lived reality of their 
disease into the predictive language of biomarkers or statistics. These patients, some with the 
advice of their doctors, chose instead to take feedback on disease progression directly from the 
body itself:  
 
I am not convinced that 'prognostic testing' is helpful to me. Simply put my disease 
behaviour over the last year is more accurate than a battery of tests (IOB Survey 
Respondent 254). 
 
 
Doc said "The best indicator of how you are going to do, is how you are doing." I 
reluctantly accepted the doc's advise [sic] on this and as I have since become more 
informed about the disease, I have come to realize he is quite correct about all this. CLL 
TOPICS was probably the most helpful in developing my understanding of the various 
prognostic markers. Having now read many research articles and followed journeys of a 
many CLL patients who write their stories in the forums and their blogs, I have come to 
appreciate the limitations of the prognostic markers (IOB Survey Respondent 86). 
 
  
Again, this can be read as a resistance to accepting genetic biomarkers as pre-determined 
‘scripters’ of individual lives (Couser, 2004:168).  
 
Conversely however, refusal by health care providers to make prognostic information available 
from the point of diagnosis and throughout the disease course is perceived in itself a form of 
biopower by the following patient, leaving patients uninformed and unable to collaborate 
effectively in their own care: 
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Many non-medical patients do not have a clue about the significance of the diagnosis, 
let alone the potential prognoses. It seems the medical profession wants to do little until 
the symptoms call for treatment. I have seen three consultants over the years and found 
all lacking in information, care concern. The first consultant, seen privately, never even 
told me I had CLL! I already knew, so he did not last long… Knowing your prognostic 
markers and the fact that they can change really is a must for all CLL patients. Surely 
most people want to know their future? (IOB Survey Respondent 169) 
 
 
The right to accurate personal predictive markers notwithstanding, ‘The Median isn’t the 
Message’ positions us to consider how people might: “make the mistake of living their lives by 
the numbers instead of attending to the dissonance between those numbers and their 
experiences” (Woodward, [185] cited in Jurecic, 2012: 20). Evidence in the CLL networks shows 
that people are very aware of this dissonance, although learning to meaningfully relate one’s 
lived reality to prognostic predictions is a process that takes time and understanding. This 
understanding incorporates awareness of the heterogeneous nature of the disease itself, 
differentiation between prognostic and predictive markers (and the evolving role of biomarkers 
in personalized approaches to care), and acknowledgement of the limitations for individual 
cases of generic statistical evidence. Again, it becomes clear that the networks themselves play 
a significant role in this educational process through exchange of knowledge and personal 
narratives: 
 
CLL Topics gave me clear information on the test and prognosis backed up by lots of 
clinical trials, so I was not receiving conflicting information from any blog sites. What CLL 
Topics print is backed up by clinical trials or test so I feel I can trust it and it has proved to 
be the case so far (IOB Survey Respondent 179). 
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Managing the desire to personalize the impersonal language of prognostics is part of the 
process of coming to terms with the prospect of a shortened lifespan for anyone struggling to 
accommodate the impact of diagnosis with a life-threatening disease on their sense of self.  
Jurecic claims that few patients have the conceptual, linguistic, narrative, and statistical 
resources required to underpin “the confidence and knowledge necessary to quickly recast a 
sense of self in relation to a new and threatening prognosis” (Jurecic, 2012:22). This view is 
shared by the following respondent’s belief that most patients seek to interpret survival 
statistics within frameworks of a strong sense of optimism for their own circumstances rather 
than attempting to gain a realistic outlook:  
 
Discussion of prognosis comes up frequently at all sites and at all meetings. However, 
few people understand anything about statistics and certainly not how they apply to the 
individual. People always think that they are on the right hand side (the survival part) of 
the curve. However good your prognosis, it is only an indication. I feel that when people 
are asking for prognostic factors what we are really asking for is to be told that 'hey, it 
was a mistake, you are going to live forever'. It is human, and adds to the feeling that 
you are in control... (IOB Survey Respondent 168) 
 
 
There is a very real possibility of course that being given a poor prognosis will have a chilling 
effect on the quality of a patient’s remaining life, as previously cited respondents have 
concurred. I am not certain though that it is possible to polarize the effects of knowing to either 
power or cruelty. Nor am I convinced from the data gathered in this study that people are 
entirely lacking in the resources to quickly recast a sense of self in relation to a challenging 
prognosis as suggested by Jurecic, but perhaps this is where chronic cancers become distinct 
from their more aggressive counterparts. Evidence of people coming to terms with their CLL 
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prognosis over time, assisted through assimilation of the narratives of others in the networks is 
strong, and it is certainly the case that a slow growing malignancy offers its host more time to 
navigate its potential impact on their sense of self and future. When one is very often facing 
median survival times of years rather than months or weeks, the need for a very rapid recasting 
of self is to some extent ameliorated. It needs to be stated however that any prognosis with an 
incurable malignancy, particularly one such as CLL that significantly increases the risk of 
secondary malignancies, requires significant work in re-articulating the self as the previous 
chapter has shown.   
 
In truth it seems one must be prepared for the fact that power and cruelty may be at times be 
intimate bedfellows in relation to prognostic knowledge, and indeed that power itself in this 
context might not always be about the ability to beat the odds, but might just as easily be 
defined as learning to live (or die) well in the face of them, as the following respondent 
indicates:   
 
Having both "good" and "bad" markers did not help with clear conclusion. Eventually, I 
stopped giving them much thought. My challenge was to learn to live with CLL, making 
the most of whatever time I have without letting CLL hijack my life (IOB Survey 
Respondent 71). 
 
  
For someone managing to retain relatively good health and quality of life in the face of the 
disease, time not only allows for, but to a large extent demands this process of ‘learning to live 
with’ a life-threatening illness. Life goes on, threatened by a compromised immune system, 
possibly significantly curtailed in terms of its expected span and, for some, in terms of its day to 
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day potential, but intrinsically live-able in the here and now. As the above respondent declares, 
learning to live as ‘normal’ a life as possible, despite the impossibility of knowing how long that 
remaining life will pan out post diagnosis, like a skill, is something that has to be learned over 
time.   
Perspectives: Re-skilling in Risky Bodies 
 
Elizabeth Wheatley, in her 2006 ethnography of heart disease, refers to the process of reskilling 
undertaken by people after acute episodes of cardiac disease. Drawing on Anthony Giddens’ 
(1991) views of the self as a ‘reflexive project’ organized around responses to risk in late 
modern life, Wheatley focuses particularly on the ‘fateful moment’ as a galvanizing factor for 
reskilling work. Described by Giddens as a point ‘where a person learns of information with 
fateful consequences’ (Giddens, 1991: 113), the fateful moment requires decisions or actions 
that essentially recast a life course or narrative. Locating the cardiac event as such a fateful 
moment, Wheatley describes the process of reskilling as an ongoing effort to “interpret risks 
and remake the body, to redefine and reinvent the self, and to rearrange social relations and 
routines” (Wheatley, 2006: 3). For a progressive disease such as CLL, the initial ‘moment’ of 
diagnosis and subsequent moments of prognosis, treatment, remission and relapse can readily 
be interpreted in this model whereby constant re-skilling is required throughout each phase.  
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Not everybody diagnosed with this heterogeneous condition however benefits from the 
advantages of time and relative good health to smooth the reskilling process.  The survey 
yielded a jarring response from a wife whose husband’s rapidly declining health, and limited 
survival time after commencing treatment came as a cruel shock to them. This was 
compounded by learning too late from a pre-treatment FISH test of the presence of a 17p 
deletion, indicating poor response to therapy. Having to wait until treatment is required for this 
test means that poor prognostic or challenging predictive indicators remain unknown to many 
patients and their medical teams throughout their watch and wait period:   
 
Had we had prognostic tests done at the beginning, I would have retired and we would 
have done some traveling while my husband was in watch & wait. Traveling was always 
a joy and we intended to do it in retirement - with an RV. By the time we got to an expert 
and heard the bad news of 17p he was too ill to travel and never regained health. I 
encourage people to have it done if they happen to be going to a local hem/onc who 
doesn't do it - as I encourage them to see CLL experts - as I shall always regret that we 
were uninformed until it was too late. And becoming informed was totally the result of 
CLLTopics.org. The support group ACOR was helpful once we became educated about the 
disease (IOB Survey Respondent 42). 
 
 
 
As novel treatments begin slowly to roll out into clinical trials and use, the outlook for patients 
with a 17p deletion is improving. At the time of the respondent’s experience, viable options to 
chemotherapy to which this group respond so poorly were virtually non-existent. The sense 
here then is not so much that knowledge would have changed the course of the disease itself, 
but that it would have inspired a different approach to living what life was left. In hindsight, this 
respondent sees a cruelty in the lack of knowledge of her late husband’s poor prognosis, 
translated into opportunities to seize the moment now forever lost.   
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Perspectives: The Fateful Moment and the New Digital Expert 
 
Giddens points out the important role of the ‘expert’ for anyone confronting one of life’s fateful 
moments. “Experts are often brought in as a … fateful decision has to be taken … knowing that 
a decision made or a course of action followed has an irreversible quality” (Giddens, 1991:114). 
The role of the expert is writ large across the previously explored posting of respondent 42, and 
a very clear distinction is made between ‘CLL experts’ and local more generalized 
haematologist/oncologists (haem/onc), treating a broad range of heamatological conditions out 
of local hospitals.  For this respondent, her husband not being treated by a dedicated CLL expert 
translated into them remaining ‘uninformed until it was too late’. Their decision to wait until 
retirement to realize their travel plans (rendered irreversible when death intervened) was 
made in the absence of prognostic/predictive information that the respondent feels would 
have been available to them had her husband been under the care of a dedicated CLL specialist. 
We learn that the knowledge and support they were eventually exposed to, giving them the 
confidence and resources to seek out a CLL expert, came about directly through engagement 
with online networks, CLL topics and the ACOR list, both of which are identified as major nodes 
in the network map for this chapter. As addressed in the introduction, the informed ‘e’ patient 
(or ‘e’-carer) is an auto-didact, learning to negotiate the networks in order to build the 
knowledge required to actively participate in online debate in relation to their disease.  
 
For patients in a digital era, Giddens’ notion of the ‘expert’, sought out at fateful moments, just 
as likely to be an online physician, scientist, another patient, or the self – educated by exposure 
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to a range of online expertise. As we have also seen, however patients in the network go about 
achieving their own level of understanding and expertise, it increasingly translates to the 
clinical relationship in the consulting room. Those patients and carers negotiating the networks 
of knowledge exchange online require expertise from their clinicians. If they perceive that they 
are not getting that, some actively seek second opinions or even alternative clinicians, whilst 
others choose to use what they find online to negotiate with their clinicians:   
 
My doc did not do prognostic testing and I had to push for it. Cll Canada is wonderful and 
nicely organized (IOB Survey Respondent 64). 
 
 
Such negotiations require clinicians confident and willing to work with their patients in a 
collaborative relationship that allows for discussion of the knowledge gleaned online. This is 
knowledge that in many cases general haem/oncs have not had the opportunity nor time to 
consider in as much detail as their patients, who have the time and motivation to benefit from 
daily exposure to global discussion of the very latest research and shared experience of their 
disease should they choose to engage with the networks at that level.  
 
Thus far, the chapter has demonstrated how patients begin to negotiate the gap between 
prognostic indicators as tools for predicting their likely lifespan, and as predictors of potential 
disease courses. Although distinctions still tend to get made in terms of median survival times 
according to CLL ‘type’, patients engaging with prognostic information often see beyond the 
statistics to seek the frameworks for informed predictive planning, seeking out appropriate 
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trials, being able to discuss potential treatments with Doctors, making decisions about work 
and family life and so on.   
 
This section will look at three sites or nodes, operating in the CLL networks at the time of 
research, and tracing some of the key prognostic issues across them, in particular the relevance 
of IVGH mutational status. 
 
 
Figure 21: TOUCHGRAPH  (2015) zooming into networks to look at links between CLL Topics, Mutations of 
Mortality Blog and Patient Discussion on CLLSA Health Unlocked [Network Map]. [Online] Available at: 
www.touchgraph.com [Accessed 04/03/2015]. 
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The first two sites I look at are Chaya Venkat’s CLL Topics, particularly her (2010) page ‘What 
Type of CLL do you Have?’,  and Dr, Terry Hamblin’s Blog ‘Mutations of Mortality’, particularly 
his entry from Tuesday, May 08, 2007: ‘Why should I get my prognostic markers done???’ 71 
 
Although still available for viewing, both sites now lie dormant, following the retirement in 
2012 of Chaya Venkat, CLL Topics’ founder and author, and the death of Terry Hamblin in 2013, 
they were selected on the basis of their significant function and popularity as key actors in the 
networks during the fieldwork period, as evidenced by the following survey responses: 
 
My prognosis was - and still is - mixed. The more I learned, the more I realized the 
research in this area is still far too new to be more than vague guidelines for most of us. 
Chaya's "Which Bucket Are You In?" is still the best word on the subject (IOB Survey 
Respondent 54). 
 
 
CLL Topics is where I found most of my information early on. Very helpful. Online I was 
able to discuss with Dr. Hamblin specific markers. I know I would not have been able to 
do so without the internet (IOB Survey Respondent 116). 
 
 
CLLtopics. Period. The best and most informative. Susan LeClair interviews always are 
clear and in simple language. I love her for that single fact. CLL Global Research. 
CLL/SLL@yahoo.com Lastly, I loved Dr. Hamblin's (CLL doc. in Bournemouth) blog until he 
passed from an unrelated cancer. NIH for clinical trials (IOB Survey Respondent 30). 
 
 
Via CLL Topics and the ACOR list I learned of a study at the NIH and entered the study in 
order to access expert opinion and prognostic testing, as well as contribute to the 
current body of knowledge re untreated CLL (IOB Survey Respondent 121).  
 
 
 
71 http://mutated-unmuated.blogspot.co.uk/2007/05/why-should-i-get-my-prognostic-markers.html   
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In addition, I’ll look at an online discussion prior to treatment on the CLLSA Health Unlocked 
site concerning the availability of IVGH mutational testing in the UK, picking up the same 
subject and bringing it more up to date in an online patient community discussion.  
 
This tripartite approach allows me to map information exchange across three distinct nodal 
forms. Firstly, in CLL topics, a site in which complex information relevant to CLL prognostics has 
been gathered, collated and translated for a lay audience by a scientist. Secondly, Terry 
Hamblin’s Mutations of Mortality demonstrates a similar process of translation undertaken by a 
CLL specialist but presented in a more open and discursive blog format. Finally, I trace the 
debate into a patient-led CLL community following the discussion ‘Who is Getting the IGHV 
(formerly known as IgVH) Mutational Status Tests in UK?’ 
Translations:  ‘Which Bucket are you in?’ (A Scientist’s Enactment) 
      
On January 1st, 2010, Chaya Venkat posted her much-visited page ‘What type of CLL Do you 
Have?’ on her site CLL Topics. Drawing on seminal papers in the history of CLL research, it 
amounts to a 6,500 word essay on current diagnostics and their relevance to the CLL 
community. Making the point that CLL runs many different courses with significantly different 
outcomes, Venkat reminds readers that: 
 
The spectrum stretches all the way from a ‘good’ cancer that is not going to do much of 
anything for the rest of your normal life span to an aggressive, incurable cancer that 
requires treatment soon after diagnosis, compromise your quality of life with frequent 
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infections and ultimately kills you in a few short years. (Venkat, 2010) 
 
 
This chapter has so far demonstrated the ambivalence, inconsistencies, and sometimes 
confusion surrounding prognostic information that exists among CLL patients. Venkat is stark 
however in her view of the potential implications of a lack of prognostic knowledge for the CLL 
patient when she warns readers against a ‘head-in-the-sand’ approach to their diagnosis. ‘What 
you don’t know about CLL can literally kill you a lot sooner than otherwise. How is that for 
motivating you to find out more about your particular brand of CLL?’ (Venkat, 2010)  
Sorting CLL patients into what she calls ‘risk buckets’ according to various prognostic indicators, 
all contextualized by the research and clinical perspectives that underpin them, Venkat gives 
advice to each group on how to manage their particular ‘type’ of CLL. These are summarized in 
the following table (Figure 21) reproduced from the site: 
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Figure 22: VENKAT, C. (2010) The Bucket Brigade [Table] from ‘What Type of CLL Do You Have?’ CLL Topics. 
[Online] January, 1st. Available at: http://clltopics.org/PI/Type.htm [Accessed: 14.12.2013]. 
 
Table removed due to copyright restrictions 
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Acknowledging that very few people are likely to have a disease pattern that lines up all of the 
markers as neatly as the table does, Venkat offers the summary as a tool for providing baseline 
information within which patients might usefully locate their own individual experiences. 
Across the networks however, one particular prognostic indicator currently stands out as a 
consistent indicator of likely outcome, and that is what is known as a patient’s IVGH  
(ImmunoGlobin, Variable region, Heavy chain) mutational status72.   
 
In ‘Which Bucket Are You In?’, Venkat  points out that, unlike many other biomarkers that 
evolve with time, IVGH mutational status  remains consistent across the lifetime of a patient 
and, along with FISH status, is ‘probably the single most important prognostic test’ (Venkat, 
2010).  Venkat’s  web-essay refers to  ‘Unmutated  IgVH Genes Are Associated With a More 
Aggressive Form of CLL’, a paper by Terry Hamblin in Blood journal, from which she replicates a 
graph indicating median survival times for patients  in either the ‘mutated’ or ‘unmutated’ 
groups. Neither author leaves the reader in any doubt as to the dramatic difference in outlook 
for the two groups: 
 
Median survival for unmutated IgVH CLL: 95 months. 
Median survival for mutated IgVH CLL: 293 months (Venkat, 2010). 
 
 
72 IVGH was originally referred to as IgVH. CLL patients form 2 broad groups based on the  mutational status of the 
immunoglobulin heavy-chain variable-region (IgVH ) gene in leukemic cells, those with IgVH  gene mutations 
generally surviving longer than those without. For that reason, it is thought that mutation analysis may be a 
valuable indicator for planning care management strategies. Two potential surrogate markers, CD38 and ZAP-70, 
received significant focus due to their association with lack of IgVH mutation, but it has not proved possible to 
evidence 100% correlation (Quest Diagnostics, no date) 
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That represents a median survival difference of between around eight and twenty-five years 
respectively for the unmutated and mutated groups as shown on Hamblin et al.’s graph in 
Figure 22 (below). 
 
 
 
Figure 23: HAMBLIN, T. (1999) Unmutated IgVH Genes Are Associated With a More Aggressive Form of CLL 
[Graph]. From  VENKAT, C. (2010) ‘What Type of CLL Do You Have?’ CLL Topics. [Online] January, 1st. Available 
at: http://clltopics.org/PI/Type.htm [Accessed: 14/12/2013]. 
 
Before moving on to Terry Hamblin’s own blog to take a closer look at the source of his paper 
cited here translated in a different nodal context, there are two further features of the CLL 
Topics page worth drawing attention to.  
 
Graph removed due to copyright restrictions 
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Firstly, Chaya Venkat’s evident skill and patience in translating complex science for a lay 
audience seems to be at the heart of CLL Topics taking the highest popularity ranking for sites 
visited regularly among the survey respondents (68% said they used CLL topics regularly, with 
the ACOR CLL list being its closest competitor at 44%). Using familial metaphor, she sets about 
explaining mutational status and its potential impacts in a way that allows patients to relate 
median survival times to a comprehensible narrative of cell biology. Referring to the very first 
malignant B-cell that marks the genesis of CLL in a patient as the ‘patriarch of the CLL clonal 
family’, the malignant cell that produces all the rest, Venkat explains how IgVH mutation status 
stands in for the precise point in the cell’s lifecycle that it became malignant: 
 
‘In some patients, this patriarch of the CLL clonal family became a malignant cell before 
it finished its "education" in the germinal center. This "ignorance" of the first CLL cell is 
reflected in the immunoglobin (Ig) of the cell being unchanged. .. Since this first cell 
eventually gave rise to all the other cells in the CLL clonal family, all of the CLL cells in 
these patients have unchanged or "unmutated" Ig. The mutation of interest is in the 
heavy chain of the Ig, in the variable region. Put all that together, and we come up with 
unmutated IgVH (immunoglobin, variable region, heavy chain)…In other patients, their 
very first CLL cell became a cancer cell after its trip to the germinal center. In these 
patients, since the first cell had graduated from the germinal center, the IgVH of this 
first CLL cell has been changed, (“mutated”), and this trait is carried forward by all the 
off-spring of this first cell. These patients have "mutated" IgVH (Venkat, 2010). 
 
 
Translating cell biology in this way for the reader, Venkat mediates information from its research 
sources in the form of Hamblin’s paper to the lives of those reading her web page. It is as if she says to 
the reader ‘Look at the graphs, consider the figures, understand the science, and think about what it 
means to you in the context of your own disease’. She doesn’t stop there though, and this is where the 
second point of interest occurs. 
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Writing from the position of someone who has herself lost a loved one to CLL, Venkat works not only to 
translate and mediate information, but to actively encourage patients to use the information in the 
context of the clinical setting and, in doing so, to become their own advocates in a collaborative clinical 
relationship. In the case of IgVH status testing, she acknowledges a lack of consistency in general 
oncologists’ knowledge of and attitudes to the test, and encourages patients to negotiate access to it in 
a broader model of patient-led empowerment: 
 
Not all local oncologists are familiar with the IgVH status test and you may have to do a 
bit of sweet-talking to get your guy to write a script for it. What you get in life depends 
to a great deal on your ability to negotiate with other people and getting effective 
medical care is no different (Venkat, 2010). 
 
 
I will return in this work to the issue of organized online advocacy in the Treatment chapter, but 
want to look now at Terry Hamblin’s blog posting on Prognostic Markers as a differently 
formatted approach to professional sharing information with patients online. 
Translation: ‘Why Should I Get My Prognostic Markers Done?’ (Ask the 
Specialist)                                         
       
A CLL specialist at Bournemouth Hospital from 1974-2003, Terry Hamblin set up his blog 
Mutations of Mortality, subtitled  ‘Random thoughts of Terry Hamblin about leukaemia, 
literature, poetry, politics, religion, cricket and music’ in 2005. ‘Mutations of Mortality’ was 
cited by many survey respondents as a trusted online resource, and the blog exhibits strong 
links into many online CLL forums prior to his death and beyond. 
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His entry of Tuesday, May 08, 2007 is entitled ‘Why should I get my prognostic markers done?’, 
and is an excellent example of one of a number of CLL specialist clinicians voluntarily taking up 
a place in the networks, translating clinical information for online patients and sharing 
ownership of medical in ways redolent of new models of digital healthcare referred to by Tom 
Ferguson in his e-patient ‘white paper’ of 2010. 
 
Hamblin starts the entry by acknowledging the differing approaches to a desire for prognostic 
knowledge among CLL patients, reflected in the IOB survey responses: 
 
Your disease will either progress or not, and when and if it does progress there is time 
enough to consider treatment, but until it does you might as well forget about it. 
Undoubtedly, some patients are able to put it out of their minds. On the other hand 
some patients are happier if they can know all there is to know about their disease, be it 
good news or bad (Hamblin, 2007). 
 
 
 
Hamblin takes a more sanguine and fatalistic approach to the value of prognostic knowledge 
seeking than Chaya Venkat with her rallying call for prognostic self-advocacy as a potential 
lifesaver. Written eight years before the completion of this PhD thesis, Hamblin is writing prior 
to the widespread recognition of the increasing importance of predictive markers in the context 
of evolving treatment approaches (demonstrating just how rapidly CLL knowledge advances). 
The narrative of ‘Mutations of Mortality’ ended with the death of its author in 2012, and so we 
are looking here at a very particular moment of CLL history frozen in time. Cutting edge in 2007, 
inevitably it lags behind evolutionary changes in 2015, yet its sentiments are still echoed by 
some patients and their doctors. My own consultant remains unconvinced of the value of IVGH 
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testing outside of trials for example, as do many others in the UK. Seven years may be long 
enough to shift the paradigms of treatment and disease knowledge on their axis, yet not long 
enough to make those new treatments universally accessible, nor to shift the cultural attitudes 
to prognostic testing shaped by the previous decade of treatments and biological 
understanding. 
 
However, Hamblin’s blog entry remains a powerful example of several forms of translation. I 
have already mentioned that of ‘expert’ knowledge into the CLL networks for patients. I would 
also draw attention to the ways in which Hamblin situates his views in a history of prognostic 
knowledge in CLL by taking readers back to what he refers to as ‘the beginning’, a time before 
any prognostic markers were available and patients were classified using either the Rai 
(American) or Binet (European) systems according to stage. Hamblin locates these staging 
systems in a time prior to another fundamental shift in the understanding of CLL, one that he 
himself contributed significantly to as we have already seen from the CLL Topics site. The 
differentiation between the two forms of IVHG mutational status in 1999 smashed traditional 
understanding of CLL as a singular disease operating on a continuum with totally arbitrary 
points and rates of progression. Referring to two seminal papers in the history of CLL 
knowledge appearing in Blood in 1999, Hamblin et al. (his own work), and Damle et al., he 
explains how a new understanding of CLL as two distinct diseases according to mutational 
status emerged:  
 
Far from being a marker of prognosis, to know your VH gene mutational status was part 
of the diagnostic procedure; did you have this type of CLL or that type? It was as 
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important as knowing whether you had follicular lymphoma or diffuse large cell 
lymphoma (Hamblin, 2007). 
 
 
More changes were in the prognostic pipeline at the time that would complicate this binary 
view of CLL. Hamblin refers the blog reader to a paper published in 2000 in the New England 
Journal of Medicine by Dohner et al. exploring the use of FISH testing for chromosomal 
abnormalities as a prognostic factor. Now a standard part of pre-treatment prognostication, 
Hamblin’s historical overview also draws attention to the broader networks in which scientific 
discovery is translated into clinical action. By informing readers of a paper on the same subject 
of chromosomal abnormalities published in the same journal some ten years earlier than the 
Dohner paper by Juliusson et al (1990), Hamblin makes the blog reader aware of the role of 
laboratory assays in the understanding of their disease. In 1990, Hamblin tells us that ‘the 
technique of karyotyping was unsuccessful in most laboratories’ (Hamblin, 2007). Juliusson et al 
may have come up with the goods about the importance of chromosomal testing, but 
laboratory technology was as yet unable to translate that into clinical practice. A decade on, 
FISH testing enabled easy and reproducible laboratory detection of four of the most common 
chromosomal abnormalities (trisomy 12 and deletions on chromosomes 11, 13 and 17), and 
FISH testing becomes a recognizable part of every CLL patient requiring treatment’s journey. 
 
Julia Kennedy 
267 
 
In an updated entry on the subject in 2010, Hamblin describes how the optimism for Zap-7073, 
as a reliable prognostic indicator was similarly undermined by difficulties faced with commercial 
assay techniques: 
 
The trouble with ZAP-70 is finding a method that everyone can agree on. The 
concordance with IgVH mutations was over 90% using the first two published methods, 
but only 76% when the method developed in Tom Kipps lab was used. That paper 
suggested that it was a better prognosticator than IgVH mutations, but when it was 
adopted by commercial labs, very strange results indeed were apparent (Hamblin, 
2010). 
 
 
 
Through engaging with the blog, CLL patients begin to get a sense of how their personal disease 
narratives intersect with multiple histories, narratives and disciplines. Advances in prognostic 
testing can succeed or fail on the basis of the laboratory technologies and economies that 
enable it, and the potential impact of that on the lives of those living with CLL is significant. For 
those patients who wish to understand how they are situated in the broader networks of CLL 
enactments (and perhaps go on to advocate or campaign for changes in specific areas of care), 
this ‘bigger picture’ knowledge is helpful. 
 
The blog entry goes on to update current information on VH genes and chromosomal 
abnormalities in relation to relevant clinical experience and trial results, and Hamblin closes the 
entry by returning to his observations on the different attitudes patients may take towards 
 
73 Zap-70 is a tyrosine kinase and crucial molecule for the selective activation of T cells. It is used in the 
transmission of signals from the T-cell receptor to downstream pathways. B cells generally lack ZAP-70, using  
related tyrosine kinase, Syk, instead. In most cases of CLL with mutated IgVH genes, stimulation of the B cell 
receptor fails to cause a signal to get through, although  most cases with unmutated IgVH genes signal 
satisfactorily (Hamblin, 2006) 
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prognostic information, but stating clearly that those who want it should have access to it. “As I 
said, some patients relish this sort of information; some disdain it. I am not going to judge 
between them. However, I think that everybody should be able to access it if they want it” 
(Hamblin, 2007). 
 
Six patients posted responses to the blog, Hamblin responding to each in turn. Questions were 
largely seeking clarity around the statistical implications of Hamblin’s own work on mutational 
status, indicating a desire from the questioner to locate the narrative of their own disease 
within the inferences of the research. As one of the blog respondents put it: ‘I am one of those 
who relish knowing all the numbers’. 
 
During Terry Hamblin’s life, ‘Mutations of Mortality’ came to represent a powerful node in the 
CLL networks. Linked into a range of other popular sites such as CLL Topics and often referred 
to in forums and listservs such as ACOR, Hamblin’s status as a CLL expert willing to share 
information with a largely lay audience of CLL patients, and to interact with them personally 
secured his status as an important mediator of clinical CLL information and opinion, and a key 
network actor. Through Hamblin’s online hypertextual presence, the networked patient had 
access to a degree of specialist consultation. No amount of informal online contact with a 
doctor can wholly substitute a patient’s own relationship with their doctor, but there is little 
doubt that the ability to ask specific questions about and gain a broader specialist 
understanding of their disease outside of the clinical setting can impact significantly on the 
conversations and decisions taking place within it, as 79% of IOB survey respondents indicated.  
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In reading and interacting with ‘Why should I get my prognostic markers done?’, CLL patients 
get an expert answer to that vexed question that is both broadly contextualized, contemporary 
at the point of publication, ongoing (until the author’s death ) and personalized if required 
through the interactive potential of the blog format.   
Translations: ‘Who is Getting IGHV test?’ (Ask the Community)   
 
In September, 2013, experiencing sudden aggressive disease progression and facing treatment 
with chemoimmunotherapy, I became concerned that I didn’t know my mutational status 
despite having read a great deal about its relevance to outcomes. As the previous section has 
shown, mutational status is widely acknowledged to be a reliable prognostic indicator, those 
patients testing positive for IGHV status currently having more favorable outcomes on the 
whole. Despite its prognostic value, mutational status does not currently dictate or influence 
treatment protocols and as such is regarded as a superfluous test by many hospitals. With the 
IVGH mutational test not routinely available at my own hospital, and obliged to wait until I 
needed treatment for cytogenetic testing, I decided to solicit advice directly through the online 
support networks, actively seeking to negotiate the dissonance between what I was reading 
and learning online, and what I was experiencing in the context of the management of my own 
disease by drawing on the experiences and views of others. Figure 23 shows the artwork, 
Laksmi in the Blood by Paul Heussenstamm that I use as my avatar alongside my username 
Jibs60 on the CLLSA Health Unlocked site.  
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Figure 24: HEUSSENSTAMM, P. (No date) Laksmi in the Blood Stream [painting] used by Jibs60 as an avatar on 
CLLSA HealthUnlocked [Online]. Available at: 
http://www.mandalas.com/mandala/htdocs/Agape_Show/Laksmi_in_the_Blood_Stream [Accessed 
12/06/2013]. 
 
 
I turned in the first instance to the CLLSA UK forum hosted by the HealthUnlocked platform, 
and posted the question ‘Who is Getting the IGHV (formerly known as IgVH) Mutational Status 
Tests in UK?’, articulating my desire for further information as follows:   
 
As IGHV mutational status is acknowledged to be a good indicator of likely response to 
FCR treatment, including potential clonal evolution, I'd quite like to have the test done 
now as I approach treatment. It would be useful though to get an idea of what is going 
on at other hospitals in relation to this test prior to treatment and outside of trials. I 
gather the test is not cheap, and want to make an informed decision about whether I 
should be requesting it based on the experiences of others in a similar situation here in 
the UK.  (Jibs60, 2013) 
 
Image removed due to copyright restrictions 
 
Julia Kennedy 
271 
 
The question received 13 detailed and informed responses sharing personal experience and 
links out to research papers and other sources of information in the networks. I was interested 
in ascertaining who was getting the test in the UK, whether those accessing it had found it 
useful, and which UK centres offered the test. I also wanted to know if others in the community 
had found a correlation between their CD38 and IGHV mutational status74. This issue was 
regularly addressed in various CLL forums at the time, and in my post I referred to my own 
negative CD38 expression shown in the lab report from my immunophenotyping (replicated in 
Figure 24 below), in relation to a quote from a recent discussion thread on the site:  
 
If your CD38 is under 30% your IGHV gene is likely mutated. If the percent is over 30% 
the gene is likely unmutated. This CD38 is called a marker and is about 70% correct. 
Further, the percent changes over time, but rarely goes over or under the 30% mark’ 
(Anonymous response, 2013). 
 
 
I recently got my FISH results back and had for some reason assumed that I would also 
get IGHV mutational status tested along with that as part of pre-treatment diagnostics. 
However, my consultant pointed that was not done as routine at my (non CLL specialist 
centre) hospital. My CD38 was marked simply as NEGATIVE on my flow cytometry report 
taken on diagnosis, so the assumption would be be that I am likely mutated using that 
as a surrogate test (Jibs60, 2013). 
 
 
74 For a while, alongside ZAP-70 its expression was viewed as an effective surrogate for the information provided 
by VH genes and many patients turned to the CD38 expression indicated by their initial flow cytometry read-outs 
performed on diagnosis in order to second-guess their vh mutational status. 
Julia Kennedy 
272 
 
 
 
Figure 25:  RCHT (2011) CD38 Negative status indicated on my own immunophenotyping panel  following 
diagnostic flow cytometry in March, 2011 [Lab Report]. 
 
Having read Terry Hamblin’s Mutations of Mortality blog entry on prognostication 
previously, I also drew attention to his scepticism around the usefulness of CD38 
as a stable surrogate marker: 
 
I know that some specialists, the late Terry Hamblin included, felt that the surrogate test 
provided by CD38 was unreliable due to its tendency to change over time, whereas 
IGHV remains constant (ibid).  
 
 
 
The following quote from Hamblin’s blog indicates his position on the usefulness 
of markers CD38 and Zap-70. Both were initially seen as useful additions to the 
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prognostic toolkit before gradually falling out of favour, CD38 because of its 
propensity to change over time, and Zap-70 because of the lack of an effective 
standardized assay:  
 
CD38 and ZAP-70 started out as quick and easy ways to get the same 
information as the VH gene mutations, but both have proved to be 
unsatisfactory surrogates (Hamblin, 2007). 
 
 
 
Among the 13 responses was a customarily information-rich response from 
Hairbear: 
 
 
HAIRBEAR CLL SUPPORT ASSOCIATION 
The Cardiff group published a definitive prognostics paper last year that was the result 
of a very large UK study… 
 
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. 
 
www.ncbi.nlm.nih.gov/pubmed... 
 
Excerpt from abstract; 
 
” IGHV mutation status, CD38 and age at diagnosis were independent prognostic 
variables for TTFT and OS. Therefore, IGHV mutation status and CD38 expression have 
independent prognostic value in early stage CLL and should be performed as part of the 
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routine diagnostic workup. ZAP-70 expression and FISH were not independent prognostic 
markers in early stage disease and can be omitted at diagnosis but FISH analysis should 
be undertaken at disease progression to direct treatment strategy.” 
 
The paper has been discussed by Chaya at CLL topics where the significance of IGHV is 
also focused upon.  
updates.clltopics.org/4336-...  
 
From a patient perspective I can understand thoughts ahead of treatment with FCR if 
recent data published at ASH by Anderson are suggesting that those who gain best 
results are mutated??  (Hairbear, 2013b) 
 
Hairbear’s detailed response to my question, which draws in the first instance on expert 
circulating narratives online, demonstrates how online information from the CLL networks finds 
its way into the conversations of CLL patients online in reference to their own individual 
experiences. In turn, the reading and archiving of such conversations by fellow members forms 
a continual pedagogic backdrop to online community activity that fits Tom Ferguson’s model of 
online ‘patient-helpers’ (Ferguson 2012: 1129) as valuable resources for others with the same 
condition. As the knowledge gained finds its way back into the clinical setting, we also become 
potential allies for health professionals. However, it is important to note that local care 
protocols and resourcing issues mean that patients in the network may have very different 
experiences of actually effecting any change in their own treatment with the knowledge they 
bring from the networks into their own specific clinical setting. As one member pointed out in a 
response to this question, “Well since I have had a Richter's transformation there is a 68% 
chance that I'm IGHV4-39, type 8...Absolutely nothing could change it...you play the cards you 
were given” (Anonymous, 2013). 
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However, there is some evidence that knowing one’s mutational status becomes increasingly 
more useful information in relation to prognostic outcomes, as indicated in my response: 
 
 
I agree with ****** that we play the cards we are dealt, and there is nothing we can do 
to change the deal. Playing 'blind' though makes it very hard to plan strategically for an 
increasingly complex treatment future. Knowing which mutational status card I hold 
could have an impact on my decision about whether to go with FCR now or to try and 
wait for a chance at ibrutinib next year… (Jibs60, 2013). 
 
 
Some contributors to the thread supported a desire for testing, whilst others cautioned from 
personal experience against a) the inability of markers to predict future clonal evolution, and b) 
the difficulty of dealing with an unmutated status should that be the outcome of a test. Yet 
another response outlined a similar cautionary tale of having an unmutated status in 
contradiction of very low CD38 expression. This state of ‘informed uncertainty’ is a common 
theme in networked CLL patients, again reflecting some of the gaps and inconsistencies in 
evolving knowledge. The sometimes worrying confusion this causes is well articulated by the 
following IOB survey respondent:   
 
 …the prognostic indicators are not decisive enough to the newly diagnosed as I am. I 
tested 10% CD38 which implies I have a high chance of having mutated CLL yet my IVHG 
results came back as unmutated which I understand is the definative [sic] test at this 
time. it just causes unnessary[sic] stress. It’s time to scrap unreliable indicators or at 
least waving them in the faces of patients who are scared anyway (IOB Survey 
Respondent 145). 
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An inconsistency in approaches to prognostic testing is clearly articulated across the network 
with variations between US, UK, Australian and Canadian hospitals at both national and local 
levels recounted in the feedback. This UK respondent expresses surprise that not all patients 
are offered prognostic testing as routine at diagnosis:   
 
Tests for all prognostic markers at time of diagnosis were made available to me and duly 
carried out. I assumed this to be normal for all patients diagnosed with CLL - I now know 
this not to be the case, but very much depends on where you live and whether you have 
access to a hospital with a specialised haematology department (IOB Survey Respondent 
210). 
 
 
To this date, even following treatment with FCR after my disease took an aggressive turn in 
2013, I remain unaware of my mutational status. This despite consistent acknowledgement in 
the CLL literature that mutational status is a reliable prognostic indicator with use value in 
planning treatment strategies: 
 
Several multivariate analyses have confirmed unmutated IgVH to be an independent 
adverse prognostic marker in patients with CLL. The presence of unmutated IgVH is 
strongly associated with poor-risk genomic aberrations and overexpression of CD38 and 
ZAP-70. Nevertheless, these associations are not absolute. The design of future clinical 
trials are already incorporating novel prognostic markers such as IgVH, among others, as 
part of risk-adapted strategies aimed at improving treatment outcomes by tailoring the 
aggressiveness of the therapy proportional to disease risk (Kharfan-Dabaja et al: 897). 
 
 
Thus far in the UK, if you are treated at a research centre, by a CLL specialist, or are in a trial, 
you may benefit from this. Otherwise, treatment will be planned and administered regardless 
of mutational status, and any potential difference it might make. 
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Chapter Summary 
 
Through a mapping of a variety of online resources, survey responses, and broader contexts of 
prognostic testing in CLL, from the ability of laboratory assays to translate research into clinical 
action to plans for a future interrupted by lack of knowledge of adverse genetics, this chapter 
has demonstrated the complex range of actors and narratives relating to prognostics.  
 
From documents written specifically for the newly diagnosed, and clinical research papers, 
through specialist-led information on dedicated sites and blogs aimed at CLL patients and 
patient’s own narratives, the chapter has traced how various approaches to CLL prognosis 
translate across varying professional and personal contexts in CLL networks. Key actors emerge, 
some such as Chaya Venkat of CLL Topics, and the late Terry Hamblin of Mutations of Mortality, 
directly mediate information as authors and science/medical professionals setting up nodes in 
their own right. Others, such as Professor Pettit, are co-opted into the networks to form the 
role of translating professional information for newly diagnosed patients on dedicated support 
sites. Clinical papers such as that written by John Gribben on CLL treatment are sourced from 
medical journals and linked to advocacy sites such as Lymphomation, giving patients in the 
network a clinical perspective on their disease. More generic sites such as CancerGuide.org act 
as repositories for contextual narratives such as Stephen Gould’s ‘The Median isn’t the 
Message’ which was linked from popular Listserv ACOR and referred to by several respondents 
to the survey. Finally, several of these narratives and further links can be found in the narrative 
Julia Kennedy 
278 
 
exchanges of patients in a CLL support Community, showing how a variety of narrative 
perspectives on or ‘objects’ of CLL are mediated, transported and translated across the 
particular networks mapped in this chapter.  
 
The IOB survey showed 39% of respondents claimed to actively post research they had come 
across themselves in order to help others, and there was strong evidence of this type of 
network activity related to CLL prognosis. This was perhaps unsurprising given the rapidly 
evolving and complex nature of prognostic research, and peoples’ desire to understand it in 
order to relate it to their own and fellow actors’ situations.  
 
Some key themes have emerged. At a human level prognosis is clearly an issue fraught with 
complications for patients and their physicians as the tensions between prediction, prognosis, 
time and identity play out in the lives of those who must live with the disease. Whatever 
prognostic numbers and graphs might come our way as patients, they all translate to a 
temporal endpoint – ‘when will my disease progress?’, ‘when will I die?’ Even at a point where 
prediction as a basis for treatment choices competes with abstract prognostication, it is still 
ultimately about managing the disease so we can live longer. “Living in prognosis, then, is about 
living in the folds of various representations of time” (Lochlann-Jain, 2010: 80). 
 
It is very clear from some of the examples used to demonstrate the chapter that patients are 
networking online, often in collaboration with professionals, in ways that contribute 
significantly to their understanding and informed consideration of their own prognostic factors. 
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As the chapter shows, this doesn’t necessarily translate to a desire to know everything for all 
patients and definitions of empowerment need to take into consideration the fact that a 
patient may in fact feel empowered by refusing to face a prognostic future they have little 
power to control in the current treatment landscape. As biological knowledge of CLL evolves 
rapidly however, so do the means to treat it and purely prognostic biomarkers are joined by 
more predictive markers that may in fact have an impact on evolving treatment options. In such 
a future, patients may indeed have more choices to make about future treatments and that 
raises an important question for those who currently prefer not to know, or locate themselves 
as passive recipients of the knowledge handed down to them by their medical team as the 
following survey respondent does in admitting that: 
 
I do not know if I have ever had prognostic testing if so never been told (IOB Survey 
Respondent 126). 
 
 
Importantly, this chapter also demonstrates what it means for patients to be located at a point 
in history where new knowledge and resources supersede traditional ones at differing rates 
across the networks. Some patients in the US for example are already well established in trials 
of novel agents, now gradually spreading into Europe, yet many of the (particularly treatment 
naïve) UK patients observed in this work at the time of writing remain outside the parameters 
of access to the new drugs. Exposure to exciting new developments in prognostication and 
treatment through online debate and discussion, whilst caught up in the regulatory lag of 
pharmaceutical trial bureaucracy, and the financial implications for healthcare governance of 
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expensive novel agents places many patients in an extremely frustrating position.   
 
One survey respondent talked of the difficulties of negotiating the current prognosis landscape, 
stating that ‘I have come to expect that the whole issue will be moot in the very near future. The 
new targeted nonchemo therapies will mean everyone can expect a good prognosis’ (IOB Survey 
Respondent 86). These gaps between the global perspectives of disease management that 
networked omniscience offers patients, and the often very different realities encountered at 
local points of delivery run throughout my findings, and raises questions about how network 
activity might be actively harnessed towards universalizing care approaches, and towards 
managing patient expectations where there this is not an appropriate or achievable response. 
This is a key point arising from the research, and will be returned to in conclusion.  
 
Whilst it would certainly seem that future CLL patients might reasonably expect at least a better 
prognosis, trials are still at an early stage and results across the heterogeneous spectrum of CLL 
presentation remain to be seen. However, the sense that the potential for a trouble-free future 
for CLL patients sits on a tantalizingly close horizon whilst many of us still struggle with the 
significant issues of prognosis and treatment in the current landscape was tangible across the 
networks. This raises interesting questions about what happens when a patient group becomes 
educated at a faster rate than new developments can be translated into access to clinical 
management and treatments within the existing systems of health care delivery that serve 
them.   
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Respondents viewed prognostic indicators variously as necessary tools for controlling the 
impact of CLL on their lives, useful in the short term but too unstable to be of long term 
relevance, or unnecessary and even frankly unhelpful. A sense of loss of control of one’s life is a 
major feature of living with disease. As one cancer patient puts it “My choices were never 
final… My physical state was never constant” (Goldstein, 2000, pp.95-96, cited in Vance, 2012). 
These ‘event limits’ (Vance, 2012), and restrictions on individual autonomy imposed by 
unpredictable progressive disease are frequently articulated by CLL patients, for whom 
prognostic knowledge becomes a means of seizing back at least some degree of perceived 
control. For some survey respondents this equates to having ballpark survival figures around 
which they can make life plans accordingly. Interestingly, several respondents actively sought 
this knowledge despite openly acknowledging the frankly unreliable nature of prognostic 
indicators, their tendency to change, and the fact that overall outcomes don’t always correlate 
with prognostic indicators.  
 
Even those intentionally electing not to engage with prognostic resources are exercising a form 
of control over the potential for results to invoke anxiety and helplessness, choosing instead to 
“live in the moment”. For all of us with CLL then, prognosis remains a vexed issue. As with CLL 
treatment itself, prognosis is also a dynamic field, with new indicators and tests being 
discovered on an ongoing basis, giving CLL experts cause to reflect on how they may be 
validated and incorporated into new treatment approaches and strategies for their patients. 
For example, Minimal Residual Disease (MRD) testing can now identify micro levels of disease 
in the blood and bone marrow, with the potential for assessing the efficacy of treatment, and 
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as early warning of returning disease following treatment through regular monitoring. Trials to 
assess the effectiveness of obinutuzumab monoclonal antibody consolidation therapy for those 
with remaining or rising MRD following treatment are currently in set-up in the UK75. 
Interesting work is also being undertaken in the area of mutations in the Notch signalling 
pathways, with particular reference to mutations in the Notch1 gene in CLL76.  
 
For those patients with progressive disease, prognosis is inextricably linked with treatment, and 
the next chapter will pick up on these themes in a close reading of the exchange of treatment 
narratives in the networks.  
 
 
 
 
 
 
 
 
 
 
75 At the time of writing, the Galactic Trial (GALACTIC: GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy 
In CLL) is in set up as a phase II/III, multi-centre, randomised, controlled, open, parallel group trial.across the UK. Its purpose is 
defined as : To test whether consolidation with obinutuzumab to eradicate minimal residual disease (MRD) in B-CLL patients 
who have recently responded to chemotherapy leads to prolonged progression-free survival (CTRU, Leeds, 2015) 
76 Willander et al. contend that NOTCH1 mutations are a novel risk marker on the basis that “Both NOTCH1 and TP53 mutations 
seem to be independent predictive markers for worse outcome in CLL-patients” (Willander et al., 2013). 
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Chapter 5: Treatment 
         
Introduction 
 
The kinase inhibitors, in particular, which I would know nothing about were it not for the various 
lists I belong to, have made me feel--perhaps naively--rather "safer" than I used to. I no longer 
have the sense that I have a sword of Damocles hanging over my head, or, if it is, it is hanging 
by a sturdy rope, not a thread (IOB Survey Respondent 25). 
 
 
…It gives all of us hope that at least we are closer and have a chance, rather than being 
burdened with this 'incurable cancer' label which in itself can seem hopeless… (IOB Survey 
Respondent 18). 
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Figure 26: TOUCHGRAPH (2015) network connections between sites used for Translations in Treatment chapter 
[Network Map]. [Online] Available at: www.touchgraph.com [Accessed 17/05/2015]. 
 
The Diagnosis chapter outlined the Scylla and Charybdis of watch and wait versus treatment for 
those travelling inexorably through the lowlands of fatigue, and frequent infection as their 
tumour burden increases. Unlike many acute and more aggressive cancers however, CLL does 
at least generally bring with it the relative ‘luxury’ of time to consider treatment options. As the 
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Prognosis chapter has shown, the heterogeneous cytogenetic presentation of CLL calls for a 
range of treatment approaches. Traditional ‘gold standards’ of care are based on a range of CIT 
options, the most common (for patients without a 17p deletion) being a combination of 
Fludaribine, Cyclophosmamide and Rituximab (FCR). Advancing genomic knowledge is changing 
the world of cancer treatment however and CLL, once regarded with little interest as  a disease 
predominately of old men,  now plays an active role at the forefront of cancer research. CLL 
was singled out for ASCO’s cancer treatment advances of the year 2014/15, and online CLL 
communities buzz with anticipation about new treatments. We are moving it seems towards a 
time when long-term palliation with toxic agents, will be replaced by long-term management 
with gentler regimes, and the potential of a future “cure” for the disease occasionally whispers 
across the networks.   
 
I was interested in how this environment of hope and massive optimism might impact on CLL 
patients in the here and now, and how and where they got their information from about these 
new treatments. The IOB survey attracted 157 text responses to this question, with 
respondents generally articulating optimism about the potential of new, less toxic treatment 
regimes, and citing CLL networks online as a dominant source of information: 
 
Fill me with so much hope and at the end of the day touchwood I will be ok that's all you 
want through all this is someone to say you will be ok but you can't at the moment. I'm 
tough as old boots now (IOB Survey Respondent 207). 
 
 
I keep up with what's happening mainly through ACOR and Patient Power (Andrew 
Schorr). As for my attitude, all this progress is beginning to make me a bit concerned 
Julia Kennedy 
286 
 
that I might actually get "cured" and find myself 94 years old, blind and toothless (IOB 
Survey Respondent 90). 
 
 
Mostly I read the forums for the links others post on research and news. I read hundreds 
of abstracts from the ASH [American Society of Haematology] Conference. What seems 
to be happening with treatment and research make me wonder what I was so concerned 
about just last year (IOB Survey Respondent 86). 
 
 
I have a much better attitude after learning about promising new treatments, and no 
longer look at SLL as my husband's "death sentence". Nor do I look at future chemo as a 
foregone conclusion. He might be able to take an oral agent with better success rate and 
fewer side effects. I would not know any of this without the internet (IOB Survey 
Respondent 84). 
 
 
 
Despite this optimism, the idea of a “cure” produced widespread scepticism across the 
responses, patients aspiring instead to manageable disease and less toxic treatments: 
 
I'm glad to see the mortality graph lines flattening a bit, but I take the talk of "cures" 
with a keg of salt. I am aware that often the lab touting a cure is also hoping to profit 
from the sales of it (IOB Survey Respondent 110). 
 
 
…Cure? have you any idea of the genetic changes in the CLL cells? Unlikely isn't it. Lets 
[sic] settle for good remissions (IOB Survey Respondent 169). 
 
 
Unsurprisingly, there was a clear distinction in responses between treatment naïve respondents 
still in watch and wait for whom the likelihood of access to new drugs when needing treatment 
is greater, and those fast approaching, currently in, or previously having been treated:  
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ok, here I get quite lost. I have read about some of them but until i get to a stage where I 
need treatment I am just sitting back and ignoring it mostly - will it be available? will the 
NHS pay for new treatments? when will I need it? don't know.... so not worrying too 
much about it at this stage - what will be will be, and I just hope its the best that can be 
accessed at that time (I do wonder that my local Consultant(s) are fully versed in all 
aspects of CLL, i don't have much faith in them, which worries me). I use CLL Health 
Unlocked to keep an eye on comments about new treatments - interesting but not 
relevant to me at this stage - this is only because the alerts pop up daily and I see the 
references in the titles within the notification emails, otherwise I would not be 
researching this aspect from other sites (IOB Survey Respondent 187). 
 
 
  
This respondent shows how the site architecture of CLL Health Unlocked as read through the 
notification e-mails they receive daily, alerts them to and keeps them in touch with topics they 
may not otherwise follow. When the time comes for treatment, this respondent will be well 
versed in the changes that have taken place in protocols simply through daily contact with the 
community.  
 
Equally though, those having experienced the unpleasant or toxic effects of chemo already and, 
in some cases, running out of options with them, were optimistic at the prospect of future non-
chemo therapies: 
 
I am hoping I dont [sic] have to have FCR again, something easier on the body, I know I 
will need further treatment as I have a more aggressive type, the internet allows me to 
read research, sadly this is mostly from the USA (IOB Survey Respondent 210). 
 
 
The cumulative effects of previous treatment, or adverse treatment reactions can leave 
patients feeling that they have burned some of their future treatment bridges, and for some of 
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these patients the future is viewed with a degree of trepidation, despite the generalized 
excitement: 
 
I would be more excited if I had not reacted badly twice to BR with the result I am now 
on FC without R, where remission is not statistically very long. (IOB Survey Respondent 
224) 
 
 
For some CLL patients, particularly those in the US, or fortunate enough to throw lucky dice in 
randomized trials here in the UK and across Europe, the hype presages reality as they enter into 
a treatment landscape in which highly toxic chemotherapy  is no longer the only option for 
staying alive. The internet was cited as a major source of information for trials giving access to 
the new drugs: 
 
Again I am in a cutting edge trial because of the internet (IOB Survey Respondent 32). 
 
So the current binary tradition of watching until waiting for treatment that, in itself, is a risky 
prospect, may soon be superseded by the potential of new prognostic and pharmacological 
technologies to create more nuanced, individually tailored, and safer treatment protocols. For 
all of us living with CLL now this is undoubtedly good news. It brings with it though inevitable 
frustration for those needing treatment at the cusp between traditional approaches to care and 
emergent brave new protocols and concern about time scales and access to the novel agents 
was commonly expressed: 
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Since I know that new treatments and drugs take a long time to find their way into the market 
place, and since I don't know when I will need treatment, I don't hang a lot of hope on them 
being available to me. I completely trust my doctor to know about availability of new option and 
trial studies (big city, specialized leading hospital, doctor being a CLL specialist, etc.)….. I use the 
CLL topics, CLL Canada, and other credible online resources to read about new developments 
(IOB Survey Respondent 107). 
 
 
 
Observations were also common surrounding the current lack of reliable evidence surrounding 
side effects and long term survival rates with the new drugs: 
 
UK CLL Forum- medics site. You might be able to access some of these treatments as a trial, but 
there is no firm evidence of common cures or good remissions for secondary or tertiary 
treatments... (IOB Survey Respondent 169). 
 
 
 
In relation to access, serious questions are raised about the current process for getting drugs 
from research to market, the clinical trials process, drug pricing and the relationship of the 
pharmaceutical industry with global health care systems. The road from research to market for 
drugs is a slow one, trials are not always available in a patient’s health care region, clinicians 
aren’t always prepared to prescribe drugs recently licensed for use with specific patient groups 
“off-label” to other patients who may benefit from them and health authorities may not 
approve prescription of new drugs with a high tariff. In reality then, patients currently facing 
treatment can find themselves with little or no choice at all but to accept traditional (cheaper) 
chemoimmunotherapy, despite the prevailing discourse of hope and change, or hope for 
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compassionate access77: 
 
….most promising time for newly diagnos, [sic] around the block a few times hoping 
compassion use will be available now.... (IOB Survey Respondent 49). 
 
 
Obstacles to accessing novel agents constitute a number of factors from the economic to the 
regulatory. In addition, this work has demonstrated the significant role that access to 
information about new treatments and trials plays in accessing the treatments themselves. 
Patients not hooked into CLL information networks are vulnerable to this weak link in 
knowledge exchange, especially if their doctors are non-specialists, and/or their treatment 
centres don’t participate in trials. However, it is clear that, even for some networked patients, 
difficulty in assimilating and making sense of often highly scientific reports and debates 
surrounding new treatments in relation to such a heterogeneous disease with differing 
treatment protocols can leave them feeling equally confused and ill informed:  
 
I only look at the CLL newsletter when it is sent to me. I am not scientifically minded and I 
find a lot of the information online is not really written for patients but for professionals 
who understand it (IOB Survey Respondent 199). 
 
 
Currently I am totally bamboozled. I need to find time to zone in on issues key to my 
situation, and at the moment I think this might be challenging - there is a lot of buzz 
 
77 Some drug companies themselves will initiate what are often known as compassionate or ‘named person’ access 
to their new drugs still in trials, or negotiate confidential discounts with payers for innovative drugs considered too 
risky or costly on what are known as expanded access programmes for patients for whom new drugs represent a 
significant benefit over what is already available. These access routes still require approval by the appropriate 
regulatory body, and by the prescribing clinician, and are wholly at the discretion of the drug companies in 
question. See EMA European Medicines Agency (EMA) 2007.    
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(which is good), but how do you focus on the specifics to the individual situation? 
Making this simpler would be good! (IOB Survey Respondent 131) 
 
 
 
Problems with medical literacy can be seen to have the consequence of undermining effective 
self-advocacy among patients. Engagement with a range of circulating narratives is only as 
empowering as a patient’s capacity to understand them, or to have them translated on their 
behalf. The previous chapter has outlined some of the network activities undertaken contribute 
to these processes of ‘translation’ or explanation, and going offline to consolidating often 
complex online information in face to face settings can be an effective strategy for enhancing 
understanding: 
 
It was very very very interesting to hear the talk by Prof Pettitt at a recent NW CLLSA 
meeting. The talk explained a lot more than I'd been able to previously understand by 
reading online resources (IOB Survey Respondent 148). 
 
 
As with other areas of this research, not all patients surveyed extolled the virtues of pro-active 
patienthood through online networked activity. Although in the minority, some respondents 
profess to reliance on their doctors to keep up for them:  
 
I rely on my consultant to give me the appropriate treatment (and to look online 
himself!) (IOB Survey Respondent 216). 
 
Others confessed to not keeping up with developments at all, although two of those mentioned 
that the survey itself had inspired them to be more pro-active in the future, demonstrating its 
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own network effects:  
  
CLL is in the back of my mind most of the time, I didn't even know about these new 
treatments and trials in the pipeline (IOB Survey Respondent 219). 
 
 
 I'm afraid I don't keep very up to date with them - but maybe I will now...(IOB Survey 
Respondent 246). 
 
 
 It is good to know that such advances offering hope of better things to come are being 
made but I somehow feel separated from them and have as yet not looked into any of it 
online. (perhaps now I will as this survey is renewing my desire to discover more)  (IOB 
Survey Respondent 160). 
 
 
 
Motivations for engaging with online information or otherwise differ however, and the 
following respondent eschews online discourses of cure and longer remissions in favour of a 
more spiritual approach to living and dying well with CLL: 
 
ASH and the listservs indicated earlier. They don't really change anything. Whether I die 
in 2 years or 20 years doesn't matter. Embracing mortality, using the life I have and 
preparing for a graceful, loving and hopefully even humorous exit is what matters to me 
(IOB Survey Respondent 70). 
 
 
Network sites mentioned in the IOB responses include blogs by physicians, Jeff Sharman, and 
Brian Koffman, Andrew Schorr’s Patient Power site, Chaya Venkat’s CLL Topics, CLLSA UK HU, 
and several references to ASH (American Society of Haematologists).  Fieldwork shows that a 
significant amount of network traffic is concerned with issues surrounding CLL treatment, from 
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raising bigger political and institutional issues of access through informed debate, and 
organized large-scale advocacy to everyday exchanges of the experiences of side effects and 
how to manage them. 
 
Building on these responses, this chapter explores circulating narratives in a network living 
through an evolution in approaches to the management and treatment of CLL. This is a network 
in which the traditional and the new come together through complex explorations of 
biomedical science, in which discourses of hype and hope for novel treatments and 
personalized care targeted at individual genetic profiles play out alongside the pragmatic 
realities of access, the political economy of the pharma industry, its relationship with health 
care governance, and the legal and regulatory systems that frame the drugs market. 
 
In line with mapping out this territory, this chapter will focus on four main themes in the 
circulating narratives of treatment: 1) new approaches to treatment and management of CLL, 
and their impact on the networked patient population; 2) narratives of cancer treatments in the 
mainstream news media and network responses to these;  3) the role and inscriptions of the 
pharmaceutical and biotech industries in the networks; and 4) access to CLL treatments 
(including trials), and the variety of approaches to networked information exchange 
surrounding treatment and its effects including organized advocacy and big data.   
 
The circulating narratives selected for the Translations sections align with these interests and 
include an entry entitled ‘What is FCR’ from US Haematologist Dr. Sharman’s blog, a page from 
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CLL topics exploring access to novel agents, a news feature on novel agent ibrutinib, postings to 
support sites sharing information about clinical trials and drug side-effects, and a snapshot of 
the CLL group on health data sharing site PatientsLikeMe.  
  
Perspective: The changing landscapes of CLL treatment (Living with CLL on 
the Cusp) 
 
CLL received its first mention in the medical literature in 1827 (in relation to a 63 year old 
Parisian florist turned lemonade vendor, Monsieur Vernis), and was distinguished as a distinct 
form of leukaemia in the mid nineteenth century. Little else changed up until the nineteen 
fifties when the nature of the immune deficiency underlying the disease was defined, and a 
handful of drugs able to temporarily slow down progress (chlorambucil, melphalan, 
mechlorethamine and corticosteroids) emerged alongside radiation therapy to enhance 
palliation.  
 
As the prognosis chapter has shown, the staging systems introduced by Rai and Binet in the 
1970s went some way to predicting survival for cohort, but did little to predict individual 
progress of this heterogeneous cancer. Early intervention for those in high-risk cohorts was 
largely unsuccessful, often exacerbating decline. The emergence of cytogenetics and IGH 
mutational state discussed in the Prognosis chapter led to the ability to identify those with a 
particularly poor prognosis. At the same time, the advent of fludaribine and cyclophosphamide, 
followed by rituximab and eventually bendamustine and alemtuzumab alongside auto- and 
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allotransplants78 made some impact on the outcomes of high-risk CLL but the disease remains 
incurable.  Improved understanding of the molecular antecedents and biology of the disease 
alongside the advent of a new breed of effective drugs including ibrutinib, ofatumumab, 
obinutuzumab, and idelalisib in addition to Bcl2 inhibitors such as ABT199 make for a more 
optimistic outlook. Contributing to this optimism is the ability to keep track of the disease at 
micro-levels through measurable residual disease (MRD) tests with the potential to predict 
early progress in remission. As Gale and Hochhaus79 (2015) point out, it remains to be seen 
whether all or any of this will contribute to a cure.   
 
The initial draft of this chapter was written as I recovered from a six month course of 
chemoimmunotherapy (CIT) known as FCR.  Purine analogs fludaribine and cyclophosphamide 
make up the ‘chemo’ part alongside monoclonal antibody rituximab which constitutes the 
‘immuno’ element of therapy. For around a decade since its inception, FCR has been regarded 
as the gold standard of care for younger fitter patients, and indeed for some of those patients 
with particularly favourable biomarkers and who remain in remission some 12 years since their 
 
78 Allogeneic and autologous stem cell transplantation (SCT) are sometimes considered as experimental therapies 
for high risk younger CLL patients running out of traditional treatment options. Successful SCTs are considered to 
be the only possible route to ‘cure’ for some CLL patients, although it is a high risk intervention where even those 
patients who survive the transplant may still relapse in due course. For a detailed 2002 analysis of the two 
approaches, See Dreger and Montserrat’s (2002) paper, ‘Autologous and allogeneic stem cell transplantation for 
chronic lymphocytic leukemia’, published in Nature in June 2002.  
For a more up to date lay explanation, see also see Sharman (2013b) ‘Stem Cell Transplant’. 28.09.13 in Dr. 
Sharman's CLL & Lymphoma Blog: Translating basic science and clinical breakthroughs into language we all can 
understand.  
79 Gale and Hochhaus’s introduction to the special ‘Leukaemia’ edition of Nature magazine presented with the 
support of Janssen Pharmaceuticals in 2015 outlines a detailed history of the emergence and evolution of CLL as a 
specific haematological malignancy in its own right. I am indebted to their work for underpinning the short potted 
history presented here.  
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involvement in the first trials, the possibility that it might even provide a ‘cure’ is being 
tentatively discussed. However, many patients will in fact relapse within two to six years 
following treatment with FCR, and around 10% go on to develop treatment-induced further 
malignancies, often superseding CLL with a potentially more deadly prognosis. As CLL specialist 
Jeff Sharman notes, “FCR is pretty close to the maximum amount of chemotherapy you can put 
into a single regimen” (Sharman, 2012). 
 
As the Prognosis chapter has also shown, individuals can now be tested for the particular 
genetic mutations that characterize their personal disease. The same advances in genetic 
knowledge have paved the way for the development of novel agents targeted at specific cells. 
Biomedical advances in the field of chimeric antigen receptors (CARS)80 , BCL2 inhibitors such as 
ABT19981, and BTK inhibitors82 such as ibrutinib have produced promising treatments trickling 
through clinical trials and, in some cases, out into the global marketplace.  Figure26 shows one 
 
80  CARs (chimeric antigen receptors) are genetically attached to the surface of T-cells, which are circulating 
immune cells that protect the body from infection. CARs are engineered to persuade the T-cells to seek out certain 
proteins. All cells have proteins specific to the cell type. B-cells, including CLL cells, express a number of proteins on 
their surface such as CD19, CD20 and CD23. CLL is a type of B-cell malignancy. The first CARs being used to target 
B-cell malignancies have been programmed against the surface protein CD19. These CD19-specific CARs have been 
investigated extensively over the last few years...a CAR study led by Drs. Carl June and Bruce Levine has proven 
successful with dramatic initial responses in three CLL patients. See Introduction to CLL Global News – ‘CARS 
Research Speeds Ahead’ - (November, 2011) for further discussion and updates of research in this area.  
81 CLL cells demonstrate overexpression of the B-cell lymphoma-2 protein, one of the standard regulators of  
apoptosis. The oral drug ABT-199/GDC-0199, in joint development by AbbVie and Genentech, mimics the BH3-
binding element universal to all cells, thereby restoring the physiologic regulatory process normally causing cancer 
cells to self-destruct. See Nancy Melville’s (2014) article for Medscape Medical News, ‘Move Over Ibrutinib? New 
Agent Shows Strong Results for CLL’, for a full account  
82 On the ‘Our Science’ page of their website, Pharmacyclics describe BTK is an important cell signalling enzyme 
that is found in hematopoietic (blood) cells including B-cells. B-cell activation is driven by the B-cell receptor (BCR), 
and BTK is a crucial part of the BCR signalling pathway. BCR signalling is thought to promote cell proliferation, 
adhesion, and survival in many types of B-cell malignancies (cancers). Inhibitors of BTK such as the Pharmacyclics 
compound, ibrutinib (PCI-32765), act downstream of the BCR and block BTK activity, and in preclinical models this 
resulted in an inhibition of proliferation, a disruption of tumor cell adhesion, and apoptosis (cell death) in 
malignant B-cells.  
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of the ways in which this highly scientific information can be disseminated in the CLL support 
networks, in this case translated for CLL patients and carers in a feature in the newsletter for 
global CLL charity CLL Global.  
 
 
Figure 27: CLL GLOBAL (2011) 'BTK Inhibitors' in CLL Global Newsletter, 2, 2011 [Screenshot]. [Online] Available 
at: http://www.cllglobal.org/CLLnews/btk-latest-news-combined.pdf [Accessed 03.05.2013]. 
 
Instead of killing cancer cells (and non-cancer cells along with them), small molecule drugs 
(kinase inhibitors) such as ibrutinib work to disrupt the communication pathways that enable 
mutant cells to suppress natural cell death or apoptosis (and accelerate disease progression), 
and have been used with great success in the form of gleevec to treat chronic myeloid 
Image removed due to copyright restrictions 
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leukaemia (CML)83. CLL has a more complex biology than CML though and, despite a raft of 
novel agents currently going through the trials process and producing promising results with 
varying patient groups and CLL sub-types, the heterogeneity of CLL doesn’t lend itself quite as 
easily to a one size fits all gleevec equivalent.    
 
Some patients are already in trials or receiving novel agents as second line therapies for which 
they have won recent approval:  
 
 have just completed a clinical trial of GA-101 monoclonal antibody, with minimal side 
effects and "a complete response." I feel better than I have in years. Clearly, we are 
finally making progress in the treatment of cancer, the first real progress in my lifetime, 
where the treatment isn't worse than the disease. I would not have known about the 
exciting new options without CLL Topics and ACOR (IOB Survey Respondent 55). 
 
 
I have been through all the protocols. I am now taking an experimental drug that is a 
kinase inhibitor. It has saved my life. I believe it will be the next wave of treatment – non- 
toxic & it works!  (IOB Survey Respondent 29) 
 
 
 
As already demonstrated though, evolution to a world without CIT is a slow process with no 
guarantees, leaving many CLL patients currently facing treatment with traditional CIT with all of 
 
83 Investigations of the BCR-ABL tyrosine kinase as a target for therapeutic intervention led to the discovery in 1993 
by Brian Druker of STI571, a compound capable of killing CML cells in vitro while preserving healthy cells. In 1998, 
STI571 underwent its first human clinical trial. Now commonly known as Imatinib Mesylate or Gleevec , the drug is 
at the forefront of the quest to develop personalized therapies for haematological cancers and has redefined CML , 
once a life-threatening cancer, into a manageable chronic disease, raising hopes that similar agents could be 
developed across the spectrum of blood cancers (see the National Cancer Institute paper: ‘YS Budget 2003’ for 
further information.  
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its toxic implications:   
  
I wonder whether these new treatments will be available 'in time' for some of us. I'm 
encouraged by them and I am sure there will be a 'cure' in time and happy for those who 
will be able to take advantage of them. Meanwhile, we will have to take the 'toxic shock' 
of chemo… Patient Power and CLL Support Org in Health Unlocked are resources I have 
used to keep up with developments (IOB Survey Respondent 180). 
 
 
Although revolutionary changes in treatment open doors onto a possibility for relatively low-
impact long-term management, as it stands many CLL patients must acknowledge that sooner 
or later their bodies and available treatment options  may well run out of resources to fight the 
disease. As my own consultant’s letter to my GP informing him of my treatment starkly states, 
‘Julia has commenced FCR treatment…remission is likely, but cure cannot be achieved.’ (See 
figure 27 below for an excerpt from that letter). 
 
 
Figure 28: RCHT (2013) Extract from Consultant letter to my GP [Scan]. 
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As with other forms of cancer, contemporary CLL patients and their clinicians must negotiate a 
complex landscape of individual cytogenetics, existing chemo-immunotherapeutic treatments, 
emerging novel therapies, and the issues of regulation, access and affordability that accompany 
them. Networks are currently populated by narratives and actors located at various points on 
the current treatment continuum. Inevitably, many CLL patients will find themselves excluded 
from access to new treatments, and must find ways of negotiating any potential frustrations 
within their own narratives:  
 
 I have accepted what I have and I believe that the consultants are giving me the best 
treatment possible at the present time. I am glad that progress is being made with new 
treatments, but I am not going to feel that I have been cheated because the new 
treatment is not available now. I need to live now with what I have and what treatments 
are available now. Any jealously, if that is the correct word, for any future sufferers who 
receive the new drugs/cure will not help me, and there is very little made of how lucky 
present day sufferers are compared to CLL sufferers in the past. We are lucky compared 
to them and hopefully every future generation will be luckier than the present/last one 
as progress is made to cure CLL…  (IOB Survey Respondent 179). 
 
 
As this response implies, whether or not they receive new treatments, the contemporary CLL 
patient is undoubtedly in a better place than their historical counterparts, and there will always 
be transitional phases in which some patients are benefitting from new treatment advances 
whilst others are not. My own story of beginning treatment is not an unusual one and, coming 
when it did right on this cusp of treatment paradigms, serves to represent some of the 
dilemmas and frustrations faced by those of us directly straddling the old and new worlds. 
Diagnosed in March, 2011, the status of my CLL as progressive was clear, although relatively 
contained for the first two years. My wbc was 67k on diagnosis, and hovered just below 200k 
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some two years later. A lymphocyte doubling time of six months or less is considered indicative 
of a need to treat and mine, although rising inexorably, had not demonstrated such a leap. By 
summer 2013 however, it became clear that my disease was ‘taking off’ as my lymph nodes 
became more swollen, and my spleen palpable, a fact confirmed by my consultant at my 
regular check-up in September. Although I knew I had a progressive CLL, the rapidity with which 
it became aggressive and requiring urgent treatment was unexpected, and I began trawling 
online for information on treatment where it became clear that new treatments were causing 
much excitement and hope, but that not everyone needing immediate treatment would be part 
of that.   
 
The following three Translations focus on ways in which these sometimes disparate narratives 
of hype, hope and reality are playing out among patients in CLL support communities, and 
evidence complex narrative associations and translations from physician bogs, through patient 
advocate sites, to personal opinion in online support communities.  
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Translations: Hype, Hope and Reality: Staying alive in the interstices of 
the   treatment revolution 
Translation 1: Dr Sharman’s CLL and Lymphoma Blog: ‘What is FCR?’ 
 
 
Figure 29: TOUCHGRAPH (2012) Network connections to Dr Sharman’s CLL and Lymphoma Blog post 'What is 
FCR?' [Network Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=http%3A%2F%2Fwww.cll-
nhl.com%2Fsearch%3Fq%3Dwhat%2Bis%2Bfcr%23.VTO6gvnF-So%20%20%20%20%20%20 
[Accesssed30/11/2014] . 
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During this period I encountered many network narratives extolling the virtues of new 
treatments and looking forward to a chemo-free future, and I also encountered a useful entry 
on a blog by physician Jeff Sharman. I will start with a brief outline of that blog as a network 
narrative that sets the scene for the dilemmas faced by patients and physicians alike in 
navigating the changing terrain. Entitled ‘Dr. Sharman’s CLL and Lymphoma Blog: Translating 
basic science and clinical breakthroughs into language we all can understand’ (see figure 29) , 
haematologist-oncologist Jeff Sharman’s blog is a highly popular node in the networks, 
mentioned frequently in the IOB Survey, and experiencing a significant flow of traffic.  
 
 
Figure 30: SHARMAN, J. (2012) ‘What is FCR?’ [Screenshot].  Dr. Sharman’s CLL & Lymphoma Blog. [Online] 
Available at: post http://www.cll-nhl.com/search?q=what+is+fcr#.VTkyI_nF-So [Accessed: 24/04/13]. 
 
A practicing haematologist at the Willamette Valley Cancer Institute in Eugene Oregon, 
Sharman is also Medical Director of Haematology Research for community based research 
Image removed due to copyright restrictions 
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network US Oncology, with sites throughout the United States. Acknowledging the impact of 
time restraints in the clinical setting on the level of discussion and explanation of CLL 
achievable, he describes his blog as an additional resource for the patients he sees on an 
everyday basis:  
 
In our visits, I often find I want to give a more comprehensive discussion than what time 
allows. I hope this blog allows my patients to feel more informed about what we are 
doing and why we are recommending it (Sharman, 2012a). 
 
 
Seeking to use online resources to set out the broader research contexts within everyday 
clinical decisions are made and put into practice for his patients, Sharman is demonstrative of 
the kind of clinician at the heart of evolving models of clinical knowledge exchange and 
partnership proposed by Tom Ferguson in his e-patient white paper (Ferguson, 2007). With 
slightly under half a million visits to this page alone, it is clear that his remit extends way 
beyond his original intended audience of his own patients. Jeff Sharman is a key actor in CLL 
networks online, his blog pages reflecting the dominant current debates among patients and 
clinicians in the field and translating them for lay audiences.   
 
The post explored here is entitled simply ‘What is FCR?’, and appeared on 14th September, 
201284.  Sharman begins by addressing “a lot of emotional debate among academic physicians” 
about how broadly to utilize FCR, currently the standard regimen for most CLL patients. 
 
84 As at 27th October, 2014, total page views for the post registered 431,398. 
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Drawing on “patterns of care” data from leading global CLL researchers, Sharman makes a 
distinction between the “real world” of 90% community practice, 10% academic clinicians” 
(Sharman, 2012a).  This is important as non-clinical readers can reflect on the actual landscapes 
within which they are treated.  Much like global news networks, the CLL networks tend to 
amplify the more dramatic and outstanding stories, and to source big stories of treatment 
advances from a limited range of key voices in the field. On the whole, those key clinical voices 
circulating in the networks tend to represent Sharman’s claimed 10% of academic clinicians, 
which are not necessarily representative of the remaining 90% of clinical providers servicing 
most of the CLL population through smaller regional centres.  Small wonder perhaps that the 
leading stories of change and progress don’t always mirror the experience of many patients in 
the network (nor presumably those outside of them). The playing field for CLL patients is by no 
means a level one:  
 
 If you have the means, resources, insight, and physical ability to travel to Houston you 
are not the “typical” patient with CLL seen in the community.  Consequently, what can 
be done well there does not always reflect what can be done elsewhere (ie. the input 
influences the output) (Sharman, 2012a). 
 
 
This sense of an ‘elite’ group among CLL patients who are relatively young, wealthy, well-
informed, and well enough to travel was mirrored in the following respondent’s tangible sense 
of exclusion:  
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…I am also pretty certain that I will be limited to only treatments "allowed" by Medicare. 
So perhaps there is more hope for those who have more resources in terms of money or 
accessibility to research hospitals or medical centers that specialize in blood cancers (IOB 
Survey Respondent 151). 
 
Optimism for a chemo-free future is tangible but, as Sharman points out, FCR (for all of its 
flaws) provides some of the most durable remissions currently achievable in CLL.  For readers 
who may understandably have simply black-boxed FCR as ‘chemo’, Sharman explains the way 
the three drugs work in the body and interact with each other, and sets out some of their long-
term side-effects, including the possibility of ‘clonal evolution’85. Thus far the reader is in no 
doubt that FCR, whilst highly effective for particular patient groups, is no free lunch. They will 
also be aware that this is a contentious area amongst CLL specialists. Sharman makes that clear 
when he points out that “There are some very passionate feelings out there among thought 
leaders about the role of FCR and I need to tread carefully here” (Sharman, 2012a).   
 
Again, the ‘black-boxing’ of chemo is exploded as readers are made aware that this particular 
regime in its broader contexts is about more than cells, symptoms and side-effects. The 
allegiances, aspirations (individual and institutional), histories and politics of a particular 
treatment regime are implicit in Sharman’s acknowledgement of the passions invested in 
clinical approaches to FCR, and in his need as a fellow CLL spokesperson to “tread carefully” 
around them. He settles on stating that he thinks it is still felt to be the “treatment of choice” in 
 
85 Whereby all but a bunch of highly resistant clones (usually associated with P53 abnormalities indicated by a 17p 
deletion in CLL patients but not necessarily apparent on a patients initial cytogenetic panel if only present in small 
numbers) are killed off by the chemo. The resistant genes can them become the dominant gene, and a patient not 
17p deleted on diagnosis can become so on relapse, making them difficult to treat with current CIT regimes. 
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younger, healthier patients without a 17p deletion on diagnosis.  However, the impact of novel 
agents is beginning to erode what Sharman describes as FCRs current “king of the hill” status, 
and he predicts that we are not “too far away from providing targeted treatments that may 
allow some patients to never get traditional chemotherapy” (ibid).  Again, a brighter treatment 
future is promised, but most readers engaging with Dr Sharman’s blog will be acutely aware of 
his reminder that “things never move as fast in science as our patients want.  Investigators are 
hoping to “replace” FCR but we have a ways to go before we are there” (ibid).  
 
This is precisely the situation I found myself in in September, 2013. Scanning through the daily 
postings on the Health Unlocked CLL site, I came across links to a number of optimistic 
circulating narratives discussing a potential chemo-free treatment future. Among these was a 
video posted to Andrew Schorr’s Patient Power advocacy site on 7th January, 2013, entitled ‘An 
Expert’s Perspective on Advancing Treatment Progress for Blood Cancers’ (see screenshot in 
figure 31 below):   
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Image removed due to copyright restrictions 
 
Figure 31: PATIENT POWER (2013) An Expert’s Perspective on Advancing Treatment Progress for Blood Cancers – 
Dr. Steven Rosen [Screenshot of Video]. [Online] Available at:  http://www.patientpower.info/video/an-
experts-perspective-on-advancing-treatment 
 
The film shows edited footage of an interview in which Andrew Schorr questions Steven Rosen 
about his views on the new treatments emerging, and is just one example of an evolving genre 
of videos depicting interviews between patient advocates and CLL experts and patients posted 
across the networks. Commonly, these are filmed at conferences or annual meetings of 
Haematological Associations such as ASH (American Society of Haematologists) or EHA 
(European Haematology Association) where global experts in the field gather to present on 
their most recent research findings. Interviews are conducted in a manner that allows for 
findings to be summarized and presented by clinician-researchers in a way that makes them  
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accessible to patient audiences, and directed towards the kinds of questions patients 
themselves might ask. 
 
The video is of interest for three main reasons:  1) Picking up on the points made in Jeff 
Sharman’s blog, it prefaces the hoped for the imminence of tailored molecular treatment for all 
– for a chemo-free treatment landscape; 2) it demonstrates how patient advocacy sites are 
working with clinicians to translate complex treatment issues into accessible video form for 
networked patients, and using these as a platform to encourage patient engagement and 
autonomy in selecting clinicians and treatments. This particular video raises some very 
pertinent points about the changing nature of the patient/clinician relationship as CLL 
treatment becomes increasingly about long-term management; 3) it demonstrates how 
circulating narratives such as this catalyse debate among patients relating them to their own 
personal narratives in support communities.  (See appendix 12  for network map and detailed 
analysis of some of the points made in discussion).  
 
The experience of watching this video (and others like it) is an overwhelmingly positive one, in 
which advancing biomedical futures translate into the potential of access to treatments that 
can save or prolong life for all CLL patients. In which the consequent long-term nature of 
survivorship underpins informed and equal partnerships with clinicians who are interested in 
holistic approaches to their patients. In which universal agency for patients in terms of choice 
and access is never seriously questioned. It is encouraging indeed, and is just one of many such 
videos contributing to the buzz of hope for brighter CLL futures. From my position as someone 
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entering a very aggressive disease phase and becoming increasingly aware that my treatment 
choices would be excluding me from novel therapies, as was the case for a significant number 
of CLL patients in similar positions posting in the forums, it was at the same time incredibly 
frustrating, and motivated my response to the posting of the video discussed in the following 
translation.   
Translation 2: Approaching Treatment with FCR in a Support Community 
(Patient Experiences) 
 
 
Figure 32: TOUCHGRAPH (2013) Network connections to Jibs60 post ‘Making Peace with FCR in the Squeezed 
Middle on CLLSA UK HU [Network Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=making%20peace%20with%20fcr%20in%20the%20squeezed%20mi
ddle%20j ibs60 [Accessed: 22/04/15]. 
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Figure 33: JIBS60 (2014) ‘Making Peace with FCR in the Squeezed Middle: Response to another very hopeful 
video from Steven Rosen’ [Screenshot of forum discussion on CLLSA UK HU]. [Online] Available at 
https://healthunlocked.com/cllsupport/posts/130236845/making-peace-with-fcr-in-the-squeezed-middle-
response-to-another-very-hopeful-video-from-steven-rosen [Accessed 23/04/2015]. 
 
The screenshot replicated in Figure 32 (above) shows my response to the Steven Rosen video 
posted to the CLLSA HealthUnlocked site in September, 2013. Starting my response by 
observing that:  
 
it’s brilliant to see such optimism, and to hear someone say that he can tell his CLL 
patients that they'll never need chemo...however, for those of us facing an imminent 
need for treatment now...those of us in clear and present danger that isn't going away 
while we wait until early 2014 in the UK to see if we can get a 50/50 chance of 
ibrutinib in the …. phase 3 trial, I'm afraid it simply isn't true... (jibs60, 2013). 
 
 
 
Image removed due to copyright restrictions 
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I went on to point out that, with a rapidly growing spleen, increasingly bulky nodes and 
anaemia/thrombocytopenia alongside crashing fatigue and frequent infections, my own 
treatment 'choices' were starkly limited. I could, against medical advice and the insistent 
warning signs from my own body, wait for a trial to start up somewhere local for a 50/50 
chance of getting access to ibrutinib (potentially missing the window of opportunity to start 
treatment while fit enough to respond well). Alternatively, I could just go with FCR (given that 
there's a 50% chance that's what I would end up with anyway), and that was the decision I felt 
I had no choice but to make. I made it clear that, whilst I welcomed the possibility of a durable 
remission offered by FCR, and didn’t wish to undermine the optimism for brave new 
treatment futures, I found it incredibly frustrating that so much of the optimistic discourse 
elides the present reality for many of us as if it has just conveniently disappeared: 
 
…this is a tough place to be right now, and to acknowledge that for anyone else in a 
similar position, and for those who may draw the FCR arm in the upcoming randomized 
trials. We will all need to find a way of making peace with, and retaining a positive 
attitude to our experiences with a treatment that is already being consigned by many to 
a rhetorical past, but that we must rely on to keep us alive in a present already 
overlapping with a future buzzing with hype and hope for another way... (jibs60, 2013). 
 
 
Of the 25 responses, all were supportive and expressed empathy for the sense of frustration 
experienced at the overwhelming failure in the majority of circulating discourses of new 
treatment to acknowledge the fate of very many CLL patients still consigned to traditional 
treatments in the interim:   
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So well put J. I am sorry to read that treatment time is here and recognize how 
frustrating some of the hype and insensitive messaging contained in these broadcasts 
must be especially to the younger untreated patient (Hairbear, 2013). 
 
 
 
And this community member, also facing imminent treatment with chemotherapy concurs with 
what she suspects is a widespread sense of frustration: 
 
Your post explains precisely the frustrations that I (and I suspect many others) are 
struggling with, though we can't always express it as clearly as you. (I too am treatment 
naive, but have been told to expect treatment within the next year, of either R 
Bendamustine or FCR)  (Anonymised HealthUnlocked community respondent). 
 
 
 
This sense of frustration was mirrored by a number of ITB survey respondents:  
 
It is exciting to know that a lot is happening on the CLL front, but a little caution about 
immediate availability is in order (IOB Survey Respondent 107). 
 
 
 Due to a number of perceived mitigating factors around access and efficacy, patients spoke of 
not wanting to get their hopes up surrounding the prospect of radically improved prognosis or 
cure. One patient articulated the potential damaging impact in emotional terms for CLL patients 
of over-zealous optimism from clinicians:  
 
I’m afraid to get my hopes up. I was at the CLL Conference in Niagara Falls last year 
(fantastic!) and a Dr. from the states was saying how CLL would be cured in the next 
couple of years. I think his positive attitude was good but he played with our emotions. 
Julia Kennedy 
314 
 
For us will CLL it is very serious when you say something like that (IOB Survey 
Respondent 118). 
 
 
 
In a response that draws attention to the ongoing cycle of evolving cancer treatments, and the 
history of those patients that must negotiate them, another forum respondent makes analogies 
with the introduction of rituximab over a decade earlier:   
 
I recall a similar situation 12 years ago when rituxan was in clinical trials. It didn't quite 
work out as envisaged, but rituxan has become one of the most important cancer 
therapies ever, and nothing gives a longer remission or overall survival than FCR, other 
than an allogenic transplant in some cases. I think people loose [sic] sight of this fact, 
sometimes (Anonymised HealthUnlocked community respondent). 
 
 
 
This respondent also makes the point that FCR’s status as the therapy most productive of long 
and successful remissions for particular patient groups is in danger of being overlooked as 
attention shifts towards the novel agents. Another respondent spoke if his previous successful 
treatment with FCR which had enabled him to survive long enough to enter a trial for ibrutinib 
on relapse, again demonstrating that novel agents – albeit as second-line treatments - remain 
in the bank for those currently needing treatment but unable to access them. Yet another 
proffered advice to perhaps negotiate with my consultant to try and hold out for the trial using 
blood transfusions and steroids to avoid the stress of undergoing a therapy that was clearly not 
my first choice. The latter prompted an interesting response from a fellow community member 
about the dangers inherent in the tendency shown by some patients to try and stave off CIT for 
Julia Kennedy 
315 
 
as long as possible in the hope of access to a safer alternative: 
 
…Both paths (trials and standard treatments) have their uncertainties but doing nothing 
when the time has clearly come for treatment is an even poorer choice… (Anonymised 
HealthUnlocked community respondent). 
 
 
 
In a subsequent post reflecting on the input of fellow community members who had taken the 
time to engage with this topic, I summarized my point that facing chemo at any time is not 
something anyone would take lightly, but to face it at a time where the CLL networks are 
buzzing with hope for new treatments continually heralded as a huge improvement on the 
existing regimes with increasing polarity makes it an even more difficult decision: 
 
Richard Furman's recent video on patient power discussed the obvious benefits of 
ibrutinib in direct opposition to the dangers of FCR in terms of clonal evolution, 
secondary tumours, and MDS further down the line. Increasingly we see this as a very 
polarized issue in the available discourse - FCR the devil we know - Ibrutinib the angel 
(even though we don't actually know it)... and that I think makes it more difficult to feel 
comfortable about FCR right now (jibs60, HealthUnlocked, 2013). 
 
 
 
From 14th-16th February, 2014, a debate unfolded on the ACOR CLL forum between patients 
also addressing the difficulties faced by those having to negotiate a treatment terrain growing 
in its apparent polarity, particularly with reference to the dire warnings often attached to 
contemporary discussion of FCR therapies in relation to novel agents. The conversation thread 
was erudite, and highly informed, linking out to four published research papers on the link 
between clonal evolution and chemotherapy and one on secondary cancers resulting from FCR. 
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Despite this, several correspondents acknowledged that FCR treatment had enabled them to 
live productive and useful lives, that they went into it aware of the risks, and that they would 
do so again. Undoubtedly, this is a debate that is destined to continue through the interregnum 
period of old to new, and as more information emerges concerning the long-term efficacy of 
the newer treatments. CLL is certainly not alone as a disease in locating those who live with it in 
the frustrating interstitial spaces of biomedical advance and everyday access to the drugs that 
accompany it. Perhaps that frustration might be experienced more acutely in chronic cancers 
where the sense of having at least some degree of control over treatment issues can appear 
wholly illusory when progress becomes aggressive and treatment is, as with other cancers, 
required as a matter of life-saving urgency and limited only to what is locally available.  
 
Certainly, as I became progressively unwell, and the opportunity to be part of the bright new 
chemo-free future I had hoped to inhabit slipping away from me, I was acutely aware of Jeff 
Sharman’s observations that “things never move as fast in science as our patients want” 
(Sharman, 2012).  
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Figure 34: KENNEDY, B. (2014) ‘The fight to avoid chemo is lost’ [photograph] private collection Julia Kennedy. 
 
Never more so than the November afternoon when my fight to avoid CIT with all its attendant 
side-effects and long term risks came to a definitive end on the chemotherapy ward as I 
watched the first liquid line of rituximab snake into my vein (see photograph in Figure 33 
above).    
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Translation: A Network Account of Ibrutinib’s Road to Market (Tracing a 
Complex Journey) 
 
 
Figure 35: TOUCHGRAPH  (2015) Network connections to SHAYWITZ, D. (2013) ‘The Wild Story Behind A 
Promising Experimental Cancer Drug’ in Forbes online newspaper [Network Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=http%3A%2F%2Fwww.cll- 
nhl.com%2Fsearch%3Fq%3Dwhat%2Bis%2Bfcr%23.VTO6gvnF-So%20%20%20%20%20%20 [Accessed 
05/01/2015]. 
Julia Kennedy 
319 
 
The first cold flush of Rituximab in my arm may have seemed like a momentary symbol of 
failure, but I forced myself to remember its own place as a game-changing, life-extending drug, 
access to which patients just like myself had eagerly pursued a decade earlier. A link stumbled 
across in a support forum thread took me to a Forbes news feature by David Shaywitz86 telling 
the story of ibrutinib’s unlikely success story. In this narrative of unlikely liaisons, and calculated 
risk-taking leading to the development of one of the most exciting drugs to impact on the CLL 
care environment to date, I learned that the Rituximab potentiating the impact of the 
chemotherapy on my cells was pioneered by biotech company IDEC (merged with Biogen in 
2003), among whose founder members was a Dr. Richard Miller. In his role as former CEO of 
Pharmacyclics, Miller consolidated his interest in B-cell cancers inspired in part by the work of 
Stanford oncology fellow and CLL specialist Dr. Jeff Sharman (recognizable as a key CLL network 
actor from this chapter’s earlier Translation), with his purchase for a relative pittance of biotech 
company Celera and its BTK inhibitor (PCI-32765) developed on the back of the Human Genome 
Project, but with no definitive application to treatment yet established. Readers of this study 
will by now recognize BTK inhibitors from their previous appearances in perspectives and 
translations.  
 
Also in the lot was a promising ‘tool compound’ created by Celera researchers – a molecule 
capable of binding BTK permanently (covalently), of being fluorescently labelled, and of 
 
86 Shaywitz is listed on his blog as a Forbes biotech writer, MD, and partner in CATCH (collaboration between MIT 
and Massachussets General Hospital to develop a Center for Assessment Techonology for Continuous Health).  For 
further biographical details see https://davidshaywitz.wordpress.com/      
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identifying further compounds that could bond BTK tightly but not covalently or permanently.  
Adopting the unusual model of studying the compound in spontaneously occurring canine 
lymphomas to circumvent the unsuitability of existing experimental models for these new 
compounds, early results were only moderately positive. Miller’s decision to stick with PCI-
32765, because “I have patients in clinic who are dying, and need something right away…” 
(cited in Shaywitz, 2013a) prefigures what for CLL actors has become history as PCI-32765 now 
known as ibrutinib rolls out into discourse and treatment across the global networks. A preview 
of a full report of the RESONATE phase 3 randomized trial of ibrutinib compared with 
monoclonal antibody ofatumumab authored by John Byrd et al., and published in the New 
England Journal of Medicine in May 2014 concluded that:  
 
Ibrutinib, as compared with ofatumumab, significantly improved progression-free 
survival, overall survival, and response rate among patients with previously treated CLL 
or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, 
NCT01578707) (Byrd et al, 2014). 
 
 
 
David Shaywitz’s early stage story of ibrutinib peels back some of the layers of activity and 
associations that underpin the success stories of big pharma, and in doing so reveals some of 
the economic factors involved from the outset – and some of the points at which the 
translation could have failed87, most particularly the team’s ability to recognize and overcome 
the limitations of experimental models, the value of translational champions on both academic 
and industry sides (Sharman and Miller), and the element of luck inherent returning successes 
 
87 Like Latour in Aramis (1996), Shaywitz (2012) positions the reader as network actor in this story of successful 
translations, mediations, and pure good fortune that took the drug ibrutinib to success where Paris’s proposed 
transport system Aramis had failed.   
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on the risks they took. Shaywitz reminds us how narrative outcomes are always susceptible to 
some degree of fortune when he says that he could “easily envision how following this exact 
approach might have led to a far less favorable outcome, and a very different narrative [e.g. 
‘cavalier physician imperils patients in reckless pursuit of flawed vision’]”  (Shaywitz, 2012). 
 
Miller is a highly significant actor in the world of CLL. Like other key scientists working under the 
lid of CLL, his name is rarely mentioned in the day to day network discourse, although his 
contribution as a determined biotech entrepeneur has underpinned the ongoing CLL treatment 
revolution (and much of the work in this chapter), transforming the lives of many CLL patients 
and re-shaping the future for many more.  
 
Of equal interest is how much network interest and activity surrounds particular narratives.  For 
example, whilst ibrutinib, its potential side-effects, costs, and availability are among the key 
discourses in CLL forums over the past two to three years, relatively little debate arises 
surrounding the political economy driving the industries responsible for innovating and 
producing drugs. Network actors seeking to read about ibrutinib could easily access this story 
which was itself told with painstaking attention to associations and translations in the bio-
entrepeneurial networks by clinician, scientist, and Forbes contributor David Shaywitz. In fact 
the article was linked into the CLLSA HU forum through a member posting in 2012, yet 
responded to by only one other member who makes observations about the fragile bonds 
holding this success story together in its ‘shaky’ journey into the lives of CLL patients and the 
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bank accounts of the companies innovating it:  
 
A fascinating story which is well worth finding the time to read. Rather sobering to learn 
that the research knowledge that lead to ibrutinib was picked up by Pharmacyclics at 
zero value and further that animal based research only lead to shaky preclinical results 
(Anonymised CLLSA HU Member).  
 
 
 
 Nor is it often discussed just how few drugs actually make it from the conceptual stage to 
prescription. Even with the increased productivity enabled by new biotech tools, there has 
been no significant change in the approximate 15 year period that it takes for the staggeringly 
low average of one in every ten thousand new compounds that ultimately makes it through the 
hugely costly pre-clinical and clinical trials to reach approval (Kessel and Frank, 2007).  What’s 
more, if one considers that even among those rare but highly promising drugs with the 
potential to warrant a human clinical trial, only one in five will eventually be approved and that, 
according to the Tufts University Centre for the Study of Drug Development (2006) “the average 
cost involved in the development of a single successful biotech drug is estimated at $1.2 billion” 
(Kessel and Frank, 2007), it is a wonder that any novel agents make it to market and into the 
lives of CLL patients at all. 
 
It seems that some CLL patients are hooked into the importance of getting the black box of this 
aspect of CLL treatment. The IOB survey results registered just two respondents adding the 
stock exchange and financial media to their list of sources for information. These network 
actors went direct to pharma or biotech company trading reports and press releases to stay in 
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touch with future developments, watching the evolution of treatments directly through the 
marketplace: 
 
I'm not following them very closely at this time as I'm staying so stable. I do also look at 
some of the biological companies such as Celgene or Biogen.  (In Our Blood Survey 
Respondent 36) 
 
 
Perspectives: Access to Novel Agents: Trials and Tribulations 
 
Despite the relatively low levels of detailed attention paid to many of their working practices by 
patients, the actors in the CLL networks with the most power and influence over the lives of CLL 
patients and the clinical decisions that affect them are the biotech and pharmaceutical 
industries and the previous translation shows that, like all other networks, the drug industry is 
itself a complex array of actors and associations often bracketed or black-boxed in everyday 
discourse. This perspective will focus now on the process of clinical trials, the more public face 
of pharmaceutical innovation and a vibrant source of network activity in my research. 
 
Over the course of this study from 2011 to 2015, considerable traffic has been generated in the 
networks surrounding a number of clinical trials for novel agents and treatment combinations. 
Patient, clinician, regulatory and industry positions are represented in the circulating stories of 
drug trials. Keating and Cambrosio (2008) reveal the development and articulation of the 
components of what they describe as a new style of practice in contemporary trials, evolving on 
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an ad-hoc basis from post WW2 innovations. These components are identified as “protocols, 
oncologists, statistics, patients, and diseases” (Keating and Cambrosio, cited in Cantor, 
2008:197). Particularly relevant is their observation that the often seemingly ‘mundane’ work 
of Phase 3 clinical trials (comparing well-known procedures and resulting in incremental 
improvements in cancer therapy) to some extent ‘buries’ all of the work that has gone before, 
and will go on after the Phase 3 ‘endpoint’ (ibid:223). This chapter has already acknowledged 
circulating narratives that attempt to make visible the hidden work of pharma/biotech pairings, 
and as noted in the previous section, it is usually at Phase 2 when a drug starts to provoke 
significant interest in the networks as a treatment whose potential may be realized in the not 
too distant future. Phase 2 trials build on Phase 1 work to evaluate the move from in vitro to in 
vivo, working with larger cohorts of patients with the disease to identify short term side effects 
before moving into larger phase 3 trials assessing the efficacy and safety of the medicine, and 
informing the labelling and patient information when the drug goes to market. Phase three 
trials can be ‘randomized’ as with the UK ‘Flair’ trial currently testing new small molecule drug 
ibrutinib in combination with rituximab against traditional FCR. Others have ‘crossover arms’ 
allowing recruits to switch where one drug protocol is clearly producing more effective results. 
It is also not unknown for randomized trials to be stopped early ‘for benefit’ where 
overwhelmingly positive results in the trial cohort lead to the assumption that the drug is safe, 
effective, and that its early release to market would be beneficial to patients.   
 
In January 2014, the phase 3 RESONATE  trial pitching oral ibrutinib against IV ofatumumab in 
391 relapsed/refractory CLL/SLL patients  in over 70 sites across 10 countries was stopped early 
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for benefit after Pharmacyclics issued an interim trial analysis demonstrating  a statistically 
significant improvement in progression-free s and overall survival for those patients taking 
ibrutinib. Subsequently, the Independent Data Monitoring Committee recommended cessation 
of the trial and the offer to all patients on ofatumumab of treatment with ibrutinib (Chustecka, 
2014).  
 
A degree of weighing up potential future issues against current benefits will always be part of a 
decision to stop a trial early, or to expedite licensing of a drug, which can be contentious in the 
long run.  Bassler et al. conclude that RCTs stopped early for benefit “systematically 
overestimate treatment effects for the outcome that precipitated early stopping” (2010:1180).  
 
In the US, drugs intended for use either alone or in combination with other drugs to treat 
serious or life threatening conditions, and showing preliminary clinical evidence of  ‘substantial 
improvement over existing therapies on one or more clinically significant endpoints’   are 
granted the designation of ‘Breakthrough Therapy’ drugs88. This leads to expedited 
development and review processes, and is roughly analogous to the Promising Innovation 
Medicine (PIM) designation introduced under the Governments Early Access to Medicines 
scheme89 (EAMS) here in the UK. In the 2014 Medicines & Healthcare products Regulatory 
Agency (MHRA)  document outlining the government response to the latter, regulation, and an 
 
88 Under section 902 of the Food and Drug Administration Safety and Innovation Act (FDASIA), 2012 
89 On 5 December 2011 the Prime Minister announced a new Strategy for UK Life 
Sciences, including a commitment to bring forward proposals for an early access to medicines scheme based on 
the guiding principles that “eligible products will be determined by a scientific opinion that the likely clinical 
benefits outweigh the risks identified to date where there is high unmet need; NHS funding for product must be 
cost effective; the UK economy should benefit from the scheme” (MHRA, 2014:2). 
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urgent need is articulated to reflect the: 
 
profound changes – driven by Genomics, Data, and the rise of Stratified and 
Personalised Medicines – transforming the drug discovery landscape away from the 
traditional ‘blockbuster’ model of the post-war years to the world of ‘Translational’ or 
‘Experimental’ Medicine in which drugs are designed with and around patients, their 
data and tissues, in clinical research facilities and hospitals (MHRA, 2014:3). 
 
 
 
Interventions such as the 100,000 Genomes Project whose UK roll-out was announced by Chief 
Scientist at Genomics England, Mark Caulfield on 22nd December, 2014 are important 
contributors to new approaches to research, and have the potential to aid biotech and pharma 
industries in the task of drug development by increasing the range of data available to them at 
the r & d phase. The project has the express aim of collecting and interpreting whole genome 
data across a range of rare and debilitating conditions (including CLL) on an unprecedented 
scale, and to feed findings back into mainstream healthcare at a rate able to “produce more 
rapid results for patients” (cited in Genomics England, 2014). Acknowledging the importance of 
collaborative data sharing in the complicated and fragile translation from ‘molecular insights 
into useful therapeutic approaches’ to personalized medicine, Park et al. (2004) propose that:  
 
 
An integrated, collaborative effort is needed among pharmaceutical, biotechnology, 
government, academic, and patient advocacy groups to translate laboratory insights 
into rationally designed agents (Park et al., 2004:3885). 
 
 
The intersection of multiple practices of disease experience is articulately expressed in this call 
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for appropriate methodologies. 
 
Despite such interventions and aspirations, the question of cost for targeted oncology drugs 
remains an immediately pressing one. Research and development overheads for oncology 
drugs are around 20% higher in comparison to the average of all other drugs anyway, and an 
increasingly competitive marketplace between the growing number of novel targeted therapies 
that by their very specific nature produce small ‘niche’ markets (unlike the ‘one size fits all or 
many’ nature of traditional oncological drugs) potentially increases the challenge for 
pharmaceutical companies to actually recoup their large investments in the field of targeted 
oncotherapies (Tigue et al, 2007:2).   
 
The promise of a patient databased world of experimental medicine emerging from the 
traditional lab-based ‘blockbuster’ model of drug research clearly anchors clinical contexts to 
the economic and cultural models of contemporary drug production and it is vital to explore to 
what extent networked patients are aware of and engaged in these debates. For example, 
resistance to the EAMS scheme based on the UK’s Faculty of Public Health (FPH) concerns that 
there is "no substantive research that allowing medicines into the market place earlier" would 
benefit improvements in population health, and that reduced requirements for evidence could 
be exploited by the pharmaceutical industry keen to extend the potential revenue generating 
life of a drug by up to a third through accelerated progress through the trials process 
(Pharmaphorum, 2014; Skipla-Serry, 2013).   
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Despite these seemingly rational concerns, I was unable to locate any such caution in the 
central hubs of the CLL networks, where the concerns of the FPH put forward in the 
consultation period of the EAMS scheme seem largely to be overridden by enthusiasm for early 
access. After all, where traditional treatments bring enough of their own dangers, and people 
are running out of options, individual perceptions of risk are likely to differ from the broader 
discourses of government health bodies.  
 
Perspectives: Online Narratives of the Price of Drugs 
 
Whatever the trial type, it is clear that successful transition to trial for novel agents begins a 
new and more public narrative phase in the networks. It is at this point that patients begin to 
interface directly or indirectly with the drug itself, and with its narrative trajectory into the 
disease community. Issues of access to trials and expedited access to drugs through 
Breakthrough Therapy or Promising Innovation Medicine designation as a result of successful 
early data are a dominant theme among patient group narratives, again often accompanied by 
concerns surrounding cost. After being granted ‘breakthrough status’ by the FDA in the US in 
2013 for the treatment of CLL, SLL and Mantle Cell Lymphoma, Pharmacyclics and Johnson and 
Johnson set the tariff on their novel agent Imbruvica (ibrutinib) at over $90 or £58 per tablet, 
bringing the annual costs for a CLL patient to around $98,400, or £63,500 (2014 conversion 
rates) before the added costs of adjunct therapies.  
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In the UK, the National Institute for Health and Care Excellence (NICE) is responsible for making 
decisions about which drugs the NHS will routinely fund (under the broad umbrella of the ??? in 
Europe, and the job of the FDA in the US). The cost-benefit calculations required to underpin 
these decisions on a regular basis by NICE are based on a unit of measurement referred to as a 
QALY – a ‘quality adjusted life year’, gauging a drug’s effectiveness in relation to the cost of a 
year of healthy life. The ‘quality adjusted’ element of the tool evaluates justification for funding 
through improving life even if not prolonging it. As noted, the cost of many of the newer cancer 
drugs places them outside the NHS reach. If we consider however that NICE sets a limit of less 
than £20,000 to £30,000 per Qaly (with almost a 100% hike for some end-of-life drugs), the 
price tag attached to novel agents such as ibrutinib place them way outside the budget (Cook, 
2014).   
 
In England (specifically), the Cancer Drugs Fund (CDF) was set up by former Health Minister 
Andrew Lansley in 2010 in political recognition of this fact to help fund equitable access to 
expensive cancer treatments across English NHS trusts. The CDF (estimated to have treated 
some 55,000 patients with drugs falling outside of NICE’s benchmarks of cost effectiveness) 
announced in November 2014 that, despite being given a 40% increase in funding for the next 
two years from £200m to £280m a year, financial restrictions would mean removing from its list 
any drugs that are overpriced or of questionable clinical benefit90 (Hawkes, 2014:349).   
 
90 The ultimate decision to remove a number of blood cancer drugs from the fund was met by disappointment and 
anger across the CLL networks. Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, 
said: “We are very concerned indeed that so many drugs for blood cancers like leukaemia, lymphoma and 
myeloma have been delisted from the Cancer Drugs Fund. The decision to remove effective drugs from so many 
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In September, 2014, a private posting on the Health Unlocked site about the CDF linked readers 
to a BBC report by BBC flagship news programme, Newsnight‘s Policy Editor, Chris Cook. 
Entitled ‘How Much is a Year of Life Worth?’, the report opens by directly addressing readers as 
taxpayers and asking them to consider in relation to the decisions made by NICE on their 
behalf, just how much how should “you, the taxpayer, be willing to pay to keep someone alive? 
(Cooke, 2014: no page). Given the statistical spread of cancer across the UK population (stats), 
many tax-paying readers of the article across the general population will either have direct or 
family-related experience of cancer, so the “someone” in the question may not turn out to be 
as impersonal or detached as it may initially sound. Cooke asks the question whether the CDF 
by its very existence ultimately encourage corporate pharma to retain high drug tariffs, an issue 
also addressed by John Appleby, Chief Policy Editor of the Kings Fund (2014), alongside his 
consideration of the mind-melting moral maze constructed by the cause and effect 
considerations required to fully understand the implications of using ‘qalys’ to measure cost-
effectiveness:  
 
The corollary of this is that the true (but hidden) cost of the CDF is not the £280 million 
financial value of the fund itself, but rather the value of the forgone benefits (lives 
saved, pain averted, QALYs gained etc.) if the money had been spent on other patients 
(Appleby, 2014).  
 
 
                                                                                                                                                                                                    
patients represents a dramatic step backwards. Many of these treatments can significantly prolong survival times 
and provide a good quality of life for diseases that can have devastating symptoms. In many cases, patient 
populations for the drug indication are very small, so the total cost burden to the NHS is actually relatively low. See 
staff post ‘RESPONSE TO THE REMOVAL OF BLOOD CANCER DRUGS FROM THE CANCER DRUG FUND’ on the 
Leukaemia and Lymphoma Research website, 12th January, 2015 for the full response from this influential 
organization. 
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Translated in this way, the calculation is nigh on impossible, but it is a sobering thought that the 
cost of the CDF extends way beyond the simple financial matter of 280million pounds. The 
impact of this on the lives of other patients is rarely, if ever, raised as an issue in the CLL 
networks when anxiously awaiting CDF decisions about funding CLL related drugs. Perhaps a 
degree of self-interest is inevitable among patients facing down any potentially fatal disease, 
but it is also the case that where broader contexts are not addressed due to a lack of 
understanding of process/economics, more fulsome discourse surrounding the wider socio-
cultural impacts of disease-specific issues is obstructed. Meshing disease community networks 
into the political and economic networks that influence choices has the potential to raise 
fundamentally political questions about how we manage the complex interrelationships, as the 
following translation exploring CLL Topics as a locus of advocacy for early access to ibrutinib in 
the case of patients with few options demonstrates. 
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Translation: Advocating for Compassionate Access Online (CLL Topics 
and Compassionate Access for Ibrutinib) 
 
 
Figure 36: TOUCHGRAPH (2015) network connections to Chaya Venkat’s  post on compassionate use access 
programmes for ibrutinib [Network Map]. [Online] Available at:  
http://www.touchgraph.com/seo/launch?q=cllsa%20uk%20health%20unlocked [Accessed 05/01/2015]. 
 
If we follow ibrutinib through the networks an interesting story of a drug’s entry into a disease 
community emerges to underpin further exploration of the role of patient and clinician 
advocacy in gaining access to new drugs moving slowly (and expensively) through the pipelines 
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of development and regulation. In February 2013 in the US, Pharmacyclics announced that 
ibrutinib had been granted breakthrough designation as monotherapy for the treatment of CLL 
(Asco Post, 2013).  
 
Just five months earlier on September 19th, 2012, Chaya Venkat writes about the exciting 
potential of ibrutinib even for those patients with the high-risk 17p deletions. The drug was at 
the point of its developmental phase where phase two trials were full, and phase three trials 
(randomized into two arms in many cases) were only just opening, with long lists of inclusion 
criteria limiting applicants, and Venkat forcefully articulates the human pain and frustration 
behind the struggle to access novel therapies in their early stages:  
 
I have had to face this heartbreaking question several times in the past few months:  
what do I tell patients with aggressive CLL with the 17p chromosomal deletion, who 
cannot get into one of the ibrutinib trials underway, and who cannot afford to wait for 
future trials and definitely cannot wait for the drug to become commercially available? 
This drug may give them a much needed lifeline, perhaps set them up with a good 
enough remission that allows them to get into a transplant program. Or it may give 
them a couple more years of high quality of life with their families. Who can put a dollar 
value on that? (Venkat, 2012) 
 
 
As previous translations have shown, Chaya Venkat’s (now dormant) site CLL Topics was very 
much driven by an ethos of advocacy. We learn from the page that Johnson and Johnson have 
already tapped into the potential data collecting potential of patient advocacy sites such as CLL 
Topics by contacting Venkat to discuss the possibility of a collaborative survey of CLL patients 
along the lines of a prior survey with the Mayo Clinic into the quality of life for 1482 CLL 
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patients conducted between June and October 200691. We also learn that Venkat took the 
opportunity to lobby the company for compassionate access to ibrutinib in her response, and 
the extract she provides on the site from her letter gives the reader a perspective into a 
potential model for productive relationships between pharma companies and patient 
communities:   
 
Well-publicized compassionate use access programs are a hugely important way of 
reaching out the patient community, a way of establishing good faith on behalf of the 
pharmaceutical company. J&J is a large company, with the human and financial 
resources needed to manage such a program, a corporate culture that does not look 
only at profits or stock price. If anyone can take the lead in establishing a badly needed 
new paradigm for working with the patient community, it is going to be companies such 
as J&J (ibid). 
 
 
Venkat’s report back on the response from J & J at the time took the form of resigned 
acceptance to their refusal to acknowledge her request: “The perfunctory brush-off I got is 
nothing personal, I am well aware of that. But it is one more sour note in the long story of 
pharmaceutical industry’s inability to establish good-faith and two way communications with 
the very patients that they will be marketing to down the road” (ibid). Twenty six responses 
totaling just over 3,100 words from the CLL patient/carer community agree with her, including 
those already fortunate enough to have accessed trials through the traditional route and 
expressing their frustration that others too could not benefit from a drug as life-changing and 
as effective for certain patient groups as ibrutinib.   
 
91 Results of this survey were written up in Shanafelt’s (2007) paper, ‘Quality of life in chronic lymphocytic 
leukemia: an international survey of 1482 patients’, published in Br J Haematol. October, 2007.  This paper has 
been referred to several times in this work.  
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Although doubtless too late for some patients, just two years on at the time of writing, we 
know now that the trials Venkat refers to were stopped early and FDA approval for relapsed 
and refractory CLL granted early. Ibrutinib was approved in US for previously treated CLL 
patients in February, 2014. It was approved in UK (and rest of EU) in October 2014 for MCL 
(mantle cell lymphoma), or patients with CLL who have received at least one prior therapy, or 
first-line in those with the chromosomal abnormalities deletion 17p or TP53 mutation. Its 
journey through the licensing process can be seen documented on the NHS pharmacy based UK 
Medicines Information site, publically accessible and demonstrative to those interested readers 
of the complexities, nuances and time frames involved in the passage of a drug through phase 2 
and three trials to market (UKmi: no date). 
 
In the meantime, and for patients unable to access trials, compassionate access programmes 
for ibrutinib were eventually instigated both in the US and UK.  A Janssen press release by Chloe 
Dix for Reynolds Mackenzie published on Pharmaweb on 19th December, 2014, documents the 
successful launch of ibrutinib in the UK and quotes Janssen M.D., Mark Hicken, stating his 
company’s apparent dedication to making the drug accessible to as wide as possible a range of 
patients through their appeal to the NCDF to support funding of the drug in England:  
 
Janssen is working to bring new therapies to patients living with complex and 
challenging-to-treat blood cancers. We are dedicated to ensuring that patients suffering 
from chronic lymphocytic leukaemia and mantle cell lymphoma have access to ibrutinib 
and we have therefore submitted an application to the National Cancer Drugs Fund to 
ensure eligible patients in England can access this advancement in the treatment of 
blood cancer (Hicken, cited in Dix, 2014). 
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As Dix points out in her closing paragraph, “About 600 UK patients with CLL have already 
received ibrutinib via a Named Patient Supply provided by Janssen at no cost to the NHS”. 
However, access to the compassionate use programme ended in September, 2014. This study 
has already drawn attention to the current pressures on the NCDF and its aims to streamline 
and cut costs accordingly, and to the staggeringly high price tag attached to ibrutinib at over 
£80,000 a year, so a positive response to the application was by no means a given92. Two other 
drugs targeting CLL are included in the list of revisions and additions, including novel agent 
idelalisib to be administered in conjunction with anti-CD20 antibody based agent Rituximab (in 
place of cytotoxic drugs for certain refractory patients), and changes in the protocols for 
bendamustine  for CLL patients (NHS England 2015).  
 
It is also significant that, whilst the CDF has approved funding for use in England, its appraisal 
with NICE for generic NHS approval is still in process at the time of writing. Online CLL support 
community responses to this news provide further evidence of narrative circulation and sharing 
in the context of CLL treatment as a regulatory issue intersecting with clinical perspectives on 
the future of new treatment protocols. This is beautifully demonstrated in a posting made by 
CLLSAUK member and active network contributor Hairbear who, as part of an ongoing thread 
on the progress of ibrutinib in the US and Europe offers updated information on the CDF 
decision and the position of the drug in relation to NICE approval, also linking members out to 2 
videos from a US panel discussion on the future of CLL treatments among CLL expert clinicians 
 
92  I am now in a position to update this speculation with a firm decision from the CDF on 12th January, 2015 to 
fund ibrutinib for those patients with refractory CLL, failing to respond to CIT, experiencing a progression-free 
period of less than three years, or considered too old or unfit to withstand CIT. 
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(Onc Live Peer Exchange93).  
 
Hairbear offers members the opportunity to engage with the interesting peer debates 
contained in the videos concerning when and whether to stop ibrutinib treatment, and 
discussing the continuing benefits of ‘one-off’ six-monthly FCR treatments (as opposed to 
ongoing treatment with novel agents such as ibrutinib) for certain patient groups (younger, 
fitter, 13q deleted), the pros and cons of discontinuing CIT early in the presence of positive 
responses, and research comparing less toxic alternatives to FCR such as BR (bendamustine and 
rituximab). All of this he states that he finds reassuring, “knowing that front line use of novel 
therapies or novel therapy combos will not come available to treat the fitter younger group 
outside of trial for quite some time and FCR and BR are the NHS available options for UK 
patients in this group” (Hairbear, 2015: CLLSA UK). The regulatory decisions of the CDF, and 
anticipation of those of NICE in a UK setting are intersected here with the broader global 
debates taking place about treatment protocols, new, old and hybrid. 
 
As Hairbear himself reports, others living with CLL in the networks may well find exposure to 
the way in which these multiple practices of their disease intersect to some extent reassuring. 
“I can’t access ibrutinib and I want it” may, in some circumstances at least (i.e. for the non-
refractory, and generally otherwise healthy) becomes less of a definitive rallying cry of loss or 
exclusion for patients exposed to an understanding of the regulation and economics of drug 
 
93 CLL specialist Drs. Kipps, Bird and Furman discuss the changing landscape in a YouTube video posted on the 
OncLive TV channel. ‘Selecting First-Line Treatment for Chronic Lymphocytic Leukemia (CLL)’.Online (OncLive, 
2015).  
Julia Kennedy 
338 
 
development and licensing, the trials process, and the limits of knowledge in relation to 
immature data surroundings novel agents. For others however, inability to access novel agents 
may well be a case of life or death as the following perspective attempts to show. However, 
those patients for whom access to any of the twenty five other drugs dropped by the CDF in the 
same evaluation round announced in January, might have made a tangible difference to their 
futures need to be kept in mind. It remains impossible to speculate whether exposure to similar 
versions of their own disease contexts would prove equally reassuring or otherwise. Gains for 
some patients inevitably translate to losses for others in a cash-limited treatment fund and 
disease specific research of this nature might have a useful role in exploring the implications of 
that through tracing circulating narratives in other disease networks.    
 
Perspectives: Counting the Cost of Unequal Access to Novel Agents in 
Human Terms 
 
 
Keeping cancer patients alive is, as we are becoming aware, an increasingly costly business, 
particularly as novel agents make their way out of the clinical trial’s process and onto the tariffs 
of the insurance companies and healthcare budgets required to fund them. Decisions about 
meeting costs where resources are finite ultimately come down to issues of perceived value, 
which will vary according to the perspective of the inquirer. In relation to cancer drugs, Tigue et 
al. (2007) sort patients, physicians, policy makers, insurance providers, and pharmaceutical 
manufacturers into the wider perspectival categories of ‘societal’, ‘patient’ and ‘payer’, pointing 
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out that, despite their undeniably positive outcomes for patients, the current high tariff of 
novel agents is proving unsustainable against a backdrop of soaring healthcare costs94. Such 
drugs produce costly side effects, themselves responsible for significant healthcare 
expenditure95,   and are often administered along with already expensive therapeutic agents 
such as rituximab for example. Outside of these concerns, the global playing field for decisions 
concerning access is not a level one though, and that means some patients may be suffering or 
dying from restricted access while others aren’t. 
 
In their (2006) pan-European comparison regarding patient access to cancer drugs, Nils Wilking 
and Bengt Jönsson  refer to this as “the reality that cancer patients in Europe do not have equal 
or rapid access to cancer drug therapies” (2006). This chapter has already focused sharply on 
the vagaries and frustrations of access to novel therapies, outlining the potential physiological 
and psychological impacts for those caught in the regulatory and market-driven interstices of 
traditional/new treatment approaches. As Chaya Venkat’s CLL Topics translation shows, this is 
not just a case of frustration and envy for those unable to access new drugs. In his foreword to 
Wilking and Jonsson’s report, President-Elect of the Federation of European Cancer Societies, 
John F. Smyth makes this simple but powerful assertion: 
 
The essential facts are: cancer is a significant cause of morbidity and mortality in 
Europe, and scientific advances have given us the potential for more treatment 
approaches than are currently provided. New medicines have no benefits unless they 
 
94 That saw the total cost of cancer care in the US alone in 2005 set at $209.9 billion and rising.  (Tigue et al., 2007)    
95 – measured in terms of time lost during the first year of cancer treatment – produce indirect costs of around 
$2.3 billion dollars in the US alone  (ibid) 
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are used by the patients who need them, and the need to balance benefits, costs and 
available resources should not prevent patients from gaining access to novel drug 
therapies (Smyth, 2006, cited in Wilking and Jonsson: foreword). 
 
 
 
In his analysis of access to cancer drugs in the USA, Dr. Frank Lichtenberg of Columbia 
University equated access to more cancer drugs with improved survival rates for patients, citing 
a 50-60% increase in survival rates in the first 6 years post diagnosis in relation to an increased 
stock of available cancer drugs (ibid:3). Furthermore, Lichtenberg correlates an increase in the 
number of available drugs across Europe and the US with an increase in survival rates at both 
one and five years, concluding that “it is clearly in the best interest of cancer patients that new, 
innovative drug therapies are made available to them as soon as possible. Reduced or delayed 
access to cancer drugs has a very real impact on patient survival” (cited in ibid: 3). But delayed 
access is a very real issue, happening to very real patients, as this work has shown in the case of 
CLL.   
 
Wilking and Jonsson identify a number of key themes reflecting those already addressed in this 
chapter, such as “research funding, the drug approval process, the role of health economics 
[including health technology assessments and economic evaluations96] and budgetary issues 
limiting the uptake to new drugs” (ibid: 3). Economic evaluations tend to follow a monetary 
cost/benefit analysis model of evaluating the  ‘cost-effectiveness’ of new drugs that Wilking and 
Jonsson argue should account for the total economic impact of a new drug therapy (long term 
 
96 Health technology assessments and economic evaluations can represent a significant hurdle to patients 
accessing new drugs, having earned the title of the ‘fourth hurdle’ in this context.   
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likelihood of relapse, patient ability to work through treatment and return to productive life 
beyond treatment, and so on), instead of a singular focus on the cost of the drug to a specific 
healthcare budget at a specific chronological point (ibid: 5). 
 
The report notes an interesting anomaly in relation to the UK that, despite ranking highest in 
Europe in terms of direct cancer research funding (with charities contributing more than the 
government), currently lags behind other EU countries in terms of patient ability to access new 
cancer drugs. The authors go on to point out that the UK is more susceptible to the role of 
economic evaluation than anywhere else in Europe, guidance issued in England by the National 
Institute for Health and Clinical Excellence (NICE), in Wales by the All Wales Medicines Strategy 
Group (AWMSG), and in Scotland by the Scottish Medicines Consortium (SMC).   
 
A favorable evaluation for a new treatment from NICE should in principle accelerate and 
broaden access to the drug, but growing workloads impact on the institute’s capacity to handle 
evaluations in a reasonable timescale. According to 2015 guidelines, the minimum timeline for 
seeing a drug through the appraisal process with NICE is around ninety weeks (see Appendix 13: 
for diagrammatic timeline). During any delay period, allocation of budgetary resources to new 
drugs is frozen consequently further delaying innovative treatments from entering the 
healthcare system and the lives of cancer patients in England which could potentially be saved, 
extended, or improved by them.  Patient access to novel therapies is highly contingent on 
financial resources and the politics of funding allocation within the healthcare systems at any 
given time. Wilking and Jonsson make it clear just how contingent access to innovative cancer 
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therapies can be on broader political gestures concerning healthcare expenditure policy: 
Although cancer drugs account for less than 10% of the total healthcare expenditures for 
cancer and represent 3.5-7% of the total drug costs, they are an easily identified target. In 
efforts to manage healthcare or budgetary costs, healthcare policy and decision makers may 
therefore seek to delay or restrict access to these new innovative drugs. Such actions have very 
real impact on survival rates (Wilking and Jonsson, 2006: 5). 
 
Of course, the time consuming process of a convoluted evaluation doesn’t automatically equate 
to a drug being accepted, as demonstrated in October 2014 when Roche’s monoclonal antibody  
treatment for CLL, obinutuzumab, (marketed by Roche as gazyvaro) was rejected for frontline 
CLL treatment by NICE on the following grounds as reported by Ben Hirschler for Reuters: 
“Although obinutuzumab is a clinically effective treatment, there were too many uncertainties 
in the company’s submission and we cannot be confident that it is an effective use of NHS 
resources," said NICE's chief executive, Andrew Dillon” (Hirschler, 2014).  
 
This news quickly found its way into the support networks, heralded by a private member 
posting on CLLSA Health Unlocked and linking members out to the Reuters article from which 
the above quote is extracted, and to the official announcement on the NICE site. The member 
responsible for posting the original comment and the main contributor to the ensuing debate 
are both highly active actors in the CLLSA network, often responsible for introducing news to 
the site about trials and the drugs development process for relevant CLL drugs. They 
demonstrate the important role played by the highly informed members of support networks in 
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increasing the hypertextual network vibrancy of these narrative nodes, and contributing to the 
knowledge and understanding of the broad range of processes and actors underlying issues 
such as access to novel agents for cancer patients, the quality and duration of whose lives may 
depend on them.  
 
Update posts on gazyvaro indicate that it was approved in December 2014 for frontline use 
combined with chlorambucil in fludaribine unsuitable patients by the SMC (Scottish Medicines 
Consortium), and in Switzerland for the same indications in June, 2014. The difference in tone 
and attitude to the drug’s effectiveness between the NICE recommendations for use in England 
(see previous quote), and the Roche press release following approval success in Switzerland are 
worth considering: 
 
Marketing authorization for Gazyvaro was granted on the basis of the results from the 
Phase 3 study CLL11, which showed that patients treated with Gazyvaro and 
chlorambucil-based chemotherapy had a 61% lower risk of disease progression or death 
compared with the current standard therapy comprising MabThera  [rituximab]and 
chlorambucil (Roche Switzerland, 2014).  
 
 
 
Alongside the information included in the press release that due to favourable comparisons 
with existing therapies of its clinical benefits for certain patient groups “Gazyvaro has become 
the first medicine in the world to be designated as a Breakthrough Therapy by the US health 
authority FDA” (ibid), patients in the network may remain confused by the nature of the 
‘uncertainties in the companies submission’ (Dillon, cited in Hirschler, 2014) articulated by NICE 
CEO Andrew Dillon in the institute’s December, 2014 rejection statement for the drug.  
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Perspective: Narrative Networks and trials Participation (Patient 
Attitudes to Trials) 
 
 
Founder of online support site ‘Lymphomation’, Karl Schwartz made a plea on the site in 2013 
for funding to increase lymphoma patients’ involvement in clinical trials after noting a drop in 
trial interest and uptake in patients polled from 27% in 2009 to 12% in 2013 (Schwartz, 2009). 
Seeking further information to identify obstacles for the 2013 respondents, Schwartz notes that 
the (126) 2009 survey patients who declined trial participation after consideration identified 
the following factors as contingent on their decisions: “Randomization (70), Insurance (49), 
Study Risks / Toxicities (42), Travel and Lodging (30), Eligibility (28), Tests and Procedures (12), 
and a perception that Regular Treatment is superior (6)” (Schwartz, 2009). Randomisation is by 
far the biggest obstacle identified in this group, with patients seemingly unhappy to cede 
control to chance when the stakes are so high.  
 
Also significant in trial involvement is the inclusion of trials for consideration in pre-treatment 
discussions with a Consultant.  In the 2009 study, of the 112 (45%) patients whose consultants 
had discussed trials with them, 95 (85%) answered that they would consider a trial, and 59 
(53%) participated in trials (Schwartz, 2009: abstract, no page). In 2013, only 15 (12%) of 
patients said their consultant has discussed trials with them, perhaps contributing to the very 
low recorded involvement figure of 12% trial involvement.  This omission of trials from pre-
treatment conversations is not confined to haematological cancers alone, with less than 5% of 
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adults with any form of cancer participating in trials.  According to Cameron Scott of Health 
Information aggregation site ‘Healthline’, this is not a simple case of too many patients for too 
few trials. Between 2000 and 2007, over two in ten National Cancer Institute (USA) sponsored 
trials significantly under-recruited,  one in ten trials closes due to lack of participation, and 
nearly 40 percent of all cancer trials failing to complete do so because of low patient 
participation (Scott, 2014: Part 1). 
 
Although CLL patients in the support networks express a degree of trepidation about some 
elements of trial participation, there is a general sense of a desire to seize perhaps the only 
current opportunity to access the novel agents being evaluated. Brian Koffman draws attention 
to the fact that the accrual rate for trials of novel CLL agents is generally high, with some of 
these trials filling at record rates (Koffman, 2013), but there is a clear advantage for those 
patients treated by research-active clinicians, and/or already hooked into information 
circulating in online networks. The worry is what happens to those patients solely reliant on 
their Doctors for information and encouragement to exploit the treatment potential offered by 
trials. 
 
So why are doctors not doing more to encourage their patients into the trials process? As noted 
previously, everyday time and financial constraints can place very real obstacles in the way of 
patient education in clinical contexts. Patients who are unaware of trials as potential treatment 
options face less choice and opportunity than those who have either researched trials for 
themselves or had them suggested by their doctors.  As this work has already demonstrated, it 
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is too reductive to read this solely as the responsibility of negligent or uncaring clinicians 
overlooking their patient’s needs. Deputy chief medical officer at the American Cancer Society, 
Dr. Leonard Lichtenfeld believes that, in the face of the devastating nature of cancer “Doctors 
are doing the best they can and for whatever reason they don’t know about trials,” (Scott, 
2014: Part2). A trial system that places the emphasis on already over-stretched clinicians to 
keep up to date with ongoing trials, screening, and consent processes can have a significant 
impact on the planned timeline of patient flow through clinics. As clinical oncologist and 
researcher, Dr. Ajai Chari puts it, “Unless you have a vested interest as a clinician, you’re not 
going to find the time” (cited in Scott, 2014: Part 2). What might constitute those ‘vested 
interests’ is an important issue in understanding clinicians’ motivation to encourage patient 
involvement in the clinical trial process. 
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Translations: CLL Specialists Encourage Trials Participation (Patient 
Advocacy Video from European Haematological Association Conference 
Milan, 2014)  
 
Figure 37: TOUCHGRAPH (2014) network connections to ‘Positive News & Developments When Treating Chronic 
Lymphocytic Leukaemia’ video from European Haematological Association Conference  in Milan, 2014 [Network 
Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DSxYBcO9Y
8VQ [Accessed 10/01/2015]. 
 
In a video made at the European Haematological Association (EHA) meeting in Milan, 2014, and 
posted to CLLSA UK’s YouTube channel, viewers see three leading UK specialists, Professors 
Julia Kennedy 
348 
 
Pete Hillmen, Simon Rule, and John Gribben actively encouraging patients to canvass their own 
doctors about available trials. Professor Hillmen, working out of Leeds, plays a leading role in 
heading up UK CLL trials, and describes a number of trials for novel agents in detail in the video. 
Professor Rule from Plymouth,  specializing in mantle cell lymphoma, and instrumental in early 
UK work with ibrutinib,  talks of the contemporary treatment landscape as a ‘fascinating’ time 
for CLL patients who are faced with a number of ‘game-changing’ compounds as alternatives to 
traditional CIT rolling out in pivotal trials in the UK. Figure 37 is a screenshot from the video 
showing Professor Rule appealing directly to patients to “ask the question – where is this 
available, and can I be considered?” 
 
 
Figure 3812: CLLSA UK (2014) ‘Positive News & Developments When Treating Chronic Lymphocytic Leukaemia’ 
video filmed at the EHA meeting in Milan, 2014 [Screenshot]. [Online] Available at:  
https://www.youtube.com/watch?v=SxYBcO9Y8VQ [Accessed 07/09/2014]. 
Image removed due to copyright restrictions 
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Professor John Gribben, working out of Barts Hospital in London, and previously explored as a 
network actor in the diagnosis chapter of this work, advances the rhetoric of patient advocacy 
in the video. Gribben points out the importance of patient participation and involvement in 
decision making about treatment, stating that this involvement is “important in terms of 
lobbying for access to some of the impressive agents being developed”, and acknowledging the 
importance of CLL patients being “more empowered” in the face of potential economic 
challenges to accessing new drugs”. The excitement is tangible among these three leading 
haematologists, but perhaps more encouraging is the active canvassing of patient participation 
in trials and political involvement in issues of access. The ‘vested interest’ so integral to 
clinicians’ motivation to make time to speak to patients about trials is clearly evident in these 
three highly research-active clinicians, but for patients treated by non-specialists in smaller 
regional centres, outside of the major research nodes, this degree of clinical motivation, or 
indeed awareness of the up to date trials landscape, may not be integral to discussions 
concerning potential treatments.  In those cases, the sharing of videos like this in the networks 
could be a significant factor in raising patient awareness of the potential to apply for relevant 
trials, and even to lobby for access to drugs.   
 
In bringing such discussions to the clinical table, patients might in turn expose busy, general 
haematologists to cutting edge specialist CLL research and trials information. This video was 
screened to around 120 CLL patients and carers at a face to face CLLSA patient meeting in 
Cambridge as well as being posted on CLLSA’s YouTube channel, and linked out into the global 
community via the health unlocked site. At the same meeting, a panel of CLL patient advocates 
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chaired by Andrew Schorr, included a member of CLLSA active in lobbying for access to CLL 
drugs, and seeking support and involvement from the CLL community present. Many of the CLL 
patients and carers in the audience were not already aware of the channels through which 
patient advocates might campaign for access to novel agents prior to the meeting.  
 
As demonstrated by Schwartz (2013) in his work on attitudes to trials among lymphoma 
patients, the issue of randomization is a major block to patients. With many of the recent trials 
for CLL novel agents, there is no other way to access the desired drug outside of trials, and the 
non-preferred treatment of the control arm tends to be the traditional gold standard for the 
particular disease profile being tested anyway. However, it is sometimes the case that patients 
don’t have a thorough understanding of the randomization process, therefore not making fully 
informed decisions, but rather ones based on emotional responses or gut-feelings.  
 
As Scott (2014) points out, researchers and patient advocacy groups observe that often patients 
are worried about participating in randomized trials in which they fear they might be given a 
placebo.  Once again, poor medical literacy emerges as a powerful obstacle to patient 
empowerment, and is clearly demonstrated in the following comment from an IOB survey 
respondent who, despite making active steps towards engagement through the networks, 
remains unable to understand much of what they read:  
 
Healthunlocked and CLLtopics are my main sources of information. I follow all links to 
learn more. Frankly so much of what I read is so afar above my ability to understand and 
remember I feel all I accomplish is to be aware. I am acrid [sic] of clinical trials because 
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of the risk of getting a placebo and not the actual trial medicine (IOB Survey Respondent 
151). 
 
 
 
Reticent about trial involvement based on the risk of being given a ‘placebo’ instead of ‘the 
actual trial medicine’, this respondent shows a poor understanding of phase 3 trials procedures 
for cancer drugs which would not be set up on a placebo v trial drug basis, rather an existing 
and provenly effective cancer drug v trial drug.  The need for further research into ways of 
improving medical literacy in online disease networks already addressed in this work is 
fundamentally important in relation to trials knowledge and awareness as new drugs with the 
potential to change outcomes for the better emerge through the trials system. 
 
Also of interest are Brian Koffman’s views on cultural attitudes to randomization. In a 2014 blog 
entry exploring a paper given by CLL specialist Professor Hallek at the iwCLL 2013 (international 
workshop on CLL) in Cologne, Koffman draws attention to Prof. Hallek’s failure to address  
European patients’ greater willingness to participate in randomized trials demonstrated in the 
generally lower accrual in US trials having two or more randomized arms. This Koffman 
attributes to the fact that “Canadians and Americans prefer more control in deciding their 
therapy” (Koffman, 2014: no page).    
 
Even where patients have a good grasp of the trials process, and are well-informed either by 
their clinicians, network activities, or both, it would be wrong to assume that trial participation 
is a straightforward decision to make. As the Lymphoma Research Foundation’s chief program, 
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policy, and communications officer, Meghan Gutierrez points out in relation to trial 
participation, and the hotline the foundation has set up to educate patients about trials, “It’s 
one thing to think of it in the abstract and quite another when you have received a potentially 
life-threatening diagnosis and are thinking about the ways in which you’re going to treat your 
disease” (Gutierrez, cited in Scott, 2014: Part 3). Arguably then, it is times when patients are 
most likely to be dealing with potentially overwhelming emotional responses to their diagnosis, 
or disease progression that well-informed, rational debate surrounding their treatment choices, 
including the possibility of joining a trial, is most important.  
 
As I have attempted to show, outside of the vagaries of the pharma/biotech industries and the 
inconsistencies of the regulatory bureaucracy of drugs development across the globe, a 
significant element of successful access to new drugs depends on patient knowledge. Knowing 
what trials are available and where, understanding inclusion criteria and being able to relate 
that to their individual disease profile,  and having some awareness of the trials process 
alongside other possible access routes are all fundamentally important in increasing an 
individual’s chances of accessing novel therapies.  
 
Encouraging patients to ask about trials is an excellent way of sparking patient involvement in 
managing their own care. Appendix 14 analyses a posting by key CLL network actor Hairbear, 
employing the ‘It’s OK to ask’ campaign97 to encourage CLL patients specifically to get involved 
 
97  In May, 2014, the National Institute for Health Research (NIHR) marked International Clinical Trials Day with the 
launch of its UK ‘OK to ask’ campaign promoted across national mainstream and social media, and encouraging 
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in trials. It demonstrates how the kind of advocacy for patients to seek out trials encouraged by 
doctors such as Simon Rule, Pete Hillmen, and John Gribben in the EHA video explored in the 
previous translation is reflected in national campaigns, and picked up by key patient/actors in 
disease-specific support communities online. More work is needed however to assess the 
degree of confidence and medical literacy surrounding their disease required by patients in 
order to feel comfortable enough both to ask about trials, and also to gauge the response of 
those clinicians not already engaged in this dialogue with their patients. 
Perspectives: The Networked Trial Community 
 
Patients are doing it for themselves? Advocacy Groups and the Pharmaceutical 
Industry 
 
 
This exploration of trials in the CLL networks concludes by looking in context at the ways 
patients use network activity in relation to trials. This includes patients working alongside 
pharmaceutical companies to advocate for access to drugs, and patients using online networks 
to collaborate and communicate with each other during trials with a number of implications 
that I will explore in this section. 
 
The chapter has already introduced readers to engaged clinicians actively canvassing patients to 
enter trials, and even to lobby government and industry for access to the novel agents that 
                                                                                                                                                                                                    
patients to ask their doctors about the availability of current  treatment trials for their particular disease. This 
underscores a sense of access to trials as a right for patients, and one that they should activity seek. 
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might change their lives. The role of support communities in circulating information about trials 
and access to drugs has also been highlighted. It remains true however that, despite the 
emergence of informed patients actively engaged with the drug development and licensing 
process, control over what drugs are made available and when still lies largely with the 
pharmaceutical industry and the relevant regulatory and policy institutions. Where 
compassionate or early access is not already a possibility, it may be incumbent on patients (and 
their physicians) to lobby directly for access. This short sub-section explores how patient 
advocacy groups are working together with big pharma to improve access and information, 
often aided by online networking among patient groups.  Importantly, I seek to explore the 
nature and power dynamics of that relationship as the networked patient (and their data) 
becomes more and more potentially valuable to the pharmaceutical industry. 
 
This work has set out to argue that as informed networked patients become increasingly 
exposed to the narratives and cultures of a range of practices and institutions concerned with 
their particular disease they are better prepared to collaborate effectively with them. For 
example, independent patients, organized patient advocacy groups, and the pharmaceutical 
industry itself now collaborate across a number of phases of the drug development process, 
from research funding, to trial design and recruitment, and active lobbying for approval and 
access. The previous perspective demonstrates how a CLL patient group utilizes face-to-face 
meetings alongside online networks to raise patient awareness of direct lobbying of 
government in terms of regulation, and the pharmaceutical industry in relation to drug tariffs.  
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Pharmaceutical companies themselves of course are well aware of the benefits of relating to 
patient advocate groups, many employing their own patient advocate representative. Thomas 
Sellers, cancer survivor and Senior Director for Patient Advocacy and Corporate Philanthropy at 
Millennium: The Takeda Oncology Company, told the ASCO Post98  in 2014 that US patient 
groups are gaining influence across “the entire drug development continuum” (Sellers, cited in 
Cavallo, 2014: no page). In an interview for the publication, Sellers cites the U.S. government’s 
‘21st Century Cures’ initiative, which seeks to address the widening gap between the 
accelerating ‘science of cures’ and the often slow processes of drug regulation. As this work has 
demonstrated, gaining an understanding of the complexities of drug innovation, production, 
and regulation is a time-consuming research task for independent patient advocates, but one 
that it might be assumed to be best conducted independently to ensure an unbiased 
appreciation of the various stakeholders. Sellers’ view of far reaching patient influence is 
encouraging, but what happens to patient advocacy once it is legitimized and paid for by 
pharmaceutical companies?  Are empowered patients further empowered by working with 
drugs companies for better access and attention to side-effects?    
 
Pharmaceutical giants Eli Lilly & Co. have recently launched eMEET 99, an online Medicine 
Evaluation Educational Training resource “to help patient advocates navigate the world of 
medicines development evaluation and assessment” (Taylor, 2014: no page). A multi-media 
 
98 Newspaper style publication (print and digital) of the American Society of Clinical Oncology. 
99 See O’Connor, Amy (2014) ‘eMEET: Bringing the Patient Voice to HTA’, for further information. 
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approach underpins modules on the following: 
 
introduction and scene-setting - the true value of the patient voice; the journey of a 
medicine through the complex process of discovery, development and evaluation; an 
introduction to HTA [health technology approval]; HTA in practice, with an illustration of 
the complexities of assessment; and patient advocacy group participation in HTA - how 
to engage effectively to ensure that HTA panels understand patients’ needs and 
preferences (Taylor, 2014: no page). 
 
 
 
Developing digital resources of this nature allows the industry to adopt a significant role within 
patient networks. eMEET takes up a place in online support networks as a circulating industry-
based narrative actively instructing patients about the processes of drug development and 
health technology assessment. Effective pressure on the latter might of course ease the flow of 
valuable drugs to market, potentially saving lives and sustaining an earlier return on industry 
investment. 
 
The mutual benefit seems clear, but collaboration between relatively poor patient 
organisations and the wealthy pharmaceutical companies on who they depend for innovative 
(or indeed any) treatment for their disease is a contested area. Apart from their tendency to get 
sick and require drugs, patients, particularly when networked into groups, offer other forms of 
capital to the pharmaceutical industry. They can be used as active lobbiers of 
government/regulatory agencies for access to drugs, a rich source of feedback on the side 
effects of products, a ready source for disease-specific market research, and an effective PR 
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tool for demonstrating commitment to patient needs.  
 
What may be viewed on the surface as a straightforward symbiotic relationship is of course 
massively skewed in terms of the economic power balance. In concluding that funding from and 
collaborative projects with pharmaceutical companies can aid the growth and influence of 
patient organisations, Herxheimer (2013) also acknowledges that such interventions have the 
potential to distort or even misrepresent the agendas of patient groups.  Transparency then is 
vital, with relationships “fully acknowledged and open, without public relations flummery” 
(Herxheimer, 2003: 1210). There is a tangible sense across network debates that, despite the 
obvious power imbalance, there are advantages for both parties in the relationship. As such, it 
might be assumed that a stubborn adherence to the antagonistic binary between powerful neo-
liberal corporate interests and potentially exploitable patients100 belies the complex networks 
of associations both within and between the two groups, as well as what stands to be gained 
and lost in collaboration.  
 
Herxheimer suggests replacing models in which VHOs (voluntary health organisations) are 
passive recipients of industry funding with those in which they retain independence while 
working collaboratively on practical or policy initiatives pertinent to those they advocate on 
behalf of. Herxheimer’s observation that effective collaborations are characterized by mutual 
gain and require that “each should make efforts to understand the internal culture of and 
 
100 For an interesting protest blog critique of the actions of the executive leaders of Pharmacyclics, see ‘Scientology 
Donor Bob Duggan's Company Makes $975 Million Deal With Johnson & Johnson/Janssen’ thread in ‘Media’ 
discussion on Whyweprotest.net. [Online]  2012.  
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external pressures on the other” (Herxheimer, 2003: 1210) are particularly pertinent to my own 
argument that circulating narratives of multiple enactments of CLL can make visible these 
internal cultures and external pressures for ‘other’ versions of the disease.   
 
Despite the undeniable benefits of stripping back the connections that hold big pharma, 
regulatory processes, clinicians and their patients together through narrative and material 
intersections, there remains a residual tension in relationships between corporate pharma and 
independent patient advocates, voluntary groups, and charitable organisations.  As with many 
power-imbalanced relationships, ‘transparency’ is the go-to byword for ensuring that abuses of 
power and influence don’t occur, but Batt  (2014) challenges any notion that transparency 
alone can protect patients’ interests in the case of the pharmaceutical industry: “Research into 
the financial ties between drug companies and physicians, medical researchers and other actors 
in the system shows that transparency is not sufficient to ensure that patients’ interests will 
take precedence over those of the pharmaceutical industry” (Batt, 2014a).  
 
Furthermore, Batt resists the common claim of pharmaceutical sponsored advocates (see Arie 
and Mahony, 2014; Batt 2014b)  that patients unequivocally benefit from rapid, universal 
access to all licensed drugs: 
 
Yet many new drugs are no better than those on the market and they may be less safe. 
They will inevitably be more expensive, which -- if the drugs are placed on formularies -- 
not only skews the spending priorities of universal health care systems to the detriment 
of patients but is rapidly making these systems unsustainable (Batt, ibid). 
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Uncritical acceptance of a mutually beneficial interest in the expedited approval and licensing 
of all new drugs might elide important implications for safety and funding. Previous sections in 
this chapter have demonstrated the growing strain on healthcare budgets represented by high 
tariff novel agents, and shown how in England, decisions made to approve new drugs by the 
CDF are always accompanied by decisions to stop funding others (whilst retaining the potential 
to keep drug prices high through a two tier system of approval). Fieldwork in my own study has 
observed rich network debate about how global health care providers will fund already 
expensive novel CLL agents, likely to become increasingly expensive as personalized oncology 
evolves. There is precious little network critique however of an ideology of universal rapid 
licensing and uptake that may ultimately serve to exacerbate broader fundamental issues of 
funding and access. As Batt (2014a) points out, pharma-funded patient advocates are generally 
adamant that their industry sponsors don’t tell them what to say, as evidenced in her own 
research with industry-sponsored breast cancer patients.  More chilling though is her assertion 
that “pharma funding buys silence on issues that groups speaking for patients ought [my 
emphasis] to bring to the table” (ibid), and  the lack of open debate about the potential impacts 
of pharmaceutical industry  sponsorship among the CLL patient communities I researched may 
represent an example of that silence.  
 
‘Bigger-picture’ critiques aside, it is hard to argue that in the case of ‘game-changing’ (Rule, 
2014) drugs such as ibrutinib, offering evidence-based hope to CLL patients, the potentially 
deleterious impact of avoidable bureaucratic delays in getting novel agents to market (Jonsson 
and Wilking, 2006) requires urgent attention. If patient groups are too poor and small in stature 
Julia Kennedy 
360 
 
to do this independently, then it might be argued they have little choice but to team up with 
pharma in order to be heard. Batt’s own longitudinal research into the Canadian breast cancer 
movement from the early 1990s (when groups had no industry funding) to 2008 (when most 
breast cancer groups in the country accepted some industry funding) reveals some of the 
political contexts that have influenced the changing relationships between patient advocate 
groups and the industry. Over the two decades tracked by Batt, what she describes as 
increasingly ‘neoliberal government policies’ gradually depleted funding available to health 
sector groups engaged in advocacy, actively encouraging industry partnerships that the latter 
were all too happy to engage in. The outcome was “to split, and gradually change, the 
[advocacy] movement. Leaders critical of the pharmaceutical industry left in frustration while 
groups that refused industry money were marginalized, or died for want of funds.” (Batt, 
2014b: 132)  
 
The question of how advocacy groups can secure adequate funding without undermining 
independent representation of the patient voice remains a vexed one. The networks provide 
the potential of patient empowerment in terms of knowledge and the ability to mobilise action, 
but the problem of independently funding activism remains. It seems that dissensus is 
successfully chipping away at traditional models of knowledge ownership in the clinical 
relationship. As narratives underpinning ‘expert’ knowledge intersect more freely with patient’s 
own narratives in network spaces, many patients are becoming more empowered in managing 
their disease. Notions of ownership of expert knowledge are now highly contested, and clinical 
relationships are evolving to accommodate that. Patients too are learning about the political 
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economy of the pharmaceutical industry, the complexities of drug development, and the 
process of global regulatory mechanisms for new drugs. But the ownership of the resources to 
produce new drugs remains under the control of a small but powerful network of amount of 
global pharmaceutical and biotech companies.   
 
However much patients know about the biomedical science and political economies of drug 
development, they remain dependent on corporate funding and profits to get the drugs they 
need. Unlike knowledge about one’s body and disease, the means to develop and access drugs 
isn’t accessible to all who seek it. Dissensus is perhaps less productive for patients desperate to 
access what the pharma companies have, and they need – in many cases urgently, although the 
underground US AIDS movement of the eighties provides an interesting case study of resistance 
to  the powerful combinations of private-sector and state influence in the pharmaceutical 
industry. I want to focus briefly on that here as an example of the potential of patient networks 
to mobilize effective resistance even in a pre-digital era. 
  
Dallas Buyers: A Model for Dissensus 
 
This section opens with reference to a film, and a book. In 2013, Jean-Marc Vallée’s film ‘Dallas 
Buyers Club’ was released to box-office success. Set in the mid-1980s AIDS ‘epidemic’, the film 
dramatizes the real-life story of Texan electrician Ron Woodroof (played by Matthew 
McConaughey). Woodroof was diagnosed with AIDS, and told that he couldn’t access the drugs 
needed to keep him alive until they had undergone full FDA approval and trials. Under the 
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shadow of a thirty day prognosis, he launched a mission with a fellow AIDS patient to access 
and smuggle unapproved drugs into the U.S. for sale to other men destined to die before the 
drugs they need legitimately filter through into the medical establishment. Woodroof’s venture 
represented a small node in a much bigger underground network of ‘underground pharmacies’ 
across the USA (New York and San Francisco particularly) sourcing unlicensed drugs in Mexico, 
Japan and elsewhere to smuggle back into the USA.  In his (1992) book, Acceptable Risks, 
Jonathan Kwitny outlines the story of underground AIDS activists Martin Delaney and Jim Corti, 
and their attempts to research and access their own drugs, resist the hegemony of ‘preferred’ 
drugs such as AZT, set up their own ‘trials’, working with co-operative doctors, and generally 
subvert and circumvent mainstream regulatory processes in the face of an aggressive, lethal 
disease unbound by the rhythms of mainstream corporate drug development.  
 
Both the book and the film show how ordinary men forced powerful politicians, pharmaceutical 
firms and doctors to critically examine the processes by and speed at  which the US licenses 
medicines  for dying people. Importantly, as popular cultural narratives they allow for 
consideration of the possibility of dissensus in relation to the hegemony of corporate pharma 
and its relationship with clinical and regulatory practices. This is particularly pertinent in 
relation to multi-faceted networked disease communities such as the online CLL community 
explored in this work. While I have seen little outright dissent in the CLL specific networks 
themselves, which are more strategically concerned with tracking and staying on top of the 
narratives of new drug developments and access that may save or prolong the lives of CLL 
patients, it is useful to remember that patients are hooked into much broader networks of 
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narrative exchange in their daily lives. In the cinema, or bookshop, they may be exposed to a 
range of equally influential narrative possibilities as they too intersect with the more localised 
networks they are embedded in.  
 
As I have argued, the potential impact of networked sharing among patient communities 
extends across multiple facets of disease experience, and one of those is the clinical trial itself. 
Patients in the underground AIDS activist movement adopted a range of strategic practices of 
resistance such as navigating blinded clinical trials, and the sharing out of drugs on randomized 
trials with those on the placebo arm. Head of Clinical Innovation for Worldwide Research & 
Development at Pfizer in New York at the time of writing, Craig Lipset (2014) uses these as 
examples of how the scientific validity of the trials process can be undermined by networked 
patients even without access to contemporary technological communications. Once trials 
patients are socially connected on global social media, rather than confined to localized waiting 
room conversations of a pre-internet era, there is no telling what acts of (conscious or 
unconscious) challenge to trial protocol they might exhibit.  For example ‘coaching’ each other 
how to successfully negotiate complicated eligibility criteria, and how (where not already 
obvious) to work out which trial arm they had been randomized to. Lipset also suggests that 
sharing experiences of side effects (so called ‘safety events’) might trigger similar anticipatory 
responses among fellow participants, affecting ‘data integrity through a false spike in safety 
reports’ (Lipset, 2014: no page).  
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In short, the potential for patients to mess with scientific method in trials contexts in a socially 
networked culture is considered significant by Lipset, who suggests that, whilst such 
information sharing can be positive, it also has the potential to “undermine the scientific 
integrity of medical research” (ibid).  
 
My own study has coincided with increased trial activity in the CLL networks studies as the 
novel CLL agents described continue to roll out. Fieldwork reveals one of the dominant forms of 
traffic across support communities to be peer-to-peer debate on managing the side effects of 
drugs among trial participants (and those being treated with traditional CIT). Such exchanges 
are delivered in the spirit of mutual support and help among community members, rather than 
a desire to influence trials procedure, or to ‘plot’ or feed information on side effects back into 
trials data (another potential use of online information sharing in relation to trials which will be 
explored in the final section). However, networked exchange of personal treatment experience 
can be viewed variously depending on which versions of CLL they intersect with. Patients may 
feel mutually supported and reassured through peer sharing (although not necessarily of 
course) at the same time as trial organizers and sponsors may feel anxious about the potential 
for such exchanges to influence outcomes and findings. Lipset’s (2014) call for further research 
into the impact of participant peer-to-peer exchanges on the scientific integrity of the trial 
process, could be echoed by calls for further research exploring trial participant perceptions of 
control and empowerment through networked communication. It seems to me a naïve hope 
that increasing patient awareness of “the potential implications of social media use on the 
scientific integrity of the study in which they are participating” (ibid) or having clinical trial 
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sponsors and regulators “monitor social media use by trial participants to understand if 
conversations on the internet will affect their interpretation of study results” (ibid) will act to 
modify peer to peer sharing practices.  
 
The varied motivations behind a desire to cure or manage a disease inevitably intersect, but are 
generally powered by entirely different drivers. The genie of trial participant peer to peer 
support will not go back into the medicine bottle in order to privilege the scientific research 
version of CLL over the vibrant web of versions of living with CLL exchanged in support 
communities every day. Trial design and expectation will need to evolve to accommodate the 
manner in which contemporary patients communicate, harnessing rather than attempting to 
control the rich seam of experiential trial data accumulating in informal online archives. That of 
course brings with it a whole new set of considerations surrounding the potential uses and 
abuses of aggregating individual patient data online, and the next, and final brief Translation 
and Perspective will look at these issues and bring the overview of network narratives and 
contexts surrounding treatment to a close.   
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Translation: Data Sharing in Online Networks (PatientsLikeMe) 
 
 
Figure 3913: TOUCHGRAPH (2015) network connections to PatientsLikeMe/CLL/Genentech/Roche [Network 
Map]. [Online] Available at: http://www.touchgraph.com/seo/launch?q=patientslikeme%20cll. [Accessed 
26/07/2015]. 
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This Translation provides a very brief snapshot of the patient data-sharing health site, 
PatientsLikeMe as a case study of the ways in which technological entrepeneurs are harnessing 
the power of collaborative online data to make available, or sell to a range of interested parties. 
Personal online narratives are translated into mass aggregate data with, as the subsequent 
perspective shows, numerous uses potentially benefitting patients, scientists, and corporate 
interests alike.  
 
Co-founded in 2004 by brothers, Benjamin and James Heywood and friend Jeff Cole in response 
to their experiences following brother and friend Stephen Heywood’s diagnosis with ALS (Lou 
Gehrig’s disease), PatientsLikeMe (PLM) is an internet application whose members volunteer 
detailed data about their disease experience in the spirit of peer sharing as a means of 
improving their outcomes. Individual patients receive their own graphic health profiles and 
aggregate data is collated into reports that can be accessed via the site, discussed within group 
forums, and individually through private messages. The site openly declares its ‘for profit’ 
status101, and informs users that it works with “trusted nonprofit, research and industry 
Partners who use this health data to improve products, services and care for patients” (site, 
2015). At the time of writing, 407 members were listed on the site with CLL.  
 
Logging in as a CLL patient, I can access an ‘overview’ page which gives me quantitative data 
about the CLL community on the site including the overall number of CLL patients, the amount 
 
101 Alongside the Omidayar Network (set up by e-bay founder Pierre Omidayar and his wife Pam), investment and 
advice for the platform was provided by e-commerce company CommerceNet, founded by Marty Tenenbaum, 
who also sits on the board.   
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of new members joining that week, age at diagnosis and at first symptom, and gender. 
Interestingly, at the time of writing the gender balance was 58% to 42% in favour of females, 
unrepresentative of the significantly higher incidence of CLL in males across the general 
population102, and perhaps indicating a greater willingness for female patients to share their 
CLL information in this way online that could sustain further research.  
 
I am presented with a drop-down list from which I can click through to data on how CLL affects 
people, how people treat it, treatment comparisons, member journals, and new members. See 
Figure 39 (below) for a screenshot of the treatment comparison data to illustrate navigation 
and data visualization: 
 
 
102 According to Cancer Research, in 2011, there were 3,233 new cases of CLL in the UK (Table 1.1): 1,957 (61%) in 
males and 1,276 (39%) in females, giving a male: female ratio of around 15:10.1-4 The crude incidence rate shows 
that there are around 6 new CLL cases for every 100,000 males in the UK, and 4 for every 100,000 females (Cancer 
Research UK, 2011).  
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Figure 40: PATIENTSLIKEME (2015) Screenshot of PLM treatment comparison page 
https://www.patientslikeme.com/conditions/186-cll-chronic-lymphocytic-leukemia/compare-treatments 
[Accessed 10/03/15]. 
 
I can also access data visualization on symptoms, symptom severities, methods and drugs used 
to alleviate them, a list of members experiencing these symptoms, and links to comments 
about these symptom specific experiences from CLL community members. Among the 
symptom data aggregated for CLL patients are insomnia, pain, fatigue and depressed mood. In 
addition, I can access aggregate patient reports on various CLL drug treatments, and access 
detailed information on CLL drug trials globally. 
 
On joining the community, patients are encouraged to provide enough detailed individual data 
about their conditions to earn three ‘stars’ (rewarded with a free PLM t-shirt). This level of data, 
patients are told, will increase the power of their voice and ‘accelerate real time research’.  
Image removed due to copyright restrictions 
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Perspectives: Aggregate Data (Who Needs It?) 
 
In an attempt to evaluate patient peer use of personal health information on the 
Patientslikeme site, Frost and Massagli (2008) analyzed a sample of 123 relevant comments 
(about 2% of the total), noting a range of communicative behaviours building on highly disease 
specific commonalities. These include the ability to pinpoint other members with similar 
disease profiles, and thus foster and maintain useful online relationships with those most likely 
to have more to offer and gain from them. My own work has demonstrated that the 
heterogeneous nature of CLL can lead to mis-communication and frustration in generalized 
support community settings, the likelihood of which this more nuanced approach to online 
disease patient networking might potentially reduce. The authors conclude that explicitly 
sharing detailed health data within a community may be beneficial to patients “helping them 
engage in dialogues that may inform disease self-management” (Frost and Massagli, 2008: no 
page). 
 
As this (and other) work has shown, networked data sharing surrounding a whole range of 
diseases occurs daily on an informal, unquantified basis on a significant scale. Some sites such 
as ACOR have their own resources for archiving threads and discussions into databases for 
members to research as necessary. This study alone, of a relatively rare blood cancer within a 
demographic of patients within which fifty is considered young, has revealed a vibrant 
community of online exchange of highly personalized disease details and experience (from 
genetic profiles to spiritual musings). The avowed aim of open sharing platforms is to provide a 
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locus for bringing together some of that global data into localized, computable nodes where it 
might be evaluated in order to improve treatment, care, and patient experience. In short, to 
take the everyday pulsing exchanges of  ‘small  disease data’ in peripheral online circulation and 
tap them into major arteries of open-source big disease data analytics that might make tangible 
differences to care and treatment protocols. If we consider that, according to Cloud Backup 
company Asigra, 90% of contemporary global data at 2014 had been created over just two 
years, and forecasts predict that by 2016 some three billion people will between them create 
around eight zettabytes of data online (cited in Hansen et al, 2014: no page), the potential for 
harnessing personal data for science and health is clear. Manovich’s (1998) work on database 
cultures indicates the broad cultural impact of the ways we store and circulate information in a 
digital era, and this move towards collaborative sharing of personal data as a kind of peer 
driven research methodology is a good example of such a cultural shift – away from the 
laboratory and organized small-scale project into global networks where individual narratives 
also function as data contributions.  
 
Potential benefits of health-related Big Data have been identified in three key fields to date, 
those being disease prevention, the identification of manageable risk factors for disease, and 
encouraging changes in health behaviour 103(Barrett et al, 2013). A tripartite approach can also 
be applied to categorizing big data flows in health informatics which Barrett et al broadly define 
 
103 These benefits are acknowledged in the design and implementation of knowledge seeking and data-motivated 
decision-making initiatives globally such as the Big Data to Knowledge (BD2K) and Infrastructure Plus Program set 
up by the National Institute for Health (NIH) in the US to provide a shared computational platform for the 
facilitation of  large-scale biomedical data analysis for the NIH community (Barrett, 2013: no page) 
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as:  1) traditional medical data of the kind stored in patient records which have the potential to 
contribute to more effective approaches to the aetiology and treatment of disease in global 
health systems (this data potential to some extent underpins current campaigns to move 
towards electronic medical records); 2) large scale biomedical datasets such as genomics, 
microbiomics and other “omics”, knowledge of which might accelerate understanding and 
implementation of individualized treatment; and 3) social media and  ‘quantified-self 
movement’ data providing an insight into how individuals and groups utilize digital platforms 
and technologies in health contexts.   
 
As database culture offers new ways of thinking about archiving and sharing information digital 
pedagogies are also evolving. The concept of connectivism acknowledges the gaps left by 
traditional pedagogic theories in effectively accounting for learning in less formal, networked, 
technology-enabled environments. Pioneer, George Siemens has produced a list of principles to 
underpin the theory, four of which seem particularly pertinent to networked database 
knowledge exchange. Firstly is the principle that learning is essentially a process of “connecting 
specialized nodes or information sources” with the implication that anyone can enhance their 
own learning exponentially through connection with existing networks. Secondly, is the 
acknowledgement that learning may reside in non-human appliances: “Learning (in the sense 
that something is known, but not necessarily actuated) can rest in a community, a network, or a 
database” (Siemens, 2015), which appears to resonate with ANT’s perspectives on the 
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relationships and associations between human and non-human actors104. Thirdly, is the 
principle that knowing where to find information is more important than knowing information 
itself, and fourthly, that nurturing and maintaining connections is vital to facilitate learning, and 
provides significantly greater returns on investment than trying to understand a single concept 
(Siemens, 2015). 
 
In a 2014 review of the literature and concepts in Big Data and science and healthcare, Hansen 
and colleagues (2014) conclude that Big Data and associated analytics are now of significant 
importance in harnessing the potential contribution of vast volumes of both formal and 
informal data in the field. This comes with a need to advance work in the fields of ethics, 
privacy, confidentiality and education surrounding the use of big data. Importantly, they 
acknowledge the need for further exploration of the contribution that the analysis of ‘small-
data’ gleaned from social media, and the ‘quantified self-movement’ might make.  But the uses 
and abuses of big data are a contested area in academia in which the fervour to read mass 
populations through an aggregation of personal health data is seen variously as panoptical, 
analogous with 19th century colonial approaches to the centralization of goods, knowledge, and 
power (Dourish and Mainwaring, 2012), commodification of the body on a grand scale, and just 
another form of biopolitical power mobilized into management of the self (Cheney-Lippold, 
 
104  See Bell (2010) who has worked on exploring the points of connection and departure between ANT and 
connectivism in his paper ‘Network theories for technology-enabled learning and social change: Connectivism and 
Actor Network theory’, published in the Proceedings of the 7th International Conference on Networked Learning 
2010.  
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2011).  
 
It is not difficult to see why powerful private sector and state institutions are keen to mobilize 
big health data into their knowledge and organizational infrastructures, but in their 
ethnographic study of the Quantified Self (QS) movement, Nafus and Sherman (2014) are 
equally interested in the forms of resistance demonstrated by individual data providers to the 
more potentially contentious uses of the information they provide.  
 
Set up in 2007 by journalists Gary Wolf and Kevin Kelly of Wired magazine to explore the impact 
of  personal tracking technologies on the lives of those using them, the QS movement now has 
over 20,000 members in thirty global locations, and is based on Wolf’s premise that instead of 
using the common approach to data as a ‘window’ on people’s activities, the movement  
instead employs the metaphor of a ‘mirror’ to evaluate “what kinds of reflection, learning, and 
personal insights might emerge” (Wolf,cited in Nafus and Sherman, 2014:1787). Nafus and 
Sherman’s ethnography of QS members is primarily concerned with devices designed to be 
worn on or work with the body and to measure physiological functions such as REM and sleep 
patterns, heart rate, pace and cadence in exercise and so on. However, working with Cheney-
Lippold’s notion of the effects of individual use of such data monitoring devices as a form of 
‘soft biopolitics’, they suggest that device users in the movement perform a kind of ‘soft 
resistance’ incorporating wildly idiosyncratic interpretations of the received wisdom behind the 
facts and figures underpinning benchmarks for achievement. A vast range of big data 
enthusiasts are drawn to the QS world in search of data supposedly indexical of optimal  
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“health”, measured, recorded, and legitimized through medical discourse, but Nafus and 
Sherman point out that “QS practices simply do not cohere in this way” (ibid:1790).  
 
My own study has demonstrated that some of the methods of data sharing that individual CLL 
patients use in the networks (listing labs, genetic profiles, and prior treatments after postings, 
using dedicated spreadsheets designed to record bloods and so on) are in some ways analogous 
to the translation of bodily functions and performance into quantifiable data that characterizes 
the QS movement. I have also demonstrated how equally idiosyncratic interpretation of the 
benchmarking behind these numbers and measurements can be in disease communities in 
terms of how people mobilize the objective nature of that knowledge into their personal 
narratives.  
 
The degree of actual empowerment offered by such acts of individualized networked resistance 
is arguably limited of course once individual data is aggregated into broader networks state and 
private sector interests. In communities of serious disease, the body itself limits empowerment 
in terms of physical survival, although empowerment is a mutable concept in the face of life-
threatening disease. As respondents in this study have shown, it can equally be applied to the 
power to live and die well with disease rather than solely how to cure or manage it medically.  
Data in the form of numbers read through the body in disease communities unarguably has 
different inferences though. Plummeting neutrophils and haemoglobin levels in a leukaemia 
patient for example have far greater implications than the indexical signs of disturbed sleep 
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patterns in the general population.   
 
Data in that sense is ‘harder’ in communities populated by the seriously ill, although ‘tracking 
devices’ such as the Fitbit ‘fitness band’ which tracks activity and sleep patterns are finding a 
foothold in disease contexts. Drug manufacturers Biogen, global producer of a number of key 
MS drugs gave out free Fitbit devices to patients to monitor activity levels in return for their 
commitment to share data on PatientsLikeMe. MS disease progress can be measured in terms 
of reduced mobility, and Biogen are keen to harness the daily data readings that such devices 
can offer them to inform drug development (Chen, 2014). 
 
The potential range of personal health device testing is vast. Diabetics already monitor their 
own glucose levels with personal devices of course, and have been doing so for many years, but 
San Diego Health monitoring startup Cue have recently launched a device that monitors the 
body at molecular levels, reading testosterone levels and diagnosing the influenza virus from a 
swab of bodily fluid (Winter, 2014). At the 2015 launch for their new smart-watch (with built in 
heart rate monitor), Apple also announced the launch of data sharing framework ResearchKit , 
a platform allowing medical researchers to create applications supporting enrolment of 
subjects into medical trials and allowing for the ongoing collection of research data.  
 
The open-sourced platform builds on and can interact with Apple’s existing personal monitoring 
framework HealthKit, and the product launch was supported by five sample apps built in 
collaboration with partner universities in US, UK and China and supporting research into 
Julia Kennedy 
377 
 
Parkinson’s Disease, Cardiovascular Disease and Breast Cancer. Standardized real-time research 
data can be collected from research subjects using a software framework like HealthKit, with 
the potential to share data across multiple studies (Glance, 2015: no page). According to news 
reports, doctors in fourteen major US hospitals are currently piloting the service in trials to 
collate data and monitor patients remotely (Williams, 2015: no page). 
 
Platforms such as Cancer Commons and PatientsLikeMe express an avowed aim to share 
scientific and experiential knowledge, to turn the mirror on data that might help speed up 
research, and improve treatment, even for patients approaching the later stages of their 
disease. There is some evidence that this is at least one of the outcomes, as demonstrated 
earlier in this section. Research is needed to evaluate how patients really feel about the 
potential uses of aggregate data, both positive and negative. Many patient responses to a 
PatientsLikeMe blog entry on openness and transparency written by co-founder Ben Heywood 
demonstrate a positive attitude to sharing their medical data (although this is likely to be a self-
selecting audience, already engaged with the community), but the following respondent 
demonstrates some of the anxieties articulated more broadly about the hegemony of big 
pharma: 
 
I have a thing against Pharma firms... they’re in the business of keeping people SICK .. 
(otherwise, let’s face it, they’d be so out of business) … after all, pharmaceuticals are a 
huge lobby … I don’t know if I’m comfortable with my personal data/information being 
sold to these firms (Bilal Ahmed May 20th, 2010).  
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It seems reasonable to suggest that patients may share with the QS movement some concerns 
about the ultimate uses of aggregate data whilst still appreciating, benefiting, and even coming 
to rely on its more positive potentials. This is usefully articulated as dialogic dependence rather 
than outright defiance, where “QS politics are not defiant toward the dominance of big data—
they are instead in dialogue with it and reliant on it” (Nafus and Sherman, 2014: 1793). I would 
suggest that this view is to some extent relevant to an exploration of the relationship between 
disease communities and big data, albeit that the stakes are significantly higher for most cancer 
patients, and the concept of ‘choice’ significantly restricted. Despite the acts of resistance, 
individual interpretation, and stories of success in sourcing, and accessing life-changing 
treatments, there is also the inevitable conclusion that users remain subject to the broader 
biopolitical reliance of late capitalism on individualism as a driver of the production and 
consumption of healthcare technologies.  
 
The sponsorship of Cancer Commons by Pfizer, and the announcement from PatientsLikeMe in 
April 2014 that they had, for an undisclosed sum, agreed to grant access to five years’ worth of 
all de-identified patient data on the site to Genentech, a division of Roche (Comstock, 2014: no 
page), perhaps serve to exemplify that point, while remaining wholly uncontroversial in terms 
of the mission statements for the platforms concerned. As PLM openly state on their site: 
 
We create partnerships between you, our patients, and the companies that are 
developing products to help you. To do that, we take the information you entrust to us 
and sell it to the companies that can use that data to improve or understand products or 
the disease market (PatientsLikeMe Help Centre, 2014). 
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This entire study has focused on everyday data sharing in CLL networks through its exploration 
of circulating and intersecting narratives therein. Often informal and serendipitous, buzzing 
between varied nodes of institutional, professional and independent interests, a cacophony of 
CLL data resonates daily, and I have attempted to trace the more vibrant, sustainable, and 
dynamic actors keeping the nodal connections alive. This section has demonstrated some of the 
contemporary approaches and attitudes to formalizing and capitalizing on that data through 
medical informatics, an industry in its infancy.  My sense (as both researcher and networked 
patient) is that there will always remain a vibrant ‘underground’ web of disease 
communication, but harnessing of individual data for aggregate evaluation is a growing market 
and an integral part of any overview of disease communication networks online. 
 
Chapter Summary             
 
Biomedical and pharmacological innovations are undoubtedly transforming the world of cancer 
treatment. CLL has become a key player in those innovations.   A genetically heterogeneous, 
relatively slow moving cancer offering huge potential for research and experimentation in drug 
development, it has rocketed from relegation to an almost ‘orphan’ disease in terms of interest 
and input, to a modern oncological media star, improving treatment experience and outcomes 
for many CLL patients, and significantly increasing the stock of the major pharma and biotech 
companies investing in it.  
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This chapter has traced clinical perspectives on changing treatment protocols, highlighting both 
the personal and political affiliations clinicians may have with particular approaches, and the 
very real challenges that face the clinical community in evaluating how best to incorporate 
novel agents into changing treatment protocols. I have shown how these clinical versions of CLL 
treatment intersect with patient experience in online networks potentially enabling patients to 
understand the broader contexts within which their experiences in discussing treatment with 
their own doctors are positioned. 
 
Aside from the challenges to clinicians and those involved in drug development posed by the 
heterogeneous and mutable genetic nature of the disease itself , this chapter has shown a 
major issue in the networks to be that of cost. Networked CLL patients are made very aware of 
the implications that the cost of new drugs such as ibrutinib105 can have on issues of access and 
sustainability for these treatments, and the chapter has traced a number of associated 
narratives across key nodes addressing the political economy of the pharmaceutical industry 
and its role in setting drug tariffs. David Shaywitz’s (2013) feature on ibrutinib’s convoluted 
evolution from concept to drug across academic labs, minor biotech companies to pharma 
giants illustrates the fragile and complex journey an ultimately successful drug might make to 
market. Fieldwork shows that this story provoked minimal member responses among CLL 
patients in the key nodes, but that it found its way in to them, and provoked some response 
demonstrates how, through the efforts of dynamic actors, disease communities are potentially 
 
105  On FDA approval in 2013, Imbruvica (ibrutinib) was given a tariff of over $90 per pill by Johnson & 
Johnson/Pharmacyclics. A standard dose of four pills per day works out in the region of $130,000 per year – one of 
the highest prices ever for a cancer drug in recent memory (Staton, 2013). 
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exposed to a sophisticated understanding of the institutions and practices behind treatment 
decisions made on their behalf (or in collaboration with them).  
 
As with the study as a whole, the circulating narratives come in many forms - from medical 
research papers to personal testaments, but perhaps more evident here in the circulating 
narratives of treatment specifically than the other themes in this has been the role of the news 
media itself in disseminating information. Stories have circulated across key nodes from 
mainstream news reports of the successes of new leukaemia treatments, through in depth 
features on particular drugs, to professional and business-to-business publications in the 
clinical, pharmaceutical, biotech, medical informatics, and business press.  
 
This chapter has traced several of those, and drawn on others both to inform perspectives and 
to demonstrate how they are circulated and responded to by networked CLL community 
members. A high degree of scepticism, resistance, and even anger in response to inaccurate 
and sensationalist mainstream reporting and its potential impact on public knowledge of what 
it means to live with CLL has been observed in this project. This aligns with contemporary 
perspectives on problems with mainstream media representations of health and science 
whereby some journalists can be seen to take a cavalier attitude to reporting and fully 
understanding the evidence they draw on. As this thesis shows, changing cultures of news 
production and consumption among more informed audiences make it more likely that 
journalists will be called to account for their errors in a world where “ Anyone can write, and 
publish online, and appear in Google news alerts: the NHS, medical research charities, 
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individual academics, journals' press offices” (Goldacre, 2009). Conversely, some networked 
patients have been observed to utilise pharma press releases in the business news as a means 
of keeping up to date with treatment evolution, demonstrating how disease communities can 
demonstrate sophisticated intertextual skills in developing a multi-versioned attitude to 
knowing their disease. 
 
Access to the new drugs is unsurprisingly a key theme in the networks, and therefore in this 
chapter, which has explored network narratives highlighting the relationships between the 
pharma industry and the regulatory bodies that control the licensing of their products. This is 
an area of disease practice attracting a high degree of patient involvement in the CLL networks 
observed. The Perspective sections show varying theoretical attitudes from critiques of an 
ideology of rapid access for all new drugs with its potentially negative implications in terms of 
safety and future economic sustainability (Pharmaphorum, 2014; Skipla-Serry, 2013), to 
Johnsson and Wilking’s (2006) bold assertions that some patients are dying as a result of 
inequities in global regulatory timelines and funding policies for new drugs. The Translation 
focus on Chaya Venkat’s unsuccessful advocacy attempts to work with pharma companies to 
secure compassionate access for ibrutinib early in 2014 immediately prior to its licensing shows 
the very human cost of being unable to access drugs outside of trials, for which patients might 
not be eligible or geographically close enough to apply for.  
 
Access to and participation in trials was a dominant theme among patient narratives 
surrounding treatment, again related to access to novel agents. Once again, network 
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observations shows the playing field to be less than level in terms of trial availability, eligibility, 
and the amount of information and encouragement patients are given by their clinicians in 
relation to considering trials as part of their treatment decisions. Perspectives uncover a 
number of obstacles to trial engagement ranging from time pressures in the clinical setting 
among clinicians not directly involved in trial delivery and recruitment to poor medical literacy, 
inadequate understanding of the trials process,  and a lack of confidence among patients to ask 
about or get involved in trials.  
 
The increasingly accepted success of novel agents is producing high accrual rates in trials for 
novel CLL agents however, and translations showed how key CLL clinicians and networked 
patients are working together in many cases to increase trial knowledge among the CLL patient 
community and strive for direct advocacy in relation to early access for these drugs. 
 
Finally, the chapter has focused on the emergence of new forms of data sharing and 
management across networked disease communities, looking at the rise of collaborative e-
science communities such as PatientsLikeMe, and their potential contribution to more effective 
and expedited research and treatment developed as an era of personalized medicine dawns. 
The work shows some interest across the CLL network in this kind of platform through disease 
specific membership on the site, and demonstrates how aggregate data is visualized and 
presented. Perspectives in this context focus on cultural aspects and attitudes of networked 
individuals sharing big disease data in relation to its biopolitical implications as individual 
experience is translated into aggregate data and mobilized into the political economies of 
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powerful public and private sector institutions.   
 
It seems that many patients are happy to enter into a more open-source data sharing 
environment, in which they trade privacy and ownership of their personal disease data for the 
greater common, and of course personal, good that may come of it. Although some unease is 
articulated surrounding pharma company access to their information, the general feeling seems 
to be that this system can only improve the restrictive and somewhat homogenized systems of 
patient feedback employed in current drug development approaches, and possibly lead to 
improved treatments and access to them. For people living with life-changing and threatening 
diseases such as CLL it seems, everyday community exchange tends to focus on the immediate 
and material concerns of staying alive, whatever the broader political implications of that might 
be. As this chapter has shown though, when those political implications impinge directly on the 
business of staying alive, for example in the setting of drug tariffs, policies surrounding funding, 
and regulatory processes impacting on access to drugs, then key actors in the community will 
become politicized in their narrative sharing practices in order to mobilize wider responses 
among the community. 
 
One of the major themes of this entire chapter has been one of perceived inequity in access to 
treatments. It is clear that the current binary tradition of watching until waiting for treatment 
that, in itself, is a risky prospect, may soon be superseded by the potential of new prognostic 
and pharmacological technologies to create more nuanced, individually tailored, and safer 
treatment protocols. For all of us living with CLL now this is undoubtedly good news.  It brings 
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with it though a good deal of frustration for those needing treatment at the cusp between 
traditional approaches to care and emergent brave new protocols as my own experience, and 
network responses to it set out as a Translation in this chapter demonstrates. 
 
One (Cornish) IOB respondent makes the point that even thinking about potential drug regimes 
has limited value given that the choice of treatment is ultimately limited to what is available 
locally/nationally:  
 
My consultant has told me that I will probably need chemo drugs this year. I have 
avoided researching drugs, because I can only have what is available. Unless I take part 
in new drug trials, which again only depends on stage of disease and availability (IOB 
Survey Respondent 2). 
 
 
 
Despite all of the sophisticated narratives circulating online in relation to various institutional, 
professional and personal enactments of CLL treatment, and the many success stories of access 
to new treatments with good outcomes to date, this respondent makes a pertinent point. She, 
and many others of us like her, represents the gap between aspirational global CLL research 
and the information that circulates about it on the web, and what patients located at regional, 
non-specialist points of delivery might actually have available to them. As new protocols 
replace old in increasingly personalized treatment approaches, it is likely that even more 
patients across a range of cancers will find themselves in the real-time void between past and 
future treatments, where some will inevitably have to rely on traditional treatments and others 
will move forward to new paradigms. Networked patients put themselves in the best position 
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to gain access to new drugs, but as the above respondent shows, that knowledge and 
understanding of drug developments doesn’t necessarily translate to access.   
 
Further research is needed to evaluate both the psychological and survival implications of these 
inequalities for increasingly informed patients who are now much more likely to know what 
they might be missing. Even more important perhaps is further research into treatment 
outcomes for those patients outside of support networks who don’t know what they’re missing 
unless their doctors tell them.  
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Chapter 6: Thesis Summary  
 
“My initial experience of illness was as a series of disconnected shocks, and my first instinct was 
to try to bring it under control by turning it into a narrative” (Anatole Broyard, 1993:308). 
 
On-line narratives are not just changing our concept of authorship; this new kind of narrative 
also refuses to fit the usual concept of genre. Electronic illness narratives are an amalgam of 
literary and nonliterary forms, including autobiography or biography, journal, and medical 
chart” (McLellan, 1997: pp100-101).  
 
 
Translation: A Diagnostic Tale 
 
It’s a cold and cheerless afternoon in late February  ... one of those occasions where incipient 
damp and gloom conspire to reduce the horizons and possibilities of a day. My tutorials are 
done, and I am frantically trying to extricate myself from the endless undone tasks for the day 
before leaving campus for an appointment with my GP. He has results for me from a recent 
blood test. I am tired  ... bone tired and feverish  ...have been for weeks now. I just make the 4 
o’ clock bus into town and collapse into my seat amongst the buoyant chatter and canned 
music of homeward-bound students. I think about my lecture tomorrow, and the prep I will 
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need to do this evening. I want to sleep. At the surgery I find another seat to sink into whilst I 
wait to be called.  Kids play noisily with the pile of broken plastic toys in the corner of the room. 
The incessant clatter is irritating, but I am reminded with some nostalgia of the days when my 
own (now teenage) boys would do the same. It seems like yesterday.  I flick through a celebrity 
magazine: tales of weight gain and loss, fashion successes and failures, the scandals, trials and 
tribulations of celebrity love. 
 
The room smells of damp clothes – it is raining outside. A number of people sit with me on the 
plastic chairs waiting to swap symptoms for a diagnosis.  I wonder what’s wrong with each of 
them as I look around me, surveying them covertly for clues. I suppose that they do the same 
with me. The previous patient exits the consulting room, and I guess I must be next. The GP 
follows him out, avoiding eye contact with anyone in the waiting area, and goes into an ante-
room where he talks to a nurse in hushed tones before returning to his room with a sheaf of 
print-outs in his hand. I think nothing of it, and continue reading the magazine. I take a 
professional interest in the cultural obsession with celebrity and am absorbed. He calls me in, 
sits me down, smiles oddly at me and then says (as if reading instructions to himself) “OK, let’s 
do this properly – would you mind getting up on the couch please so I can examine you”. I am 
slightly surprised, but do as I am bid.  He feels my abdomen, sits me up and feels in my neck.  
 
In hindsight, I know what he was looking for – the swollen liver (hepatomegaly), spleen 
(splenomegaly), and lymph nodes (lymhadenopathy) that signify the accumulation of rapidly 
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proliferating immature and malignant white blood cells in the factories and storehouses of the 
immune systems of leukaemics.  
I am back in the chair. He looks at me again and tells me that all of the tests run on my blood 
were “absolutely fine.” He pauses … “except your white count.”  
 
I look at him expectantly, awaiting numbers, explanations, maybe a prescription or an edict to 
rest at home for a couple of weeks? He says nothing.   
I shatter the heavy silence. “How high?”… I ask.  
“Sky high” he replies “67k” (a “normal” wbc would be in the range of 2-5k, but I can’t 
remember the normal counts at the time).  
 I quickly dredge the silted depths of my medical knowledge - I gave up nursing over 20 years 
ago to start my academic career. It must be an infection obviously ... I hazard my guess.  
 “No” he tells me. “It’s not an infection.”  
I am momentarily stupefied (in hindsight it seems so obvious – what was coming). 
“You were a nurse weren’t you?” he asks. 
Then – sliding the lab report across his desk to me, he points at the words “frequent smudge 
cells - probable CLL” printed in the section reserved for the pathologist’s comments. He won’t 
say it – and I genuinely don’t recognize the acronym.  I was an emergency nurse. Haematology 
was not my specialism. I shake my head.  
 “Sorry” I tell him “I don’t recognize it”. 
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I am aware of feeling annoyed with myself.  I have failed the test he has given me, disappointed 
him somehow, and now he is going to have to tell me the answer. He looks nervous.  
 
Reluctantly he translates the acronym for me. 
 
He tells me I have chronic lymphocytic.  
 
 
 
 
My ears immediately …                                                                   
 
… shut out every sound in the room                                          other than his voice as I hear it 
telling me … 
…as if through noise reducing headphones… 
…that it is        
                                           I N - CURABLE                                                                                                                                                                            
(though apparently treatable) 
L E U KAE M I A 
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 He tells me he doesn’t know very much about the disease, that he has no real idea of the 
prognosis… 
 
(…maybe five - 5 - years, maybe m o r e, maybe less...) 
 
…that bizarrely it does not fall into the “emergency” category of the NHS referral algorithm and 
that I may have to … wait “some time”… to see a consultant specialist.  
 
When I try to push him for information (I don’t really know yet what information I need, but I 
am wondering already things along the lines of  ... what will my life look like now?  How should I 
envision my future? How long will I stay in the world? Will it hurt? Will my hair fall out? What 
drugs will I have to take? Will I have to stay in a hospital..?) he tells me that I should:     
                        
                                         “look it up on the internet” 
 
And here he hands me the sheaf of papers I saw him pick up from the printer earlier – a 
summary of the disease for the newly diagnosed from an online CLL support group.   
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Finally he tells me that he is “very sorry”. I believe him, although I sense that he wants me to go 
away now. I leave the surgery in a state of profound shock.  
As I walk the short and familiar route home through the drizzly dusk, my perceptions of myself  
...of time  ...and of the way that I inhabit the world  ...begin a process of profound change. 
Everything around me looks the same, but the mundane reassurance of local topography taken 
for granted for so long has gone. What is this disease that has altered my blood, that has 
weakened my immune system, that has swollen my lymph glands, that can’t  be cured, that in 
all probability will end my life much sooner than I had expected to die, and that now defines me 
as a cancer patient? 
 
I need new maps. I take my doctor’s orders: I look it up on the internet, but it turns out to be 
many different stories which I, like others diagnosed with cancer, must now learn to navigate 
and accommodate… 
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  Perspectives: Thesis Summary (A Return to Aims) 
 
I think it useful here to return to the aims set out at the start of this work as a means of 
signposting this summary of my work: 
 
•  To explore and map the evolution of patient illness narratives as they move into 
circulation with a range of other narrative enactments of disease online. 
•  To locate and map the networks within which multiple CLL narrative enactments 
circulate and intersect online, identifying key nodes and actors. 
•  To make visible the key themes and issues faced by those living with CLL through 
mapping narrative themes online. 
• To reveal the major points of intersection of the various narrative enactments 
identified, highlighting synergies, tensions and obstacles in the bringing together of 
multiple enactments of CLL online.  
• To utilize and adapt object-oriented methodologies for mapping online narrative 
networks and flow.  
• To design a methodological approach for writing up multiple narrative enactments in a 
way that prefigures the ontological politics of the project.   
 
For clarity, I will address each aim in turn in the following sub-sections: 
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Evolving Illness Narratives: Re-territorializing through Digital Assemblage?  
 
In part, this work has been about studying an evolving form of illness narratives in digital 
contexts. Frank’s (1997) notions of bodies and voices quite literally silenced by illness and its 
treatment, and responding through the narrative approaches of chaos, restitution and quest is 
a starting point for any work on illness narratives. Frank’s work is focused on print forms 
however (now including graphic novels), and digital contexts produce different practices and 
possibilities:  
 
But in on-line, ongoing, collaboratively constructed narrative, the inner workings of the 
process--reconsiderations, retrenchments, and reaffirmations--are much more 
transparent than in a finished print work. Where the electronic narrative stands relative 
to the unfolding of the story is thus often in flux (McLellan, 1997:101).  
 
 
In this work, I have asked whether the way that many CLL patients online recontextualize a 
range of alternative texts into their own stories, including medical and scientific discourse, 
might be read as a means of re-claiming voices (and ultimately bodies) from the threat (actual 
or realized) of silencing  - not simply by narrativizing in resistance to medical and a range of 
alternative authorities but by attempting to understand different enactments of disease, 
incorporating them, and engaging with them as an integral part of our stories?  
 
Recontextualizing clinical research aimed at other clinicians and professionals; research papers 
written for a scientific community; pharmaceutical press releases written for clinical and 
business contexts; shared patient stories; lab reports written for doctors; and policy papers 
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inflected towards a range of civic and institutional contexts into everyday and ongoing personal 
illness narratives online has the potential to ‘re-centre’ more powerful (and potentially 
silencing) discourses within patients own stories. As Bauman and Briggs (1990: 74) note in their 
work on agency in digital storytelling: 
 
“decontextualization from one social context involves recontextualization in another…[it 
is interesting to consider]… what the recontextualized text brings with it from its earlier 
context(s) and what emergent form, function and meaning it is given as it is recentered 
…” (Bauman and Briggs, cited in Hull, no date:33).  
 
 
This reflects the narrative translation processes made visible by this work, in which I have 
shown how various elements of what we understand as CLL survive, but evolve as they move 
across multiple narrative versions online in a constant process of ‘re-centering’. This is better 
described for the purposes of this work as a process of re-territorialization, given the 
multiplicity and constant kinesis of ‘centres’ mapped.   
 
As Mette Hoybe and colleagues (2005) conclude, narrative action through story-telling in health 
support forums can be an empowering process, giving patients resources to move from the 
submissive and isolating effects of a cancer diagnosis to active participation in new social 
contexts. The recognition of the experience offered by the presence of such communities opens 
up opportunities for sharing information and experiences about disease that are at once 
collaborative and social yet also have the power to underpin individual approaches to learning 
to live with cancer. Hoybe and colleagues define ‘empowerment’ in the context of their 
research as that which comes about not just through obtaining information, but also, and 
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importantly, through the personal strength gained from social support in the network. 
Empowerment occurs in this model through the shift from ‘being acted upon to be acting in 
intersubjective storytelling’ (Hoybe et al., 2005:217). The intersubjective storytelling of internet 
support groups has therapeutic potential where effective story telling can “influence the 
subsequent actions of the teller and the audience” (Mattingly and Garro, 2000, cited in Hoybe 
et al., 2005:217).  
 
At the level of everyday narrative exchange in the CLL communities, clear material effects are 
observable as a result of writing, reading and sharing these narratives made manifest in 
patients changing medical teams, accessing trials, learning patterns of disease management 
through others’ stories and so on. All of this clearly has a material effect on the lives of some 
people living with CLL, and also has the potential to feed back into clinical approaches through 
the sharing of narratives between patients and their doctors. The roles of narrative distribution 
in extending the scope of this information economy are varied. Kathleen Pontius highlights one 
of the potential transformative impacts of networked narrative distribution in her work on 
young adult cancer patients and cancer narratives:  
 
Challenges to the existing dominant cancer narrative and the creation of a fully formed 
constitutive rhetoric are still in their formative stages, but the initial development of 
alternative cancer narratives are starting to expand the definitions of what cancer is 
"supposed" to look like and how it "should' be experienced” (Pontius, 2008:99).  
 
 
Working out how to ‘do’ CLL is a common aim amongst the narratives of CLL patients online, 
and by this I mean more than just understanding how the disease works and what we should be 
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doing and asking our clinicians to do in terms of managing its clinical course.  As Evans and 
colleagues have shown, the issues of liminality faced by CLL patients can make it even more 
difficult to inhabit a suitable narrative in the face of the somewhat limited cancer narratives in 
cultural circulation to date. As Pontius points out above, the production of ‘alternative’ 
narratives are slowly beginning to challenge limited and singular perspectives.  The assimilation 
of multiple circulating texts or objects of CLL into individual and group narratives has the 
potential to open up a new world of pathography that could radically expand views of how 
cancer “should” be experienced by a range of actors involves in enacting it, and not just 
patients.   
 
The utopian implications of this need to be tempered to some extent by the knowledge that the 
resources required to mobilize online support, and to contribute effectively to online debate, 
are not universally accessible. Furthermore, as observed in this project, the majority of online 
health community users are lurkers rather than active posters, who make up a small percentage 
of community members. In reality then, a relatively small amount of key actors will be 
producing the heteroglossic effects of community interaction in the networks, and the 
subsequent learning, support, and ongoing narrative reconstruction opportunities produced by 
the discussion is not equally distributed across or necessarily representative of the majority of 
community members who consume it.  It is also the case that individual perspectives of key 
network actors can at times dominate communities or particular debates as acknowledged by 
the following respondent describing her site preferences: 
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Cll topics was a great help to me around the time of diagnosis. I kept just to this site, in 
particular I valued someone putting the research studies into "layman" terms. I do miss 
this site, and although Health Unlocked is informative I have found that it is dominated 
by a few people with strong views (IOB Survey Respondent 195). 
 
 
 
The work has shown that not all patients find sharing their stories in online communities to be 
therapeutic or empowering. Some are strategic in their avoidance of online information and of 
other people’s stories which have been described by some respondents as ‘self-obsessed’, 
overly negative, or productive of dominant perspectives. Others have claimed to use online 
sites purely for information with no wish to engage socially with other CLL patients. However, 
the majority of respondents have been overwhelmingly positive about the benefits of sharing 
stories and advice online, and online narrative exchange does seem to have the potential to at 
least provide the resources for community members, active or lurking, to begin to make sense 
of life after diagnosis with a disease which is defined by uncertainty.  It would seem that digital 
pathography is an evolving illness narrative form with much potential to expand our 
understanding of disease experience in a culture that is at once informational and narrative, 
technological and grounded in the subjective experience of illness.   
 
Patient-Centredness in a Connected Information Economy 
 
One of the key points of this work has been the impact of information and knowledge gained 
online on clinical relationships. Tom Ferguson’s view of the ‘e-patient’ as an informed, engaged, 
equal partner in their own medical treatment (2007) informs my approach, but clinical 
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relationships are (at least) a two-way process, and whilst an evolution in clinical attitudes is 
underway, this work has shown it still has a way to go. This manifests in a degree of inequality 
across the CLL patients studied, with some able to collaborate with and contribute to treatment 
decisions where they wished to, and others meeting with frank resistance, or at times derision 
from their doctors.    
 
In his work on the ‘grey zone’ (ambiguity) of health and illness in society, Alan Blum disavows 
the model of professional excellence as one-way flow of technical proficiency from 
(knowledgeable) specialists to (ignorant) non-specialists. Instead, he imagines an ‘intervention’ 
in which the non-specialist is “engaged or moved to develop a stronger relation both to the 
specialty and to its subject matter, perhaps by taking initiative for influencing its redefinition in 
some sense” (Blum, 2011:98). Such interventions are consistently evident in online support 
networks, as patients engage with, gain expertise in, and become advocates for different 
models of care for CLL. Tensions persist though in a culture where medical expertise and 
specialism traditionally revolve around an axis of highly informed doctors telling poorly or un-
informed patients (and other non-doctors) how things work. Put more plainly, “The excellent 
doctor must be a specialist who cannot on his own ground risk putting his excellence into 
question because no other than he and his circle seem qualified for such an engagement” (ibid), 
and neither party engages thoughtfully with the other in a model where “the specialist can be 
expected to have no respect for the ignorant, and the ignorant can only sulk resentfully at her 
exclusion” (ibid: 100).  
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Adopting ‘patient-centred’106 practice has been one approach to acknowledging the fact that 
both patient and clinician have their own areas of ‘expertise’ that together can produce 
synergistic models of care (Bleakley, 2014). Traditionally, the distinct areas of ‘expertise’ 
recognized in this model bifurcate along a phenomenological patient/rational clinician split in 
which patient knowledge of their socially situated illness experience, attitudes to risk, and 
values/preferences is matched in a binary model by to the expertise of the clinician in diagnosis, 
aetiology, prognosis, treatment options, and outcome possibilities: 
 
 In shared decision-making the patient’s knowledge and preferences are taken into 
account, alongside the clinician’s expertise, and the decisions they reach in agreement 
with each other are informed by research evidence on effective treatment, 
care or support strategies (Coulter, and Collins, 2011:3). 
 
 
 
In other words, the knowledge-based expertise of the doctor remains stable and unchallenged 
by the experiential expertise of the patient. As addressed in the introduction, narrative itself is 
evolving to adapt to the informational and digital moment, and it seems clear that so must 
those relationships traditionally based on one party or group holding all the knowledge cards in 
a given category (as demonstrated in patient responses used so far in this work). In an 
information era, fixed dualistic distinctions dividing patients and clinicians in this way appear 
anachronistic and naïve as patients become more informed about treatment options and 
prognosis, and clinicians more keyed into socio-cultural attitudes to health and medicine. Ian 
 
106 According to Mike Farrar, chair of the Royal College of General Practitioners’  ‘An inquiry into patient centred 
care in the 21st century’, patient-centredness describes “a new type of health system where empowered citizens 
are able to identify and manage health risk factors, receive individualized and holistic care, and are demonstrably 
equal partners in managing their health” (Farrar, 2014:3). 
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Kennedy (2003 Chair of the Healthcare Commission) describes a mature culture in the NHS as 
one that will settle on: 
 
…sharing power and responsibility, on a subtle negotiation between professional and 
patient as to what each wants and what each can deliver... The currency of this 
exchange is information. The mature culture will recognise the value of information 
within a patient-centred system (Kennedy, cited in Hardy, 2004).  
 
 
 
The type of information each party is expected to contribute to a ‘patient-centred’ economy 
can no longer be hermetically boundaried though, and putting those patients actively involved 
in seeking information and support for their illness online at the ‘centre’ of clinical relationships 
requires acknowledging that they are already meshed into information networks outside of the 
clinical relationship. Put more simply, the aim may be to put every patient at the centre of the 
clinical relationship in policy terms107, but the clinical relationship may not be at the centre of 
every patient’s information and support seeking practices. Patient connectedness may better 
describe this emerging phenomenon, and should be taken into consideration when interpreting 
policy statements such as the following from Mike Farrar, Chair of the Royal College of General 
Practitioners 2014 Independent Inquiry into Patient-Centredness in the 21st Century: 
 
Critically, however, patient centred care also means that the varying needs, capabilities 
and preferences of individual patients and their carers must be met on an individual 
basis. For example, some want more involvement in their care, some are happy with a 
 
107 See the Royal College of General Practitioners’  ‘An inquiry into patient centred care in the 21st century’, 
published in November 2014 by the Royal College of General Practitioners. http://www.rcgp.org.uk/policy/rcgp-
policy-areas/~/media/Files/Policy/A-Z-policy/RCGP-Inquiry-into-Patient-Centred-Care-in-the-21st-Century.ashx 
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strong professional lead; some are very capable of drawing on new technologies, some 
less (RCGP [Farrar] 2014: 3). 
 
 
Differences in desire and capability among patients to draw on new technologies to increase 
their contribution to treatment and care decisions have certainly been evidenced in this work, 
with a very small minority preferring to leave everything to their doctors, and others struggling 
to overcome medical literacy problems. A significant majority (79%) of the 222 patients 
responding to the question of whether they discussed what they learned online with their 
doctors, said that they did. Not all of them reported positive clinical responses from their 
efforts however, begging the question of how far and how soon an internalized system of 
professional medical expertise whose exclusivity is largely dependent on lay ignorance of the 
technical aspects of anatomy, physiology and biochemistry will be willing to flex to 
accommodate a new breed of increasingly medically literate patients benefitting from the 
democratization of knowledge on the internet. This is not necessarily driven by a patient desire 
to challenge professional expertise. In the case of diagnosis with a rare disease, or one with less 
available disease-specific specialists such as CLL, a turn to online auto-didacticism and support 
seeking may seem to be more of a necessity for patients wishing to access the highest or, as 
this work demonstrates, even just acceptable standards of care. The consequent accrual of 
expert knowledge that many patients in this position demonstrate requires some sophisticated 
negotiation between them and their doctors if it is to transfer to an empowered relationship, 
rather than one that is ultimately frustrating or potentially threatening for both parties.  
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Identifying the Networks 
 
This thesis embodies four years of fieldwork, including the largest scale survey conducted to 
date of CLL patients online.  Attitudes to their disease and their online practices have provided 
a sound overview of the major nodes, actors, and networks among a predominately UK and 
North American cohort. The network shape would change were I to have included European 
sites, but this work was confined to English speaking network nodes for ease of assimilation. 
The CLL Online chapter particularly outlines the major nodes, and lays bare many of the 
practices of online use employed by the CLL patients who responded. The In Our Blood survey 
online as a source of much of that data has operated as a network node in its own right, making 
heard a number of voices that have been silent in the networks for a number of reasons. The 
work has incorporated as many of the key nodes and actors mentioned by respondents as 
Translations for closer exploration, visually mapping their links into broader networks using 
TouchGraph software where possible.  
 
Over the course of the research, some nodes have become less active than they were at the 
start (Macmillan CLL Group), others have grown significantly (CLLSA Health Unlocked), and two 
major nodes have become dormant due to retirement (Chaya Venkat’s CLL Topics), and death 
(Terry Hamblin’s Mutations of Mortality blog). A number of individuals have been identified as 
major actors in the networks studied, most of who appear in the Translation sections. Their 
actions and energies, alongside the software and hardware of multimedia platforms and global 
communications technologies mediating and translating CLL information across boundaries, are 
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largely responsible for keeping the multiple narratives explored here flowing and intersecting 
with each other. These actors effectively choreograph the network effects observed in this 
work, and usually do this for little or no financial return. CLL narratives do not flow effortlessly 
around the networks. They have to be selected, put into circulation, contextualized and often 
literally translated for lay audiences. Capable individuals may source multiple narratives for 
themselves, and what motivates and equips some people to put them into circulation with 
others, and even form vibrant network nodes themselves is beyond the scope of this research. I 
am flagging this up for future exploration however as it is central to an understanding of how 
successful network effects in cancer support might be replicated elsewhere.  
 
CLL Online: Key Issues 
 
Aside from tracing the processes and effects of network activity surrounding CLL online, it was 
one of my aims in this work to make visible the key issues emerging for those living and working 
with CLL through an exploration of the narrative circulation. This ‘political imperative for 
visibility’ (Bassett and O’Riordan, 2002: 243) draws on my own experiences of CLL as an under-
represented, and misunderstood disease, the consequences of which I, and thousands of 
others, live with daily. This was a challenging element of the research, having to balance an 
ethical responsibility to my respondents, and the stability of my own place as an active member 
in the support networks, with the sense that there was much going on in these unseen, private 
hubs of narrative exchange that could expand understanding of what it means to live with CLL, 
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and of methodological approaches to studying disease online generally.   
 
Working closely with fellow CLL actors online to set up my work, and reflecting on my 
methodological approach as I proceeded enabled me to position myself in a way that was 
ultimately neither threatening to them or myself. In that sense, I am indebted to those 
everyday network actors who took the time to get into dialogue with me about this when I 
launched the project in the community. The addition of the survey as a network node in its own 
right was fundamental to that process, producing 10,000 words of narrative account from 267 
CLL patients, along with the observations made by spending time in the networks every day 
over a four year period. I have had plenty of opportunity then to identify what concerns those 
of us living with CLL.  
 
The work has presented these key issues in three sections under the headings Diagnosis, 
Prognosis, and Treatment. This is not groundbreaking, nor CLL specific, as it might be expected 
that anyone’s disease experiences could be categorized in this way. In reality, there is a good 
deal of crossover between these categories, and it is in mining down into the minutiae of daily 
narrative exchanges that the CLL specific issues can be identified. Each chapter has dealt with 
these in fine-grained detailed, summing up observations in extensive ‘summaries’, noting here 
that ‘conclusions’ work against the grain of an ANT approach that claims close, detailed, even 
baroque description without necessarily reaching an explanation. As Bruno Latour (2007) 
claims, if the description is good enough, the explanation is redundant. 
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However, there are a number of issues that stand out in terms of the specific issues faced by 
CLL patients that are worth drawing attention to briefly in this overall conclusion. The 
heterogeneous nature of the disease with its multiple possible routes of progression and 
outcomes, and its ability to evolve along its trajectory make this a particularly slippery disease 
to live with and treat. In the context of this research it provides a double-articulation of 
multiplicity as a disease object, already having multiple identities in addition to the multiple 
enactments that constitute any disease. From the point of view of living with it, the constant 
uncertainty adds to the sense of liminality that many of my respondents reported and was 
raised by Evans and colleagues in their insightful paper on living with CLL, ‘Invisible, Incurable 
and Inconclusive’ (2013), explored as a ‘Translation’ narrative in the Diagnosis chapter. Often 
not requiring immediate treatment, presenting with a slow and insidious progress that can 
quickly become aggressive and require immediate treatment, or indeed never require 
treatment, this is a disease that locates people in a strange and unpredictable space between 
grave illness and relative health. Whilst this often gives CLL patients longer to research their 
own disease, and form long-term relationships with other CLL patients online, many 
respondents felt themselves outside of the cultural spaces and narrative possibilities reserved 
for those living with acute cancers, reflected in the attitudes of those around them, but most 
notably in their clinical relationships. Here, the significant amount of feedback indicating 
dissatisfaction with the amount of attention and information provided by some clinicians on 
diagnosis and beyond was cause for concern.  
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Numerous patients report having moved to different doctors when their online learning has 
revealed perceived inadequacies in the clinical relationship, and others have worked with their 
clinicians (where willing) to discuss what they have learned and contribute actively to their 
treatment decisions. Both network effects demonstrate how online narrative circulation spills 
over into the bricks, mortar and examining couches of the clinic and that, as some of the 
Translations of clinician-led narratives in this work have shown, has material effects on time 
and resources as well as sometimes influencing trajectories of care.  
 
The rapidly changing treatment environment for CLL and the move towards more personalized 
prognostics and treatments following the sequencing of the human genome make it a 
particularly interesting disease to explore currently. CLL has moved fairly rapidly over my period 
of research from being regarded as a ‘Cinderella’ chronic cancer of elderly, to a major player in 
contemporary haematological research with the advent of the BTK and Bcl2 inhibitors. The 
range of complex research papers circulating online and the efforts of a number of key network 
actors to circulate and translate them is a major themes in my work, as are the global 
inequalities in access to new prognostics and treatments. As cancer care generally moves 
towards a world of individually tailored and, in many cases, highly expensive novel therapies, 
inequalities in access will be inevitable.   
 
This work has demonstrated how networked, informed patients have a keener understanding 
of how to source information, trials, and CLL expert clinicians. It has also demonstrated 
networked activity surrounding narratives of both biotech and pharma industry’s roles in drug 
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innovation and production, and of the regulatory and funding processes that accompany any 
new drug’s journey to market. The work has also shown however that, despite all of this 
knowledge and organized advocacy where it occurs, some people never get the drugs they 
want or need.  
 
Across the issues faced by CLL patients, it becomes clear that highly informed network actors 
are much more aware of what they might me be missing out on where, despite their best 
efforts, knowledge doesn’t necessarily translate to access to new treatments or expertise. The 
cost of and restricted access to novel therapies is a major issue for CLL patients, and is likely to 
become a major issue for all cancer patients and the health services that care for them. This 
work has shown some of the tensions that exist between the pharmaceutical industry’s 
aggressive push to market, regulating for safety, and acknowledging that access to these new 
drugs can literally sit between life and death for a number of CLL patients.   
 
Wilking and Jonsson’s (2005) observations on the inequalities in regulatory processes Europe 
concludes that slowing down the traffic of novel agents into the marketplace definitively costs 
some patients their lives. My work has suggested further exploration of the psychological 
impacts of this on patients undergoing traditional treatment and care against a backdrop of 
hype for future, less toxic treatments. Jeff Sharman’s pertinent observations that in the US, 
around 10% of patients are treated at the large research centres by CLL experts, raises serious 
questions for the 90% who aren’t, and hints at a degree of elitism. Online studies of this nature 
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have the potential to make visible the experiences of some of them at least, and explore what 
happens to ‘expert’ patients treated in general departments at smaller regional centres. 
 
My original outline plan for the themed sections included a ‘Survival’ chapter, exploring some 
of the more general issues faced by CLL patients simply getting on with their lives in the 
moments between diagnosis, prognosis and treatment. Feedback from patients included 
observations on the impact of this disease on their sense of time, identity, spirituality, and 
relationships. Although I have threaded as many observations as I can through the various 
sections, time and space unfortunately has not allowed for inclusion of a dedicated chapter 
here. This is an area I intend to work on in the future, particularly as the issue of cancer 
‘survivorship’ becomes more pertinent in cultures where the incidence of cancer grows ever 
higher108, as do the means to treat it more effectively in many cases. 
 
I have argued that digital pathographies when read as circulating objects of CLL that intersect 
with a broad range of alternative narrative objects of the disease online have the potential to 
bring bodies, feelings, liminal spaces, science, technology, hardware, spirituality, politics and a 
whole lot more together into hybrid, collaborative and open-ended narrative acts with real 
power to exert significant material effects on the actors involved.  These actors and their 
accompanying narratives (including those of artefacts such as technologies, illustrations and 
charts) engage in potential translations that serve to expand the network and confirm nodes or 
 
108 According to Cancer Research UK’s worldwide cancer statistics, 14.1 million new cases of cancer were recorded 
in 2012, and 8.2 million cancer deaths globally in the same year (Cancer Research UK, 2012).  
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attractors within networks. Translations necessarily lead to circulations within the system or 
network as actors work the net. In my case, of course, this is literally the case as the context 
and the geography are constituted by online or internet-based communities.  
 
As well as having the positive potential to enable, empower, include, enlighten, and broaden 
perspectives (as respondents have demonstrated), exposure to multiple circulating narratives in 
CLL networks can also (as respondents too have shown)  terrify,  exclude, anger, confuse or 
frustrate. Some may reasonably ask what use knowing where we are located in relation to 
other parts of the CLL machine is if that knowledge doesn’t easily translate into the power to 
make it work differently for us, in the case of access to new treatments and prognostic testing 
for example. The omniscience gained by networked CLL patients can serve to inform them of 
global treatment advances and the experiences of others within that map, but the work has 
shown that knowledge hasn’t always equated to power, or to staying alive. The fact that 
expectations raised from patients’ initial forays into online learning are not always met by the 
treatment they receive once in the care of a consultant is a pertinent issue for CLL patients 
using the internet across all stages of their disease. It draws attention to the dissonance 
sometimes experienced between globally networked knowledge flows and locally delivered 
care, and how to manage the psychological impact of a surplus of knowledge that doesn’t 
translate to control has been a major issue for some patients in this study and warrants further 
research.   
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Methodological Innovations 
 
Methodologically, I set out to test out the application of object-oriented approaches to disease 
inspired by the work of Mol (2002) on atherosclerosis, and Law and Singleton (2004) on liver 
disease – both grounded in the wider perspective of Actor-Network-Theory (ANT) - in clinical 
and offline settings, to CLL in online settings using an auto-ethnographic/pathographic 
approach typical of ANT methods.  My work draws clearly on the trails they have blazed and the 
traces they have left in looking at disease as a concatenation of multiple enactments, held 
together by objects that remain recognizable in some ways as they shape-shift and leap across 
disciplinary and experiential boundaries. It also deviates from them in choosing to study the 
narrative inscriptions of a disease as they circulate online, to do that as an existing member of 
the networks they flow around, and to locate my research openly as a network actor or node in 
its own right. In that sense, this work is innovative, and has the potential to contribute to the 
fields of digital disease research, and object oriented methodologies in general.  
 
This is just one version of one map of a global territory as it evolved over four years however. It 
is not intended to be read as the network map of CLL use online, production of which would 
take a lifetime, and still only qualify as a singular version of multiple possibilities. Future 
researchers might adopt a similar approach to trace a particular document, set of documents, 
follow a particular actor, or focus on a specific node for example. Focus can be placed variously 
on process, flow, identifying successful and unsuccessful networks and what holds them 
together or otherwise, identifying actors, network effects, and key matters of concern in 
Julia Kennedy 
412 
 
network narratives.  In this work I set out to sketch out this (relatively) small territory of CLL 
online in as much detail as I could. 
 
Perhaps the most challenging aspect of that has been designing a coherent and legible 
structure for presenting such a complex assemblage of data in a form that prefigures my 
ontological approach. Starting with the problem of where to put my narrative self - too much 
autopathographic narrative and the object of my own CLL offers an over-is privileged account; 
none at all and I disingenuously elide what drove the research in the first place (see 
Methodology chapter for my responses to the Research Committee in this respect). Trying to 
position my own narrative as an object is of course always going to be contentious, as I write 
and live with CLL very much as a subject. However, my approach of positioning my subjective 
narratives as objects among and coming into contact with many other circulating narrative 
objects feels to me as if it has worked. I will leave other network users to judge that in the hope 
that this thesis becomes a key circulating object in time within the community I have studied. 
 
The issue of how to organize the data as a narrative thesis has been another major challenge. 
Adopt a standard social sciences structure and I am forced to abstract my findings into 
straightforward analysis enslaved to a teleological endpoint, follow the almost completely un-
bracketed, dead flat, ANT poetics of experimental authors such as Tan Lin in Heath, and I risk 
alienating all but the most committed of readers. Ultimately, I settled on the hybrid approach of 
layering selected fieldwork examples of key circulating narratives and their intersections 
through the Translation sections with relevant literature in the field through the Perspectives 
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sections.  
 
Threading voices from the survey throughout all of the sections is a way of holding the key 
translations and existing research perspectives together with multiple personal narrative 
enactments of CLL. My aim has been to achieve some degree of narrative coherence whilst 
positioning the reader to confront CLL online as a series of multiple narrative enactments 
whose various intersections play out on each other. I hope that I have shown how the individual 
everyday personal narratives of CLL intersect with each other and with the institutional 
inscriptions of CLL to make novel, and sometimes powerful narratives of change. 
 
Chapter Summary 
 
I have argued that narrative construction in online communities takes place within a range of 
additional information-seeking behaviours, where alternative CLL narratives such as research 
papers, lab results, news stories, pharmaceutical press releases, and the experiences of other 
patients can end up shaping the shared stories of individual CLL patients. Given the range of 
narrative objects of CLL that circulate in the networks, it seems that perhaps internet 
communities are as much inter-objective as they are inter-subjective. This draws on a Deleuzian 
interpretation of culture as a material force in which text operates as just one actor in a 
broader network, and is not privileged as a locus of meaning in its own right: “...here the 
cultural text itself, the narrative, is not to be explored in terms of representation but in terms of 
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how it performs, acts upon us, or materially produces an ’effect’ (Bassett, 2007:23).  
 
By exploring the intersection of circulating narratives of a single disease online from a 
perspective of their material effects rather than analyzing them primarily as units of 
representation, I have located them as inscriptions of the practices enacted by the individuals, 
organizations and institutions producing them, and putting them into circulation. In doing so, I 
believe this study has put into practice an innovative approach for studying disease and its 
narrative performances in online support and knowledge exchange networks, revealing 
complex networks of intersections among these multiple narrative inscriptions of CLL online. It 
has identified some of the key actors and narratives involved in that process, and demonstrated 
some of the network effects produced when they come together. It has never been my 
intention to reduce those effects simply to observing the collective potential for patient 
empowerment generated in online communities, although that is certainly one of the effects 
among a number of others noted throughout this work, and one that as a CLL patient myself, I 
am pleased to observe. 
 
It is important to remember that whatever this work might have shown about enactments and 
practices of CLL online, and whatever might be learned from that about the concerns of all 
parties involved with producing CLL as a disease we recognize, understand, treat, fund, regulate 
for, live with, and die with, it cannot account for those who remain outside the online networks 
I have turned my lens on here. To take the lens away from the small territory I have explored in 
such fine detail here is to recognize that those not inhabiting it, and therefore not accounted 
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for in this work, constitute almost certainly the majority of current CLL patients and their 
clinicians globally. Given some of the more positive observations made about the potential for 
patients to take more control over their own illness  narratives in online networks, maybe the 
biggest challenge is to turn more patients from ‘centred’ to ‘networked’, and to help more 
clinicians to understand the implications of that. More clinicians in the CLL support networks 
online would certainly expose the medical profession more broadly to what it means to do CLL 
online, and to understand where their patients are, or might be located within circulating 
inscriptions of disease outside of the clinic setting. 
 
This work has raised a number of issues surrounding lives with CLL as read through online 
narratives. I have made my own suggestions for further research, but in the multiple narratives 
offered here, my hope is that readers may see other questions that need addressing. I have 
worked throughout with the philosophy that “The overall aim of a multi-voiced form of 
investigative story telling need not necessarily be to come to a conclusion. Its strength might 
very well be in the way it opens questions up.” (Mol and Law, 2004:17). As this work continues 
its journey as a CLL network actor, I hope that strength is realized. 
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Potential Shortcomings and Suggestions for Future Work 
 
I have worked hard to overcome the potential shortcomings of this work but, as with all 
research projects, I am aware that some remain. I will address those briefly in this short 
postscript. 
 
As stated, the multi-layered narrative approach of presentation is a methodological gesture 
towards encouraging readers to adopt the position of actor network theorist in the reading 
process. The differing enactments of CLL online are, as exemplified to some extent here in the 
‘Translations’ sections, wide –ranging and diverse.  They tap into an equally broad range of 
potential contextual observations as set out in the ‘Perspectives’ sections. It has not been my 
intention to abstract or draw definitive conclusions on the Translations through the 
Perspectives (or ‘explain’ the enactments through the theoretical frames in other words). 
Rather, I have sought to present the contextual work as further layers of enacting disease in the 
broader cultural sense – as a means of asking further questions about what it means to do 
disease in online contexts rather than providing definitive ‘answers’.  There is always the 
potential that, particularly for readers not familiar with the ontological stance of Actor Network 
Theory, this approach may seem frustrating and/or confusing. My hope is that the expository 
work invested in the Methodology section makes my intentions and rationale for my narrative 
choices and structuring clear, but I am aware of the potential risk of alienating readers.  This is 
particularly pertinent in the case of a thesis which such multi-disciplinary reach and potential 
significance. Throughout the work, I have strived to create a balance between the politics of 
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research methodology and form, and a desire for the work to remain accessible to the multiple 
actors making up the CLL community that the work ultimately sets out to serve, represent, and 
inform. In attempting to address both form and content in meaningful ways, it is inevitable that 
this iteration of the work may itself need a degree of ‘translating’ before it is circulated in 
various forms into some of the distinct communities of actors it describes. As the author, I see 
that not as a failing, but as an inevitable outcome of the research’s own position as a network 
actor meshed  into varying broader networks, and potentially subject to multiple translations in 
its own right (see appendix 15 for examples of varied iterations of the work currently in 
circulation, including a copy of a paper published in the online proceedings of a conference on 
chronic illness (2012), a presentation of elements of the work given at a pan-European CLL 
advocacy planning meeting (2014), an e-mail exchange with a major UK Leukaemia and 
Lymphoma Charity using data to advise on the tone and content of CLL patient support 
literature, various videos of me talking about the work in circulation throughout the CLL 
networks,  and a book chapter for an edited Medical Humanities collection currently in press).   
 
I am aware that some readers not familiar with ANT may feel they have been thrown rather 
unceremoniously into the deep end of the field.  I had to make a decision about how many of 
my allocated words I wanted to devote to explaining ANT itself in relation to my desire to do 
justice to the significant amounts of novel data I have uncovered with the work.  ANT is a well-
documented methodological approach, and I hope that the necessarily circumscribed 
descriptors, outlines, and references I have provided give the reader enough of a framework to 
allow them to feel comfortable with the complex and often baroque assemblages of narratives 
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that the work presents them with from the outset (or at least to feel comfortable with any 
potential discomfort as part of the process of engaging with an ANT study of this nature). As a 
researcher, I felt the weight of my responsibility more strongly aligned towards representing my 
respondents and the narrative translations selected than to the task of re-iterating in time-
consuming methodological detail that which can easily be found elsewhere. I hope I got the 
balance right in this respect, but again appreciate a possible need to adjust that balance in 
future, and more audience-specific iterations of this work. 
 
The large amounts of data gleaned, and word-count restrictions made it difficult for me to work 
with phenomena observed beyond the thematic sections of Diagnosis, Prognosis, and 
Treatment addressed herein. A significant amount of online narrative circulation pertains to the 
business of simply ‘surviving’ or living with CLL and, inevitably in the case of an incurable 
hematological malignancy, dying from the disease. These important experiences are addressed 
to some extent in appropriate sections of the thesis, but there is much to be learned from a 
closer and more nuanced  mapping of the themes of ‘Survival’ and ‘Dying’ specifically in my 
opinion. To that end, it is my intention to work this thesis up into a book in which both of those 
thematic areas will be mapped as dedicated additional chapters. 
 
Finally, and as addressed in the Summary section of this chapter, this work represents the 
voices of CLL patients who have, at the very least, gone on line to respond to my ‘In Our Blood’ 
online survey. It is a study of online narrative circulation, and samples some of the actors 
involved in those networks. Although I have asked respondents about their practices, and 
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attitudes to online sharing in relation to their disease, and have made some observations about 
the more negative experiences and resistant attitudes expressed by some survey respondents, 
the work can make no claim to speak for the presumably significant amount of CLL patients not 
using online resources at all. In terms of representation, the work is also restricted largely to 
the English-speaking CLL patients using the CLL Support networks selected for the sample.  
 
Whilst my observations apply to a relatively large-scale sample group for a one-woman-led 
research project, I am aware that further work needs to be done in exploring to what extent 
any findings might be meaningfully extrapolated to those sections of the CLL community 
remaining outside the remit of this thesis. It is also important to work towards understanding 
how those patients (and other CLL actors) currently not engaged in the kind of knowledge 
exchange, advocacy, and often demonstrable empowerment demonstrated through this 
research might be encouraged to engage in the future. 
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Appendix 1: TouchGraph showing Available Data 
 
   
 
Figure 41: TOUCHGRAPH (2015) network connections and data for Macmillan CLL [Network Map]. [Online] Available at: 
http://www.touchgraph.com/seo/launch?q=macmillan%.20cll showing search results and graph for the initial search term ‘Macmillan CLL’ [Accessed 
06/08/2015]. 
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Appendix 2: Initial Invitation to Participate 
 
Posted by juliak on  
11-19-2012 6:54 PM 
Hello - and hope everyone is doing okay, 
I'm writing to you all today to ask if you would consider giving your vital input on my doctoral project "In the Blood" 
looking at how the CLL community  gain knowledge and support from the internet. 
I am giving a talk on my work at the Cardiff meeting on 30th January, 2013 alongside Professor Chris Fegan and Dr. 
Chris Pepper who will be talking about their clinical and research work.  Some of you may have read my introduction 
to the project in the recent CLLSA Newsletter. If not, here's an extract: 
“In the Blood”, my doctoral project, explores an online support community as a “hub” of knowledge and support 
exchange. From complex medical research papers to individual accounts of living with the disease (and much in 
between), the project will document the various stories that come together in the online support community, enabling 
users to make collaborative sense of a chronic disease that shapes our lives.  Apart from identifying the key themes 
that occupy the lives of those living with (and around) CLL, the project looks at the relationships between research, 
clinical, and patient perspectives in the dialogues of support communities. How are we translating and utilizing the 
advanced information at our fingertips? How are we supporting and educating each other? How are we contributing 
to raising awareness of the disease? What impact is this having on our relationships with our clinicians and carers? 
Through this approach I aim to show how biomedical research, clinical management, and popular cultural beliefs 
about what it means to live with cancer translate to everyday experience for those of us living with CLL."   
I think that work like this is fundamental to understanding how we gain knowledge and support about our disease. 
CLL remains relatively under-researched in this respect (unlike breast cancer for example). Very few researchers of 
the communication networks surrounding disease actually have the experience of living with the disease.  As a 
member of the community, a CLL patient, and a researcher, I think I can change that with your help, and I am proud 
and pleased to have the support of CLLSA who have read my proposal, and research paper. 
If you are interested in being part of this work, please take a look at my blog 
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  http://julesk-inourblood.blogspot.co.uk/ 
The blog explains the rationale behind the work, sets out information about how to give informed consent to being 
part of the project, and gives you information about how I would protect the privacy and anonymity of any input you 
consented to me using.  This PhD project has been through a rigorous ethics process with my University, and has 
been passed by the committee (who commended it for breaking new ground for online research ethics). I have also 
informed Macmillan about this work through the site's channels for communicating research projects within the online 
community. 
If you have any further queries after reading the blog, please message me, or add a post to this thread.  Please 
remember, this community is as much a lifeline to me as it is to everyone else here, so my presence as a 
trusted member, and your continued sense of comfort and safety in using the site are my primary 
concerns. If this research compromises that in any way, I will adjust it accordingly, or take it elsewhere. 
However, between us, I think we have so much to share that could impact on the way that the clinical and academic 
worlds understand what it means to live with and communicate about CLL. If you would like to be part of that 
adventure, I give you my absolute word that I will treat any postings or observations you consent to me using as the 
precious things they are. I also give you my word that if you don't want your contributions used to inform this research 
project in any way, that they absolutely will not be.  
Have a think about this, read the information, and please get back to me with your thoughts or any comments. If you 
have any problems accessing the link or navigating the information there, please let me know asap. 
Jules 
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Appendix 3: In Our Blood Blog Screenshot and URL 
 
Showing how link from initial invitation (Appendix 2a) gives respondents access to further 
information about the project on the blog site. 
 
 
Figure 42: JULESK (2013). “In Our Blood” Blog set up to inform participants and provide information and consent 
forms [Screenshot] 02/01/2013. Available at: http://julesk-inourblood.blogspot.co.uk/ [Accessed 02/01/2013]. 
 
Feedback indicates that people found this approach useful for reading more about the project, 
without me having to overload the invitation to respond with excess information that might 
have proved off-putting in the first instance. Interestingly, those people who had further 
queries tended to contact me directly rather than posting to the blog. In that sense, the blog 
didn’t really function as a dialogic space in its own right as I had initially anticipated. However, it 
certainly functioned successfully to mediate information and ultimately strengthened the 
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research as a network.  There are a number of potential reasons for the seeming reluctance to 
post to the blog itself including: privacy/confidentiality; unfamiliarity among respondents with 
the blog format; maintaining existing lines of communication with me through support 
sites/private messaging among those respondents already in dialogue with me online; and my 
own willingness to communicate with respondents through their preferred channels.  
Further research into using blogs as a means of disseminating information and communicating 
with potential research respondents would be useful in this context. 
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Appendix 4: Response to Potential Respondent  
 
 
Posted by juliak on  
11-22-2012 9:22 PM 
In response to your initial misgivings around confidentiality and feeling studied, I'm happy that you've raised 
that issue. This is of course one of the main areas I've had to focus on in the year long negotiation of 
rigorous ethics processes that I've been working on. Confidentiality is absolute - I'm not using anything that 
people don't consent to - quotes which people have consented to being used will be anonymized if the 
author wishes (although many people like to "own" their published quotes and get upset if their name is 
changed or replaced with a number). As far as being studied goes, I don't see myself as "studying" 
individuals in the community. I'll explain why. 
Firstly, I'm not coming in from the outside to study the community in a 'colonial' manner - I'm already a 
member, and I joined because I needed the support and knowledge I get from the community to help 
manage my own life with CLL, and not to do the research. I was interested in looking at support communities 
for cancer patients on the internet in general when I joined, but got interested in how this community deals 
with knowledge exchange and support after joining because I think it does something quite different from 
other CLL communities that I am a member of. If I say something next about what it is that I think we do here 
that make those principles worth sharing with the wider world,  that might also help answer your next 
questions about what it is exactly that I will be looking at within the group. 
What I noticed from the outset here was an incredibly sophisticated approach to circulating a whole range of 
other information sources about CLL on the site.  These range from complicated clinical research papers, 
information from alternative CLL websites, reports from clinical consultations including blood results, bone 
marrow biopsy results, scan readings, to newspaper reports about CLL celebrities such as the discussions 
about Clive James and the Daily Mirror feature on him that provoked a lot of discussion in the community a 
few months back and so on.  What I'm interested in here is how those various stories or narratives of CLL, 
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be they scientific, clinical, educational, or popular cultural, find their way into people's own stories of their 
everyday experiences of living with CLL.   
In this community, we translate a vast range of the circulating information that defines CLL into our own 
experiences. I'm interested in tracing all of the stories back to their origins (science, news, fund-raising 
campaigns, clinical) and then looking at how they are translated into the experiences of those community 
members who are happy to contribute. An example might be taking an illustration from "nature" magazine 
that shows Zap 70 as a branch amongst many others, then looking at a clinical research paper on the 
significance of Zap 70 in CLL prognostics, relating it to say Chaya Venkat's transaltion of the Zap 70 debate 
over on CLL topics, then looking at how we in the community relate the issue of knowing about our genetic 
mutations to our real lives (all of those texts and sites can be traced back from this community).  I'm using a 
method known as Actor Network Theory to achieve that (a method designed by Bruno Latour to explore the 
way that science and scientists produce knowledge). 
That is just one example, but it demonstrates how the community and our responses are just one part of a 
much bigger map of connections that join the scientific (in this case) to the everyday realities of knowing and 
living with this disease. For the purposes of this work, the community is the "hub" where a vast range of 
different narratives about CLL come together through the experience of the members. The work will also 
have an element of autobiographical writing about the disease from myself, and how I've come to know and 
live with it through what I've learned. That will be layered with all of the other texts that we learn from, and 
quotes from those who are happy to be involved under the following headings (which represent the main 
themes that concern those living with CLL emerging from my own experience and other stories I have 
encountered about living with CLL to date): 
Diagnosis (how we understand it and how that feels); Prognosis (lots here about the impact of all the new 
research ant treatments on our expectations); Living well with CLL (coming to terms with the impact of the 
disease on our lives); Impact of CLL on our perception of time (watch and wait and its implications for our 
view of the future); Relationships with others (impact of the disease on our connections with friends, family, 
and the rest of those we come into contact with). 
If you're still here (I can't answer all the questions you've asked me without explaining them all clearly, so 
hang in there), you should be able to get a clearer picture of what I'm actually doing, and what my aims are 
by now.  It should also become clear that I'm not actually looking at dynamics/hierarchies/roles of individuals 
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in the community - but at the way we are linking and circulating information, and translating it into our 
everyday experiences. I need some examples of that translation, but I don't need to look 
at everyone's contributions for this to work - it's not an ethnography of the community itself, but of the 
disease at is represented in the community (if you're interested in this method see AnneMarie Mol's 
excellent book "The Body Multiple" which is an ethnography of atherosclerosis conducted in a hospital - I 
think you would really enjoy it). There is also a book by an academic called Jackie Stacey entitled 
Teratologies - the story of her own experiences with cancer that does something similar...  Essentially I'm 
doing the same for CLL, but online, and - hugely importantly in my opinion - researching our disease from 
the inside out. There is so much written about cancer by people without cancer - it is part of my 
methodological politics to change that. 
Finally - will I "contaminate" the data?  It's another good question, and one my ethics committee asked. They 
were very positive about  my response that I'm not making any claims to be objective in the positivist sense 
in this research because I am a native researcher - exploring the world I now live in through narrative 
associations, and through a significant element of my own autobiography. My presence here as a person 
with CLL is fundamental to the politics and design of the project. I get to write enough in this work about my 
own experience, so I don't need or want to influence the discussion on the site according to my research 
aims. Ultimately my PhD will be the story of 4 years of living with CLL, how I have come to understand it, 
and what I have observed about how others have come to understand it - all focused on all of the 
information and some of experience that converges at the "hub" of the Mac site... 
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Appendix 5: Revised invitation  
 
jibs60   
 
29 Dec 2012 
Hello,  
 
I hope that you have had an enjoyable Christmas holidays, and still have some energy left to 
celebrate as we head into the New Year...  
 
I hope you don't mind me messaging you personally, but I'm looking for volunteers to contribute to 
my Doctoral Project 'In our Blood', looking at the way those of us living with CLL make sense of the 
impact of the disease on our lives through all of the different perspectives we come across when 
researching the disease online.  
 
When I was diagnosed my GP had little knowledge of the disease. He was unable to answer many 
of my questions and told me to go away and "look it up on the internet". It was here that it became 
clear to me that "CLL" as we understand it is a disease constructed out of many perspectives, some 
mainstream and rooted in biomedical research and clinical practice, some tied into popular cultural 
belief systems about disease, others marginalised and "alternative", and many drawing from 
biographical autobiographical experience as we negotiate our own perspectives in relation to those 
already out there.  
 
My project 'In our Blood' was born shortly after my diagnosis. The work traces the networks and 
associations between all of the different perspectives that come together both on and off-line to 
produce knowledge of a disease. The whole is looped into my own autobiographical narrative of 
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what it means to live with this disease, and refers out to the biographical experiences of others 
through postings, blogs, videos etc. This is where I need your help to get as many perspectives from 
others living with CLL into the work...  
 
I am particularly interested in drawing on people's experiences of:  
 
Diagnosis (what it feels like to get the diagnosis, and how we deal with it)  
Prognosis (what resources we use to deal with that - how research and other patient experiences 
affects our expectations)  
Learning to Live with CLL (how we adjust our lifestyles and attitudes, and what resources we draw 
on to help with that)  
How a diagnosis of CLL affects our sense of time (I guess this one is about the impact of an 
increased sense of mortality)  
How having CLL impacts on our relationships with others (what happens to existing relationships 
with family/friends/colleagues - do we come to feel like 'strangers' in our own lives, and how do we 
deal with that?)  
 
I would be delighted if anyone on this site would consider allowing me to use some of their own 
perspectives on living with CLL in my work. If not, no worries, and you can be sure that no dialogue 
we have online or elsewhere will find its way into my work. I am a fellow CLL traveller first and 
foremost, and my research is secondary to that (although I believe it to be important work that can 
benefit all of us living with cancer in some small way).  
 
For those who are interested in contributing, I would be happy to use quotes and excerpts from the 
blogs and postings online on this forum pertaining to the above issues. This site is a rich source of 
experience and sharing of the fundamental issues we all face in learning to live with CLL. However, 
if people would prefer to write something privately to me about their experiences rather than giving 
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consent for me to use blog postings or responses, please let me know, and I'll send some questions 
for you to respond to at your leisure...  
 
I launched a blog to explain the work to respondents in an online support community for people with 
CLL a while back:  
julesk-inourblood.blogspot....  
 
If you are interested, perhaps you could take a look at the information, download and read through 
the consent forms linked to the site under the Information and Consent Forms for Downloading 
heading on the right hand margin, and message me back either through this site, or on 
julia.kennedy@falmouth.ac.uk.  
 
You will need to confirm clearly in writing the following (just copy and paste into your response, 
deleting options as appropriate):  
 
"I confirm that I have downloaded a copies of the participant information sheet and the consent form 
to keep,and have read and understood them. I am willing to allow my postings/blog entries/e-mail 
interview responses (please include or delete as appropriate)  
to be used in the research project 'In our Blood'. I would prefer my contributions to be cited 
anonymously/attributed to me personally (for which I will need your full name)/attributed to my online 
name (please include or delete as appropriate)."  
 
I'm working with this online consent process at present as getting people to fill in hard copy forms 
and send them back to me is proving tricky and can create problems for those wishing to remain 
anonymous.  
 
Please get back to me if you would like to participate in any way, or if you have any questions about 
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the work.  
 
I'm presenting a paper on the project at the Cardiff meeting of the CLLSA on 30th January. The work 
has been through a rigorous ethics committee process and gained full ethics clearance from my 
University (University of the Arts London/Falmouth University). It has also been before the 
committee of the CLLSA and has its full support, and has received expressions of interest from the 
Lymphoma and Leukaemia Research Organisation.  
 
I really look forward to having the privilege of working with your thoughts and experiences if you are 
willing to share them.  
 
With kind regards, and wishing you a fine New Year ... Julia  
e-mail: julia.kennedy@falmouth.ac.uk 
 
 
 
 
 
 
 
 
Appendix 6: SurveyMonkey Consent Form 
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This page outlines the aims of the research project you are being asked to contribute to, provides 
information on your expected role, the security of your data and issues of confidentiality, and gives 
details of where further information can be sought. It is very important that you read and understand 
this information before consenting to take part in the project. 
 
The Project and its Aims 
As a fellow CLL patient (diagnosed in February 2011), former nurse, and current communications academic, I 
am interested in what we can learn about living with disease from the networks of support and information 
available on the internet. There is a vibrant community of people whose lives are touched by CLL using the 
internet in many ways to share information and experience. This is where I have learned nearly everything 
that I know about the disease, and connected with others who live and work with CLL. Yet this remains an 
under-represented body in CLL research. 
 
I am asking for your permission to use selected excerpts of postings or other contributions you have made to 
discussions about CLL online from archived material and over the coming months. These will be cited 
anonymously unless you state otherwise in this consent form. All you are required to do is to contribute 
online as you usually would and trust that, as a fellow CLL patient, I will handle any excerpts that I use 
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carefully and sensitively. I want as many voices from the online CLL community as possible to be heard in this 
research. 
 
As far as I am aware, this doctoral project is the first potential large-scale research into how patients and 
carers use online resources to make sense of CLL. The ultimate aim of the project is to enhance 
understanding of how the internet provides a hub of information and support to help us negotiate the 
challenges of living with chronic blood cancer in the twenty-first century.  
 
Taking Part 
You are being asked to provide your consent to the researcher using selected excerpts of your online 
postings/contributions to CLL specific sites for the duration of the project which is due for completion in 
2014. You don't need to do anything other than contribute to those sites as you usually would. 
 
This form provides the means for you to access the relevant information to enable you to provide that 
consent in an informed manner, and to indicate your preferences for how you would like to be attributed in 
any published work arising from the project. Your IP address will not be stored, and information is encrypted 
and transmitted over secure channels. 
 
How the Data will be Used 
The results will be submitted as part of my PhD thesis for University of the Arts London and Falmouth 
University. Work in progress will be written up for journal articles and conference papers. The project is 
receiving no external funding.  
 
Risks 
Whilst every effort will be made to protect your identity and maintain your confidentiality, it is important to 
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be aware that even anonymized quotes taken from online spaces can be traced back to any sites to which the 
searcher has access. This is a minimal risk in this research context, but you should be aware of it. 
 
Benefits 
The benefits are long-term and are about contributing to improved understanding of what it means to live 
with CLL. 
 
If you have any questions please contact me in the first instance at: 
 
Julia Kennedy, Senior Lecturer, BA (Hons) Journalism, University College Falmouth, Treliever Road, Penryn, 
Cornwall, TR10 9EZ 
julia.kennedy@falmouth.ac.uk 
Further information about the project, along with hard copies of participant information and consent forms 
to download if you wish to can be found on the research blog http://julesk-inourblood.blogspot.co.uk/ 
 
All of the following four statements need a response. By completing the form and submitting it you are 
confirming that you have read the description of the study, are over the age of 18, and that you are freely 
consenting to take part in the project.  
 
This is not binding, and you are free to withdraw at any point simply by contacting the researcher 
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Sample Response:
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Appendix 7: Sample Messages of Endorsement/Support 
 
These have been copied and printed removing identifying details where appropriate in line with 
ethical guidelines for the project. 
 
Message Received 6/12/12 
Dear Julia, 
I am glad you have posted your Project on the Acor list, being one of the oldest and a very respected one, 
very well run. 
I do not contribute as much as I used to do for many years, but I know most of the old members and 
when I give updates I get many mails in private. 
Not sure if you have put your rfesearch on the www.cllcfriends.com and also the cllforum.com, both very 
respectable and both started by original members of acor that felt wanted more than just a list. 
The original people of CLLSA we met through Acor in the first place, sadly several have now passed 
away but they stay in our memories and many were very influencial in our beginings. 
I wish you well and hope you get many responses,  
I am a User Representative for Thames Valley Cancer Network for Haematology as well as my local 
hospital in Swindon I find that it is now after 10 years that the UK people are using the internet more, you 
would be amazed by the comments I had rom a consultant 10 years ago talking about internet, we have 
to be tghankful for people like Prof. Terry Hamblin who really push patient influence and helped many 
people using the internet. 
If I am fully honest I would rather be diagnosed with CLL over the last couple of years than when I did 10 
years ago, it was hard work dealing with medics in those days, I can sit back and see the amazing 
progress we have made, I can see how in TVCN patients are welcome to be involved in many things and 
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their influence is great. At Swindon we are going to produce a DVD for newly diagnosed patients, one 
other hospital in TVCN has already done it and proved very helpful. 
I am busy the next couple of days but will do your survey and if you need any other help, please let me 
know. 
Rest [sic] Regards 
 
Message received  11/02/13 
Dear Julia, 
As a fellow reader of the CLL list – and also an academic - I was sorry to see that you have had to join the 
CLL community but interested to hear that you are developing this project.  I was diagnosed at age 47 
and after the initial trauma of getting such a diagnosis when one has children, have stayed off treatment 
for 15 years despite some rise in my WBC (now around 100k too) and drops in platelets.  
I run a research unit on cancer prevention and early detection at XXX, part of which involves an interest 
in health communication and internet use.  So if you were ever in London and wanted to visit, it would 
be good to meet up. 
Best wishes 
XXXXXXXXXXMA, PhD, FMedSci 
Professor of Clinical Psychology 
Director, XXXXXXXXXXXXXXXXXX 
Department of Epidemiology and Public Health 
XXXXXXX 
XXXXXXX 
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Message : received 7/1/13 
Hi Julia, 
It was great to read about your research project on the ACOR CLL listserv. 
I've added you as a reader to my password protected blog, located 
here: http://revolvingat900milesanhour.blogspot.ca/. There you'll find my husband's history, along with 
a short overview of how the internet and web essentially provided him with many extra years of life.  
Please be in touch if I can be of more help. I work in health research in British Columbia so am happy to 
be of any assistance. 
xxxxxxxxxx 
Victoria, Canada & one of the initial ACOR CLL listserv users 
 
Message received 30.12.12 
Happy to help but this all gets too complicated.. 
 
Remember CLL is a disease of OLDER people..!! 
 
Have to have a Facebook account, or sign up to yet more rubbish e-mails.. 
 
Simplify and I will help..!! 
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Happy New Year.. 
 
Message received 6.1.13 
Please take a look at PatientPower.info, my blog and my book, The Web-Savvy Patient. I'd be happy to help 
you. 
Best Wishes, 
Andrew Schorr, Barcelona 
 
Andrew Schorr | Founder and Host | andrew@patientpower.info | 206.973.7390 or +34 
622069835 
 
PatientPower.info | Facebook | YouTube | Twitter 
 
(public site – and frequently mentioned key network node in research - so details not 
anonymized) 
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Appendix 8: Sample selection of completed ‘In Our Blood’ survey forms  
 
This appendix contains: 
 
Four completed survey forms. 
 
Summary data visualization and % figures for quantitative questions 2-8. 
 
Data summary for qualitative question 15 requesting respondents to identify any issues they 
felt I had omitted in the survey. This was an important part of the survey as it allowed me to 
consider themes and issues not identified in my initial fieldwork online, and thus not already 
represented in the themed survey questions.   
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Appendix 9: Initial Response to Ethics Committee recommendations 
(February, 2012) 
 
Response to Research Ethics Sub-Committee decision on Application for research ethics approval 
Julia Kennedy – paper 7/11-12 (my responses represented below committee recommendations, in bold, 
italicized script) 
In the Blood: Narrative and Rhetoric in online communications of patients with blood cancers 
8.2.2   Following the discussion of the proposal the Committee had the following comments: 
 
i. The application needs to make clear which organisations are running the websites and 
online communities being used in the research and the applicant should confirm that she 
will be complying with their terms of use.  If any sites are being run by the NHS then the 
applicant would also need to comply with the NHS’ research ethics procedures. 
 
It is my intention to focus on Macmillan’s online community if possible.  I have contacted 
Macmillan’s head office and the local online administrator of the specific community I 
would like to research. I have been given an in principle approval, and  am awaiting a 
formal response.  If this proves difficult or not possible, I will re-focus onto the global 
ACOR listserv community (although this would not be my preference as I want to look at 
UK activity specifically if possible). 
 
ii.  In question 7 of the Ethics application form the student should clarify how she will ensure 
that the participants (who are self-nominating) will not be children or vulnerable adults. 
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In as far as any researcher conducting research other than in face to face contexts can be 
sure that respondents are who they say they are (i.e. not masquerading as eligible 
participants when they are in fact not), I consider that the following  filters (naturally 
occurring or imposed by myself) will  reinforce the probability of eligibility in 
respondents.   
 
Firstly, the specific chronic blood cancers that I am researching  are not childhood 
diseases.  The average age at diagnosis is 55-60.  The stated ages in the biographical 
details offered by members of the community I wish to research are between early 
forties to late eighties.  In that sense, I feel this community is self-regulating in terms of 
excluding children.  Even in cases where a child of a parent with CLL has posted to the 
community for advice, they have been adults in their own right.  Members of the 
community have to sign up and create a user name and password before posting.  No 
new members post without an introduction to other community members, so 
biographical detail, including age is offered as part of the introduction, and integration 
process.   
 
In terms of the likelihood of respondents being vulnerable adults, arguably Macmillan’s 
co-operation with my research plans might make what could be considered as members 
of a vulnerable social group feel coerced into co-operation. I will make sure that all 
group members are contacted with clear and concise details of the project, its aims, and 
the ways in which their postings may be used should they give their consent.  It will be 
made very clear that anyone who does not wish to participate will not have their 
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contributions used for the purposes of the research project.  Consent will be seen as a 
dynamic and ongoing process, with frequent updates to include new members, and final 
consent individually requested before including any postings in the finished PhD 
document, or any work published as part of the research process. 
 
Due to the highly textual and self-motivated nature of exchanges being researched, it is 
not anticipated that any of the respondents will be adults considered incompetent to 
consent to research. 
 
iii. Section 12 should be removed from the Professional Carers participant information sheet 
and section 11 from the Online Community Members participant information sheet. 
I have removed section 12 (reward) from professional carers participant form. 
I have removed section 11 (reward) from online community members participant form. 
 
iv. The consent form needs to be more concise. 
I have edited consent forms for both professionals and online community members to 
contain only that information which is relevant to making informed consent 
 
v. The participant consent forms should be adapted for different audiences and further 
consideration is required on how consent will be given and recorded in an online context 
where signing a consent form is likely to be impractical 
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Since submitting the RF3, the project focus has sharpened to an ethnographic study of a 
specific community – the Macmillan online community.  The online community member 
participant consent has been adapted to suit that audience.  It would also suit any other 
dedicated online support community for people with chronic blood cancers. 
 Professional carer input, if solicited at all, is likely to be a minor part of this 
ethnographic project (see point vi below). However, I have revised the form, although it 
is not yet possible to adapt to a specific professional role until that part of the research 
process is reached. Therefore I have left a range of possible roles in situ on the form, but 
would adapt accordingly should this element of the research take place in future. The 
generic wording of the document would remain appropriate to all professional roles in 
my opinion. 
 
As far as giving and recording consent in an online context is concerned, this is 
acknowledged to be a major obstacle for online researchers.  My sample group is likely 
to be relatively small.  The cancers I am looking at are relatively rare, and the group I 
propose to look at is at present a small group in terms of membership.  If hard copies of 
signed consent forms are considered essential by the chair, I can mail consent forms to 
home addresses if participants are willing to provide these, with a stamped addressed 
envelope for return to myself. Alternatively, I could send forms as attachments to 
participants e-mail addresses for signing, scanning and returning electronically.   
 
I appreciate that the validity of e-mail consent in comparison to a signature is a 
contested area. However, if the chair agrees to an e-mail confirmation from respondents 
of receipt, understanding and accordance with the information provided and consent 
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required, this would probably be the most practical approach. The community I plan to 
research has the facility to follow individual members as friends (if they choose to accept 
a friendship request) and to message those members privately.  This facility allows me to 
contact group members on an ongoing basis and to exchange information in a private 
domain.  Mann and Stewart (2000) suggest this as a possible solution to the issue of 
consent in online research.  
 
Also underpinned by Mann and Stewart (2000) is the suggestion of setting up a separate 
site outlining the research aims, objectives, and design.  I intend to create a site with a 
section for FAQs and a short video explaining each stage of the consent process.  All 
potential respondents would be directed to the site with the initial e-mail 
communication.  A comment section would allow for participants to check out 
information, and they are all able to contact me privately anyway through the 
community. It would also be possible to create a downloadable consent form accessible 
from the site which could then be posted back to me if e-mail consent alone is not 
considered adequate for the project. 
 
vi        Further information is required on the role that medical staff would play in the   
            research. 
 
          As stated above, the research has focused more intensely on a narrative ethnographic  
           study of the online community itself.  The membership of community I propose to  
look at is largely constituted of people with chronic cancers, rather than carers.  
However, it may be that I wish to draw on the perspectives of professional carers, such 
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as representatives of Macmillan, CLL specialists, or specialist nurse practitioners to 
contextualize the work at a later point.  Should that be the case, I would be interested in 
soliciting general opinion about the use and benefits of online support communities by 
the people with chronic blood cancers in their care. It is by no means a given that this 
element of the work will be necessary to achieving my research aims.  However, I 
decided to include it at this stage to obviate the necessity of re-applying for consent 
should I wish to pursue this possibility at a later stage. 
 
vii    The applicant needs to reconsider the  way in which she presents her research to ensure  
         that it was not coercive towards participants and  only provided factual information  
         information about the project.  In particular, the applicant should consider the effects      
         of disclosing her own circumstances on this matter. 
 
         Part of my methodology is to include an element of auto-ethnographic engagement. I       
         am researching  online communities of people with blood cancers as a native      
         researcher, and this is intrinsic to the research process.  As such, my own status as a  
         person with CLL cannot be concealed  within the current project design. Prospective                       
         participants in my proposed research community are already aware of my status as a  
fellow group members  with a chronic blood cancer, and my status as an academic and 
researcher (though not yet of my intention to research within this specific community).  
My membership of this community is of real value and importance to me, and I deeply 
value the friendships and associations I have made in the community.  It is in my interests 
to collaborate with the community, subject to their informed consent, in a way that 
protects and sustains those relationships of trust in a freely consensual and non-coercive 
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context. The spirit of this research as a collaborative endeavour within an already 
established group of which I am an active member is fundamental to achieving my aims, 
and will be communicated at all times within the research site.  
 
Following  Sharf (1999), I would make concerted efforts to  contact by e-mail all 
individuals whose quotes I want to use for published material arising from the research, 
personally requesting consent to use them. As part of this process, I would remain open to 
feedback from participants on my interpretation of their quotes. 
 
 If at any point it is felt that my position as a native researcher, and Macmillan’s co-
operation with my research presence within the community renders the environment of 
non-coercive consent and collaboration unworkable, I will re-focus my aims and site of 
study accordingly. 
 
        It is possible that I could omit my circumstances from information sent to professional  
        carers (with the exception of Macmillan representatives) should I pursue that element 
        of the research process in due course.  
 
References 
Mann C., and Stewart, F, (2000) Internet Communication and Qualitative Research: a handbook for 
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Sharf, B. (1997) ‘Communicating Breast Cancer On-Line: Support and Empowerment on the Internet, 
Woman and Health, 26 (1), pp 65-84. 
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Appendix 10: Extract from the minutes of the Research Ethics Sub-
Committee’s consideration of my revised research ethics application  
 
Confidential 
RESEARCH ETHICS SUB-COMMITTEE 
Extract from the minutes of the Research Ethics Sub-Committee’s consideration of your 
revised research ethics application submitted in response to the Committee’s comments 
made at their meeting on 21st February 2012 
Julia Kennedy (University College Falmouth) 
8. APPLICATIONS FOR RESEARCH ETHICS APPROVAL 
8.2 Student – (Julia Kennedy) Paper 7/11-12 
In the Blood: Narrative and Rhetoric in online communications of patients with 
blood cancers. 
8.2.4 Received: Julia Kennedy’s revised ethics application. 
8.2.5 Agreed: The Committee were impressed with the thoroughness with which the 
applicant had addressed the ethical issues relating to her research and also with 
the thought and effort that had gone into her response to the Committee’s 
comments. 
8.2.6 Following the discussion of the proposal the Committee had the following 
comments: 
i. The correct contact details for the Research Management & 
Administration Office should be given on the participant consent form. 
ii. The ‘thank you’ paragraph in the participant consent form should be 
removed. 
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iii. The phrase ‘Please take a moment to complete the enclosed 
survey and return it to me’ in the ‘invitation’ section of the 
information sheet for Professional s should be changed to: ‘Please 
consider whether or not to respond to the enclosed survey and if 
yes, please complete it and return it to me’. 
iv. A suggestion that the applicant incorporates a full ethics section into 
her PhD or produces a journal article on this topic, as her discussion 
and resolutions seem to advance the field rather than merely comply 
with it. 
8.2.7 Agreed: The student is required to make the amendments detailed in points 
8.2.6i-iii for consideration by her Director of Studies. Once approved by the 
Director of Studies, the Committee Secretary should be informed and sent a 
copy of the approved application. Point 8.2.6iv was offered as a 
recommendation for the student. 
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Appendix 11: Key additional sites used by In Our Blood Survey respondents 
and a narrative overview of key sites/analytics observed through early 
fieldwork  
 
SITE                                                                                                                            RESPONSES 
CLLSA UK (original site)                                                                                                  11 
Bad to the Bone FB page                                                                                                 9 
Blogs (Dr. Sharman – CLL Specialist; Dr, Brian Koffman 
- Family Doctor and CLL patient; Dr Terry Hamblin 
- CLL specialist (deceased date); David Arensen 
- CLL patient (deceased date)                                                                                   8 
Cancer Research UK                                                                                                         6 
Patient Power (Andrew Schorr)                                                                                    6 
Other FB pages 
(inc. cll watch and wait warriors/BTK inhibitor group)                                            5               
http://cllforum.com/                                                                                                      5 
Yahoo CLL/SLL groups                                                                                                     4 
www.ukcllforum.org/                                                                                                     4 
Leukaemia and Lymphoma Research                                                                            3 
 
The following sites also received either one or two mentions across the 77 responses: 
ASH   (American Society of Haematology)                                              
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Leukemia Lighthouse Connection (FB group)                                         
Cancer journals                                                                                             
Cll Christian Friends                                                                                     
www.leukaemiacare.org.uk/                                                                     
Generic Google search                                                                                 
NHS patient info                                                                                                                              
Mayo Clinic                                                                                                     
ITP support ass. UK                                                                                       
http://lymphomasurvival.com/                                                                
Leukemia and Lymphoma Soc. Of Alberta/Canada                              
http://www.lymphomation.org/                                                             
Wikipedia                                                                                                      
National Cancer Institute                                                                           
Kimball’s Biology Pages                                                                              
Maggies UK                                                                                                   
Pubmed                                                                                                          
Medscape                                                                                                      
Medical conference proceedings/research papers           
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CLL Sites Online – a narrative overview of some key sites and analytics taken early in 
the research project (March, 2013) 
 
As suggested in the introduction, CLL patients have a particularly active online presence. The 
chronic progressive nature of the disease potentially gives people more time to deeply research 
their condition and potential treatments, and to set up and maintain long-term online 
associations in support groups than those facing the immediate need for clinical intervention 
associated with more acute conditions. The impact of the internet on health communications 
and knowledge exchange generally will be explored in the following section, but it is clear that 
information and support provided in the clinical setting is now just one of a range of ways in 
which many computer literate CLL patients come to understand the bigger pictures of their 
disease. This overview provides a quick snapshot of CLL networks currently operating online in 
the UK and US, identifying the major sites, and their current membership or traffic as of March, 
2013. 
 
Acor.org, the association of cancer online resources operates as a listserv with membership-
only mailing lists covering a range of 170 cancer types. The global CLL list registers 2683 
subscribers, with dedicated sub-lists for Canada and the UK recording memberships of 138 and 
115 respectively (although it is likely that these people are also members of the global list). 
Interestingly, the only group currently showing a slightly higher membership of 2866 
subscribers is the Myeloproliferative Neoplasm Support group. This is also a haematological 
malignancy, characterized in this case by excessive production of blood cells, again usually 
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diagnosed in older patients and demonstrating a chronic, but incurable progression trajectory 
similar to that of CLL. The third highest membership is registered by the carcinoid cancer 
support group with 1399 members. Again, this group of slow growing neuro-endocrine tumours 
present with indolent, chronic progression.  This supports my own observations about the 
highly active online presence of CLL patients as correlative to the chronic nature of the disease, 
and fits the profile of the conclusions of the 2010 Pew Internet Research team surrounding the 
significance of online information in relation to treatment decisions for those with chronic 
illness (Fox, S., and Purcell, K., 2010).   
 
The Yahoo CLL and SLL (small lymphocytic leukemia) Listserv Group currently registers 989 
members, and the Yahoo CLL-Research and Advocacy group currently stands at 651 members.  
The two major UK-based groups configure as follows as at March, 2013. The Macmillan CLL/SLL 
group registers 160 members. The CLLSA UK site set up on the Health Unlocked platform in 
2012 registers 306 members.  
 
Non-membership support and information sites such as CLL Topics, CLL Canada, and the 
CLLGLobal Research Foundation are important nodes in the network.  Traffic for CLL Canada 
can’t currently be tracked online, but web analytics site Alexa currently registers 17 sites 
recording inward links to the site. Traffic to CLL topics was ranked at 2,238,090 globally 
(461,720 in the US) by Alexa, with a total of 112 sites linking in as at March, 2012. The 
CLLGlobal Research Foundation is ranked 7,629,257 in the world by Alexa, with 33 sites linking 
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in.  Journalist and CLL patient, Andrew Schorr’s site Patient Power has a well-established global 
CLL advocacy role, alongside growing provision for a range of other diseases. Both CLLGlobal 
and Patient Power regularly make and disseminate short video interviews with global CLL 
experts covering current issues in disease research and management, and common questions 
asked by those living with the disease. 
 
Dedicated, membership-only Facebook group, ‘Bad to the Bone: Living with Chronic 
Lymphocytic Leukemia’, registers 316 members as at March, 2013. In addition, there is a 
significant network of individual and small group CLL websites, blogs, and user-generated 
videos on YouTube. Several of the larger institutions, particularly those in the US such as the 
Mayo Clinic, have their own dedicated information pages for CLL patients. There is also a 
wealth of haematological information for medical professionals, and a rich databank of 
research papers, and online journals pertaining to the disease. Many of the support sites 
compile lists of journals and research papers, and link out to them for easy access. 
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Appendix 12: Network map and analysis of discussion from Dr Stephen 
Rosen’s video ‘An Experts Perspective on AdvancingTreatment Progress for 
Blood Cancers’  
 
Posted to Andrew Schorr’s Patient Power advocacy site on 7th January, 2013.    
 
 
 
Figure 43: TOUCHGRAPH  (2013) Network connections for Stephen Rosen’s  video  ‘An Expert’s Perspective…’ 
[Network Map]. [Online] Available at: www.touchgraph.com [Accessed 03/01/2014]. 
 
The video is prefaced with the following introduction: 
 
Dr. Steven Rosen, from the Robert H. Lurie Comprehensive Cancer Center of 
Northwestern University in Chicago, expresses his excitement about advancements in 
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blood cancer treatments presented at the 2012 American Society of Hematology annual 
meeting. Dr. Rosen explains one of the key factors for determining the best treatment 
course is understanding the genetics of each individual's cancer. As survivorship 
increases, the paradigm of care is shifting to focus on long term disease management 
and maintaining quality of life. (Patient Power, 2013) 
 
Combining his skills as a journalist, with his knowledge and experience as a CLL patient, Andrew 
Schorr leads Dr, Rosen through a number of questions aimed at educating a patient audience. 
Kicking off with the very current issue of personalized treatment, Schorr raises the question of 
the role of individual cytogenetics in making treatment decisions. Dr. Rosen responds that the 
ability to target treatments to the unique biological features of an individual’s tumour allows 
for tailored therapies, and “hopefully by putting together this cocktail of targeted agents you 
can induce very significant response and remission with very good quality of life (Rosen, cited in 
Patient Power, 2013).  
 
Rosen then responds to Schorr’s question about the new small molecule oral agents, “pills that 
people can take to control their cancer” (Schorr, cited in Patient Power, 2013). Listing the pros 
and cons of the small molecules, on the positive side Rosen cites ease of administration, 
obviating the necessity to come into clinic for treatment, and the rigorous testing process they 
go through prior to licensing. More problematic in his view is the potential for non-compliance 
in long-term daily oral drug regimes, (particularly when patients begin to perceive themselves 
as well after a period of effective treatment), and what he describes as “some unfortunate 
economic considerations related to oral medications” (ibid).  This American video naturally 
presents a US- focused economic perspective. Insurance costs are the issue here, rather than 
whether or not Health Authorities such as those in the UK and other countries with state run 
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health care systems can afford, or are willing to prescribe such expensive drugs. However, 
whatever their geographical location, financial considerations will ultimately apply to all CLL 
patients in relation to access to treatments, and the issues of managing survivorship highlighted 
in the comment from Rosen below will play out in a contested economic arena: 
 
…the very practical issues of how you live with an illness for 10, 20 years in some 
instances on constant therapy but with good quality of life, how do you balance the 
treatment of your disease with all the other important things that you want to 
accomplish and all the unique relationships that you have. (ibid) 
 
 
There is very real possibility that a patient will be cared for by one key clinician over the course 
of many years, so the clinical relationship itself becomes one of the ‘unique relationships’ that 
Rosen refers to. Schorr turns at this point in the interview to the question of how that might 
impact on the nature of patient-clinician relations, suggesting that “open communication” and 
a sense of “partnership” (ibid) are important aspects in long-term clinical relationships. Patient 
Power is a patient advocacy site and, as such, is concerned with encouraging patients to get the 
most out of their relationships with those responsible for delivering their care. It is perhaps not 
surprising then that the audience of this video is encouraged to consider the changing nature of 
clinical relationships in a new era of cancer treatments. Many points are raised in the networks 
concerning long-term treatment regimes, predominately issues of economy, access, 
compliance, long-term efficacy, and physical side-effects. Rarely however is the impact of 
evolving approaches to treatment and care on the clinical relationship itself directly addressed. 
Dr. Rosen implies that lifelong partnership with patients and their families lead to holistic 
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involvement, and increased job satisfaction:    
 
You become very close to your patients.  You become part of each other’s families.  The 
patient has to feel comfortable they can call on you at any time if they have an 
issue.  The issue doesn’t necessarily have to be directly relevant to the cancer itself but 
relevant to their health that you can help with, and it’s what makes oncology the most 
rewarding field in medicine. (ibid) 
 
 
This doesn’t necessarily chime with some of the less engaged clinical relationships reported by 
patients in this thesis, nor with some of the observations made by clinicians themselves about 
time constraints in over-stretched clinical settings. Dr. Rosen is a global CLL expert working out 
of a globally recognized treatment centre. Perhaps it only the 10% of patients suggested by Jeff 
Sharman (2012) being treated by specialists that can be guaranteed this kind of care, with the 
other 90% taking their chances among more generalist and pressured regional clinicians. This 
an important issue indeed as models of all forms of cancer survivorship evolve into potentially 
much longer periods of ongoing treatment and care for potentially much better informed and 
engaged patients. The issues Dr. Rosen and Andrew Schorr raise here are of fundamental 
importance in laying out blueprints for changing clinical relationships for the audience of this 
video. This is a debate that would usefully incorporate a broader range of clinical voices and 
experiences, although it is likely that the majority of the Patient Power audience would be 
patients.  
 
Winding the interview down, Schorr asks Dr. Rosen if he is “encouraged about where we’re 
headed, where we are now?” Rosen’s reply that the fields are evolving so quickly that “you can 
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provide hope for just about every individual you see even at the different stages of the 
disease”(ibid ), again gives the patient audience the sense that, whatever their CLL subset or 
situation, they are part of this universal hope. Although with very different stakes on the table 
(job satisfaction versus survival and longevity), in expressing regret that he is not “20 years 
younger to take advantage of everything that’s going on and to see how it will evolve in the 
next few decades” (ibid), Rosen shows how the horizons of doctors and patients might be fused 
in a desire to be part of this future.   
 
Building on this perhaps, Schorr concludes the interview with a return to the all-important issue 
of patient advocacy in the context of pro-active selection of an appropriate clinician when he 
states that “It would seem that there is some responsibility for patients now to get educated 
and to seek out a specialist such as yourself so the best care is brought to bear for them” 
(ibid). Dr. Rosen’s reply that this is fundamentally important and that “…you need to be in the 
hands of experts who treat those diseases, who have an understanding of how to sequence the 
treatments, how to control the side effects and how to maximize the potential for cure or 
control of the disease and minimize side effects” (ibid) may seem more suited to a US audience 
for whom the choice of clinician is part of a more generalized consumerist approach to health 
care decisions. However, and as this work has already shown, choice – where it is available - can 
be restricted by a number of contingencies such as geography and wellness. It is clearly also the 
case that some patients outside the US also change doctors when their knowledge leads them 
to conclude that they could access better care elsewhere. Again, this is dependent on access to 
information, and the wealth, time and capacity to travel to see a specialist. 
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Appendix 13: Summary of the NICE STA process  
 
 
Figure 44: NICE (2014) 'Figure 3 - Summary of the STA process'. NICE ‘Guide to the Process of Technology 
Appraisal’, 2014 [Table]. [Online] Available at:  https://www.nice.org.uk/article/pmg19/chapter/3-The-
appraisal-process [Accessed 03/08/2015]. 
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Appendix 14: Advocacy for Access in the networks - It’s Okay (Essential) to Ask  
 
Figure 45: TOUCHGRAPH (2014) Network Connections for inks from UK CLL Forum discussion thread entitled 
‘ibrutinib’, September, 2014 [Network Map]. [Online] Available at: www.touchgraph.com [Accessed 
03/12/2014]. 
 
For a variety of reasons, some discussed earlier, not all clinicians go out of their way to seek out 
and suggest relevant trials to their patients.  In May, 2014, the National Institute for Health 
Research (NIHR) marked International Clinical Trials Day with the launch of its UK ‘OK to ask’ 
campaign promoted across national mainstream and social media. Simon Denegri, NIHR 
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National Director for Patient and Public Participation and Engagement in Research highlights 
the reciprocal benefits of trial involvement when he points out that: 
 
Much of the life-saving clinical research carried out in the NHS could not happen 
without hundreds of thousands of patients and carers stepping forward every year to 
take part. Those who volunteer in this way report a range of benefits and are pleased to 
be potentially helping others like them with the same condition. NIHR’s national ‘OK to 
ask’ campaign taking place on International Clinical Trials Day is about encouraging 
many more people to ask their doctor about being in research as part of their care and 
treatment and highlighting that they have a right to information about ‘relevant and 
appropriate’ research under the NHS Constitution. (cited in NIHR CRN,2014) 
 
Although articulated primarily as something patients can do to advance the cause of medical 
research, Denegri finishes the statement by encouraging patients to see information about and 
access to trials appropriate to their condition as their ‘right’ under the terms of the NHS 
constitution. 
The emphasis is on patients taking responsibility to pursue that right themselves, and not 
waiting to be offered it by their clinician. This campaign found its way into the CLL networks in 
the UK in a number of forms, and I will look briefly here at a posting to the UK CLL forum by 
Member ‘Nick’ (Hairbear elsewhere). The final post in a 12 post thread entitled simply 
‘ibrutinib’, the contribution is pitched in relation to the planned closure of the ibrutinib 
compassionate access programme in September, 2014, and the need to share news of new UK 
clinical trials that might take over in the provision of access to CLL patient groups. Introducing 
the ‘OK to ask’ campaign, Nick cites Denegri in his post: 
 
We want patients to know that research is happening in the NHS and to enable them to have 
access to information about local opportunities and to feel empowered to speak to their doctors 
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about the possibilities, commented the NIHRs Simon Denegri. This campaign is about getting 
that conversation going, and letting patients know that they don't have to wait to be 
approached by their doctor or nurse.  (Nick, UKCLL forum, 2014)  
 
 
The shift on emphasis, or indeed responsibility for pursuing trials information away from health 
professionals and onto the patient in Denegri’s quote is interesting, and again follows the ethos 
of patients actively pursuing information as their ‘right’. Nick picks up on the patient-
empowerment ethos of the campaign to preface a couple of links to campaign information:  
 
If you are approaching treatment it's OK to Ask your doctor about a clinical trial. 
http://www.nihr.ac.uk/newsroom/the-nihr-%27ok-to-ask%27-campaign-encourages-
patients-to-take-part-in-research/1192  
http://www.ct-toolkit.ac.uk/news/its-ok-to-ask-the-nihrs-new-patient-empowerment-
campaign  
 
 
Before listing relevant CLL trials currently running or planned in the UK, along with details, 
layman summaries, and links to more generic trials information through the UK Clinical Trials 
Gateway: 
 
You may interested to know that the latest CLL trial, FLAIR, opened last week in Leeds 
and we should start to see this opening at other hospitals around the UK in the next few 
weeks.  
 
FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab to assess whether 
IR is superior to FCR in terms of progression-free survival  
 
Participants will be 555andomized [sic] on a 1:1 basis to receive either FCR or 
Ibrutinib+R.  
Planned Sample Size: 754; UK Sample Size: 754  
 
http://www.ukctg.nihr.ac.uk/trialdetails/ISRCTN01844152?view=healthprofessional  
 
This is the latest of the new kinase inhibitor trials that are now open. Others include  
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IcICLLe: (recently opened) Ibrutinib  
 
http://www.ukctg.nihr.ac.uk/trialdetails/ISRCTN12695354  
 
layman summary http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-
ibrutinib-chronic-lymphocytic-leukaemia-iciclle  
 
For other UK CLL trials info: NCRI study group portfolio map PDF  
 
http://csg.ncri.org.uk/wp-content/uploads/2013/10/NCRI-CSG_HaemOnc-Portfolio-
Map_Chronic-Leuk-.pdf  
 
UK Clinical Trials Gateway: 
http://www.ukctg.nihr.ac.uk/search?query=keyword:chronic+lymphocytic+leukaemia&r
esultsfrom=1&resultsto=20000&advanced=true&pagesize=20000 
 
If you are approaching treatment and interested in a trial, now would be a good time to  
chase this up with your doctor.  
 
 
A posting such as this is information rich, and demonstrates how key actors in specific localized 
disease communities might respond to larger networked endeavors to empower patients such 
as the ‘OK to Ask’ Campaign. The importance of key actors like Nick (and Chaya Venkat) can’t be 
overestimated in bringing patients closer to empowerment through localized network activity, 
vividly bringing to life Bruno Latour’s contention that a network that is expanding is better 
termed a ‘work net’ with emphasis on the ‘work’ (Latour, 2007). 
 
Although some patients in the community will undoubtedly have the resources to pursue this 
information independently, this study has shown that even those patients tapped into narrative 
networks surrounding their disease have varying levels of engagement, and different degrees of 
understanding of what they encounter therein. The momentum of activity in response to the 
campaign in CLL networks will be boosted or maintained by those members willing to put in the 
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legwork to provide resources for relevant information for others, as demonstrated here in 
Nick’s post. Of course it is important as ever to bear in mind that those not tapped into such 
networks may have little or no knowledge of their disease outside what their doctors tell them. 
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Appendix 15: List of translations of this PhD research currently in circulation 
a) Hanging with ‘the Chronics’ Online:   Autopathography and Narrative Associations in an online 
support group for Chronic Lymphocytic Leukaemia – abstract of paper given at Interdisciplinary.net 
‘Chronicity’ Conference, Oxford University, 2012 and published in conference proceedings. 
 
b)  (Not just) In the Blood: ppt. presentation of research (with notes) from CLLSA UK Pan-
European Advocacy Meeting, Cambridge, 2014. List of attendees at presentation also 
included. 
 
c) Screenshots and URLS from ‘Julia’s Story:  From CLL diagnosis to a doctorate study of how 
CLL people use the internet’ on Patient Power, YouTube, and CLLSA UK website. 
 
d) Screenshots and URL for Panel discussion from the CLL Support Association UK Patient 
Meeting in Cambridge, 21st June, 2014: CLLSA UK and YouTube. 
 
e)  Copied e-mail exchange documenting use of PhD data to review and inform patient 
information booklet for the Leukaemia and Lymphoma Research Charity (to be known as 
‘Bloodwise’ from September, 2015) 2014. 
 
f) Forthcoming events at which PhD data will be presented. 
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Appendix 15 (a): Abstract for Hanging with the “The Chronics” online: 
Autopathography and Narrative Associations in an online support group for Chronic 
Lymphocytic Leukaemia – Presented at ‘Chronicity’ Conference, Oxford University, 
2012 
 
Often externally invisible, and currently considered incurable, chronic lymphocytic leukaemia 
(CLL) occupies several stages from indolent, through progressive, to terminal in some cases. 
Variable patterns of disease progression position those with the condition in ongoing 
negotiation with various points on a conceptual continuum between “wellness” and “illness” 
with no definitive hope of cure. This ethnography of a chronic disease traces networks of 
narratives surrounding CLL coalescing in and around the hub of an online support 
community for people with the disease. Amongst other examples, these include patient 
stories, medical research papers, online advice for those diagnosed with CLL, medical results 
and documents. Diagnosed with CLL myself, I have embodied investment and full member 
status in the research field. Using autopathographic narrative (Couser, 1997), the work will 
draw on Latour’s object-oriented philosophy to map ways in which these narrative objects are 
transported and translated around varying experiences of the disease. Autopathography and 
online ethnography allow for expression of the lifeworlds of those experiencing CLL, and a 
revealing of how lived experiences of CLL intersect with the texts and technologies that 
define CLL as a disease through, CLL research, diagnostics, treatment protocols, online 
support groups and professional support. Particular attention will be given to the impact of 
differing relations with time experienced by those with chronic disease on their lifeworlds. 
This paper outlines the project design for my doctoral project on narratives in an online 
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community for those with CLL, and summarizes work in progress. Through this process of 
early-stage sharing of work to date, the paper considers strategies for innovative and effective 
presentation of complex assemblages of data incorporating biographical and autobiographical 
narrative alongside a range of broader narrative, cultural, and technological objects in 
exploring the experiences of knowing, understanding, and living with chronic, incurable 
disease.   Keywords: Chronic Lymphocytic Leukaemia; auto-ethnography; online support community; 
actor network theory; narrative; autopathography.                                              Full paper available at:  
 
http://repository.falmouth.ac.uk/300/1/RR_Hanging%20with%20the%20Chronics_021013_nid252.pdf 
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Appendix 15 (b): Ppt. Presentation of research given at CLLSA UK Pan-European Advocacy Meeting, Cambridge, 2014, with list of 
attendees and affiliations 
 
First 
name 
Surname     Organisation Position/role   Web site address Country 
xxxxxx xxxxxx CLL Support Association  CLLSA Chair, CLL patient www.cllsupport.org.uk UK 
xxxxxx xxxxxx CLL Support Association  CLLSA advocacy CLL 
patient  
www.cllsupport.org.uk UK 
xxxxxxx xxxxxxx CLL Support Association CLLSA advocacy CLL 
patient  
www.cllsupport.org.uk UK 
Nick York CLL Support Association CLLSA trustee, CLL patient www.cllsupport.org.uk UK - Wales 
Ceri York  CLL carer/facilitator  UK - Wales 
Julia Kennedy Falmouth University PHD research 
CLL on-line 
CLL advocate, CLL patient www.falmouth.ac.uk/content/julia-
kennedy 
UK 
George Follows UK CLL Forum & Cambridge 
University Hospitals 
CLL Clinical lead, CLL 
forum Chair 
www.ukcllforum.org  UK 
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xxxxxx xxxxxxx Leukaemia Care  CEO, CLL patient? www.leukaemiacare.org.uk  UK 
xxxxxxx xxxxxx Lymphoma Association  CEO  www.lymphomas.org.uk  UK 
xxxx xxxxxxxx Leukaemia & Lymphoma 
Research 
Head of Patient Services www.leukaemialymphomaresearch.org
.uk     
UK 
xxxx  xxxxxx Older People’s Advocacy Alliance  CEO www.opaal.org.uk UK 
xxxxxxx xxxxxx Patient Power/Brandcast media   www.brandcastmedia.com  UK 
Andrew Schorr Patient Power EU  Founder, CLL patient www.patientpower.eu  Spain 
xxxxx xxxxx CML Advocates network                              Co founder www.cmladvocates.net Israel 
xxx xxxxxxxx  CLL patient advocate www.miabonhomme1.wix.com  Belgium 
xxx xxxxx  CLL patient advocate  Ireland 
xxxxxxx xxxxx   CLL carer advocate  Ireland 
xxxxx    xxxxxxxx   SILLC Board member www.sillc-asso.org  France 
xxxxxxx xxxxxxx   CLL patient advocate  Ireland 
xxxxxxx    xxxx    CLL patient blogger  Spain/Portug
al 
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xxxxxx xxxxx   ?? CLL patient advocate  Germany 
xxxx  xxxxxxx   ?? CLL patient advocate  Germany 
xxxx    xxxxxxxx    CLL patient advocate  France 
xxx     Xx xxxx Hematon Leukemie en MDS  Board member www.leukemie.nfk.nl  Netherland 
xxxxxx  Beat Leukemia  www.beat-leukemia.com  ? Italy 
 
Figure 46: CLLSA UK (2014) List of attendees (and affiliations) at CLLSA UK Pan-European Advocacy Meeting, Cambridge, 2014 [Table]. 
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(Not just) In the Blood: Presentation with Notes 
 
What I will do today: 
1. Tell you how my doctoral research project In the Blood began 
2. Give you a very brief overview of its aims 
3. Draw out some of my main observations and findings into an advocacy context to 
underpin some of the work we’ll be doing later 
To cut a very long story very short indeed, back in February 2011, I visited my GP to get the 
results of a recent blood test. He told me I had CLL, that it was incurable, that he didn’t 
know what my prognosis was, and that I should go away and LOOK IT UP ON THE 
INTERNET 
I followed Drs orders and did just that – in that early process of researching to survive I 
was overwhelmed by the amount and range of information I found.  
The researcher in me saw a gap in the market … 
 Here was Tom Ferguson’s informed, connected and empowered ‘e-patient’ at work – 
tapping into and sharing a wealth of information about this most common yet seemingly 
little understood of adult leukaemias, from the complex hard science of  a disease poised at 
the crossroads of biomedical understanding,  through its various global political-
economies,  to the existential impacts of living with a disease that produces lower 
emotional well-being scores amongst those that live with it than any other type of cancer 
…(Shanafelt et al, 2007) 
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Yet this vibrant exchange of knowledge and experience and the mechanisms that enable it 
remains largely hidden away in semi-closed communities online …. 
For the benefit of us, and our carers, and other people with chronic cancers - the world 
needs to see this. 
‘In the Blood’ is my way of telling that story from the inside as an academic and a CLL 
patient 
So what have I learned from the networks that is relevant here today..? 
 
Here’s a network map – 3 clicks  
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And if we look at the sites we’ll see that they all function  differently individually but 
connect as a network – facilitating information exchange across network boundaries - 
although some types more popular than others… 
Core CLL sites link out into related sites: medical education, pharma press releases, 
benefits advice, trials sites, generic health related and everyday news… 
A delicate and important eco-system of everyday advocacy already exists amongst 
members of the network … 
People are advocating in all kinds of ways for themselves  (Seeking advice from other 
members online – going direct to databases for research - influencing treatment decisions 
through bringing online information into the clinical relationship with their Drs) 
And indirectly for others by sharing their stories and their research findings 
Or more directly, by actively seeking out research and sharing it across networks, setting 
up or becoming actively involved in managing sites and blogs  
All important roles – but it is the latter – the organizers and innovators who are the KEY 
MEDIATORS in the network providing the frameworks within which the exchange of 
information and support takes place 
Raising important issues for discussion amongst CLL patients across the network (Wayne 
Wells and recent discussion re CT scanning across networks) 
Careful consideration needs to be given to how and when we harness that and take it to the 
next level – strategic, Political, awareness-raising, lobbying, and so on… whilst retaining the 
diversity and independence of the patient led communities 
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Much evidence of locally specific issues drawing on global networks of knowledge and 
support 
 – local both in terms of an individual’s experience of their disease as located in their own 
body and social contexts 
- And in terms of regional, national and international differences in care delivery 
systems, governance, and cultural attitudes (the disease shape shifts across these 
boundaries – but the concerns and trials of living with CLL have universal points of 
identification… 
- Important point for advocacy across cultural and geographical boundaries 
- (indymedia model) 
Let’s zoom into an analysis of core network use in 2012 
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And this gives us the lead on areas that may need addressing 
Where advocacy is working, or needs to work harder, at both everyday and more organized 
strategic levels  
 
• Diagnosis 
• Understanding CLL as a form of ‘cancer’ 
• Struggling with watch and wait 
• Lack of info at GP level 
• Geographical Inconsistencies in  allocation of specialist care 
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• Prognosis 
• Making sense of stats 
• Understanding significance of prognostic/predictive markers - Power or Paralysis? 
• Inconsistencies in tests available 
• Treatment 
• Keeping up with new developments 
• Access to trials/drugs 
• 2nd best?  Still doing  chemo in  the brave new world  
• Survival 
• Living in ‘prognosis’: Risky bodies/uncertainty/identity 
• Psychosocial/cultural/economic issues 
• Spiritual/existential :understanding limits of control/addressing mortality 
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1. CLL, like any disease, is about much more than dysfunctional cells and bodily 
symptoms.  It’s held together by a complex mesh of social, political, economic, and 
cultural threads – connected by global systems of information exchange, yet 
grounded in local contexts of health care delivery, disease management, and 
personal experience.   
Grassroots advocacy draws on global knowledge and networked support to improve 
localized lives  
Looked at in this way (socially and culturally embedded)– CLL is a complex piece of 
machinery. 
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2.  Just as we need to understand how each part of any machine we rely on relates to 
the others in order to function,  we need to get the ‘black box’ off CLL online to see 
how all of the components work together to make it into the disease we recognize 
But if we’re honest, most of us aren’t that interested how our machines are put 
together until we need to fix or modify them …to make them work better for us… 
…and advocacy is essentially a process of doing just that – of recognizing where the 
circuitry breaks down for some of us and working together to try and make it function 
better … 
We may want to fix the fact that many of the challenging aspects of living with a chronic 
cancer of the immune system remain unrecognized 
Or that new drugs get caught up in regulatory bureaucracy and don’t make it to market 
quickly enough to save lives 
Or are too costly to be broadly accessible 
Or that our haematologists aren’t talking to our dermatologists and too many of us are 
dying of melanomas, and so on 
If we want to tinker with it, we must first understand the complex circuitry holding CLL 
together as a single entity 
To advocate successfully, we must be aware of all of the actors in the networks, human and 
non-human  
Connect genetic mutations at cellular level to that tube of blood where it all began for most 
of us – to the laboratory technology, research and funding that progresses diagnostic, 
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prognostic and treatment options, to the medical education that trains and frames our 
clinicians, to the pharmaceutical industry and those who invest in and regulate it, to the 
governance of global and local health care systems, to the employment and benefit laws 
that impact on people with CLL, through the information technology that allows us to share 
our experiences, to the cultural attitudes that frame the stories we all tell each other and 
ourselves about this disease… 
If we want to fix or change any part of the many faces of CLL – we really need to see the 
bigger picture… 
3. The expanding ‘common-wealth’ of networked  information allows us to do just 
that 
 It smashes apart traditional hierarchies of political and knowledge sharing hierarchies 
It replaces them with collaboration, participatory politics and grassroots activism 
online…patient ‘centred’ care evolves into the model of the ‘networked patient’ (and Dr) 
 It generates new forms of capital – for instance, those good at inspiring ‘identification 
empathy’ in online communities become stand-out actors and advocates.  
One caveat – we need to consider ways of being more inclusive for those voices currently 
going unheard…Lurkers are by no means IN-active, but their voices and actions are 
currently unharnessed… 
To finish - we are undoubtedly in the best environment to date in which to advocate 
for this one-time ‘Cinderella’ of the disease world 
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A number of external factors are influencing the fact that CLL is finally getting to go to the 
ball, BUT online access means we can all play a role in becoming our own collective fairy 
godmother… 
Thankyou 
Julia Kennedy, Falmouth University, June 2014           julia.kennedy@falmouth.ac.uk 
If citing any material from this presentation, please contact me for citation details.  
 
 
Figure 47: CLLSA UK (2014) Homepage of CLLSA UK showing image from the CLLSA UK Pan-European Advocacy 
Meeting, Cambridge, 2014 [Screenshot]. [Online] Available at: http://www.cllsupport.org.uk/home [Accessed 
02/08/2015]. 
 
 
 
Image removed due to copyright restrictions 
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Appendix 15 (c): Screenshots and URLS from videos discussing this work online 
 
 
Figure 48: PATIENT POWER EU. (2014) 'Julia's Story: from CLL diagnosis to a doctorate study of how people use 
the internet' [Video Screenshot]. [Online] Available at: http://www.patientpower.eu/videos/julias-story-from-
cll-diagnosis-to-a-doctorate-study-of-how-cll-people-use-the-internet/ [Accessed 28/07/2015]. 
. 
Julia’s story: From CLL diagnosis to a doctorate study of how CLL people use the internet 
Julia shares with us: her experience of diagnosis with chronic lymphocytic leukaemia (CLL); her 
first questions and the general doctor’s knowledge; how being selective when sourcing 
information is important; the importance of relationships and working together with her 
doctors, and following what’s happening in the community; how this all lead to her interest into 
how people use online communities and information resources to support and inform each 
other; and that not all have access to, are able or confident using the internet and there is a 
large older group of CLL patients we don’t know much about. (Patient Power Eu., 2014) 
 
575 
 
 
Figure 49: YOUTUBE (2014)  ‘Julia’s Story: from CLL diagnosis to a doctorate study of how people use the 
internet' [Video Screenshot]. [Online] Available at: https://www.youtube.com/watch?v=9SP5OML9-FA. 
[Accessed 28/07/2015]. 
 
 
 
Figure 50: CLLSA UK HEALTH UNLOCKED (2014) ‘Julia’s Story: from CLL diagnosis to a doctorate study of how 
people use the internet' [Video Screenshot]. [Online] Available at:  
https://healthunlocked.com/cllsupport/posts/131147447/archive-of-latest-cllsa-videos [Accessed 28/07/2015]. 
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Appendix 15 (d): Panel discussion from the CLL Support Association UK Patient Meeting in 
Cambridge, 21st June, 2014: CLLSA UK and YouTube 
 
 
 
Figure 51: Panel discussion video published on 26 Jun 2014 [Screenshot]. [Online] Available at: 
https://www.youtube.com/watch?v=9882LmKVMRc [Accessed 28/07/2015]. 
 
In this video from the CLLSA UK Patient Meeting in Cambridge, 21st June, 2014, Patient 
Advocate Andrew Schorr chairs a panel of UK patient advocates in a discussion of the important 
roles that advocacy can play in living with and raising awareness of less understood diseases 
such as CLL. From small 'a' to large 'A', the panel traces the impact of advocacy from the 
personal to the political and the local to the global. 
 
Kath Parson from OPAAL (Older People's Advocacy Alliance), adds her professional perspective 
to the experiences of CLL patient advocates Julia Kennedy and Tricia Gardom. Andrew, Julia and 
Image removed due to copyright restrictions 
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Tricia share their experiences in the transformation from patient to advocate and discuss what 
motivated them. 
 
The panel concludes that advocacy works at a number of levels, beginning with the immense 
day to day benefits that sharing experiences with other patients in support groups brings to 
those living with CLL. From the positive impacts on the sense of isolation, fear and 
powerlessness that often accompanies diagnosis, grow more strategic advocacy campaigns 
such as lobbying for improved access to costly transformational therapies among the CLL 
community. Finally, the panel considers the potential benefits to the patient and clinical 
communities of collective individual experience on-line providing a global insight into living with 
CLL. All agreed that, whilst face to face support was important, staying connected online was an 
increasingly effective source of networked empowerment. The panel strongly encouraged as 
many people living with CLL as possible to improve outcomes and raise awareness of the 
disease by getting involved in advocating for themselves and others (YouTube, 2014). 
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Appendix 15 (e) E-mail exchange documenting use of PhD data to review patient information 
booklet for the Leukaemia and Lymphoma Research Charity, 2014 
 
 
Inbox 
16 September 2014 10:03 
Hi Julia, 
Thanks very much for your email. Your PHD data sounds really interesting – would I be able to 
access this once you’ve completed the work? I’m sure there’s lots in there that would be 
valuable to us. 
  
Thanks again for your help, and if we can use your skills and experience again in the future that 
would be terrific. 
  
Kind regards, 
Jon 
 
 
Kennedy, Julia 
 
Sent Items 
09 September 2014 11:02 
Jon, 
 
You're very welcome. 
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I would add that I have a wealth of qualitative data from CLL patients about their experiences of living 
with CLL, particularly in relation to internet use, gathered during my PhD. I'm writing up at the moment 
and intend to publish it as a whole, and as a number of individual research papers on discrete topics once 
it is complete (hopefully in the New Year 2015).  
 
 If I can be of any further help to you as a patient/researcher, just let me know. 
 
With kind regards. 
 
Julia 
 
 
Julia Kennedy 
Senior Lecturer 
School of Writing and Journalism 
Falmouth University 
 
E-mail:  julia.kennedy@falmouth.ac.uk 
 
Tel: 01326 370400 ext 1715 
 
 
  
  
 
 
580 
 
  
 Jon Hoggard [JHoggard@beatingbloodcancers.org.uk] 
  
Inbox 
08 September 2014 11:43 
Dear Julia 
My name is Jon Hoggard and I'm the patient information manager at Leukaemia & Lymphoma Research. 
I just wanted to write to thank you for taking the time to review the new CLL booklet, especially at such 
short notice! I'd also like to apologise for the delay in getting back to you. 
  
We really appreciated your comments and have done our best to include them as much as possible, 
with guidance from our Medical Advisor. The information is always evolving however, and so we 
welcome any further comments you might have. 
  
I'm arranging to send some printed copies to Sarah at the CLLSA, but if you would like me to send you a 
copy of the booklet directly, please reply with your contact address and I'll gladly post one out to you. 
  
Thank you once again for your help with the project. 
Best wishes, 
  
Jon Hoggard 
Patient Information Manager 
Leukaemia & Lymphoma Research 
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Kennedy, Julia 
 
Actions 
To: 
 JHoggard@beatingbloodcancers.org.uk  
Cc: 
 nick.york@cllsupport.org.uk  
Sent Items 
11 August 2014 14:00 
Hi Jon, 
 
I am among those CLLSA members asked by Nick to take a quick look at the new booklet and comment. 
 
Generally, I think it to be a good resource for the newly diagnosed. The tone is accessible without being 
patronising (a major problem in a lot of literature for the newly diagnosed in my view). 
 
Just a couple of observations then, based on a very quick look given the time-frame: 
 
1) I think more emphasis could be placed on the importance of keeping informed and supported through 
self advocacy online (or encouraging people to get someone to help them with this if they are not 
particularly computer literate).  83% of the 260 CLL patients I surveyed for my current doctoral project 
about online use and information/support seeking behaviour among CLL patients said unequivocally that 
using online resources has helped them to live with CLL. A similar significant majority said that discussing 
their research with their medical teams had led to them feeling more able to understand their clinicians'  
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decisions in respect of their care and, in some cases, had even led to selecting a different approach in 
response to new treatments, trials and protocols learned about online after discussion with their doctor.  
The emotional support gained from getting into dialogue with other CLL patients is also of significant 
importance for CLL patients (who currently record emotional well being related quality of life indexes 
below those of patients with any other form of cancer). Not all CLL patients will see a CLL specialist, as 
you point out in the booklet, so I think it is important to really emphasise the benefits of gaining support, 
and keeping up to date with current treatments and trials through the use of reliable sites such as 
CLLSA.  
 
2)When I received my own recent FCR treatment, I felt I didn't get enough information about following a 
neutropenic diet during my extreme neutropenic phases. I notice that this isn't mentioned anywhere in 
the treatment information, so maybe a couple of words about food hygiene and a neutropenic diet would 
be useful so patients can raise it with their medical teams for further info if needed. 
 
3)  I was under the impression that inconsistencies in laboratory testing made Zap-70 a controversial 
marker in practice, and that many centres don't offer it? 
 
4) Finally - perhaps more emphasis on getting information on trials given the current rapidly evolving 
treatment landscape.  Despite mentioning new treatments in the pipeline, the booklet gives the 
impression that FCR is really still the only way forward unless you are 17p deleted or refractory in some 
other way. I understand the difficulties of raising hopes for new treatments which may not be available to 
all, and are still in trial in the UK, but perhaps a link to the UK clinical trials gateway 
http://www.ukctg.nihr.ac.uk/default.aspx somewhere so patients can at least see what's out there and 
raise this possibility with their doctors. Many patients are prepared to travel to different centres to get on 
a trial, but if their own hospital doesn't offer it and isn't a specialist CLL centre, they may never get to  
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hear about trials elsewhere in the country that they may be eligible for (another reason to encourage 
them to get online...) 
 
As I say though, generally an informative and comprehensive guide in an accessible and well-designed 
format that I think will be of real use to the newly diagnosed. 
 
All the best. 
 
Julia 
 
Julia Kennedy 
Senior Lecturer 
School of Writing and Journalism 
Falmouth University 
 
E-mail:  julia.kennedy@falmouth.ac.uk 
 
Tel: 01326 370400 ext 1715 
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Appendix 15 (f): Forthcoming Presentations of PhD Data 
 
Keynote Invitation accepted for: 
 
ePatients  
 
The Medical, Ethical and Legal Repercussions of Blogging and  
Micro-Blogging Experiences of Illness and Disease 
 
 
 
Queen’s University Belfast, 11-12 September 2015 
 
https://epatientsconference.wordpress.com/2015/06/24/programme-and-registration/ 
http://blogs.bmj.com/medical-humanities/2015/03/22/epatients-the-medical-ethical-and-legal-
repercussions-of-blogging-and-micro-blogging-experiences-of-illness-and-disease-call-for-papers-and-
conference-details/ 
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Guest speaker invitation accepted for: 
September 2015 
 
Bristol - Wales & West - Members Meeting  
Registered Charity No 1113588, www.cllsupport.org.uk 
  
Dear Member 
We would like to invite you to a Members' meeting of the CLLSA at 
Armada House, Telephone Avenue, Bristol, BS1 4BQ 
September 28th 2015, 10:30 – 16:00 hours 
  
Travel & parking details are available here   
Lunch and refreshments will be provided free of charge. 
  
There is no charge to attend, the purpose of patient meetings is for you, the patient, 
carer or friend to meet other people living with CLL, and to exchange experiences and 
learn from expert speakers. 
The provisional programme for the day (see below) provides presentations from: 
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• Professors Chris Fegan and Chris Pepper from Cardiff School of 
Medicine   discussing the CLL treatment and care landscape, new treatments, 
clinical trials, prognostics and latest developments in prognostic testing 
• Julia Kennedy CLL patient, senior lecturer in journalism Falmouth University 
discussing CLL and her PHD study of how people come together to make sense 
of living with a chronic disease in a contemporary landscape 
• Penny Brohn Cancer Care, discussing self-help techniques for living with CLL 
• CLL patient & CLLSA volunteer (anonymous) The Patients View 
http://www.cllsupport.org.uk/civicrm/event/info?reset=1&id=28 
